22. Literaturverzeichnis – Lungenkarzinom
1. Barta, J. A., Powell, C. A., Wisnivesky, J. P., Global Epidemiology of Lung Cancer, Ann Glob Health, 2019. 85(1):, https://www.ncbi.nlm.nih.gov/pubmed/30741509
2. Wild, Christopher, Weiderpass, Elisabete, Stewart, Bernard W., International Agency for Research on Cancer, World Health Organization, World cancer report cancer research for cancer preventionIARC Press, 2020., https://pubmed.ncbi.nlm.nih.gov/39432694/
3. Barnes, Benjamin, Kraywinkel, Klaus, Nowossadeck, Enno, Schönfeld, Ina, Starker, Anne, Wienecke, Antje, et.al. Bericht zum Krebsgeschehen in Deutschland 2016Robert Koch-Institut, 2016.
4. Hoebel, J, Kroll, LE, Fiebig, J, Lampert, T, Katalinic, A, Barnes, B, et.al. Socioeconomic Inequalities in Total and Site-Specific Cancer Incidence in Germany: A Population-Based Registry Study., Front Oncol, 2018. 8 (): p. 402., https://pubmed.ncbi.nlm.nih.gov/30319967/
5. Sidorchuk, A, Agardh, EE, Aremu, O, Hallqvist, J, Allebeck, P, Moradi, T, Socioeconomic differences in lung cancer incidence: a systematic review and meta-analysis., Cancer Causes Control, 2009. 20 (4)(4): p. 459-71., https://pubmed.ncbi.nlm.nih.gov/19184626/
6. Geyer, S, Social inequalities in the incidence and case fatality of cancers of the lung, the stomach, the bowels, and the breast., Cancer Causes Control, 2008. 19 (9)(9): p. 965-74., https://pubmed.ncbi.nlm.nih.gov/18431680/
7. Kuznetsov, L., Mielck, A., [Regional concentration of social disadvantage and of risks for lung cancer and colon cancer: systematic review and recommendations for research], Gesundheitswesen, 2012. 74(6): p. e42-51.
8. Van der Heyden, J. H., Schaap, M. M., Kunst, A. E., Esnaola, S., Borrell, C., Cox, B., et.al. Socioeconomic inequalities in lung cancer mortality in 16 European populations, Lung Cancer, 2009. 63(3): p. 322-30., https://www.ncbi.nlm.nih.gov/pubmed/18656277
9. Menvielle, G, Boshuizen, H, Kunst, AE, Dalton, SO, Vineis, P, Bergmann, MM, et.al. The role of smoking and diet in explaining educational inequalities in lung cancer incidence., J Natl Cancer Inst, 2009. 101 (5)(5): p. 321-30., https://pubmed.ncbi.nlm.nih.gov/19244178/
10. Hastert, TA, Ruterbusch, JJ, Beresford, SA, Sheppard, L, White, E, Contribution of health behaviors to the association between area-level socioeconomic status and cancer mortality., Soc Sci Med, 2016. 148 (): p. 52-8., https://pubmed.ncbi.nlm.nih.gov/26650930/
11. Finke, I, Behrens, G, Weisser, L, Brenner, H, Jansen, L, Socioeconomic Differences and Lung Cancer Survival-Systematic Review and Meta-Analysis., Front Oncol, 2018. 8 (): p. 536., https://pubmed.ncbi.nlm.nih.gov/30542641/
12. Finke, I, Behrens, G, Maier, W, Schwettmann, L, Pritzkuleit, R, Holleczek, B, et.al. Small-area analysis on socioeconomic inequalities in cancer survival for 25 cancer sites in Germany., Int J Cancer, 2021. 149 (3)(3): p. 561-572., https://pubmed.ncbi.nlm.nih.gov/33751564/
13. Wong, MCS, Lao, XQ, Ho, KF, Goggins, WB, Tse, SLA, Incidence and mortality of lung cancer: global trends and association with socioeconomic status., Sci Rep, 2017. 7 (1)(1): p. 14300., https://pubmed.ncbi.nlm.nih.gov/29085026/
14. Alberg, A. J., Samet, J. M., Epidemiology of lung cancer, in Encyclopedia of human nutrition, Sadler, M. J.Caballero, B. and Strain, J., Editors. 2005, Academic Press: London. p. 272-284., https://www.ncbi.nlm.nih.gov/pubmed/12527563
15. Wichmann H. E.; Molik B., Pott F., Jöckel K. H., Luftverunreinigungen und Lungenkrebs - Ergebnisse einer PilotstudieErich Schmidt Verlag, Umweltbundesamt, 1991.
16. Erdmann, Friederike, Spix, Claudia, Katalinic, Alexander, Christ, Monika, Folkerts, Juliane, Hansmann, Jutta, et.al. Krebs in Deutschland für 2017/2018,Robert Koch-Institut, 2021., http://dx.doi.org/10.25646/8353
17. Nowak D., Huber R. M., Berufliche Risikofaktoren, Berufskrankheit, arbeitsmedizinische Begutachtung, in Manual der Tumore der Lunge und des Mediastinums, 2020 (12. Auflage), Tumorzentrum München: München.
18. International Agency for Research on Cancer, Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 83 Tobacco Smoke and Involuntary Smoking. Lyon, World Health Organization, 2004., https://www.ncbi.nlm.nih.gov/pubmed/15285078
19. Gredner, T, Mons, U, Niedermaier, T, Brenner, H, Soerjomataram, I, Impact of tobacco control policies implementation on future lung cancer incidence in Europe: An international, population-based modeling study., Lancet Reg Health Eur, 2021. 4 (): p. 100074., https://pubmed.ncbi.nlm.nih.gov/34029359/
20. Zeeb, H, Loss, J, Starke, D, Altgeld, T, Moebus, S, Geffert, K, et.al. Public health in Germany: structures, dynamics, and ways forward., Lancet Public Health, 2025. 10 (4)(4): p. e333-e342., https://pubmed.ncbi.nlm.nih.gov/40049182/
21. United States Public Health Service Office of the Surgeon, General, National Center for Chronic Disease, Prevention, Health Promotion Office on, Smoking, Health, Publications and Reports of the Surgeon General, in Smoking Cessation: A Report of the Surgeon General, 2020, US Department of Health and Human Services. ():, https://pubmed.ncbi.nlm.nih.gov/32255575/
22. Toll, BA, Brandon, TH, Gritz, ER, Warren, GW, Herbst, RS, Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement., Clin Cancer Res, 2013. 19 (8)(8): p. 1941-8., https://pubmed.ncbi.nlm.nih.gov/23570694/
23. Gritz, ER, Talluri, R, Fokom Domgue, J, Tami-Maury, I, Shete, S, Smoking Behaviors in Survivors of Smoking-Related and Non-Smoking-Related Cancers., JAMA Netw Open, 2020. 3 (7)(7): p. e209072., https://pubmed.ncbi.nlm.nih.gov/32614423/
24. Caini, S, Del Riccio, M, Vettori, V, Scotti, V, Martinoli, C, Raimondi, S, et.al. Quitting Smoking At or Around Diagnosis Improves the Overall Survival of Lung Cancer Patients: A Systematic Review and Meta-Analysis., J Thorac Oncol, 2022. 17 (5)(5): p. 623-636., https://pubmed.ncbi.nlm.nih.gov/34995798/
25. Klosterhalfen, S, Viechtbauer, W, Kotz, D, Disposable e-cigarettes: Prevalence of use in Germany from 2016 to 2023 and associated user characteristics., Addiction, 2025. 120 (3)(3): p. 557-567., https://pubmed.ncbi.nlm.nih.gov/39488907/
26. Sahu, R, Shah, K, Malviya, R, Paliwal, D, Sagar, S, Singh, S, et.al. E-Cigarettes and Associated Health Risks: An Update on Cancer Potential., Adv Respir Med, 2023. 91 (6)(6): p. 516-531., https://pubmed.ncbi.nlm.nih.gov/37987300/
27. Sanner, T, Grimsrud, TK, Nicotine: Carcinogenicity and Effects on Response to Cancer Treatment - A Review., Front Oncol, 2015. 5 (): p. 196., https://pubmed.ncbi.nlm.nih.gov/26380225/
28. Kundu, A, Sachdeva, K, Feore, A, Sanchez, S, Sutton, M, Seth, S, et.al. Evidence update on the cancer risk of vaping e-cigarettes: A systematic review., Tob Induc Dis, 2025. 23 ():, https://pubmed.ncbi.nlm.nih.gov/39877383/
29. National Academies of Sciences, Engineering, Medicine, Public Health Consequences of E-CigarettesThe National Academies Press, 2018. p. 774., https://nap.nationalacademies.org/catalog/24952/public-health-consequences-of-e-cigarettes
30. Bracken-Clarke, D, Kapoor, D, Baird, AM, Buchanan, PJ, Gately, K, Cuffe, S, et.al. Vaping and lung cancer - A review of current data and recommendations., Lung Cancer, 2021. 153 (): p. 11-20., https://pubmed.ncbi.nlm.nih.gov/33429159/
31. Goldberg Scott, S, Feigelson, HS, Powers, JD, Clennin, MN, Lyons, JA, Gray, MT, et.al. Demographic, Clinical, and Behavioral Factors Associated With Electronic Nicotine Delivery Systems Use in a Large Cohort in the United States., Tob Use Insights, 2023. 16 (): p. 1179173X221134855., https://pubmed.ncbi.nlm.nih.gov/36636234/
32. Bittoni, MA, Carbone, DP, Harris, RE, Vaping, Smoking and Lung Cancer Risk., J Oncol Res Ther, 2024. 9 (3)(3):, https://pubmed.ncbi.nlm.nih.gov/39210964/
33. Zeiher, Johannes, Starker, Anne, Lampert, Thomas, Kuntz, Benjamin, Passivrauchbelastung bei Erwachsenen in DeutschlandRobert Koch-Institut, 2018. p. 72 - 80.
34. Carreras, G, Lugo, A, Gallus, S, Cortini, B, Fernández, E, López, MJ, et.al. Burden of disease attributable to second-hand smoke exposure: A systematic review., Prev Med, 2019. 129 (): p. 105833., https://pubmed.ncbi.nlm.nih.gov/31505203/
35. Raupach, T, Schäfer, K, Konstantinides, S, Andreas, S, Secondhand smoke as an acute threat for the cardiovascular system: a change in paradigm., Eur Heart J, 2006. 27 (4)(4): p. 386-92., https://pubmed.ncbi.nlm.nih.gov/16230308/
36. Bridevaux, PO, Cornuz, J, Gaspoz, JM, Burnand, B, Ackermann-Liebrich, U, Schindler, C, et.al. Secondhand smoke and health-related quality of life in never smokers: results from the SAPALDIA cohort study 2., Arch Intern Med, 2007. 167 (22)(22): p. 2516-23., https://pubmed.ncbi.nlm.nih.gov/18071176/
37. Possenti, I, Romelli, M, Carreras, G, Biffi, A, Bagnardi, V, Specchia, C, et.al. Association between second-hand smoke exposure and lung cancer risk in never-smokers: a systematic review and meta-analysis., Eur Respir Rev, 2024. 33 (174)(174):, https://pubmed.ncbi.nlm.nih.gov/39537242/
38. Elkefi, S, Zeinoun, G, Tounsi, A, Bruzzese, JM, Lelutiu-Weinberger, C, Matthews, AK, Second-Hand Smoke Exposure and Risk of Lung Cancer Among Nonsmokers in the United States: A Systematic Review and Meta-Analysis., Int J Environ Res Public Health, 2025. 22 (4)(4):, https://pubmed.ncbi.nlm.nih.gov/40283819/
39. Frazer, K, Callinan, JE, McHugh, J, van Baarsel, S, Clarke, A, Doherty, K, et.al. Legislative smoking bans for reducing harms from secondhand smoke exposure, smoking prevalence and tobacco consumption., Cochrane Database Syst Rev, 2016. 2 (2)(2): p. CD005992., https://pubmed.ncbi.nlm.nih.gov/26842828/
40. Pesch B., Jöckel K. H., Wichmann H. E., Luftverunreinigung und Lungenkrebs, Biometrie und Epidemiologie in der Medizin und Biologie, 1995. p. 134-153.
41. Who, Air Quality Guidelines Global Update 2005, WHO Copenhagen, 2006.
42. Agency, Us-Epa Environmental Protection, Air Quality Criteria for Particulate Matter, EPA/600/P-99/D02bF, Washington 2004, 2004.
43. Berg, CD, Schiller, JH, Boffetta, P, Cai, J, Connolly, C, Kerpel-Fronius, A, et.al. Air Pollution and Lung Cancer: A Review by International Association for the Study of Lung Cancer Early Detection and Screening Committee., J Thorac Oncol, 2023. 18 (10)(10): p. 1277-1289., https://pubmed.ncbi.nlm.nih.gov/37277094/
44. Darby, S., Hill, D., Auvinen, A., Barros-Dios, J. M., Baysson, H., Bochicchio, F., et.al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies, BMJ, 2005. 330(7485): p. 223., https://www.ncbi.nlm.nih.gov/pubmed/15613366
45. Bundeswehr, Informationen zur Strahlung von Radargeräten der Bundeswehr und der ehemaligen Nationalen Volksarmee sowie zu möglichen Ansprüchen in diesem Zusammenhang, 2008.
46. Bruske-Hohlfeld, I., Mohner, M., Ahrens, W., Pohlabeln, H., Heinrich, J., Kreuzer, M., et.al. Lung cancer risk in male workers occupationally exposed to diesel motor emissions in Germany, Am.J Ind.Med, 1999. 36(4): p. 405-414., https://pubmed.ncbi.nlm.nih.gov/10470005/
47. Bhatia, R., Lopipero, P., Smith, A. H., Diesel exhaust exposure and lung cancer, Epidemiology, 1998. 9(1): p. 84-91., https://www.ncbi.nlm.nih.gov/pubmed/9430274
48. Benbrahim-Tallaa, L., Baan, R. A., Grosse, Y., Lauby-Secretan, B., El Ghissassi, F., Bouvard, V., et.al. Carcinogenicity of diesel-engine and gasoline-engine exhausts and some nitroarenes, Lancet Oncol, 2012. 13(7): p. 663-4., https://www.ncbi.nlm.nih.gov/pubmed/22946126
49. Romero Starke, K, Bolm-Audorff, U, Reissig, D, Seidler, A, Dose-response-relationship between occupational exposure to diesel engine emissions and lung cancer risk: A systematic review and meta-analysis., Int J Hyg Environ Health, 2024. 256 (): p. 114299., https://pubmed.ncbi.nlm.nih.gov/38194821/
50. International Agency for Research on Cancer, Monographs Volume 2: Some Inorganic and Organometallic Compounds. Lyon, World Health Organization, 1973.
51. International Agency for Research on, Cancer, Monographs Volume 14: Asbestos. Lyon, World Health Organization, 1977.
52. (HVBG), Hauptverband der gewerblichen Berufsgenossenschaften, Faserjahre. Berufsgenossenschaftliche Hinweise zur Ermittlung der kumulativen Asbestfaserstaubdosis am Arbeitsplatz (Faserjahre) und Bearbeitungshinweise zur Berufskrankheit Nr. 4101 Lungenkrebs oder Kehlkopfkrebs, in BK-Report 1/2007, 2007: St. Augustin.
53. Drechsel-Schlund, C., Butz, M., Haupt, B., et al., Asbestverursachte Berufskrankheiten in Deutschland - Entstehung und Prognose. Hauptverband der gewerblichen Berufsgenossenschaften (HVBG), http://www.hvbg.de/d/pages/statist/brosch/asbest1.pdf, 2003.
54. International Agency for Research on, Cancer, Monographs Volume 33: Polynuclear Aromatic Hydrocarbons, Part 2, Carbon Blacks, Mineral Oils (Lubricant Base Oils and Derived Products) and Some Nitroarenes. Lyon, World Health Organization, 1983.
55. International Agency for Research on, Cancer, Monographs Volume 34: Polynuclear Aromatic Compounds Part 3, Industrial Exposures in Aluminium Production, Coal Gasification, Coke Production, and Iron and Steel Founding. Lyon, World Health Organization, 1984.
56. International Agency for Research on, Cancer, Monographs Volume 35: Polynuclear Aromatic Compounds Part 4, Bitumens, Coal-tars and Derived Products, Shale-oils and Soots. Lyon, World Health Organization, 1985.
57. International Agency for Research on, Cancer, Monographs Volume 68: Silica. Lyon, World Health Organization, 1997.
58. International Agency for Research on, Cancer, Monographs Volume 23: Some Metals and Metallic Compounds. Lyon, World Health Organization, 1980.
59. Wichmann H. E., Positive gesundheitliche Auswirkungen des Einsatzes von Partikelfiltern bei Dieselfahrzeugen - Risikoabschätzung für die Mortalität in Deutschland, Umweltmedizin in Forschung und Praxis, 2004. 9: p. 85-99.
60. Figueroa, W. G., Raszkowski, R. W., Lung cancer in chloromethyl methylether workers, N Engl J Med, 1973. 288: p. 1096-1097., https://www.ncbi.nlm.nih.gov/pubmed/4727973
61. Thiess, A. M., Hey, W., Zeller, H., Zur Toxikologie von Dichlordimethyl„ther - Verdacht auf kanzerogene Wirkung auch beim Menschen, Zbl Arbeitsmed Arbeitsschutz, 1973. 23: p. 97-102., https://pubmed.ncbi.nlm.nih.gov/4751658/
62. International Agency for Research on, Cancer, Monographs Volume 58: Beryllium, Cadmium, Mercury, and Exposures in the Glass Manufacturing Industry. Lyon, World Health Organization, 1993.
63. International Agency for Research on Cancer, Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 86, Cobalt in Hard Metals and Cobalt Sulfate, Gallium Arsenide, Indium Phosphide and Vanadium Pentoxide. Lyon, World Health Organization, 2006., https://pubmed.ncbi.nlm.nih.gov/16906675/
64. GBIA, Berufsgenossenschaftliches Institut für Arbeitsschutz (BGIA), 2006.
65. Ang, L, Chan, CPY, Yau, WP, Seow, WJ, Association between family history of lung cancer and lung cancer risk: a systematic review and meta-analysis., Lung Cancer, 2020. 148 (): p. 129-137., https://pubmed.ncbi.nlm.nih.gov/32892102/
66. Caini, S, Gorini, G, Del Riccio, M, Saieva, C, Carreras, G, Bonomo, P, et.al. Upgrading your best chances: postdiagnosis smoking cessation boosts life expectancy of patients with cancer - a systematic review and meta-analysis., Tob Control, 2025. ():, https://pubmed.ncbi.nlm.nih.gov/39762052/
67. Lai, H, Liu, Q, Ye, Q, Liang, Z, Long, Z, Hu, Y, et.al. Impact of smoking cessation duration on lung cancer mortality: A systematic review and meta-analysis., Crit Rev Oncol Hematol, 2024. 196 (): p. 104323., https://pubmed.ncbi.nlm.nih.gov/38462148/
68. Allbright, K, Villandre, J, Crotty Alexander, LE, Zhang, M, Benam, KH, Evankovich, J, et.al. The paradox of the safer cigarette: understanding the pulmonary effects of electronic cigarettes., Eur Respir J, 2024. 63 (6)(6):, https://pubmed.ncbi.nlm.nih.gov/38609098/
69. Mohapatra, S, Tiwari, A, Kandala, A, Winayak, R, Ghose, A, Das, R, et.al. The risk of lung cancer from vaping or e-cigarette usage: a systematic review., ESMO Open, 2025. 10 (12)(12): p. 105910., https://pubmed.ncbi.nlm.nih.gov/41259896/
70. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report., Am J Prev Med, 2008. 35 (2)(2): p. 158-76., https://pubmed.ncbi.nlm.nih.gov/18617085/
71. Gemine, RE, Davies, GR, Lanyon, K, Rees, SE, Campbell, I, Lewis, KE, Quitting smoking improves two-year survival after a diagnosis of non-small cell lung cancer., Lung Cancer, 2023. 186 (): p. 107388., https://pubmed.ncbi.nlm.nih.gov/37820539/
72. Cinciripini, PM, Kypriotakis, G, Blalock, JA, Karam-Hage, M, Beneventi, DM, Robinson, JD, et.al. Survival Outcomes of an Early Intervention Smoking Cessation Treatment After a Cancer Diagnosis., JAMA Oncol, 2024. 10 (12)(12): p. 1689-1696., https://pubmed.ncbi.nlm.nih.gov/39480450/
73. Frazer, K, Bhardwaj, N, Fox, P, Stokes, D, Niranjan, V, Quinn, S, et.al. Systematic Review of Smoking Cessation Interventions for Smokers Diagnosed with Cancer., Int J Environ Res Public Health, 2022. 19 (24)(24):, https://pubmed.ncbi.nlm.nih.gov/36554894/
74. McRobbie, H, Bullen, C, Glover, M, Whittaker, R, Wallace-Bell, M, Fraser, T, New Zealand smoking cessation guidelines., N Z Med J, 2008. 121 (1276)(1276): p. 57-70., https://pubmed.ncbi.nlm.nih.gov/18574510/
75. Lindson, N, Theodoulou, A, Ordóñez-Mena, JM, Fanshawe, TR, Sutton, AJ, Livingstone-Banks, J, et.al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses., Cochrane Database Syst Rev, 2023. 9 (9)(9): p. CD015226., https://pubmed.ncbi.nlm.nih.gov/37696529/
76. Selbach, C, Siebel, C, Lilienthal, J, Grouven, U, Knelangen, M, Kastaun, S, et.al. Weaning From Tobacco with Nicotine or Varenicline in Severe and Mild Tobacco Dependence—Findings of a Meta-Analysis., Dtsch Arztebl Int, 2025. 122 (1)(1): p. 7-11., https://pubmed.ncbi.nlm.nih.gov/39628402/
77. Jose, T, Schroeder, DR, Warner, DO, Changes in Cigarette Smoking Behavior in Cancer Survivors During Diagnosis and Treatment., Nicotine Tob Res, 2022. 24 (10)(10): p. 1581-1588., https://pubmed.ncbi.nlm.nih.gov/35311999/
78. Streck, JM, Rigotti, NA, Livingstone-Banks, J, Tindle, HA, Clair, C, Munafò, MR, et.al. Interventions for smoking cessation in hospitalised patients., Cochrane Database Syst Rev, 2024. 5 (5)(5): p. CD001837., https://pubmed.ncbi.nlm.nih.gov/38770804/
79. Halms, T, Strasser, M, Hasan, A, Rüther, T, Trepel, M, Raab, S, et.al. Smoking and quality of life in lung cancer patients: systematic review., BMJ Support Palliat Care, 2024. 13 (e3)(e3): p. e686-e694., https://pubmed.ncbi.nlm.nih.gov/37607808/
80. Zeng, L, Yu, X, Yu, T, Xiao, J, Huang, Y, Interventions for smoking cessation in people diagnosed with lung cancer., Cochrane Database Syst Rev, 2019. 6 (6)(6): p. CD011751., https://pubmed.ncbi.nlm.nih.gov/31173336/
81. Pipe, AL, Evans, W, Papadakis, S, Smoking cessation: health system challenges and opportunities., Tob Control, 2022. 31 (2)(2): p. 340-347., https://pubmed.ncbi.nlm.nih.gov/35241609/
82. Glantz, SA, Nguyen, N, Oliveira da Silva, AL, Population-Based Disease Odds for E-Cigarettes and Dual Use versus Cigarettes., NEJM Evid, 2024. 3 (3)(3): p. EVIDoa2300229., https://pubmed.ncbi.nlm.nih.gov/38411454/
83. Piñeiro, B, Simmons, VN, Palmer, AM, Correa, JB, Brandon, TH, Smoking cessation interventions within the context of Low-Dose Computed Tomography lung cancer screening: A systematic review., Lung Cancer, 2016. 98 (): p. 91-98., https://pubmed.ncbi.nlm.nih.gov/27393513/
84. Cadham, CJ, Jayasekera, JC, Advani, SM, Fallon, SJ, Stephens, JL, Braithwaite, D, et.al. Smoking cessation interventions for potential use in the lung cancer screening setting: A systematic review and meta-analysis., Lung Cancer, 2019. 135 (): p. 205-216., https://pubmed.ncbi.nlm.nih.gov/31446996/
85. Iaccarino, JM, Duran, C, Slatore, CG, Wiener, RS, Kathuria, H, Combining smoking cessation interventions with LDCT lung cancer screening: A systematic review., Prev Med, 2019. 121 (): p. 24-32., https://pubmed.ncbi.nlm.nih.gov/30753860/
86. Huang, S, Tang, O, Zheng, X, Li, H, Wu, Y, Yang, L, Effectiveness of smoking cessation on the high-risk population of lung cancer with early screening: a systematic review and meta-analysis of randomized controlled trials until January 2022., Arch Public Health, 2023. 81 (1)(1): p. 101., https://pubmed.ncbi.nlm.nih.gov/37268972/
87. Moldovanu, D, de Koning, HJ, van der Aalst, CM, Lung cancer screening and smoking cessation efforts., Transl Lung Cancer Res, 2021. 10 (2)(2): p. 1099-1109., https://pubmed.ncbi.nlm.nih.gov/33718048/
88. Steliga, MA, Yang, P, Integration of smoking cessation and lung cancer screening., Transl Lung Cancer Res, 2019. 8 (Suppl 1)(Suppl 1): p. S88-S94., https://pubmed.ncbi.nlm.nih.gov/31211109/
89. Taylor, KL, Hagerman, CJ, Luta, G, Bellini, PG, Stanton, C, Abrams, DB, et.al. Preliminary evaluation of a telephone-based smoking cessation intervention in the lung cancer screening setting: A randomized clinical trial., Lung Cancer, 2017. 108 (): p. 242-246., https://pubmed.ncbi.nlm.nih.gov/28216065/
90. Taylor, KL, Williams, RM, Li, T, Luta, G, Smith, L, Davis, KM, et.al. A Randomized Trial of Telephone-Based Smoking Cessation Treatment in the Lung Cancer Screening Setting., J Natl Cancer Inst, 2022. 114 (10)(10): p. 1410-1419., https://pubmed.ncbi.nlm.nih.gov/35818122/
91. Pastorino, U, Ladisa, V, Trussardo, S, Sabia, F, Rolli, L, Valsecchi, C, et.al. Cytisine Therapy Improved Smoking Cessation in the Randomized Screening and Multiple Intervention on Lung Epidemics Lung Cancer Screening Trial., J Thorac Oncol, 2022. 17 (11)(11): p. 1276-1286., https://pubmed.ncbi.nlm.nih.gov/35908731/
92. Lococo, F, Cardillo, G, Veronesi, G, Does a lung cancer screening programme promote smoking cessation?, Thorax, 2017. 72 (10)(10): p. 870-871., https://pubmed.ncbi.nlm.nih.gov/28747323/
93. Fucito, Lisa M, Czabafy, Sharon, Hendricks, Peter S, Kotsen, Chris, Richardson, Donna, Toll, Benjamin A, et.al. Pairing smoking-cessation services with lung cancer screening: A clinical guideline from the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco., Cancer, 2016., https://www.ncbi.nlm.nih.gov/pubmed/26916412
94. Minnix, JA, Karam-Hage, M, Blalock, JA, Cinciripini, PM, The importance of incorporating smoking cessation into lung cancer screening., Transl Lung Cancer Res, 2018. 7 (3)(3): p. 272-280., https://pubmed.ncbi.nlm.nih.gov/30050765/
95. Joseph, AM, Rothman, AJ, Almirall, D, Begnaud, A, Chiles, C, Cinciripini, PM, et.al. Lung Cancer Screening and Smoking Cessation Clinical Trials. SCALE (Smoking Cessation within the Context of Lung Cancer Screening) Collaboration., Am J Respir Crit Care Med, 2018. 197 (2)(2): p. 172-182., https://pubmed.ncbi.nlm.nih.gov/28977754/
96. Heiden, BT, Eaton, DB, Chang, SH, Yan, Y, Schoen, MW, Chen, LS, et.al. Assessment of Duration of Smoking Cessation Prior to Surgical Treatment of Non-small Cell Lung Cancer., Ann Surg, 2023. 277 (4)(4): p. e933-e940., https://pubmed.ncbi.nlm.nih.gov/34793352/
97. Mills, E, Eyawo, O, Lockhart, I, Kelly, S, Wu, P, Ebbert, JO, Smoking cessation reduces postoperative complications: a systematic review and meta-analysis., Am J Med, 2011. 124 (2)(2): p. 144-154.e8., https://pubmed.ncbi.nlm.nih.gov/21295194/
98. Fiddes, RA, McCaffrey, N, Preoperative Smoking-Cessation Interventions to Prevent Postoperative Complications: A Quality Assessment and Overview of Systematic Review Evidence., Anesth Analg, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/39466689/
99. Lindström, D, Sadr Azodi, O, Wladis, A, Tønnesen, H, Linder, S, Nåsell, H, et.al. Effects of a perioperative smoking cessation intervention on postoperative complications: a randomized trial., Ann Surg, 2008. 248 (5)(5): p. 739-45., https://pubmed.ncbi.nlm.nih.gov/18948800/
100. Batchelor, TJP, Rasburn, NJ, Abdelnour-Berchtold, E, Brunelli, A, Cerfolio, RJ, Gonzalez, M, et.al. Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS®) Society and the European Society of Thoracic Surgeons (ESTS)., Eur J Cardiothorac Surg, 2019. 55 (1)(1): p. 91-115., https://pubmed.ncbi.nlm.nih.gov/30304509/
101. Neudecker, J, Andreas, MN, Lask, A, Strauchmann, J, Elsner, A, Rückert, JC, et.al. [ERAS Implementation in Thoracic Surgery]., Zentralbl Chir, 2025. 150 (1)(1): p. 88-97., https://pubmed.ncbi.nlm.nih.gov/38604234/
102. Rupp, A, Sohrab, S, Pankow, W, Raspe, M, Kotz, D, Rustler, C, et.al. [Implementation of smoking cessation in the workflow of a lung cancer screening program in Germany - A Position Paper of the German Respiratory Society (DGP)]., Pneumologie, 2024. 78 (9)(9): p. 612-619., https://pubmed.ncbi.nlm.nih.gov/39019465/
103. Ratner, PA, Johnson, JL, Richardson, CG, Bottorff, JL, Moffat, B, Mackay, M, et.al. Efficacy of a smoking-cessation intervention for elective-surgical patients., Res Nurs Health, 2004. 27 (3)(3): p. 148-61., https://pubmed.ncbi.nlm.nih.gov/15141368/
104. Vu, JV, Lussiez, A, Smoking Cessation for Preoperative Optimization., Clin Colon Rectal Surg, 2023. 36 (3)(3): p. 175-183., https://pubmed.ncbi.nlm.nih.gov/37113283/
105. Fox, J. L., Rosenzweig, K. E., Ostroff, J. S., The effect of smoking status on survival following radiation therapy for non-small cell lung cancer, Lung Cancer, 2004. 44(3): p. 287-293., https://www.ncbi.nlm.nih.gov/pubmed/15140541
106. Nguyen, SK, Masson-Côté, L, Fortin, A, Dagnault, A, Influence of smoking status on treatment outcomes after post-operative radiation therapy for non-small-cell lung cancer., Radiother Oncol, 2010. 96 (1)(1): p. 89-93., https://pubmed.ncbi.nlm.nih.gov/20541274/
107. Roach, MC, Rehman, S, DeWees, TA, Abraham, CD, Bradley, JD, Robinson, CG, It's never too late: Smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival., Pract Radiat Oncol, 2016. 6 (1)(1): p. 12-8., https://pubmed.ncbi.nlm.nih.gov/26598909/
108. Sheikh, M, Mukeriya, A, Shangina, O, Brennan, P, Zaridze, D, Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality : A Prospective Cohort Study., Ann Intern Med, 2021. 174 (9)(9): p. 1232-1239., https://pubmed.ncbi.nlm.nih.gov/34310171/
109. Rades, D, Setter, C, Schild, SE, Dunst, J, Effect of smoking during radiotherapy, respiratory insufficiency, and hemoglobin levels on outcome in patients irradiated for non-small-cell lung cancer., Int J Radiat Oncol Biol Phys, 2008. 71 (4)(4): p. 1134-42., https://pubmed.ncbi.nlm.nih.gov/18258387/
110. Videtic, G. M., Stitt, L. W., Dar, A. R., Kocha, W. I., Tomiak, A. T., Truong, P. T., et.al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival, J Clin Oncol, 2003. 21(8): p. 1544-1549., https://www.ncbi.nlm.nih.gov/pubmed/12697879
111. Gritz, E. R., Dresler, C., Sarna, L., Smoking, the missing drug interaction in clinical trials: ignoring the obvious, Cancer Epidemiol Biomarkers Prev, 2005. 14(10): p. 2287-2293., https://www.ncbi.nlm.nih.gov/pubmed/16214906
112. Sarihan, S., Ercan, I., Saran, A., Cetintas, S. K., Akalin, H., Engin, K., Evaluation of infections in non-small cell lung cancer patients treated with radiotherapy, Cancer Detect.Prev, 2005. 29(2): p. 181-188., https://www.ncbi.nlm.nih.gov/pubmed/15829379
113. Monson, J. M., Stark, P., Reilly, J. J., Sugarbaker, D. J., Strauss, G. M., Swanson, S. J., et.al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma, Cancer, 1998. 82(5): p. 842-850., https://www.ncbi.nlm.nih.gov/pubmed/9486572
114. Kawaguchi, T, Matsumura, A, Iuchi, K, Ishikawa, S, Maeda, H, Fukai, S, et.al. Second primary cancers in patients with stage III non-small cell lung cancer successfully treated with chemo-radiotherapy., Jpn J Clin Oncol, 2006. 36 (1)(1): p. 7-11., https://pubmed.ncbi.nlm.nih.gov/16368713/
115. Condoluci, A, Mazzara, C, Zoccoli, A, Pezzuto, A, Tonini, G, Impact of smoking on lung cancer treatment effectiveness: a review., Future Oncol, 2016. 12 (18)(18): p. 2149-61., https://pubmed.ncbi.nlm.nih.gov/27424719/
116. Perlík, F, Impact of smoking on metabolic changes and effectiveness of drugs used for lung cancer., Cent Eur J Public Health, 2020. 28 (1)(1): p. 53-58., https://pubmed.ncbi.nlm.nih.gov/32228818/
117. O'Malley, M, King, AN, Conte, M, Ellingrod, VL, Ramnath, N, Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer., J Thorac Oncol, 2014. 9 (7)(7): p. 917-926., https://pubmed.ncbi.nlm.nih.gov/24926542/
118. Garces, YI, Yang, P, Parkinson, J, Zhao, X, Wampfler, JA, Ebbert, JO, et.al. The relationship between cigarette smoking and quality of life after lung cancer diagnosis., Chest, 2004. 126 (6)(6): p. 1733-41., https://pubmed.ncbi.nlm.nih.gov/15596667/
119. Lu, JF, Eppler, SM, Wolf, J, Hamilton, M, Rakhit, A, Bruno, R, et.al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer., Clin Pharmacol Ther, 2006. 80 (2)(2): p. 136-45., https://pubmed.ncbi.nlm.nih.gov/16890575/
120. Norum, J, Nieder, C, Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature., ESMO Open, 2018. 3 (6)(6): p. e000406., https://pubmed.ncbi.nlm.nih.gov/30305940/
121. Luo, D, Yang, D, Cao, D, Gong, Z, He, F, Hou, Y, et.al. Effect of smoking status on immunotherapy for lung cancer: a systematic review and meta-analysis., Front Oncol, 2024. 14 (): p. 1422160., https://pubmed.ncbi.nlm.nih.gov/39439965/
122. Dai, L, Jin, B, Liu, T, Chen, J, Li, G, Dang, J, The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis., EClinicalMedicine, 2021. 38 (): p. 100990., https://pubmed.ncbi.nlm.nih.gov/34505024/
123. Corke, LK, Li, JJN, Leighl, NB, Eng, L, Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer., Curr Oncol, 2022. 29 (9)(9): p. 6260-6276., https://pubmed.ncbi.nlm.nih.gov/36135061/
124. Cortellini, A, De Giglio, A, Cannita, K, Cortinovis, DL, Cornelissen, R, Baldessari, C, et.al. Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study., Thorac Cancer, 2021. 12 (6)(6): p. 880-889., https://pubmed.ncbi.nlm.nih.gov/33527756/
125. Reck, M., Rodriguez-Abreu, D., Robinson, A. G., Hui, R., Csoszi, T., Fulop, A., et.al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, 2016., https://www.ncbi.nlm.nih.gov/pubmed/27718847
126. Aredo, JV, Luo, SJ, Gardner, RM, Sanyal, N, Choi, E, Hickey, TP, et.al. Tobacco Smoking and Risk of Second Primary Lung Cancer., J Thorac Oncol, 2021. 16 (6)(6): p. 968-979., https://pubmed.ncbi.nlm.nih.gov/33722709/
127. Luo, SJ, Choi, E, Aredo, JV, Wilkens, LR, Tammemägi, MC, Le Marchand, L, et.al. Smoking Cessation After Lung Cancer Diagnosis and the Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study., JNCI Cancer Spectr, 2021. 5 (5)(5):, https://pubmed.ncbi.nlm.nih.gov/34611582/
128. Phua, ZJ, MacInnis, RJ, Jayasekara, H, Cigarette smoking and risk of second primary cancer: a systematic review and meta-analysis., Cancer Epidemiol, 2022. 78 (): p. 102160., https://pubmed.ncbi.nlm.nih.gov/35430427/
129. Mao, Y., Pan, S., Wen, S. W., Johnson, K. C., Physical activity and the risk of lung cancer in Canada, Am.J Epidemiol, 2003. 158(6): p. 564-575., https://pubmed.ncbi.nlm.nih.gov/12965882/
130. Lee, I. M., Sesso, H. D., Paffenbarger, R. S., Jr., Physical activity and risk of lung cancer, Int J Epidemiol, 1999. 28(4): p. 620-625., https://www.ncbi.nlm.nih.gov/pubmed/10480687
131. Thune, I., Lund, E., The influence of physical activity on lung-cancer risk: A prospective study of 81,516 men and women, Int J Cancer, 1997. 70(1): p. 57-62., https://www.ncbi.nlm.nih.gov/pubmed/8985091
132. Skuladottir, H., Tjoenneland, A., Overvad, K., Stripp, C., Christensen, J., Raaschou-Nielsen, O., et.al. Does insufficient adjustment for smoking explain the preventive effects of fruit and vegetables on lung cancer?, Lung Cancer, 2004. 45(1): p. 1-10., https://www.ncbi.nlm.nih.gov/pubmed/15196728
133. Wright, M. E., Mayne, S. T., Swanson, C. A., Sinha, R., Alavanja, M. C., Dietary carotenoids, vegetables, and lung cancer risk in women: the Missouri women's health study (United States), Cancer Causes Control, 2003. 14(1): p. 85-96., https://www.ncbi.nlm.nih.gov/pubmed/12708729
134. Holick, C. N., Michaud, D. S., Stolzenberg-Solomon, R., Mayne, S. T., Pietinen, P., Taylor, P. R., et.al. Dietary carotenoids, serum beta-carotene, and retinol and risk of lung cancer in the alpha-tocopherol, beta-carotene cohort study, Am J Epidemiol, 2002. 156(6): p. 536-547., https://pubmed.ncbi.nlm.nih.gov/12226001/
135. Neuhouser, M. L., Patterson, R. E., Thornquist, M. D., Omenn, G. S., King, I. B., Goodman, G. E., Fruits and vegetables are associated with lower lung cancer risk only in the placebo arm of the beta-carotene and retinol efficacy trial (CARET), Cancer Epidemiol.Biomarkers Prev., 2003. 12(4): p. 350-358., https://www.ncbi.nlm.nih.gov/pubmed/12692110
136. Feskanich, D., Ziegler, R. G., Michaud, D. S., Giovannucci, E. L., Speizer, F. E., Willett, W. C., et.al. Prospective study of fruit and vegetable consumption and risk of lung cancer among men and women, J Natl.Cancer Inst., 2000. 92(22): p. 1812-1823., https://www.ncbi.nlm.nih.gov/pubmed/11078758
137. Miller, A. B., Altenburg, H. P., Bueno-de-Mesquita, B., Boshuizen, H. C., Agudo, A., Berrino, F., et.al. Fruits and vegetables and lung cancer: Findings from the European Prospective Investigation into Cancer and Nutrition, Int.J.Cancer, 2004. 108(2): p. 269-276., https://www.ncbi.nlm.nih.gov/pubmed/14639614
138. Smith-Warner, S. A., Spiegelman, D., Yaun, S. S., Albanes, D., Beeson, W. L., van den Brandt, P. A., et.al. Fruits, vegetables and lung cancer: a pooled analysis of cohort studies, Int J Cancer, 2003. 107(6): p. 1001-1011., https://www.ncbi.nlm.nih.gov/pubmed/14601062
139. Peto, R., Doll, R., Buckley, J. D., Sporn, M. B., Can dietary beta-carotene materially reduce human cancer rates?, Nature, 1981. 290(5803): p. 201-208., https://www.ncbi.nlm.nih.gov/pubmed/7010181
140. Bond, G. G., Thompson, F. E., Cook, R. R., Dietary vitamin A and lung cancer: results of a case-control study among chemical workers, Nutr.Cancer, 1987. 9(2-3): p. 109-121., https://www.ncbi.nlm.nih.gov/pubmed/3562289
141. Brennan, P., Fortes, C., Butler, J., Agudo, A., Benhamou, S., Darby, S., et.al. A multicenter case-control study of diet and lung cancer among non-smokers, Cancer Causes Control, 2000. 11(1): p. 49-58., https://www.ncbi.nlm.nih.gov/pubmed/10680729
142. Hu, J., Mao, Y., Dryer, D., White, K., Risk factors for lung cancer among Canadian women who have never smoked, Cancer Detect.Prev, 2002. 26(2): p. 129-138., https://www.ncbi.nlm.nih.gov/pubmed/12102147
143. Zhuo, H., Smith, A. H., Steinmaus, C., Selenium and lung cancer: a quantitative analysis of heterogeneity in the current epidemiological literature, Cancer Epidemiol.Biomarkers Prev., 2004. 13(5): p. 771-778., https://www.ncbi.nlm.nih.gov/pubmed/15159309
144. De, Stefani E., Brennan, P., Boffetta, P., Mendilaharsu, M., eo-Pellegrini, H., Ronco, A., et.al. Diet and adenocarcinoma of the lung: a case-control study in Uruguay, Lung Cancer, 2002. 35(1): p. 43-51., https://www.ncbi.nlm.nih.gov/pubmed/11750712
145. Knekt, P., Jarvinen, R., Teppo, L., Aromaa, A., Seppanen, R., Role of various carotenoids in lung cancer prevention, J Natl.Cancer Inst., 1999. 91(2): p. 182-184., https://www.ncbi.nlm.nih.gov/pubmed/9923861
146. Mannisto, S., Smith-Warner, S. A., Spiegelman, D., Albanes, D., Anderson, K., van den Brandt, P. A., et.al. Dietary carotenoids and risk of lung cancer in a pooled analysis of seven cohort studies, Cancer Epidemiol.Biomarkers Prev., 2004. 13(1): p. 40-48., https://www.ncbi.nlm.nih.gov/pubmed/14744731
147. Wright, M. E., Mayne, S. T., Stolzenberg-Solomon, R. Z., Li, Z., Pietinen, P., Taylor, P. R., et.al. Development of a comprehensive dietary antioxidant index and application to lung cancer risk in a cohort of male smokers, Am.J.Epidemiol., 2004. 160(1): p. 68-76., https://www.ncbi.nlm.nih.gov/pubmed/15229119
148. Comstock, G. W., Alberg, A. J., Huang, H. Y., Wu, K., Burke, A. E., Hoffman, S. C., et.al. The risk of developing lung cancer associated with antioxidants in the blood: ascorbic acid, carotenoids, alpha-tocopherol, selenium, and total peroxyl radical absorbing capacity, Cancer Epidemiol Biomarkers Prev, 1997. 6(11): p. 907-916., https://www.ncbi.nlm.nih.gov/pubmed/9367064
149. Yuan, J. M., Ross, R. K., Chu, X. D., Gao, Y. T., Yu, M. C., Prediagnostic levels of serum beta-cryptoxanthin and retinol predict smoking-related lung cancer risk in Shanghai, China, Cancer Epidemiol Biomarkers Prev, 2001. 10(7): p. 767-773., https://www.ncbi.nlm.nih.gov/pubmed/11440962
150. Michaud, D. S., Feskanich, D., Rimm, E. B., Colditz, G. A., Speizer, F. E., Willett, W. C., et.al. Intake of specific carotenoids and risk of lung cancer in 2 prospective US cohorts, Am J Clin Nutr., 2000. 72(4): p. 990-997., https://www.ncbi.nlm.nih.gov/pubmed/11010942
151. American Institute for Cancer, Research, Food, nutrition, and the prevention of cancer: a global perspective. Washington, DC:, World Cancer Research Fund, American Institute for Cancer Research, 1997., https://www.ncbi.nlm.nih.gov/pubmed/10378216
152. Hartman, T. J., Woodson, K., Stolzenberg-Solomon, R., Virtamo, J., Selhub, J., Barrett, M. J., et.al. Association of the B-vitamins pyridoxal 5'-phosphate (B(6)), B(12), and folate with lung cancer risk in older men, Am.J.Epidemiol., 2001. 153(7): p. 688-694., https://www.ncbi.nlm.nih.gov/pubmed/11282797
153. Spitz, M. R., Duphorne, C. M., Detry, M. A., Pillow, P. C., Amos, C. I., Lei, L., et.al. Dietary intake of isothiocyanates: evidence of a joint effect with glutathione S-transferase polymorphisms in lung cancer risk, Cancer Epidemiol Biomarkers Prev, 2000. 9(10): p. 1017-1020., https://www.ncbi.nlm.nih.gov/pubmed/11045782
154. Zhao, B., Seow, A., Lee, E. J., Poh, W. T., Teh, M., Eng, P., et.al. Dietary isothiocyanates, glutathione S-transferase -M1, -T1 polymorphisms and lung cancer risk among Chinese women in Singapore, Cancer Epidemiol Biomarkers Prev, 2001. 10(10): p. 1063-1067., https://pubmed.ncbi.nlm.nih.gov/11588132/
155. London, S. J., Yuan, J. M., Chung, F. L., Gao, Y. T., Coetzee, G. A., Ross, R. K., et.al. Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms, and lung-cancer risk: a prospective study of men in Shanghai, China, Lancet, 2000. 356(9231): p. 724-729., https://www.ncbi.nlm.nih.gov/pubmed/11085692
156. Hirvonen, T., Virtamo, J., Korhonen, P., Albanes, D., Pietinen, P., Flavonol and flavone intake and the risk of cancer in male smokers (Finland), Cancer Causes Control, 2001. 12(9): p. 789-796., https://www.ncbi.nlm.nih.gov/pubmed/11714106
157. Le, Marchand L., Cancer preventive effects of flavonoids--a review, Biomed.Pharmacother., 2002. 56(6): p. 296-301., https://www.ncbi.nlm.nih.gov/pubmed/12224601
158. Neuhouser, M. L., Dietary flavonoids and cancer risk: evidence from human population studies, Nutr.Cancer, 2004. 50(1): p. 1-7., https://www.ncbi.nlm.nih.gov/pubmed/15572291
159. Fleischauer, A. T., Arab, L., Garlic and cancer: a critical review of the epidemiologic literature, J.Nutr., 2001. 131(3s): p. 1032S-1040S., https://www.ncbi.nlm.nih.gov/pubmed/11238811
160. Korte, J. E., Brennan, P., Henley, S. J., Boffetta, P., Dose-specific meta-analysis and sensitivity analysis of the relation between alcohol consumption and lung cancer risk, Am.J.Epidemiol., 2002. 155(6): p. 496-506., https://www.ncbi.nlm.nih.gov/pubmed/11882523
161. Olson, J. E., Yang, P., Schmitz, K., Vierkant, R. A., Cerhan, J. R., Sellers, T. A., Differential association of body mass index and fat distribution with three major histologic types of lung cancer: evidence from a cohort of older women, Am J Epidemiol, 2002. 156(7): p. 606-615., https://www.ncbi.nlm.nih.gov/pubmed/12244029
162. Kelley, M. J., McCrory, D. C., Prevention of lung cancer: summary of published evidence, Chest, 2003. 123(1 Suppl): p. 50S-59S., https://www.ncbi.nlm.nih.gov/pubmed/12527564
163. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group, The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers, N Engl J Med, 2004. 330: p. 1029-1035., https://www.ncbi.nlm.nih.gov/pubmed/8127329
164. Blumberg, J., Block, G., The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study in Finland, Nutr.Rev., 1994. 52(7): p. 242-245., https://www.ncbi.nlm.nih.gov/pubmed/8090376
165. Hennekens, C. H., Buring, J. E., Manson, J. E., Stampfer, M., Rosner, B., Cook, N. R., et.al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease, N Engl J Med, 1996. 334(18): p. 1145-1149., https://www.ncbi.nlm.nih.gov/pubmed/8602179
166. Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J., Cullen, M. R., Glass, A., et.al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease, N Engl J Med, 1996. 334(18): p. 1150-1155., https://www.ncbi.nlm.nih.gov/pubmed/8602180
167. Cook, N. R., Lee, I. M., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., et.al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial, JAMA, 2005. 294(1): p. 47-55., https://www.ncbi.nlm.nih.gov/pubmed/15998890
168. Steering Committee of the Physicians' Health Study Research, Group, Final report on the aspirin component of the ongoing Physicians' Health Study, N Engl J Med, 1989. 321: p. 129-135., https://www.ncbi.nlm.nih.gov/pubmed/2664509
169. Lippman, S. M., Lee, J. J., Karp, D. D., Vokes, E. E., Benner, S. E., Goodman, G. E., et.al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer, J.Natl.Cancer Inst., 2001. 93(8): p. 605-618., https://www.ncbi.nlm.nih.gov/pubmed/11309437
170. van, Zandwijk N., Dalesio, O., Pastorino, U., de, Vries N., van, Tinteren H., EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups, J.Natl.Cancer Inst., 2000. 92(12): p. 977-986., https://www.ncbi.nlm.nih.gov/pubmed/10861309
171. Gray, J., Mao, J. T., Szabo, E., Kelley, M., Kurie, J., Bepler, G., Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition), Chest, 2007. 132(3 Suppl): p. 56S-68S., https://www.ncbi.nlm.nih.gov/pubmed/17873160
172. Lee, J. S., Lippman, S. M., Benner, S. E., Lee, J. J., Ro, J. Y., Lukeman, J. M., et.al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia, J Clin Oncol, 1994. 12(5): p. 937-945., https://www.ncbi.nlm.nih.gov/pubmed/8164045
173. Lam, S., leRiche, J. C., McWilliams, A., Macaulay, C., Dyachkova, Y., Szabo, E., et.al. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium, Clin.Cancer Res., 2004. 10(19): p. 6502-6511., https://www.ncbi.nlm.nih.gov/pubmed/15475437
174. Hong, W. K., Benner, S. E., Lippman, S. M., Evolution of aerodigestive tract 13-cis-retinoid acid chemoprevention: the M.D. Anderson experience. Leukemia, Leukemia, 1994. 8(Suppl 3): p. S33-S37., https://www.ncbi.nlm.nih.gov/pubmed/7808022
175. Manser, R., Lethaby, A., Irving, L. B., Stone, C., Byrnes, G., Abramson, M. J., et.al. Screening for lung cancer, Cochrane Database Syst Rev, 2013. 6: p. CD001991., https://www.ncbi.nlm.nih.gov/pubmed/23794187
176. Fontana, R. S., Sanderson, D. R., Taylor, W. F., Woolner, L. B., Miller, W. E., Muhm, J. R., et.al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study, Am Rev.Respir Dis, 1984. 130(4): p. 561-565., https://www.ncbi.nlm.nih.gov/pubmed/6091507
177. Frost, J. K., Ball, W. C., Jr., Levin, M. L., Tockman, M. S., Baker, R. R., Carter, D., et.al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study, Am Rev.Respir Dis, 1984. 130(4): p. 549-554., https://www.ncbi.nlm.nih.gov/pubmed/6091505
178. Melamed, M. R., Flehinger, B. J., Zaman, M. B., Heelan, R. T., Perchick, W. A., Martini, N., Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York, Chest, 1984. 86(1): p. 44-53., https://www.ncbi.nlm.nih.gov/pubmed/6734291
179. Muhm, J. R., Miller, W. E., Fontana, R. S., Sanderson, D. R., Uhlenhopp, M. A., Lung cancer detected during a screening program using four-month chest radiographs, Radiology, 1983. 148(3): p. 609-615., https://www.ncbi.nlm.nih.gov/pubmed/6308709
180. Kubik, A., Polak, J., Lung cancer detection: results of a randomized prospective study in Czechoslovakia, Cancer, 1986. 57: p. 2428-2437., https://www.ncbi.nlm.nih.gov/pubmed/3697941
181. Oken, M. M., Hocking, W. G., Kvale, P. A., Andriole, G. L., Buys, S. S., Church, T. R., et.al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial, JAMA, 2011. 306(17): p. 1865-73., https://www.ncbi.nlm.nih.gov/pubmed/22031728
182. Hunger, T, Wanka-Pail, E, Brix, G, Griebel, J, Lung Cancer Screening with Low-Dose CT in Smokers: A Systematic Review and Meta-Analysis., Diagnostics (Basel), 2021. 11 (6)(6):, https://pubmed.ncbi.nlm.nih.gov/34198856/
183. Passiglia, F, Cinquini, M, Bertolaccini, L, Del Re, M, Facchinetti, F, Ferrara, R, et.al. Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis., J Clin Oncol, 2021. 39 (23)(23): p. 2574-2585., https://pubmed.ncbi.nlm.nih.gov/34236916/
184. Bonney, A, Malouf, R, Marchal, C, Manners, D, Fong, KM, Marshall, HM, et.al. Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality., Cochrane Database Syst Rev, 2022. 8 (8)(8): p. CD013829., https://pubmed.ncbi.nlm.nih.gov/35921047/
185. Jiménez-Ruiz, CA, Andreas, S, Lewis, KE, Tonnesen, P, van Schayck, CP, Hajek, P, et.al. Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit., Eur Respir J, 2015. 46 (1)(1): p. 61-79., https://pubmed.ncbi.nlm.nih.gov/25882805/
186. Vogel-Claussen, J., Bollmann, B.A., May, K., Stiebeler, S., Dettmer, S., Faron, A., et.al. OA07.04 Effectiveness of NELSON versus PLCOm2012 Lung Cancer Screening Eligibility Criteria: First Results from the German HANSE StudyElsevier, Journal of Thoracic Oncology, 2023. 18(11): p. S59., https://doi.org/10.1016/j.jtho.2023.09.049
187. Vogel-Claussen, J., Bollmann, B., May, K., Stiebeler, S., Dettmer, S., Faron, A., et.al. MA18.05 Effectiveness of NELSON vs PLCOm2012 Lung Cancer Screening Eligibility Criteria: Final Analysis of the Prospective German HANSE StudyElsevier, Journal of Thoracic Oncology, 2024. 19(10): p. S129 - S130., https://doi.org/10.1016/j.jtho.2024.09.233
188. Krist, AH, Davidson, KW, Mangione, CM, Barry, MJ, Cabana, M, Caughey, AB, et.al. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement., JAMA, 2021. 325 (10)(10): p. 962-970., https://pubmed.ncbi.nlm.nih.gov/33687470/
189. Mazzone, PJ, Silvestri, GA, Souter, LH, Caverly, TJ, Kanne, JP, Katki, HA, et.al. Executive Summary: Screening for Lung Cancer: Chest Guideline and Expert Panel Report., Chest, 2021. 160 (5)(5): p. 1959-1980., https://pubmed.ncbi.nlm.nih.gov/34270965/
190. Wolf, AMD, Oeffinger, KC, Shih, TY, Walter, LC, Church, TR, Fontham, ETH, et.al. Screening for lung cancer: 2023 guideline update from the American Cancer Society., CA Cancer J Clin, 2024. 74 (1)(1): p. 50-81., https://pubmed.ncbi.nlm.nih.gov/37909877/
191. Baldwin, DR, O'Dowd, EL, Tietzova, I, Kerpel-Fronius, A, Heuvelmans, MA, Snoeckx, A, et.al. Developing a pan-European technical standard for a comprehensive high-quality lung cancer computed tomography screening programme: an ERS technical standard., Eur Respir J, 2023. 61 (6)(6):, https://pubmed.ncbi.nlm.nih.gov/37202154/
192. O'Dowd, EL, Tietzova, I, Bartlett, E, Devaraj, A, Biederer, J, Brambilla, M, et.al. ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer., Eur Respir J, 2023. 62 (4)(4):, https://pubmed.ncbi.nlm.nih.gov/37802631/
193. Field, JK, Vulkan, D, Davies, MPA, Baldwin, DR, Brain, KE, Devaraj, A, et.al. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis., Lancet Reg Health Eur, 2021. 10 (): p. 100179., https://pubmed.ncbi.nlm.nih.gov/34806061/
194. Jonas, DE, Reuland, DS, Reddy, SM, Nagle, M, Clark, SD, Weber, RP, et.al. Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force., JAMA, 2021. 325 (10)(10): p. 971-987., https://pubmed.ncbi.nlm.nih.gov/33687468/
196. Blum, TG, Vogel-Claussen, J, Andreas, S, Bauer, TT, Barkhausen, J, Harth, V, et.al. [Statement paper on the implementation of a national organized program in Germany for the early detection of lung cancer in risk populations using low-dose CT screening including management of screening findings]., Pneumologie, 2024. 78 (1)(1): p. 15-34., https://pubmed.ncbi.nlm.nih.gov/37816379/
197. Aberle, Denise R, Adams, Amanda M, Berg, Christine D, Black, William C, Clapp, Jonathan D, Fagerstrom, Richard M, et.al. Reduced lung-cancer mortality with low-dose computed tomographic screening., N Engl J Med, 2011. 365(5): p. 395-409., https://www.ncbi.nlm.nih.gov/pubmed/21714641
198. van den Bergh, K. A., Essink-Bot, M. L., Bunge, E. M., Scholten, E. T., Prokop, M., van Iersel, C. A., et.al. Impact of computed tomography screening for lung cancer on participants in a randomized controlled trial (NELSON trial), Cancer, 2008. 113(2): p. 396-404., https://www.ncbi.nlm.nih.gov/pubmed/18484588
199. van den Bergh, K. A., Essink-Bot, M. L., Borsboom, G. J., Th Scholten, E., Prokop, M., de Koning, H. J., et.al. Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON), Br J Cancer, 2010. 102(1): p. 27-34., https://www.ncbi.nlm.nih.gov/pubmed/19935789
200. van den Bergh, K. A., Essink-Bot, M. L., Borsboom, G. J., Scholten, E. T., van Klaveren, R. J., de Koning, H. J., Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial, Eur Respir J, 2011. 38(1): p. 154-61., https://www.ncbi.nlm.nih.gov/pubmed/21148229
201. van de Wiel, J. C., Wang, Y., Xu, D. M., van der Zaag-Loonen, H. J., van der Jagt, E. J., van Klaveren, R. J., et.al. Neglectable benefit of searching for incidental findings in the Dutch-Belgian lung cancer screening trial (NELSON) using low-dose multidetector CT, Eur Radiol, 2007. 17(6): p. 1474-82., https://www.ncbi.nlm.nih.gov/pubmed/17206426
202. de Koning, HJ, van der Aalst, CM, de Jong, PA, Scholten, ET, Nackaerts, K, Heuvelmans, MA, et.al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial., N Engl J Med, 2020. 382(6): p. 503-513., https://pubmed.ncbi.nlm.nih.gov/31995683/
203. Infante, Maurizio, Cavuto, Silvio, Lutman, Fabio Romano, Brambilla, Giorgio, Chiesa, Giuseppe, Ceresoli, Giovanni, et.al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial., Am J Respir Crit Care Med, 2009. 180(5): p. 445-53., https://www.ncbi.nlm.nih.gov/pubmed/19520905
204. Infante, Maurizio, Cavuto, Silvio, Lutman, Fabio Romano, Passera, Eliseo, Chiarenza, Maurizio, Chiesa, Giuseppe, et.al. Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography., Am J Respir Crit Care Med, 2015. 191(10): p. 1166-75., https://www.ncbi.nlm.nih.gov/pubmed/25760561
205. Saghir, Z., Dirksen, A., Ashraf, H., Bach, K. S., Brodersen, J., Clementsen, P. F., et.al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT, Thorax, 2012. 67(4): p. 296-301., https://www.ncbi.nlm.nih.gov/pubmed/22286927
206. Wille, Mathilde M W, Dirksen, Asger, Ashraf, Haseem, Saghir, Zaigham, Bach, Karen S, Brodersen, John, et.al. Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling., Am J Respir Crit Care Med, 2016. 193(5): p. 542-51., https://www.ncbi.nlm.nih.gov/pubmed/26485620
207. Lopes Pegna, A, Picozzi, G, Falaschi, F, Carrozzi, L, Falchini, M, Carozzi, FM, et.al. Four-year results of low-dose CT screening and nodule management in the ITALUNG trial., J Thorac Oncol, 2013. 8 (7)(7): p. 866-75., https://pubmed.ncbi.nlm.nih.gov/23612465/
208. Lopes Pegna, A, Picozzi, G, Mascalchi, M, Maria Carozzi, F, Carrozzi, L, Comin, C, et.al. Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT., Lung Cancer, 2009. 64 (1)(1): p. 34-40., https://pubmed.ncbi.nlm.nih.gov/18723240/
209. Paci, E, Puliti, D, Lopes Pegna, A, Carrozzi, L, Picozzi, G, Falaschi, F, et.al. Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial., Thorax, 2017. 72 (9)(9): p. 825-831., https://pubmed.ncbi.nlm.nih.gov/28377492/
210. Gohagan, J, Marcus, P, Fagerstrom, R, Pinsky, P, Kramer, B, Prorok, P, Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute., Chest, 2004. 126 (1)(1): p. 114-21., https://pubmed.ncbi.nlm.nih.gov/15249451/
211. Gohagan, JK, Marcus, PM, Fagerstrom, RM, Pinsky, PF, Kramer, BS, Prorok, PC, et.al. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer., Lung Cancer, 2005. 47 (1)(1): p. 9-15., https://pubmed.ncbi.nlm.nih.gov/15603850/
212. Becker, Randomized Study on Early Detection of Lung Cancer with MSCT in Germany: Results of the First 3 Years of Follow-up After Randomization., J Thorac Oncol, 2015. 10(6): p. 890-6., https://www.ncbi.nlm.nih.gov/pubmed/25783198
213. Becker, N, Motsch, E, Trotter, A, Heussel, CP, Dienemann, H, Schnabel, PA, et.al. Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial., Int J Cancer, 2020. 146 (6)(6): p. 1503-1513., https://pubmed.ncbi.nlm.nih.gov/31162856/
214. Pastorino, U., Rossi, M., Rosato, V., Marchiano, A., Sverzellati, N., Morosi, C., et.al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial, Eur J Cancer Prev, 2012. 21(3): p. 308-15., https://www.ncbi.nlm.nih.gov/pubmed/22465911
215. Pastorino, U, Silva, M, Sestini, S, Sabia, F, Boeri, M, Cantarutti, A, et.al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy., Ann Oncol, 2019. 30 (7)(7): p. 1162-1169., https://pubmed.ncbi.nlm.nih.gov/30937431/
216. Blanchon, T, Bréchot, JM, Grenier, PA, Ferretti, GR, Lemarié, E, Milleron, B, et.al. Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR)., Lung Cancer, 2007. 58 (1)(1): p. 50-8., https://pubmed.ncbi.nlm.nih.gov/17624475/
217. de Koning, HJ, van der Aalst, CM, de Jong, PA, Scholten, ET, Nackaerts, K, Heuvelmans, MA, et.al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial., N Engl J Med, 2020. 382 (6)(6): p. 503-513., https://pubmed.ncbi.nlm.nih.gov/31995683/
218. Field, JK, Vulkan, D, Davies, MPA, Baldwin, DR, Brain, KE, Devaraj, A, et.al. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis., Lancet Reg Health Eur, 2021. 10 (): p. 100179., https://pubmed.ncbi.nlm.nih.gov/34806061/
219. Patz, EF, Pinsky, P, Gatsonis, C, Sicks, JD, Kramer, BS, Tammemägi, MC, et.al. Overdiagnosis in low-dose computed tomography screening for lung cancer., JAMA Intern Med, 2014. 174 (2)(2): p. 269-74., https://pubmed.ncbi.nlm.nih.gov/24322569/
220. Ten Haaf, K, van Rosmalen, J, de Koning, HJ, Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials., Cancer Epidemiol Biomarkers Prev, 2015. 24 (1)(1): p. 154-61., https://pubmed.ncbi.nlm.nih.gov/25312998/
221. González Maldonado, S, Motsch, E, Trotter, A, Kauczor, HU, Heussel, CP, Hermann, S, et.al. Overdiagnosis in lung cancer screening: Estimates from the German Lung Cancer Screening Intervention Trial., Int J Cancer, 2021. 148 (5)(5): p. 1097-1105., https://pubmed.ncbi.nlm.nih.gov/32930386/
222. Meza, R, Jeon, J, Toumazis, I, Ten Haaf, K, Cao, P, Bastani, M, et.al. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force., JAMA, 2021. 325 (10)(10): p. 988-997., https://pubmed.ncbi.nlm.nih.gov/33687469/
223. Li, M, Zhang, L, Charvat, H, Callister, ME, Sasieni, P, Christodoulou, E, et.al. The influence of postscreening follow-up time and participant characteristics on estimates of overdiagnosis from lung cancer screening trials., Int J Cancer, 2022. 151 (9)(9): p. 1491-1501., https://pubmed.ncbi.nlm.nih.gov/35809038/
224. Rampinelli, C, De Marco, P, Origgi, D, Maisonneuve, P, Casiraghi, M, Veronesi, G, et.al. Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis., BMJ, 2017. 356 (): p. j347., https://pubmed.ncbi.nlm.nih.gov/28179230/
225. Nekolla, EA, Brix, G, Griebel, J, Lung Cancer Screening with Low-Dose CT: Radiation Risk and Benefit-Risk Assessment for Different Screening Scenarios., Diagnostics (Basel), 2022. 12 (2)(2):, https://pubmed.ncbi.nlm.nih.gov/35204455/
226. Brain, K, Lifford, KJ, Carter, B, Burke, O, McRonald, F, Devaraj, A, et.al. Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised controlled trial., Thorax, 2016. 71 (11)(11): p. 996-1005., https://pubmed.ncbi.nlm.nih.gov/27471048/
227. Gareen, IF, Duan, F, Greco, EM, Snyder, BS, Boiselle, PM, Park, ER, et.al. Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening Trial., Cancer, 2014. 120 (21)(21): p. 3401-9., https://pubmed.ncbi.nlm.nih.gov/25065710/
228. Rasmussen, JF, Siersma, V, Pedersen, JH, Brodersen, J, Psychosocial consequences in the Danish randomised controlled lung cancer screening trial (DLCST)., Lung Cancer, 2015. 87 (1)(1): p. 65-72., https://pubmed.ncbi.nlm.nih.gov/25433982/
229. Williamson, S, Patterson, J, Crosby, R, Johnson, R, Sandhu, H, Johnson, S, et.al. Communication of cancer screening results by letter, telephone or in person: A mixed methods systematic review of the effect on attendee anxiety, understanding and preferences., Prev Med Rep, 2019. 13 (): p. 189-195., https://pubmed.ncbi.nlm.nih.gov/30666286/
230. Kaaks, R, Delorme, S, Lung Cancer Screening by Low-Dose Computed Tomography - Part 1: Expected Benefits, Possible Harms, and Criteria for Eligibility and Population Targeting., Rofo, 2021. 193 (5)(5): p. 527-536., https://pubmed.ncbi.nlm.nih.gov/33212540/
231. Knoke, JD, Shanks, TG, Vaughn, JW, Thun, MJ, Burns, DM, Lung cancer mortality is related to age in addition to duration and intensity of cigarette smoking: an analysis of CPS-I data., Cancer Epidemiol Biomarkers Prev, 2004. 13 (6)(6): p. 949-57., https://pubmed.ncbi.nlm.nih.gov/15184251/
232. Vlaanderen, J, Portengen, L, Schüz, J, Olsson, A, Pesch, B, Kendzia, B, et.al. Effect modification of the association of cumulative exposure and cancer risk by intensity of exposure and time since exposure cessation: a flexible method applied to cigarette smoking and lung cancer in the SYNERGY Study., Am J Epidemiol, 2014. 179 (3)(3): p. 290-8., https://pubmed.ncbi.nlm.nih.gov/24355332/
233. Moyer, VA, Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement., Ann Intern Med, 2014. 160 (5)(5): p. 330-8., https://pubmed.ncbi.nlm.nih.gov/24378917/
234. Hüsing, A, Kaaks, R, Risk prediction models versus simplified selection criteria to determine eligibility for lung cancer screening: an analysis of German federal-wide survey and incidence data., Eur J Epidemiol, 2020. 35 (10)(10): p. 899-912., https://pubmed.ncbi.nlm.nih.gov/32594286/
235. Bach, PB, Gould, MK, When the average applies to no one: personalized decision making about potential benefits of lung cancer screening., Ann Intern Med, 2012. 157 (8)(8): p. 571-3., https://pubmed.ncbi.nlm.nih.gov/22893040/
236. Cheung, LC, Berg, CD, Castle, PE, Katki, HA, Chaturvedi, AK, Life-Gained-Based Versus Risk-Based Selection of Smokers for Lung Cancer Screening., Ann Intern Med, 2019. 171 (9)(9): p. 623-632., https://pubmed.ncbi.nlm.nih.gov/31634914/
237. Ten Haaf, K, Jeon, J, Tammemägi, MC, Han, SS, Kong, CY, Plevritis, SK, et.al. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study., PLoS Med, 2017. 14 (4)(4): p. e1002277., https://pubmed.ncbi.nlm.nih.gov/28376113/
238. Katki, HA, Kovalchik, SA, Petito, LC, Cheung, LC, Jacobs, E, Jemal, A, et.al. Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening., Ann Intern Med, 2018. 169 (1)(1): p. 10-19., https://pubmed.ncbi.nlm.nih.gov/29800127/
239. Toumazis, I, Cao, P, de Nijs, K, Bastani, M, Munshi, V, Hemmati, M, et.al. Risk Model-Based Lung Cancer Screening : A Cost-Effectiveness Analysis., Ann Intern Med, 2023. 176 (3)(3): p. 320-332., https://pubmed.ncbi.nlm.nih.gov/36745885/
240. Tammemägi, MC, Ruparel, M, Tremblay, A, Myers, R, Mayo, J, Yee, J, et.al. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study., Lancet Oncol, 2022. 23 (1)(1): p. 138-148., https://pubmed.ncbi.nlm.nih.gov/34902336/
241. Vogel-Claussen, J, Lasch, F, Bollmann, BA, May, K, Kuhlmann, A, Schmid-Bindert, G, et.al. Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography., Rofo, 2022. 194 (12)(12): p. 1333-1345., https://pubmed.ncbi.nlm.nih.gov/35917826/
242. Kondo, KK, Rahman, B, Ayers, CK, Relevo, R, Griffin, JC, Halpern, MT, Lung cancer diagnosis and mortality beyond 15 years since quit in individuals with a 20+ pack-year history: A systematic review., CA Cancer J Clin, 2024. 74 (1)(1): p. 84-114., https://pubmed.ncbi.nlm.nih.gov/37909870/
243. Landy, R, Cheung, LC, Young, CD, Chaturvedi, AK, Katki, HA, Absolute lung cancer risk increases among individuals with >15 quit-years: Analyses to inform the update of the American Cancer Society lung cancer screening guidelines., Cancer, 2024. 130 (2)(2): p. 201-215., https://pubmed.ncbi.nlm.nih.gov/37909885/
244. Robbins, HA, Berg, CD, Cheung, LC, Chaturvedi, AK, Katki, HA, Identification of Candidates for Longer Lung Cancer Screening Intervals Following a Negative Low-Dose Computed Tomography Result., J Natl Cancer Inst, 2019. 111 (9)(9): p. 996-999., https://pubmed.ncbi.nlm.nih.gov/30976808/
245. Robbins, HA, Cheung, LC, Chaturvedi, AK, Baldwin, DR, Berg, CD, Katki, HA, Management of Lung Cancer Screening Results Based on Individual Prediction of Current and Future Lung Cancer Risks., J Thorac Oncol, 2022. 17 (2)(2): p. 252-263., https://pubmed.ncbi.nlm.nih.gov/34648946/
246. González Maldonado, S, Hynes, LC, Motsch, E, Heussel, CP, Kauczor, HU, Robbins, HA, et.al. Validation of multivariable lung cancer risk prediction models for the personalized assignment of optimal screening frequency: a retrospective analysis of data from the German Lung Cancer Screening Intervention Trial (LUSI)., Transl Lung Cancer Res, 2021. 10 (3)(3): p. 1305-1317., https://pubmed.ncbi.nlm.nih.gov/33889511/
247. Horeweg, N, van Rosmalen, J, Heuvelmans, MA, van der Aalst, CM, Vliegenthart, R, Scholten, ET, et.al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening., Lancet Oncol, 2014. 15 (12)(12): p. 1332-41., https://pubmed.ncbi.nlm.nih.gov/25282285/
248. Patz, EF, Greco, E, Gatsonis, C, Pinsky, P, Kramer, BS, Aberle, DR, Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial., Lancet Oncol, 2016. 17 (5)(5): p. 590-9., https://pubmed.ncbi.nlm.nih.gov/27009070/
249. Behr, CM, Oude Wolcherink, MJ, IJzerman, MJ, Vliegenthart, R, Koffijberg, H, Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations., Pharmacoeconomics, 2023. 41 (4)(4): p. 395-411., https://pubmed.ncbi.nlm.nih.gov/36670332/
250. Hofer, F, Kauczor, HU, Stargardt, T, Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach., Lung Cancer, 2018. 124 (): p. 189-198., https://pubmed.ncbi.nlm.nih.gov/30268459/
251. Ten Haaf, K, Tammemägi, MC, Bondy, SJ, van der Aalst, CM, Gu, S, McGregor, SE, et.al. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada., PLoS Med, 2017. 14 (2)(2): p. e1002225., https://pubmed.ncbi.nlm.nih.gov/28170394/
252. Toumazis, I, de Nijs, K, Cao, P, Bastani, M, Munshi, V, Ten Haaf, K, et.al. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening., JAMA Oncol, 2021. 7 (12)(12): p. 1833-1842., https://pubmed.ncbi.nlm.nih.gov/34673885/
253. Treskova, M, Aumann, I, Golpon, H, Vogel-Claussen, J, Welte, T, Kuhlmann, A, Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting., BMC Med, 2017. 15 (1)(1): p. 162., https://pubmed.ncbi.nlm.nih.gov/28838313/
254. Morgan, H, Baldwin, DR, Important parameters for cost-effective implementation of lung cancer screening., Br J Radiol, 2023. 96 (1145)(1145): p. 20220489., https://pubmed.ncbi.nlm.nih.gov/36607805/
255. van Meerbeeck, JP, Franck, C, Lung cancer screening in Europe: where are we in 2021?, Transl Lung Cancer Res, 2021. 10 (5)(5): p. 2407-2417., https://pubmed.ncbi.nlm.nih.gov/34164288/
256. Balata, H, Ruparel, M, O'Dowd, E, Ledson, M, Field, JK, Duffy, SW, et.al. Analysis of the baseline performance of five UK lung cancer screening programmes., Lung Cancer, 2021. 161 (): p. 136-140., https://pubmed.ncbi.nlm.nih.gov/34583222/
257. Potter, AL, Rosenstein, AL, Kiang, MV, Shah, SA, Gaissert, HA, Chang, DC, et.al. Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study., BMJ, 2022. 376 (): p. e069008., https://pubmed.ncbi.nlm.nih.gov/35354556/
258. Yang, CY, Lin, YT, Lin, LJ, Chang, YH, Chen, HY, Wang, YP, et.al. Stage Shift Improves Lung Cancer Survival: Real-World Evidence., J Thorac Oncol, 2023. 18 (1)(1): p. 47-56., https://pubmed.ncbi.nlm.nih.gov/37650698/
259. Duell, Melanie, Wiethege, Thorsten, Dr. rer. medic., Das erweiterte Vorsorgeangebot (EVA) zur Lungenkrebsfrüherkennung – Update 2019, DGUV Forum, 2020., https://forum.dguv.de/ausgabe/1-2020/artikel/das-erweiterte-vorsorgeangebot-eva-zur-lungenkrebsfrueherkennung-update-2019
260. Blum, TG, Morgan, RL, Durieux, V, Chorostowska-Wynimko, J, Baldwin, DR, Boyd, J, et.al. European Respiratory Society guideline on various aspects of quality in lung cancer care., Eur Respir J, 2023. 61 (2)(2):, https://pubmed.ncbi.nlm.nih.gov/36396145/
261. Christensen, Jared, Prosper, Ashley Elizabeth, Wu, Carol C., Chung, Jonathan, Lee, Elizabeth, Elicker, Brett, et.al. ACR Lung-RADS v2022: Assessment Categories and Management RecommendationsElsevier, Journal of the American College of Radiology, 2024. 21(3): p. 473 - 488., https://doi.org/10.1016/j.jacr.2023.09.009
262. Oudkerk, M, Devaraj, A, Vliegenthart, R, Henzler, T, Prosch, H, Heussel, CP, et.al. European position statement on lung cancer screening., Lancet Oncol, 2017. 18 (12)(12): p. e754-e766., https://pubmed.ncbi.nlm.nih.gov/29208441/
263. Crosbie, PA, Balata, H, Evison, M, Atack, M, Bayliss-Brideaux, V, Colligan, D, et.al. Implementing lung cancer screening: baseline results from a community-based 'Lung Health Check' pilot in deprived areas of Manchester., Thorax, 2019. 74 (4)(4): p. 405-409., https://pubmed.ncbi.nlm.nih.gov/29440588/
264. Tanner, Nichole T, Kanodra, Neeti M, Gebregziabher, Mulugeta, Payne, Elizabeth, Halbert, Chanita Hughes, Warren, Graham W, et.al. The Association between Smoking Abstinence and Mortality in the National Lung Screening Trial., Am J Respir Crit Care Med, 2016. 193(5): p. 534-41., https://www.ncbi.nlm.nih.gov/pubmed/26502000
265. Evans, WK, Gauvreau, CL, Flanagan, WM, Memon, S, Yong, JHE, Goffin, JR, et.al. Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model., CMAJ Open, 2020. 8 (3)(3): p. E585-E592., https://pubmed.ncbi.nlm.nih.gov/32963023/
266. Fucito, LM, Czabafy, S, Hendricks, PS, Kotsen, C, Richardson, D, Toll, BA, Pairing smoking-cessation services with lung cancer screening: A clinical guideline from the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco., Cancer, 2016. 122 (8)(8): p. 1150-9., https://pubmed.ncbi.nlm.nih.gov/26916412/
267. Herth, FJF, Reinmuth, N, Wormanns, D, Antoch, G, Biederer, J, Vogel-Claussen, J, et.al. [Joint Statement of the German Radiological Society and the German Respiratory Society on a Quality-Assured Early Detection Program for Lung Cancer with Low-dose CT]., Pneumologie, 2019. 73 (10)(10): p. 573-577., https://pubmed.ncbi.nlm.nih.gov/31537020/
268. Rabenstein, A, Aydin, D, Lochbühler, K, [Smoking cessation interventions in clinical practice]., MMW Fortschr Med, 2021. 163 (15)(15): p. 32-34., https://pubmed.ncbi.nlm.nih.gov/34478087/
269. Sasco, AJ, Day, NE, Walter, SD, Case-control studies for the evaluation of screening., J Chronic Dis, 1986. 39 (5)(5): p. 399-405., https://pubmed.ncbi.nlm.nih.gov/3700581/
270. Braitmaier, M, Kollhorst, B, Heinig, M, Langner, I, Czwikla, J, Heinze, F, et.al. Effectiveness of Mammography Screening on Breast Cancer Mortality - A Study Protocol for Emulation of Target Trials Using German Health Claims Data., Clin Epidemiol, 2022. 14 (): p. 1293-1303., https://pubmed.ncbi.nlm.nih.gov/36353307/
271. Fontana, R. S., Screening for lung cancer, in Screening for cancer, Miller, A. B. , Editor. 1985, Academic Press: New York. p. 377-395., https://www.ncbi.nlm.nih.gov/pubmed/1991274
272. Fontana, R. S., Screening for lung cancer: recent experience in the United States, in Lung Cancer: Basic and clinical aspects, Hansen, H. H. , Editor. 1986, Ma: Martinus Nijhoff Publishers: Boston. p. 91-111., https://link.springer.com/chapter/10.1007/978-1-4613-2295-5_6
273. Levin, M. L., Tockman, M. S., Frost, J. K., Ball, W. C., Jr., Lung cancer mortality in males screened by chest X-ray and cytologic sputum examination: a preliminary report, Recent Results Cancer Res, 1982. 82: p. 138-146., https://www.ncbi.nlm.nih.gov/pubmed/7111836
274. Stitik, F. P., Tockman, M. S., Radiographic screening in the early detection of lung cancer, Radiol.Clin North Am, 1978. 16(3): p. 347-366., https://www.ncbi.nlm.nih.gov/pubmed/746141
275. Stitik, F. P., Tockman, M. S., Khouri, N. F., Chest radiology, in Screening for cancer, Miller, A. B. , Editor. 1985, Academic Press: New York. p. 163-191.
276. Tockman, M. S., Levin, M. L., Frost, J. K., et al., Screening and detection of lung cancer, in Lung Cancer, Aisner, J. , Editor. 1985, Churchll Livingstone: New York.
277. Melamed, M. R., Flehinger, B. J., Zaman, M. B., et al., Detection of true pathologic stage I lung cancer in a screening program and the effect on survival, Cancer, 1981. 47(5 Supl): p. 1182-1187., https://www.ncbi.nlm.nih.gov/pubmed/6263446
278. Marek, W., Kotschy-Lang, N., Muti, A., Kohler, C. H., Nielsen, L., Topalidis, T. H., et.al. Can semi-automated image cytometry on induced sputum become a screening tool for lung cancer? Evaluation of quantitative semi-automated sputum cytometry on radon- and uranium-exposed workers, Eur Respir J, 2001. 18(6): p. 942-950., https://www.ncbi.nlm.nih.gov/pubmed/11829100
279. Xing, S., Khanavkar, B., Nakhosteen, J. A., Atay, Z., Jockel, K. H., Marek, W., Predictive value of image cytometry for diagnosis of lung cancer in heavy smokers, Eur.Respir.J., 2005. 25(6): p. 956-963., https://www.ncbi.nlm.nih.gov/pubmed/15929948
280. Marek, W., et, Sputumscreening auf Lungenkrebs ehemals asbest-exponierter Arbeitnehmern, Trauma und Berufskrankheit, 2006. 8: p. 96-102.
281. Palcic, B., Garner, D. M., Beveridge, J., Sun, X. R., Doudkine, A., Macaulay, C., et.al. Increase of sensitivity of sputum cytology using high-resolution image cytometry: field study results, Cytometry, 2002. 50(3): p. 168-176., https://www.ncbi.nlm.nih.gov/pubmed/12116340
282. Hirsch, F. R., Franklin, W. A., Gazdar, A. F., Bunn, P. A., Jr., Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology, Clin Cancer Res, 2001. 7(1): p. 5-22., https://www.ncbi.nlm.nih.gov/pubmed/11205917
283. Hirsch, F. R., Prindiville, S. A., Miller, Y. E., Franklin, W. A., Dempsey, E. C., Murphy, J. R., et.al. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study, J Natl.Cancer Inst., 2001. 93(18): p. 1385-1391., https://www.ncbi.nlm.nih.gov/pubmed/11562389
284. Gazdar, A. F., Minna, J. D., Molecular detection of early lung cancer, J Natl.Cancer Inst., 1999. 91(4): p. 299-301., https://www.ncbi.nlm.nih.gov/pubmed/10050857
285. Grote, H. J., Schmiemann, V., Kiel, S., Bocking, A., Kappes, R., Gabbert, H. E., et.al. Aberrant methylation of the adenomatous polyposis coli promoter 1A in bronchial aspirates from patients with suspected lung cancer, Int J Cancer, 2004. 110(5): p. 751-755., https://www.ncbi.nlm.nih.gov/pubmed/15146565
286. Grote, H. J., Schmiemann, V., Geddert, H., Rohr, U. P., Kappes, R., Gabbert, H. E., et.al. Aberrant promoter methylation of p16(INK4a), RARB2 and SEMA3B in bronchial aspirates from patients with suspected lung cancer, Int J Cancer, 2005. 116(5): p. 720-725., https://www.ncbi.nlm.nih.gov/pubmed/15849750
287. Grote, H. J., Schmiemann, V., Geddert, H., Bocking, A., Kappes, R., Gabbert, H. E., et.al. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer, Cancer, 2006. 108(2): p. 129-134., https://www.ncbi.nlm.nih.gov/pubmed/16444703
288. Schmiemann, V., Bocking, A., Kazimirek, M., Onofre, A. S., Gabbert, H. E., Kappes, R., et.al. Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study, Clin Cancer Res, 2005. 11(21): p. 7728-7734., https://www.ncbi.nlm.nih.gov/pubmed/16278393
289. Miozzo, M., Sozzi, G., Musso, K., Pilotti, S., Incarbone, M., Pastorino, U., et.al. Microsatellite alterations in bronchial and sputum specimens of lung cancer patients, Cancer Res, 1996. 56(10): p. 2285-2288., https://www.ncbi.nlm.nih.gov/pubmed/8625300
290. Kersting, M., Friedl, C., Kraus, A., Behn, M., Pankow, W., Schuermann, M., Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers, J Clin Oncol, 2000. 18(18): p. 3221-3229., https://www.ncbi.nlm.nih.gov/pubmed/10986054
291. Virmani, A. K., Rathi, A., Zochbauer-Muller, S., Sacchi, N., Fukuyama, Y., Bryant, D., et.al. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas, J Natl.Cancer Inst., 2000. 92(16): p. 1303-1307., https://www.ncbi.nlm.nih.gov/pubmed/10944551
292. Zochbauer-Muller, S., Fong, K. M., Virmani, A. K., Geradts, J., Gazdar, A. F., Minna, J. D., Aberrant promoter methylation of multiple genes in non-small cell lung cancers, Cancer Res, 2001. 61(1): p. 249-255., https://www.ncbi.nlm.nih.gov/pubmed/11196170
293. Field, J. K., Brambilla, C., Caporaso, N., Flahault, A., Henschke, C., Herman, J., et.al. Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations, Int J Oncol, 2002. 21(2): p. 369-373., https://www.ncbi.nlm.nih.gov/pubmed/12118333
294. Thunnissen, F. B., Sputum examination for early detection of lung cancer, J Clin Pathol., 2003. 56(11): p. 805-810., https://www.ncbi.nlm.nih.gov/pubmed/14600122
295. Belinsky, S. A., Liechty, K. C., Gentry, F. D., Wolf, H. J., Rogers, J., Vu, K., et.al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort, Cancer Res, 2006. 66(6): p. 3338-44., https://www.ncbi.nlm.nih.gov/pubmed/16540689
296. Sagawa, M., Kobayashi, T., Uotani, C., Kibe, Y., Tanaka, M., Machida, Y., et.al. A survey about further work-up for cases with positive sputum cytology during lung cancer mass screening in Ishikawa Prefecture, Japan: a retrospective analysis about quality assurance of lung cancer screening, Jpn J Clin Oncol, 2015. 45(3): p. 297-302., https://www.ncbi.nlm.nih.gov/pubmed/25583424
297. Spiro, S. G., Hackshaw, A., Lung, Search Collaborative Group, Research in progress--LungSEARCH: a randomised controlled trial of surveillance for the early detection of lung cancer in a high-risk group, Thorax, 2016. 71(1): p. 91-3., https://www.ncbi.nlm.nih.gov/pubmed/26138736
298. Wagner, M., Ficker, J. H., Autofluoreszenz-Bronchoskopie: Grundlagen und klinische AnwendungUni-Med-Verlag, 2007.
299. Zaric, Bojan, Perin, Branislav, Carapic, Vladimir, Stojsic, Vladimir, Matijasevic, Jovan, Andrijevic, Ilija, et.al. Diagnostic value of autofluorescence bronchoscopy in lung cancer, Thoracic Cancer, 2013. 4(1): p. 1-8., https://www.ncbi.nlm.nih.gov/pubmed/28920319
300. Schneider, J., Peltri, G., Bitterlich, N., Neu, K., Velcovsky, H. G., Morr, H., et.al. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients, Anticancer Res, 2003. 23(2A): p. 899-906., https://www.ncbi.nlm.nih.gov/pubmed/12820320
301. Lianidou, E. S., Markou, A., Strati, A., The Role of CTCs as Tumor Biomarkers, Adv Exp Med Biol, 2015. 867: p. 341-67., https://www.ncbi.nlm.nih.gov/pubmed/26530376
302. Yu, N., Zhou, J., Cui, F., Tang, X., Circulating tumor cells in lung cancer: detection methods and clinical applications, Lung, 2015. 193(2): p. 157-71., https://www.ncbi.nlm.nih.gov/pubmed/25690734
303. Marquette, CH, Boutros, J, Benzaquen, J, Ferreira, M, Pastre, J, Pison, C, et.al. Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study., Lancet Respir Med, 2020. 8 (7)(7): p. 709-716., https://pubmed.ncbi.nlm.nih.gov/32649919/
304. Zhang, R., Shao, F., Wu, X., Ying, K., Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis, Lung Cancer, 2010. 69(2): p. 225-31., https://www.ncbi.nlm.nih.gov/pubmed/20004997
305. Ehmann, R., Boedeker, E., Friedrich, U., Sagert, J., Dippon, J., Friedel, G., et.al. Canine scent detection in the diagnosis of lung cancer: revisiting a puzzling phenomenon, Eur Respir J, 2012. 39(3): p. 669-76., https://www.ncbi.nlm.nih.gov/pubmed/21852337
306. Mazzone, P. J., Wang, X. F., Lim, S., Choi, H., Jett, J., Vachani, A., et.al. Accuracy of volatile urine biomarkers for the detection and characterization of lung cancer, BMC Cancer, 2015. 15: p. 1001., https://pubmed.ncbi.nlm.nih.gov/26698840/
307. Spiro, S., et al., Initial evaluattion of the patient with lung cancer: Symptoms, signs, laboratory tests, and paraneoplastic syndromes. ACCP Evidenced-Based Clinical Practice Guidelines, Chest, 2007. 132: p. 149S-160S., https://www.ncbi.nlm.nih.gov/pubmed/17873166
308. Ruano-Raviña, A, Provencio, M, Calvo de Juan, V, Carcereny, E, Moran, T, Rodriguez-Abreu, D, et.al. Lung cancer symptoms at diagnosis: results of a nationwide registry study., ESMO Open, 2020. 5 (6)(6): p. e001021., https://pubmed.ncbi.nlm.nih.gov/33214227/
309. Xing, PY, Zhu, YX, Wang, L, Hui, ZG, Liu, SM, Ren, JS, et.al. What are the clinical symptoms and physical signs for non-small cell lung cancer before diagnosis is made? A nation-wide multicenter 10-year retrospective study in China., Cancer Med, 2019. 8 (8)(8): p. 4055-4069., https://pubmed.ncbi.nlm.nih.gov/31150167/
310. Athey, VL, Walters, SJ, Rogers, TK, Symptoms at lung cancer diagnosis are associated with major differences in prognosis., Thorax, 2018. 73 (12)(12): p. 1177-1181., https://pubmed.ncbi.nlm.nih.gov/29666219/
311. Malalasekera, A, Nahm, S, Blinman, PL, Kao, SC, Dhillon, HM, Vardy, JL, How long is too long? A scoping review of health system delays in lung cancer., Eur Respir Rev, 2018. 27 (149)(149):, https://pubmed.ncbi.nlm.nih.gov/30158277/
312. Bundesamt für Strahlenschutz, Parlamentsbericht 2006 des Bundesamtes für Strahlenschutz: Unterrichtung durch die Bundesregierung - Umweltradioaktivität und Strahlenbelastung im Jahr 2006, 2006.
313. Colice, G. L., Detecting lung cancer as a cause of hemoptysis in patients with a normal chest radiograph: bronchoscopy vs CT, Chest, 1997. 111(4): p. 877-884., https://www.ncbi.nlm.nih.gov/pubmed/9106564
314. Silvestri, G. A., Littenberg, B., Colice, G. L., The clinical evaluation for detecting metastatic lung cancer. A meta-analysis, Am J Respir Crit Care Med, 1995. 152(1): p. 225-230., https://www.ncbi.nlm.nih.gov/pubmed/7599828
315. Thomas, M., et al., Empfehlungen zur Diagnostik des Bronchialkarzinoms, Pneumologie, 2000. 54: p. 361-371.
316. Minna, J. D., Higgins, G. A., Glatstein, E., Cancer of the lung, in Cancer: Principles and Practice of Oncology, de Vita, V. T.Hellman, S. and Rosenberg, S. A., Editors. 1985, J.B. Lippincott Co: Philadelphia. p. 507-597., https://www.lungcancerjournal.info/article/0169-5002(89)90182-7/fulltext
317. Darnell, Robert B., Posner, Jerome B., Paraneoplastic SyndromesOxford University Press, 2013., https://oxfordmedicine.com/view/10.1093/med/9780199772735.001.1/med-9780199772735
318. Soomro, Z, Youssef, M, Yust-Katz, S, Jalali, A, Patel, AJ, Mandel, J, Paraneoplastic syndromes in small cell lung cancer., J Thorac Dis, 2020. 12 (10)(10): p. 6253-6263., https://pubmed.ncbi.nlm.nih.gov/33209464/
319. Anwar, A, Jafri, F, Ashraf, S, Jafri, MAS, Fanucchi, M, Paraneoplastic syndromes in lung cancer and their management., Ann Transl Med, 2019. 7 (15)(15): p. 359., https://pubmed.ncbi.nlm.nih.gov/31516905/
320. Kreuter, M., et al., Diagnostik des Bronchialkarzinoms. Pneumologe 2008, 5: 187-98, Pneumologe, 2008. 5: p. 187-198.
321. Bradley, SH, Abraham, S, Callister, ME, Grice, A, Hamilton, WT, Lopez, RR, et.al. Sensitivity of chest X-ray for detecting lung cancer in people presenting with symptoms: a systematic review., Br J Gen Pract, 2019. 69 (689)(689): p. e827-e835., https://pubmed.ncbi.nlm.nih.gov/31636130/
322. Kim, JH, Lee, KH, Kim, KT, Kim, HJ, Ahn, HS, Kim, YJ, et.al. Comparison of digital tomosynthesis and chest radiography for the detection of pulmonary nodules: systematic review and meta-analysis., Br J Radiol, 2016. 89 (1068)(1068): p. 20160421., https://pubmed.ncbi.nlm.nih.gov/27759428/
323. Neal, RD, Barham, A, Bongard, E, Edwards, RT, Fitzgibbon, J, Griffiths, G, et.al. Immediate chest X-ray for patients at risk of lung cancer presenting in primary care: randomised controlled feasibility trial., Br J Cancer, 2017. 116 (3)(3): p. 293-302., https://pubmed.ncbi.nlm.nih.gov/28072761/
324. Wild, JM, Marshall, H, Bock, M, Schad, LR, Jakob, PM, Puderbach, M, et.al. MRI of the lung (1/3): methods., Insights Imaging, 2012. 3 (4)(4): p. 345-53., https://pubmed.ncbi.nlm.nih.gov/22695952/
325. Biederer, J, Beer, M, Hirsch, W, Wild, J, Fabel, M, Puderbach, M, et.al. MRI of the lung (2/3). Why … when … how?, Insights Imaging, 2012. 3 (4)(4): p. 355-71., https://pubmed.ncbi.nlm.nih.gov/22695944/
326. Biederer, J, Mirsadraee, S, Beer, M, Molinari, F, Hintze, C, Bauman, G, et.al. MRI of the lung (3/3)-current applications and future perspectives., Insights Imaging, 2012. 3 (4)(4): p. 373-86., https://pubmed.ncbi.nlm.nih.gov/22695943/
327. Lardinois, D., Weder, W., Hany, T. F., Kamel, E. M., Korom, S., Seifert, B., et.al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography, N Engl J Med, 2003. 348(25): p. 2500-2507., https://www.ncbi.nlm.nih.gov/pubmed/12815135
328. Cerfolio, R. J., Ojha, B., Bryant, A. S., Raghuveer, V., Mountz, J. M., Bartolucci, A. A., The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer, Ann Thorac.Surg, 2004. 78(3): p. 1017-1023., https://www.ncbi.nlm.nih.gov/pubmed/15337041
329. Halpern, B. S., Schiepers, C., Weber, W. A., Crawford, T. L., Fueger, B. J., Phelps, M. E., et.al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion, Chest, 2005. 128(4): p. 2289-2297., https://www.ncbi.nlm.nih.gov/pubmed/16236886
330. Mayo, P. H., Doelken, P., Pleural ultrasonography, Clin Chest Med, 2006. 27(2): p. 215-227., https://www.ncbi.nlm.nih.gov/pubmed/16716814
331. Beaulieu, M., Marik, P. E., Bedside ultrasonography in the ICU, part 2., 2009., https://www.ncbi.nlm.nih.gov/pubmed/16162786
332. Wahidi, M. M., Ernst, A., Role of the interventional pulmonologist in the intensive care unit, J Intensive Care Med, 2005. 20(3): p. 141-146., https://www.ncbi.nlm.nih.gov/pubmed/15888901
333. Evans, A. L., Gleeson, F. V., Radiology in pleural disease: state of the art, Respirology., 2004. 9(3): p. 300-312., https://www.ncbi.nlm.nih.gov/pubmed/15363000
334. Layer, G., Schmitteckert, H., Steudel, A., Tuengerthal, S., Schirren, J., van, Kaick G., et.al. MRT, CT and sonography in the preoperative assessment of the primary tumor spread in malignant pleural mesothelioma, Rofo, 1999. 170(4): p. 365-370., https://www.ncbi.nlm.nih.gov/pubmed/10341795
335. Sheth, S., Hamper, U. M., Stanley, D. B., Wheeler, J. H., Smith, P. A., US guidance for thoracic biopsy: a valuable alternative to CT, Radiology, 1999. 210(3): p. 721-726., https://www.ncbi.nlm.nih.gov/pubmed/10207472
336. Adams, R. F., Gray, W., Davies, R. J., Gleeson, F. V., Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma, Chest, 2001. 120(6): p. 1798-1802., https://www.ncbi.nlm.nih.gov/pubmed/11742904
337. Hellwig, D. R., Baum, P., Kirsch, C. M., FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: A systematic review, Nuklearmedizin: doi: 10.3413/nukmed-0217, 2009., https://www.ncbi.nlm.nih.gov/pubmed/19333516
338. Musi, M., Carbone, R. G., Bertocchi, C., Cantalupi, D. P., Michetti, G., Pugliese, C., et.al. Bronchial carcinoid tumours: a study on clinicopathological features and role of octreotide scintigraphy, Lung Cancer, 1998. 22(2): p. 97-102., https://www.ncbi.nlm.nih.gov/pubmed/10022217
339. Li, Y, Jin, G, Su, D, Comparison of Gadolinium-enhanced MRI and 18FDG PET/PET-CT for the diagnosis of brain metastases in lung cancer patients: A meta-analysis of 5 prospective studies., Oncotarget, 2017. 8 (22)(22): p. 35743-35749., https://pubmed.ncbi.nlm.nih.gov/28415747/
340. Goeckenjan, G, Sitter, H, Thomas, M, Branscheid, D, Flentje, M, Griesinger, F, et.al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]., Pneumologie, 2011. 65 (8)(8): p. e51-75., https://pubmed.ncbi.nlm.nih.gov/21830177/
341. Earnest, F., Ryu, J. H., Miller, G. M., Luetmer, P. H., Forstrom, L. A., Burnett, O. L., et.al. Suspected non-small cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for detection--pilot study, Radiology, 1999. 211(1): p. 137-145., https://www.ncbi.nlm.nih.gov/pubmed/10189463
342. Hochstenbag, MM, Twijnstra, A, Hofman, P, Wouters, EF, ten Velde, GP, MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment?, Lung Cancer, 2003. 42 (2)(2): p. 189-93., https://pubmed.ncbi.nlm.nih.gov/14568686/
343. Kim, SY, Kim, JS, Park, HS, Cho, MJ, Kim, JO, Kim, JW, et.al. Screening of brain metastasis with limited magnetic resonance imaging (MRI): clinical implications of using limited brain MRI during initial staging for non-small cell lung cancer patients., J Korean Med Sci, 2005. 20 (1)(1): p. 121-6., https://pubmed.ncbi.nlm.nih.gov/15716616/
344. Yokoi, K, Kamiya, N, Matsuguma, H, Machida, S, Hirose, T, Mori, K, et.al. Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI., Chest, 1999. 115 (3)(3): p. 714-9., https://pubmed.ncbi.nlm.nih.gov/10084481/
345. Yohena, T, Yoshino, I, Kitajima, M, Uehara, T, Kanematsu, T, Teruya, T, et.al. Necessity of preoperative screening for brain metastasis in non-small cell lung cancer patients without lymph node metastasis., Ann Thorac Cardiovasc Surg, 2004. 10 (6)(6): p. 347-9., https://pubmed.ncbi.nlm.nih.gov/15658906/
346. Wu, Q, Luo, W, Zhao, Y, Xu, F, Zhou, Q, The utility of 18F-FDG PET/CT for the diagnosis of adrenal metastasis in lung cancer: a PRISMA-compliant meta-analysis., Nucl Med Commun, 2017. 38 (12)(12): p. 1117-1124., https://pubmed.ncbi.nlm.nih.gov/28953208/
347. Herder, G. J., Kramer, H., Hoekstra, O. S., Smit, E. F., Pruim, J., van, Tinteren H., et.al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study, J Clin Oncol, 2006. 24(12): p. 1800-1806., https://www.ncbi.nlm.nih.gov/pubmed/16567772
348. Gambazzi, F, Frey, LD, Bruehlmeier, M, Janthur, WD, Graber, SM, Heuberger, J, et.al. Comparing Two Imaging Methods for Follow-Up of Lung Cancer Treatment: A Randomized Pilot Study., Ann Thorac Surg, 2019. 107 (2)(2): p. 430-435., https://pubmed.ncbi.nlm.nih.gov/30292847/
349. Mitchell, MD, Aggarwal, C, Tsou, AY, Torigian, DA, Treadwell, JR, Imaging for the Pretreatment Staging of Small cell Lung Cancer: A Systematic Review., Acad Radiol, 2016. 23 (8)(8): p. 1047-56., https://pubmed.ncbi.nlm.nih.gov/27259379/
350. Martucci, F, Pascale, M, Valli, MC, Pesce, GA, Froesch, P, Giovanella, L, et.al. Impact of , Front Med (Lausanne), 2019. 6 (): p. 336., https://pubmed.ncbi.nlm.nih.gov/32118000/
351. Granberg, D., Sundin, A., Janson, E. T., Oberg, K., Skogseid, B., Westlin, J. E., Octreoscan in patients with bronchial carcinoid tumours, Clin.Endocrinol.(Oxf), 2003. 59(6): p. 793-799., https://www.ncbi.nlm.nih.gov/pubmed/14974924
352. Bini, A., Grazia, M., Stella, F., Petrella, F., Sellitri, F., Fanti, S., et.al. The role of somatostatin receptor scintigraphy (Octreoscan) during follow-up of patients after bronchial carcinoid resection. A prospective study, J.Cardiovasc.Surg.(Torino), 2005. 46(3): p. 318-319., https://www.ncbi.nlm.nih.gov/pubmed/15956934
353. Yellin, A., Zwas, S. T., Rozenman, J., Simansky, D. A., Goshen, E., Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors, Isr.Med.Assoc.J., 2005. 7(11): p. 712-716., https://www.ncbi.nlm.nih.gov/pubmed/16308994
354. Rufini, V., Calcagni, M. L., Baum, R. P., Imaging of neuroendocrine tumors, Semin.Nucl.Med., 2006. 36(3): p. 228-247., https://www.ncbi.nlm.nih.gov/pubmed/16762613
355. Baum, R. P., Prasad, V., Hommann, M., Horsch, D., Receptor PET/CT imaging of neuroendocrine tumors, Recent Results Cancer Res., 2008. 170: p. 225-242., https://www.ncbi.nlm.nih.gov/pubmed/18019630
356. MacDonald, S. L., Hansell, D. M., Staging of non-small cell lung cancer: imaging of intrathoracic disease, Eur J Radiol., 2003. 45(1): p. 18-30., https://www.ncbi.nlm.nih.gov/pubmed/12499061
357. Gould, M. K., Maclean, C. C., Kuschner, W. G., Rydzak, C. E., Owens, D. K., Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis, JAMA, 2001. 285(7): p. 914-924., https://www.ncbi.nlm.nih.gov/pubmed/11180735
358. Hellwig, D., Ukena, D., Paulsen, F., Bamberg, M., Kirsch, C. M., Metaanalyse zum Stellenwert der Positronen-Emissions-Tomographie mit F-18-Fluorodesoxyglukose (FDG-PET) bei Lungentumoren. Diskussionsbasis der deutschen Konsensus-Konferenz Onko-PET 2000, Pneumologie, 2001. 55(8): p. 367-377., https://www.researchgate.net/publication/247463168_Metaanalyse_zum_Stellenwert_der_Positronen-Emissions-Tomographie_mit_F-18-Fluorodesoxyglukose_FDG-PET_bei_Lungentumoren1_-_Diskussionsbasis_der_deutschen_Konsensus-Konferenz_Onko-PET_2000_-
359. Ung, Y. C., Maziak, D. E., Vanderveen, J. A., Smith, C. A., Gulenchyn, K., Lacchetti, C., et.al. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review, J Natl.Cancer Inst., 2007. 99(23): p. 1753-1767., https://www.ncbi.nlm.nih.gov/pubmed/18042932
360. Nomori, H., Watanabe, K., Ohtsuka, T., Naruke, T., Suemasu, K., Uno, K., Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images, Lung Cancer, 2004. 45(1): p. 19-27., https://www.ncbi.nlm.nih.gov/pubmed/15196730
361. de-Langen, A. J., The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis, European-journal-of-cardio-thoracic-surgery-official-journal-of-the-European-Association-for-Cardio-thoracic-Surgery, 2006. 29(1): p. 26-29., https://www.ncbi.nlm.nih.gov/pubmed/16337397
362. Suzuki, K., Yamamoto, M., Hasegawa, Y., Ando, M., Shima, K., Sako, C., et.al. Magnetic resonance imaging and computed tomography in the diagnoses of brain metastases of lung cancer, Lung Cancer, 2004. 46(3): p. 357-360., https://www.ncbi.nlm.nih.gov/pubmed/15541821
363. Kuijvenhoven, JC, Leoncini, F, Crombag, LC, Spijker, R, Bonta, PI, Korevaar, DA, et.al. Endobronchial Ultrasound for the Diagnosis of Centrally Located Lung Tumors: A Systematic Review and Meta-Analysis., Respiration 99 (5)(5): p. 441-450., https://pubmed.ncbi.nlm.nih.gov/31734666/
364. Ali, MS, Sethi, J, Taneja, A, Musani, A, Maldonado, F, Computed Tomography Bronchus Sign and the Diagnostic Yield of Guided Bronchoscopy for Peripheral Pulmonary Lesions. A Systematic Review and Meta-Analysis., Ann Am Thorac Soc, 2018. 15 (8)(8): p. 978-987., https://pubmed.ncbi.nlm.nih.gov/29877715/
365. Sainz Zuñiga, PV, Vakil, E, Molina, S, Bassett, RL, Ost, DE, Sensitivity of Radial Endobronchial Ultrasound-Guided Bronchoscopy for Lung Cancer in Patients With Peripheral Pulmonary Lesions: An Updated Meta-analysis., Chest, 2020. 157 (4)(4): p. 994-1011., https://pubmed.ncbi.nlm.nih.gov/31738928/
366. Mondoni, M, Sotgiu, G, Bonifazi, M, Dore, S, Parazzini, EM, Carlucci, P, et.al. Transbronchial needle aspiration in peripheral pulmonary lesions: a systematic review and meta-analysis., Eur Respir J, 2016. 48 (1)(1): p. 196-204., https://pubmed.ncbi.nlm.nih.gov/27174878/
367. Navani, N, Nankivell, M, Lawrence, DR, Lock, S, Makker, H, Baldwin, DR, et.al. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial., Lancet Respir Med, 2015. 3 (4)(4): p. 282-9., https://pubmed.ncbi.nlm.nih.gov/25660225/
368. Korevaar, DA, Colella, S, Spijker, R, Bossuyt, PM, Konge, L, Clementsen, PF, et.al. Esophageal Endosonography for the Diagnosis of Intrapulmonary Tumors: A Systematic Review and Meta-Analysis., Respiration, 2017. 93 (2)(2): p. 126-137., https://pubmed.ncbi.nlm.nih.gov/27926910/
369. Sehgal, IS, Dhooria, S, Aggarwal, AN, Behera, D, Agarwal, R, Endosonography Versus Mediastinoscopy in Mediastinal Staging of Lung Cancer: Systematic Review and Meta-Analysis., Ann Thorac Surg, 2016. 102 (5)(5): p. 1747-1755., https://pubmed.ncbi.nlm.nih.gov/27637288/
370. Honeybourne, D., Babb, J., Bowie, P., Brewin, A., Fraise, A., Garrard, C., et.al. Honeybourne D, Babb J, Bowie P, Brewin A, Fraise A, Garrard C et al. British Thoracic Society guidelines on diagnostic flexible bronchoscopy. Thorax 2001, 56(Suppl 1):i1-i21, Thorax, 2001. 56(Suppl 1): p. i1-i21., https://www.ncbi.nlm.nih.gov/pubmed/11158709
371. Laroche, C., Fairbairn, I., Moss, H., Pepke-Zaba, J., Sharples, L., Flower, C., et.al. Role of computed tomographic scanning of the thorax prior to bronchoscopy in the investigation of suspected lung cancer, Thorax, 2000. 55(5): p. 359-363., https://pubmed.ncbi.nlm.nih.gov/10770815/
372. Xie, H. B., Cornwell, R., Grossman, J. E., Hoerl, H. D., Kurtycz, D. F., Bronchoscopy-guided transtracheal and transbronchial fine-needle aspiration biopsy: a 5-year institutional review of 111 cases. Diagnostic Cytopathology 2002, 27(5):276-81, Diagnostic Cytopathology, 2002. 27(5): p. 276-281., https://www.ncbi.nlm.nih.gov/pubmed/12411992
373. Toloza, E. M., Harpole, L., Detterbeck, F., McCrory, D. C., Invasive staging of non-small cell lung cancer: a review of the current evidence, Chest, 2003. 123(1 Suppl): p. 157S-166S., https://www.ncbi.nlm.nih.gov/pubmed/12527575
374. Yung, R. C., Tissue diagnosis of suspected lung cancer: selecting between bronchoscopy, transthoracic needle aspiration, and resectional biopsy, Respir.Care Clin.N.Am., 2003. 9(1): p. 51-76., https://www.ncbi.nlm.nih.gov/pubmed/12820712
375. Toloza, E. M., Harpole, L., McCrory, D. C., Noninvasive staging of non-small cell lung cancer: a review of the current evidence, Chest, 2003. 123(1 Suppl): p. 137S-146S., https://www.ncbi.nlm.nih.gov/pubmed/12527573
376. Spira, A., Ettinger, D. S., Multidisciplinary management of lung cancer, N Engl J Med, 2004. 350(4): p. 379-392., https://www.ncbi.nlm.nih.gov/pubmed/14736930
377. Sihoe, A. D., Yim, A. P., Lung cancer staging, J Surg Res, 2004. 117: p. 92-106., https://www.ncbi.nlm.nih.gov/pubmed/15013719
378. Eberhardt, R., Anantham, D., Herth, F., Feller-Kopman, D., Ernst, A., Electromagnetic navigation diagnostic bronchoscopy in peripheral lung lesions, Chest, 2007. 131(6): p. 1800-1805., https://www.ncbi.nlm.nih.gov/pubmed/17400670
379. Gildea, T. R., Mazzone, P. J., Karnak, D., Meziane, M., Mehta, A. C., Electromagnetic navigation diagnostic bronchoscopy: a prospective study, Am J Respir Crit Care Med, 2006. 174(9): p. 982-989., https://www.ncbi.nlm.nih.gov/pubmed/16873767
380. Herth, F. J., Ernst, A., Becker, H. D., Endobronchial ultrasound-guided transbronchial lung biopsy in solitary pulmonary nodules and peripheral lesions, Eur Respir J, 2002. 20(4): p. 972-974., https://www.ncbi.nlm.nih.gov/pubmed/12412691
381. Kurimoto, N., Miyazawa, T., Okimasa, S., et al., Endobronchial ultrasonography using a guide sheath increases the ability to diagnose peripheral pulmonary lesions endoscopically. Chest 2004;126:959-965, Chest, 2004. 126: p. 959-965., https://www.ncbi.nlm.nih.gov/pubmed/15364779
382. Asahina, H., Yamazaki, K., Onodera, Y., Kikuchi, E., Shinagawa, N., Asano, F., et.al. Transbronchial biopsy using endobronchial ultrasonography with a guide sheath and virtual bronchoscopic navigation, Chest, 2005. 128(3): p. 1761-1765., https://www.ncbi.nlm.nih.gov/pubmed/16162785
383. Kikuchi, E., Yamazaki, K., Sukoh, N., Kikuchi, J., Asahina, H., Imura, M., et.al. Endobronchial ultrasonography with guide-sheath for peripheral pulmonary lesions, Eur Respir J, 2004. 24(4): p. 533-537., https://www.ncbi.nlm.nih.gov/pubmed/15459129
384. Sehgal, IS, Dhooria, S, Aggarwal, AN, Agarwal, R, Impact of Rapid On-Site Cytological Evaluation (ROSE) on the Diagnostic Yield of Transbronchial Needle Aspiration During Mediastinal Lymph Node Sampling: Systematic Review and Meta-Analysis., Chest, 2018. 153 (4)(4): p. 929-938., https://pubmed.ncbi.nlm.nih.gov/29154972/
385. Berquist, T. H., Bailey, P. B., Cortese, D. A., Miller, W. E., Transthoracic needle biopsy: accuracy and complications in relation to location and type of lesion, Mayo Clin Proc., 1980. 55(8): p. 475-481., https://www.ncbi.nlm.nih.gov/pubmed/7401689
386. Bungay, H. K., Pal, C. R., Davies, C. W., Davies, R. J., Gleeson, F. V., An evaluation of computed tomography as an aid to diagnosis in patients undergoing bronchoscopy for suspected bronchial carcinoma, Clin Radiol, 2000. 55(7): p. 554-560., https://www.ncbi.nlm.nih.gov/pubmed/10924381
387. Micames, C. G., McCrory, D. C., Pavey, D. A., Jowell, P. S., Gress, F. G., Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: A systematic review and metaanalysis, Chest, 2007. 131(2): p. 539-548., https://www.ncbi.nlm.nih.gov/pubmed/17296659
388. Labarca, G, Folch, E, Jantz, M, Mehta, HJ, Majid, A, Fernandez-Bussy, S, Adequacy of Samples Obtained by Endobronchial Ultrasound with Transbronchial Needle Aspiration for Molecular Analysis in Patients with Non-Small Cell Lung Cancer. Systematic Review and Meta-Analysis., Ann Am Thorac Soc, 2018. 15 (10)(10): p. 1205-1216., https://pubmed.ncbi.nlm.nih.gov/30011388/
389. Layfield, LJ, Pearson, L, Walker, BS, White, SK, Schmidt, RL, Diagnostic Accuracy of Fine-Needle Aspiration Cytology for Discrimination of Squamous Cell Carcinoma from Adenocarcinoma in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis., Acta Cytol, 2018. 62 (5-6)(5-6): p. 318-326., https://pubmed.ncbi.nlm.nih.gov/30380531/
390. Schreiber, G., McCrory, D. C., Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence, Chest, 2003. 123(1 Suppl): p. 115S-128S., https://www.ncbi.nlm.nih.gov/pubmed/12527571
391. Rivera, M. P., Mehta, A., Initial diagnosis of lung cancer. ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition), Chest, 2007. 132: p. 131S-148S., https://www.ncbi.nlm.nih.gov/pubmed/17873165
392. Risse, E. K., van't Hof, M. A., Vooijs, G. P., Relationship between patient characteristics and the sputum cytologic diagnosis of lung cancer, Acta Cytol., 1987. 31(2): p. 159-165., https://www.ncbi.nlm.nih.gov/pubmed/3469848
393. Agusti, C., Xaubet, A., Monton, C., Sole, M., Soler, N., Carrion, M., et.al. Induced sputum in the diagnosis of peripheral lung cancer not visible endoscopically, Respir Med, 2001. 95(10): p. 822-828., https://www.ncbi.nlm.nih.gov/pubmed/11601749
394. Raab, S. S., Hornberger, J., Raffin, T., The importance of sputum cytology in the diagnosis of lung cancer: a cost-effectiveness analysis, Chest, 1997. 112(4): p. 937-945., https://www.ncbi.nlm.nih.gov/pubmed/9377956
395. Jay, S. J., Wehr, K., Nicholson, D. P., Smith, A. L., Diagnostic sensitivity and specificity of pulmonary cytology: comparison of techniques used in conjunction with flexible fiber optic bronchoscopy, Acta Cytol., 1980. 24(4): p. 304-312., https://www.ncbi.nlm.nih.gov/pubmed/6932142
396. Dennie, C. J., Matzinger, F. R., Marriner, J. R., Maziak, D. E., Transthoracic needle biopsy of the lung: results of early discharge in 506 outpatients, Radiology, 2001. 219(1): p. 247-251., https://www.ncbi.nlm.nih.gov/pubmed/11274565
397. Mitruka, S., Landreneau, R. J., Mack, M. J., Fetterman, L. S., Gammie, J., Bartley, S., et.al. Diagnosing the indeterminate pulmonary nodule: percutaneous biopsy versus thoracoscopy, Surgery, 1995. 118(4): p. 676-684., https://www.ncbi.nlm.nih.gov/pubmed/7570322
398. Ohno, Y., Hatabu, H., Takenaka, D., Higashino, T., Watanabe, H., Ohbayashi, C., et.al. CT-guided transthoracic needle aspiration biopsy of small (< or = 20 mm) solitary pulmonary nodules, AJR Am J Roentgenol., 2003. 180(6): p. 1665-1669., https://www.ncbi.nlm.nih.gov/pubmed/12760939
399. Chung, T., Fine needle aspiration of the solitary pulmonary nodule, Semin Thorac.Cardiovasc.Surg, 2002. 14(3): p. 275-280., https://www.ncbi.nlm.nih.gov/pubmed/12232869
400. Hartman, T. E., Radiologic evaluation of the solitary pulmonary nodule, Semin Thorac.Cardiovasc.Surg, 2002. 14(3): p. 261-267., https://pubmed.ncbi.nlm.nih.gov/12232867/
401. Yamagami, T., Iida, S., Kato, T., Tanaka, O., Nishimura, T., Combining fine-needle aspiration and core biopsy under CT fluoroscopy guidance: a better way to treat patients with lung nodules?, AJR Am J Roentgenol., 2003. 180(3): p. 811-815., https://www.ncbi.nlm.nih.gov/pubmed/12591702
402. Yamagami, T., Iida, S., Kato, T., Tanaka, O., Toda, S., Kato, D., et.al. Usefulness of new automated cutting needle for tissue-core biopsy of lung nodules under CT fluoroscopic guidance, Chest, 2003. 124(1): p. 147-154., https://www.ncbi.nlm.nih.gov/pubmed/12853517
403. Motherby, H., Nadjari, B., Friegel, P., Kohaus, J., Ramp, U., Bocking, A., Diagnostic accuracy of effusion cytology, Diagn.Cytopathol., 1999. 20(6): p. 350-357., https://www.ncbi.nlm.nih.gov/pubmed/10352907
404. Metzgeroth, G., Kuhn, C., Schultheis, B., Hehlmann, R., Hastka, J., Diagnostic accuracy of cytology and immunocytology in carcinomatous effusions, Cytopathology, 2008. 19(4): p. 205-211., https://www.ncbi.nlm.nih.gov/pubmed/17573908
405. Manhire, A., Charig, M., Clelland, C., Gleeson, F., Miller, R., Moss, H., et.al. Guidelines for radiologically guided lung biopsy, Thorax, 2003. 58(11): p. 920-936., https://www.ncbi.nlm.nih.gov/pubmed/14586042
406. Antunes, G., Neville, E., Duffy, J., Ali, N., BTS guidelines for the management of malignant pleural effusions, Thorax, 2003. 58 Suppl 2: p. ii29-ii38., https://www.ncbi.nlm.nih.gov/pubmed/12728148
407. Belani, C. P., Einarson, T. R., Arikian, S. R., Doyle, J., Costeffectiveness analysis of pleurodesis in the management of malignant pleural effusion, Journal of Oncology Management, 2004. 4: p. 24-34.
408. Porte, H., Roumilhac, D., Eraldi, L., Cordonnier, C., Puech, P., Wurtz, A., The role of mediastinoscopy in the diagnosis of mediastinal lymphadenopathy, Eur J Cardiothorac.Surg, 1998. 13(2): p. 196-199., https://www.ncbi.nlm.nih.gov/pubmed/9583827
409. Kramer, H., Groen, H. J., Current concepts in the mediastinal lymph node staging of nonsmall cell lung cancer, Ann Surg, 2003. 238(2): p. 180-188., https://www.ncbi.nlm.nih.gov/pubmed/12894010
410. Yasufuku, K., Fujisawa, T., Staging and diagnosis of non-small cell lung cancer: invasive modalities, Respirology., 2007. 12(2): p. 173-183., https://www.ncbi.nlm.nih.gov/pubmed/17298448
411. Eddy, R. J., Cost-effectiveness of CT scanning compared with mediastinoscopy in the preoperative staging of lung cancer, Can.Assoc.Radiol J, 1989. 40(4): p. 189-193., https://www.ncbi.nlm.nih.gov/pubmed/2504443
412. Hammoud, Z. T., Anderson, R. C., Meyers, B. F., Guthrie, T. J., Roper, C. L., Cooper, J. D., et.al. The current role of mediastinoscopy in the evaluation of thoracic disease, J Thorac.Cardiovasc.Surg, 1999. 118(5): p. 894-899., https://www.ncbi.nlm.nih.gov/pubmed/10534695
413. Pass, H. I., Mediastinal staging 2005: pictures, scopes, and scalpels, Semin Oncol, 2005. 32(3): p. 269-278., https://www.ncbi.nlm.nih.gov/pubmed/15988681
414. Catarino, P. A., Goldstraw, P., The future in diagnosis and staging of lung cancer: surgical techniques, Respiration, 2006. 73(6): p. 717-732., https://www.ncbi.nlm.nih.gov/pubmed/17119351
415. Bankier, AA, MacMahon, H, Goo, JM, Rubin, GD, Schaefer-Prokop, CM, Naidich, DP, Recommendations for Measuring Pulmonary Nodules at CT: A Statement from the Fleischner Society., Radiology, 2017. 285 (2)(2): p. 584-600., https://pubmed.ncbi.nlm.nih.gov/28650738/
416. MacMahon, H, Naidich, DP, Goo, JM, Lee, KS, Leung, ANC, Mayo, JR, et.al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017., Radiology, 2017. 284 (1)(1): p. 228-243., https://pubmed.ncbi.nlm.nih.gov/28240562/
417. Gould, MK, Donington, J, Lynch, WR, Mazzone, PJ, Midthun, DE, Naidich, DP, et.al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines., Chest, 2013. 143 (5 Suppl)(5 Suppl): p. e93S-e120S., https://pubmed.ncbi.nlm.nih.gov/23649456/
418. Callister, ME, Baldwin, DR, Akram, AR, Barnard, S, Cane, P, Draffan, J, et.al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules., Thorax, 2015. 70 Suppl 2 (): p. ii1-ii54., https://pubmed.ncbi.nlm.nih.gov/26082159/
419. Swensen, SJ, Silverstein, MD, Ilstrup, DM, Schleck, CD, Edell, ES, The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules., Arch Intern Med, 1997. 157 (8)(8): p. 849-55., https://pubmed.ncbi.nlm.nih.gov/9129544/
420. Herder, GJ, van Tinteren, H, Golding, RP, Kostense, PJ, Comans, EF, Smit, EF, et.al. Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography., Chest, 2005. 128 (4)(4): p. 2490-6., https://pubmed.ncbi.nlm.nih.gov/16236914/
421. McWilliams, A, Tammemagi, MC, Mayo, JR, Roberts, H, Liu, G, Soghrati, K, et.al. Probability of cancer in pulmonary nodules detected on first screening CT., N Engl J Med, 2013. 369 (10)(10): p. 910-9., https://pubmed.ncbi.nlm.nih.gov/24004118/
422. Tan, B. B., Flaherty, K. R., Kazerooni, E. A., et al., The solitary pulmonary nodule. Chest 2003; 123(suppl):89S-96S, Chest, 2003. 123(Suppl): p. 89S-96S., https://www.ncbi.nlm.nih.gov/pubmed/12527568
423. Ost, D., Fein, A. M., Feinsilver, S. H., Clinical practice. The solitary pulmonary nodule, N.Engl.J.Med, 2003. 348(25): p. 2535-2542., https://www.ncbi.nlm.nih.gov/pubmed/12815140
424. Gould, M. K., Fletcher, J., Iannettoni, M. D., Lynch, W. R., Midthun, D. E., Naidich, D. P., et.al. Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition), Chest, 2007. 132(3 Suppl): p. 108S-130S., https://www.ncbi.nlm.nih.gov/pubmed/17873164
425. Aberle, DR, DeMello, S, Berg, CD, Black, WC, Brewer, B, Church, TR, et.al. Results of the two incidence screenings in the National Lung Screening Trial., N Engl J Med, 2013. 369 (10)(10): p. 920-31., https://pubmed.ncbi.nlm.nih.gov/24004119/
426. Revel, MP, Bissery, A, Bienvenu, M, Aycard, L, Lefort, C, Frija, G, Are two-dimensional CT measurements of small noncalcified pulmonary nodules reliable?, Radiology, 2004. 231 (2)(2): p. 453-8., https://pubmed.ncbi.nlm.nih.gov/15128990/
427. Horeweg, Nanda, Scholten, Ernst Th, de Jong, Pim A, van der Aalst, Carlijn M, Weenink, Carla, Lammers, Jan-Willem J, et.al. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers., Lancet Oncol, 2014. 15(12): p. 1342-50., https://www.ncbi.nlm.nih.gov/pubmed/25282284
428. Matsuguma, H, Mori, K, Nakahara, R, Suzuki, H, Kasai, T, Kamiyama, Y, et.al. Characteristics of subsolid pulmonary nodules showing growth during follow-up with CT scanning., Chest, 2013. 143 (2)(2): p. 436-443., https://pubmed.ncbi.nlm.nih.gov/22814723/
429. Ichinose, J, Kohno, T, Fujimori, S, Harano, T, Suzuki, S, Fujii, T, Invasiveness and malignant potential of pulmonary lesions presenting as pure ground-glass opacities., Ann Thorac Cardiovasc Surg, 2014. 20 (5)(5): p. 347-52., https://pubmed.ncbi.nlm.nih.gov/24088912/
430. Gould, MK, Maclean, CC, Kuschner, WG, Rydzak, CE, Owens, DK, Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis., JAMA, 2001. 285 (7)(7): p. 914-24., https://pubmed.ncbi.nlm.nih.gov/11180735/
431. Deppen, SA, Blume, JD, Kensinger, CD, Morgan, AM, Aldrich, MC, Massion, PP, et.al. Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis., JAMA, 2014. 312 (12)(12): p. 1227-36., https://pubmed.ncbi.nlm.nih.gov/25247519/
432. Cardillo, G, Regal, M, Sera, F, Di Martino, M, Carbone, L, Facciolo, F, et.al. Videothoracoscopic management of the solitary pulmonary nodule: a single-institution study on 429 cases., Ann Thorac Surg, 2003. 75 (5)(5): p. 1607-11; discussion 1611-2., https://pubmed.ncbi.nlm.nih.gov/12735587/
433. Petersen, RH, Hansen, HJ, Dirksen, A, Pedersen, JH, Lung cancer screening and video-assisted thoracic surgery., J Thorac Oncol, 2012. 7 (6)(6): p. 1026-31., https://pubmed.ncbi.nlm.nih.gov/22588154/
434. Field, JK, Smith, RA, Aberle, DR, Oudkerk, M, Baldwin, DR, Yankelevitz, D, et.al. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report., J Thorac Oncol, 2012. 7 (1)(1): p. 10-9., https://pubmed.ncbi.nlm.nih.gov/22173661/
435. Berman, AT, Jabbour, SK, Vachani, A, Robinson, C, Choi, JI, Mohindra, P, et.al. Empiric Radiotherapy for Lung Cancer Collaborative Group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation., Transl Lung Cancer Res, 2019. 8 (1)(1): p. 5-14., https://pubmed.ncbi.nlm.nih.gov/30788230/
436. IJsseldijk, MA, Shoni, M, Siegert, C, Wiering, B, van Engelenburg, KCA, Lebenthal, A, et.al. Survival After Stereotactic Body Radiation Therapy for Clinically Diagnosed or Biopsy-Proven Early-Stage NSCLC: A Systematic Review and Meta-Analysis., J Thorac Oncol, 2019. 14 (4)(4): p. 583-595., https://pubmed.ncbi.nlm.nih.gov/30721798/
437. Tsao, MS, Rosenthal, A, Nicholson, AG, Detterbeck, F, Eberhardt, WEE, Lievens, Y, et.al. The International Association for the Study of Lung Cancer Staging Project: The Database and Proposal for the Revision of the Staging of Pulmonary Neuroendocrine Carcinoma in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer., J Thorac Oncol, 2025. 20 (7)(7): p. 856-870., https://pubmed.ncbi.nlm.nih.gov/39864546/
438. Detterbeck, FC, Woodard, GA, Bader, AS, Dacic, S, Grant, MJ, Park, HS, et.al. The Proposed Ninth Edition TNM Classification of Lung Cancer., Chest, 2024. 166 (4)(4): p. 882-895., https://pubmed.ncbi.nlm.nih.gov/38885896/
439. Detterbeck, FC, Ostrowski, M, Hoffmann, H, Rami-Porta, R, Osarogiagbon, RU, Donnington, J, et.al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor After Resection for the Forthcoming (Ninth) Edition of the TNM Classification of Lung Cancer., J Thorac Oncol, 2024. 19 (7)(7): p. 1052-1072., https://pubmed.ncbi.nlm.nih.gov/38569931/
440. Van Schil, PE, Asamura, H, Nishimura, KK, Rami-Porta, R, Kim, YT, Bertoglio, P, et.al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer., J Thorac Oncol, 2024. 19 (5)(5): p. 749-765., https://pubmed.ncbi.nlm.nih.gov/38070600/
441. Rami-Porta, R, Bolejack, V, Crowley, J, Ball, D, Kim, J, Lyons, G, et.al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer., J Thorac Oncol, 2015. 10 (7)(7): p. 990-1003., https://pubmed.ncbi.nlm.nih.gov/26134221/
442. Huang, J, Osarogiagbon, RU, Giroux, DJ, Nishimura, KK, Bille, A, Cardillo, G, et.al. The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer., J Thorac Oncol, 2024. 19 (5)(5): p. 766-785., https://pubmed.ncbi.nlm.nih.gov/37866624/
443. Robinson, L. A., Wagner, H., Jr., Ruckdeschel, J. C., Treatment of stage IIIA non-small cell lung cancer, Chest, 2003. 123(1 Suppl): p. 202S-220S., https://www.ncbi.nlm.nih.gov/pubmed/12527580
444. Robinson, L. A., Ruckdeschel, J. C., Wagner, H., Jr., Stevens, C. W., Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition), Chest, 2007. 132(3 Suppl): p. 243S-265S., https://www.ncbi.nlm.nih.gov/pubmed/17873172
445. Rusch, V. W., Asamura, H., Watanabe, H., Giroux, D. J., Rami-Porta, R., Goldstraw, P., The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer, J Thorac Oncol, 2009. 4(5): p. 568-77., https://www.ncbi.nlm.nih.gov/pubmed/19357537
446. Fong, KM, Rosenthal, A, Giroux, DJ, Nishimura, KK, Erasmus, J, Lievens, Y, et.al. The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer., J Thorac Oncol, 2024. 19 (5)(5): p. 786-802., https://pubmed.ncbi.nlm.nih.gov/38320664/
447. Rami-Porta, R, Nishimura, KK, Giroux, DJ, Detterbeck, F, Cardillo, G, Edwards, JG, et.al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer., J Thorac Oncol, 2024. 19 (7)(7): p. 1007-1027., https://pubmed.ncbi.nlm.nih.gov/38447919/
448. Wittekind, C., TNM: Klassifikation maligner TumorenWiley, 2017.
449. Warth, A., Muley, T., Herpel, E., Meister, M., Herth, F. J., Schirmacher, P., et.al. Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies, Histopathology, 2012. 61(6): p. 1017-25., https://www.ncbi.nlm.nih.gov/pubmed/22882703
450. Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H., Beasley, M. B., et.al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification, J Thorac Oncol, 2015. 10(9): p. 1243-60., https://www.ncbi.nlm.nih.gov/pubmed/26291008
451. Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., et.al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours, J Thorac.Oncol, 2007. 2(8): p. 706-714., https://www.ncbi.nlm.nih.gov/pubmed/17762336
452. Detterbeck, F. C., Boffa, D. J., Tanoue, L. T., The new lung cancer staging system, Chest, 2009. 136(1): p. 260-71., https://www.ncbi.nlm.nih.gov/pubmed/19584208
453. Travis, W. D., Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee, Histopathology, 2009. 54(1): p. 3-11., https://www.ncbi.nlm.nih.gov/pubmed/19187176
454. Rami-Porta, R., Bolejack, V., Giroux, D. J., Chansky, K., Crowley, J., Asamura, H., et.al. The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer, J Thorac Oncol, 2014. 9(11): p. 1618-24., https://www.ncbi.nlm.nih.gov/pubmed/25436796
455. Hattori, A., Matsunaga, T., Takamochi, K., Oh, S., Suzuki, K., Surgical Management of Multifocal Ground-Glass Opacities of the Lung: Correlation of Clinicopathologic and Radiologic Findings, Thorac Cardiovasc Surg, 2016., https://www.ncbi.nlm.nih.gov/pubmed/26902328
456. Dienemann, H., Trainer, C., Hoffmann, H., Bulzebruck, H., Muley, T., Kayser, K., et.al. [Incomplete resections in bronchial carcinoma: morbidity and prognosis], Chirurg, 1997. 68(10): p. 1014-9., https://pubmed.ncbi.nlm.nih.gov/9453893/
457. Passlick, B., Sitar, I., Sienel, W., Thetter, O., Morresi-Hauf, A., Significance of lymphangiosis carcinomatosa at the bronchial resection margin in patients with non-small cell lung cancer, Ann Thorac Surg, 2001. 72(4): p. 1160-4., https://www.ncbi.nlm.nih.gov/pubmed/11603430
458. Kawaguchi, T., Watanabe, S., Kawachi, R., Suzuki, K., Asamura, H., The impact of residual tumor morphology on prognosis, recurrence, and fistula formation after lung cancer resection, J Thorac Oncol, 2008. 3(6): p. 599-603., https://www.ncbi.nlm.nih.gov/pubmed/18520797
459. Riquet, M., Achour, K., Foucault, C., Le Pimpec Barthes, F., Dujon, A., Cazes, A., Microscopic residual disease after resection for lung cancer: a multifaceted but poor factor of prognosis, Ann Thorac Surg, 2010. 89(3): p. 870-5., https://www.ncbi.nlm.nih.gov/pubmed/20172145
460. Hancock, J. G., Rosen, J. E., Antonicelli, A., Moreno, A., Kim, A. W., Detterbeck, F. C., et.al. Impact of adjuvant treatment for microscopic residual disease after non-small cell lung cancer surgery, Ann Thorac Surg, 2015. 99(2): p. 406-13., https://www.ncbi.nlm.nih.gov/pubmed/25528723
461. Moreira, AL, Ocampo, PSS, Xia, Y, Zhong, H, Russell, PA, Minami, Y, et.al. A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee., J Thorac Oncol, 2020. 15 (10)(10): p. 1599-1610., https://pubmed.ncbi.nlm.nih.gov/32562873/
462. Thomas, M., Rube, C., Semik, M., von, Eiff M., Freitag, L., Macha, H. N., et.al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer, J.Clin.Oncol, 1999. 17(4): p. 1185., https://www.ncbi.nlm.nih.gov/pubmed/10561177
463. Junker, K., Therapieinduzierte Tumorregression und Regressionsgrading bei Lungenkarzinomen, Der Pathologe, 2014. 35(6): p. 574-577., https://www.springermedizin.de/therapieinduzierte-tumorregression-und-regressionsgrading-bei-lu/8301204
464. von Laffert, M., Schirmacher, P., Warth, A., Weichert, W., Büttner, R., Huber, R. M., et.al. Stellungnahme der DGP und der AG Thorakale Onkologie der AG Onkologie/Deutsche Krebsgesellschaft e. V. zur ALK-Testung beim NSCLC, Der Pathologe, 2016. 37(2): p. 187-192., https://doi.org/10.1007/s00292-016-0152-1
465. Moskalev, E. A., Stohr, R., Rieker, R., Hebele, S., Fuchs, F., Sirbu, H., et.al. Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing, Virchows Arch, 2013. 462(4): p. 409-19., https://www.ncbi.nlm.nih.gov/pubmed/23468066
466. Querings, S., Altmuller, J., Ansen, S., Zander, T., Seidel, D., Gabler, F., et.al. Benchmarking of mutation diagnostics in clinical lung cancer specimens, PLoS One, 2011. 6(5): p. e19601., https://pubmed.ncbi.nlm.nih.gov/21573178/
467. Rolfo, C, Mack, PC, Scagliotti, GV, Baas, P, Barlesi, F, Bivona, TG, et.al. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC., J Thorac Oncol, 2018. 13 (9)(9): p. 1248-1268., https://pubmed.ncbi.nlm.nih.gov/29885479/
468. Scheel, A. H., Ansen, S., Schultheis, A. M., Scheffler, M., Fischer, R. N., Michels, S., et.al. PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations, Oncoimmunology, 2016. 5(5): p. e1131379., https://www.ncbi.nlm.nih.gov/pubmed/27467949
469. Scheel, A. H., Dietel, M., Heukamp, L. C., Johrens, K., Kirchner, T., Reu, S., et.al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas, Mod Pathol, 2016. 29(10): p. 1165-72., https://www.ncbi.nlm.nih.gov/pubmed/27389313
470. Scheel, A. H., Dietel, M., Heukamp, L. C., Johrens, K., Kirchner, T., Reu, S., et.al. [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study], Pathologe, 2016. 37(6): p. 557-567., https://www.ncbi.nlm.nih.gov/pubmed/27510417
471. British Thoracic, Society, Society of Cardiothoracic Surgeons of Great, Britain, Ireland Working, Party, BTS guidelines: guidelines on the selection of patients with lung cancer for surgery, Thorax, 2001. 56(2): p. 89-108., https://www.ncbi.nlm.nih.gov/pubmed/11209097
472. Bolliger, C. T., Perruchoud, A. P., Functional evaluation of the lung resection candidate, Eur.Respir.J., 1998. 11(1): p. 198-212., https://www.ncbi.nlm.nih.gov/pubmed/9543294
473. Bolliger, C. T., Koegelenberg, C. F., Kendal, R., Preoperative assessment for lung cancer surgery, Curr.Opin.Pulm.Med., 2005. 11(4): p. 301-306., https://www.ncbi.nlm.nih.gov/pubmed/15928496
474. de, Perrot M., Licker, M., Reymond, M. A., Robert, J., Spiliopoulos, A., Influence of age on operative mortality and long-term survival after lung resection for bronchogenic carcinoma, Eur.Respir.J., 1999. 14(2): p. 419-422., https://www.ncbi.nlm.nih.gov/pubmed/10515423
475. Bolliger, C. T., Wyser, C., Roser, H., Soler, M., Perruchoud, A. P., Lung scanning and exercise testing for the prediction of postoperative performance in lung resection candidates at increased risk for complications, Chest, 1995. 108(2): p. 341-348., https://www.ncbi.nlm.nih.gov/pubmed/7634864
476. Bolliger, C. T., Heitz, M., Hauser, R., Probst, R., Perruchoud, A. P., An Airway Wallstent for the treatment of tracheobronchial malignancies, Thorax, 1996. 51(11): p. 1127-1129., https://pubmed.ncbi.nlm.nih.gov/8958897/
477. Empfehlungen zur präoperativen Lungenfunktionsdiagnostik, Pneumologie, 1994. 48: p. 296-299.
478. Assessment, Arbeitsgruppe Geriatrisches, Geriatrisches BasisassessmentBach M. et al, AGAST, 1997. 2:
479. Miller, J. I., Jr., Physiologic evaluation of pulmonary function in the candidate for lung resection, J.Thorac.Cardiovasc.Surg., 1993. 105(2): p. 347-351., https://www.ncbi.nlm.nih.gov/pubmed/8429663
480. Licker, M. J., Widikker, I., Robert, J., Frey, J. G., Spiliopoulos, A., Ellenberger, C., et.al. Operative mortality and respiratory complications after lung resection for cancer: impact of chronic obstructive pulmonary disease and time trends, Ann.Thorac.Surg., 2006. 81(5): p. 1830-1837., https://www.ncbi.nlm.nih.gov/pubmed/16631680
481. Linden, P. A., Bueno, R., Colson, Y. L., Jaklitsch, M. T., Lukanich, J., Mentzer, S., et.al. Lung resection in patients with preoperative FEV1 < 35% predicted, Chest, 2005. 127(6): p. 1984-1990., https://www.ncbi.nlm.nih.gov/pubmed/15951309
482. Brunelli, A., Belardinelli, R., Refai, M., Salati, M., Socci, L., Pompili, C., et.al. Peak Oxygen Consumption During Cardiopulmonary Exercise Test Improves Risk Stratification in Candidates to Major Lung Resectio, Chest, 2008., https://www.ncbi.nlm.nih.gov/pubmed/19029436
483. Ferguson, M. K., Little, L., Rizzo, L., Popovich, K. J., Glonek, G. F., Leff, A., et.al. Diffusing capacity predicts morbidity and mortality after pulmonary resection, J.Thorac.Cardiovasc.Surg., 1988. 96(6): p. 894-900., https://www.ncbi.nlm.nih.gov/pubmed/3193801
484. Ferguson, M. K., Vigneswaran, W. T., Diffusing capacity predicts morbidity after lung resection in patients without obstructive lung disease, Ann.Thorac.Surg., 2008. 85(4): p. 1158-1164., https://www.ncbi.nlm.nih.gov/pubmed/18355489
485. Loewen, G. M., Watson, D., Kohman, L., Herndon, J. E., Shennib, H., Kernstine, K., et.al. Preoperative exercise Vo2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238, J.Thorac.Oncol., 2007. 2(7): p. 619-625., https://www.ncbi.nlm.nih.gov/pubmed/17607117
486. Brunelli, A., Refai, M. A., Salati, M., Sabbatini, A., Morgan-Hughes, N. J., Rocco, G., Carbon monoxide lung diffusion capacity improves risk stratification in patients without airflow limitation: evidence for systematic measurement before lung resection, Eur.J.Cardiothorac.Surg., 2006. 29(4): p. 567-570., https://www.ncbi.nlm.nih.gov/pubmed/16481190
487. Brunelli, A., Refai, M., Salati, M., Xiume, F., Sabbatini, A., Predicted versus observed FEV1 and DLCO after major lung resection: a prospective evaluation at different postoperative periods, Ann.Thorac.Surg., 2007. 83(3): p. 1134-1139., https://www.ncbi.nlm.nih.gov/pubmed/17307474
488. Depierre, A., Lagrange, J. L., Theobald, S., et al., Summary report of the Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000), Br J Cancer, 2003. 89 (Suppl 1): p. S35-S49., https://pubmed.ncbi.nlm.nih.gov/12915902/
489. Pierce, R. J., Copland, J. M., Sharpe, K., Barter, C. E., Preoperative risk evaluation for lung cancer resection: predicted postoperative product as a predictor of surgical mortality, Am.J.Respir.Crit Care Med., 1994. 150(4): p. 947-955., https://www.ncbi.nlm.nih.gov/pubmed/7921468
490. Wang, J. S., Abboud, R. T., Wang, L. M., Effect of lung resection on exercise capacity and on carbon monoxide diffusing capacity during exercise, Chest, 2006. 129(4): p. 863-872., https://www.ncbi.nlm.nih.gov/pubmed/16608931
491. Wyser, C., Stulz, P., Soler, M., Tamm, M., Muller-Brand, J., Habicht, J., et.al. Prospective evaluation of an algorithm for the functional assessment of lung resection candidates, Am.J.Respir.Crit Care Med., 1999. 159(5 Pt 1): p. 1450-1456., https://www.ncbi.nlm.nih.gov/pubmed/10228110
492. Baldi, S., Ruffini, E., Harari, S., Roviaro, G. C., Nosotti, M., Bellaviti, N., et.al. Does lobectomy for lung cancer in patients with chronic obstructive pulmonary disease affect lung function? A multicenter national study, J.Thorac.Cardiovasc.Surg., 2005. 130(6): p. 1616-1622., https://www.ncbi.nlm.nih.gov/pubmed/16308007
493. Epstein, S. K., Faling, L. J., Daly, B. D., Celli, B. R., Predicting complications after pulmonary resection. Preoperative exercise testing vs a multifactorial cardiopulmonary risk index, Chest, 1993. 104(3): p. 694-700., https://www.ncbi.nlm.nih.gov/pubmed/8365278
494. Magdeleinat, P., Seguin, A., Alifano, M., Boubia, S., Regnard, J. F., Early and long-term results of lung resection for non-small-cell lung cancer in patients with severe ventilatory impairment, Eur.J.Cardiothorac.Surg., 2005. 27(6): p. 1099-1105., https://www.ncbi.nlm.nih.gov/pubmed/15896625
495. Olsen, G. N., Block, A. J., Tobias, J. A., Prediction of postpneumonectomy pulmonary function using quantitative macroaggregate lung scanning, Chest, 1974. 66: p. 13-16., https://www.ncbi.nlm.nih.gov/pubmed/4846113
496. Olsen, G. N., Block, A. J., Swenson, E. W., Castle, J. R., Wynne, J. W., Pulmonary function evaluation of the lung resection candidate: a prospective study, Am.Rev.Respir.Dis., 1975. 111(4): p. 379-387., https://www.ncbi.nlm.nih.gov/pubmed/1124884
497. Corris, P. A., Ellis, D. A., Hawkins, T., Gibson, G. J., Use of radionuclide scanning in the preoperative estimation of pulmonary function after pneumonectomy, Thorax, 1987. 42(4): p. 285-291., https://www.ncbi.nlm.nih.gov/pubmed/3616987
498. Markos, J., Mullan, B. P., Hillman, D. R., Musk, A. W., Antico, V. F., Lovegrove, F. T., et.al. Preoperative assessment as a predictor of mortality and morbidity after lung resection, Am.Rev.Respir.Dis., 1989. 139(4): p. 902-910., https://www.ncbi.nlm.nih.gov/pubmed/2930068
499. Ohno, Y., Koyama, H., Takenaka, D., Nogami, M., Kotani, Y., Nishimura, Y., et.al. Coregistered ventilation and perfusion SPECT using krypton-81m and Tc-99m-labeled macroaggregated albumin with multislice CT utility for prediction of postoperative lung function in non-small cell lung cancer patients, Acad.Radiol., 2007. 14(7): p. 830-838., https://www.ncbi.nlm.nih.gov/pubmed/17574133
500. Epstein, S. K., Faling, L. J., Daly, B. D., Celli, B. R., Inability to perform bicycle ergometry predicts increased morbidity and mortality after lung resection, Chest, 1995. 107(2): p. 311-316., https://www.ncbi.nlm.nih.gov/pubmed/7842753
501. Matsuoka, H., Nishio, W., Sakamoto, T., Harada, H., Tsubota, N., Prediction of morbidity after lung resection with risk factors using treadmill exercise test, Eur.J.Cardiothorac.Surg., 2004. 26(3): p. 480-482., https://www.ncbi.nlm.nih.gov/pubmed/15302038
502. Walsh, G. L., Morice, R. C., Putnam, J. B., Jr., Nesbitt, J. C., McMurtrey, M. J., Ryan, M. B., et.al. Resection of lung cancer is justified in high-risk patients selected by exercise oxygen consumption, Ann.Thorac.Surg., 1994. 58(3): p. 704-710., https://www.ncbi.nlm.nih.gov/pubmed/7944692
503. Smith, T. P., Kinasewitz, G. T., Tucker, W. Y., Spillers, W. P., George, R. B., Exercise capacity as a predictor of post-thoracotomy morbidity, Am.Rev.Respir.Dis., 1984. 129(5): p. 730-734., https://www.ncbi.nlm.nih.gov/pubmed/6721272
504. Singh, S. J., Morgan, M. D., Hardman, A. E., Rowe, C., Bardsley, P. A., Comparison of oxygen uptake during a conventional treadmill test and the shuttle walking test in chronic airflow limitation, Eur.Respir.J., 1994. 7(11): p. 2016-2020., https://www.ncbi.nlm.nih.gov/pubmed/7875275
505. Bechard, D., Wetstein, L., Assessment of exercise oxygen consumption as preoperative criterion for lung resection, Ann.Thorac.Surg., 1987. 44(4): p. 344-349., https://www.ncbi.nlm.nih.gov/pubmed/3662680
506. Brutsche, M. H., Spiliopoulos, A., Bolliger, C. T., Licker, M., Frey, J. G., Tschopp, J. M., Exercise capacity and extent of resection as predictors of surgical risk in lung cancer, Eur.Respir.J., 2000. 15(5): p. 828-832., https://www.ncbi.nlm.nih.gov/pubmed/10853844
507. Brunelli, A., Refai, M., Xiume, F., Salati, M., Sciarra, V., Socci, L., et.al. Performance at symptom-limited stair-climbing test is associated with increased cardiopulmonary complications, mortality, and costs after major lung resection, Ann.Thorac.Surg., 2008. 86(1): p. 240-247., https://www.ncbi.nlm.nih.gov/pubmed/18573431
508. Teschner, M., Starp, F., Lullig, H., Die Resektion von (NSCLC-) Bronchialkarzinomen mit simultaner Lungenvolumenreduktion bei terminalem Lungenemphysem, Pneumologie, 2003. 57(7): p. 367-372., https://pubmed.ncbi.nlm.nih.gov/12861492/
509. Nakagawa, M., Tanaka, H., Tsukuma, H., Kishi, Y., Relationship between the duration of the preoperative smoke-free period and the incidence of postoperative pulmonary complications after pulmonary surgery, Chest, 2001. 120(3): p. 705-710., https://www.ncbi.nlm.nih.gov/pubmed/11555496
510. Barrera, R., Shi, W., Amar, D., Thaler, H. T., Gabovich, N., Bains, M. S., et.al. Smoking and timing of cessation: impact on pulmonary complications after thoracotomy, Chest, 2005. 127(6): p. 1977-1983., https://www.ncbi.nlm.nih.gov/pubmed/15947310
511. Pate, P., Tenholder, M. F., Griffin, J. P., Eastridge, C. E., Weiman, D. S., Preoperative assessment of the high-risk patient for lung resection, Ann.Thorac.Surg., 1996. 61(5): p. 1494-1500., https://www.ncbi.nlm.nih.gov/pubmed/8633965
512. Kearney, D. J., Lee, T. H., Reilly, J. J., DeCamp, M. M., Sugarbaker, D. J., Assessment of operative risk in patients undergoing lung resection. Importance of predicted pulmonary function, Chest, 1994. 105(3): p. 753-759., https://www.ncbi.nlm.nih.gov/pubmed/8131537
513. Larsen, K. R., Svendsen, U. G., Milman, N., Brenoe, J., Petersen, B. N., Cardiopulmonary function at rest and during exercise after resection for bronchial carcinoma, Ann.Thorac.Surg., 1997. 64(4): p. 960-964., https://www.ncbi.nlm.nih.gov/pubmed/9354509
514. Algar, F. J., Alvarez, A., Salvatierra, A., Baamonde, C., Aranda, J. L., Lopez-Pujol, F. J., Predicting pulmonary complications after pneumonectomy for lung cancer, Eur.J.Cardiothorac.Surg., 2003. 23(2): p. 201-208., https://pubmed.ncbi.nlm.nih.gov/12559343/
515. Ferguson, M. K., Lehman, A. G., Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques, Ann.Thorac.Surg., 2003. 76(6): p. 1782-1788., https://www.ncbi.nlm.nih.gov/pubmed/14667584
516. Mariano-Goulart, D., Barbotte, E., Basurko, C., Comte, F., Rossi, M., Accuracy and precision of perfusion lung scintigraphy versus 133Xe-radiospirometry for preoperative pulmonary functional assessment of patients with lung cancer, Eur.J.Nucl.Med.Mol.Imaging, 2006. 33(9): p. 1048-1054., https://www.ncbi.nlm.nih.gov/pubmed/16639608
517. Win, T., Laroche, C. M., Groves, A. M., White, C., Wells, F. C., Ritchie, A. J., et.al. Use of quantitative lung scintigraphy to predict postoperative pulmonary function in lung cancer patients undergoing lobectomy, Ann.Thorac.Surg., 2004. 78(4): p. 1215-1218., https://www.ncbi.nlm.nih.gov/pubmed/15464473
518. Wu, M. T., Pan, H. B., Chiang, A. A., Hsu, H. K., Chang, H. C., Peng, N. J., et.al. Prediction of postoperative lung function in patients with lung cancer: comparison of quantitative CT with perfusion scintigraphy, AJR Am.J.Roentgenol., 2002. 178(3): p. 667-672., https://www.ncbi.nlm.nih.gov/pubmed/11856695
519. Ohno, Y., Koyama, H., Nogami, M., Takenaka, D., Matsumoto, S., Yoshimura, M., et.al. Postoperative lung function in lung cancer patients: comparative analysis of predictive capability of MRI, CT, and SPECT, AJR Am.J.Roentgenol., 2007. 189(2): p. 400-408., https://www.ncbi.nlm.nih.gov/pubmed/17646467
520. Brunelli, A., Letter to the Editor, Respiration, 2009.
521. Bolliger, C. T., Functional reserve before lung resection: how low can we go?, Respiration, 2009. 78(1): p. 20-22., https://www.ncbi.nlm.nih.gov/pubmed/19407438
522. Hadeli, K. O., Siegel, E. M., Sherrill, D. L., Beck, K. C., Enright, P. L., Predictors of oxygen desaturation during submaximal exercise in 8,000 patients, Chest, 2001. 120(1): p. 88-92., https://www.ncbi.nlm.nih.gov/pubmed/11451821
523. Ninan, M., Sommers, K. E., Landreneau, R. J., Weyant, R. J., Tobias, J., Luketich, J. D., et.al. Standardized exercise oximetry predicts postpneumonectomy outcome, Ann.Thorac.Surg., 1997. 64(2): p. 328-332., https://www.ncbi.nlm.nih.gov/pubmed/9262569
524. Varela, G., Cordovilla, R., Jimenez, M. F., Novoa, N., Utility of standardized exercise oximetry to predict cardiopulmonary morbidity after lung resection, Eur.J.Cardiothorac.Surg., 2001. 19(3): p. 351-354., https://www.ncbi.nlm.nih.gov/pubmed/11251278
525. Bolliger, C. T., Evaluation of operability before lung resection, Curr.Opin.Pulm.Med., 2003. 9(4): p. 321-326., https://www.ncbi.nlm.nih.gov/pubmed/12806247
526. Holden, D. A., Rice, T. W., Stelmach, K., Meeker, D. P., Exercise testing, 6-min walk, and stair climb in the evaluation of patients at high risk for pulmonary resection, Chest, 1992. 102(6): p. 1774-1779., https://www.ncbi.nlm.nih.gov/pubmed/1446488
527. Datta, D., Lahiri, B., Preoperative evaluation of patients undergoing lung resection surgery, Chest, 2003. 123(6): p. 2096-2103., https://www.ncbi.nlm.nih.gov/pubmed/12796194
528. Barnett, H. J., Taylor, D. W., Eliasziw, M., Fox, A. J., Ferguson, G. G., Haynes, R. B., et.al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators, N.Engl.J.Med., 1998. 339(20): p. 1415-1425., https://www.ncbi.nlm.nih.gov/pubmed/9811916
529. Eagle, K. A., Guyton, R. A., Davidoff, R., Ewy, G. A., Fonger, J., Gardner, T. J., et.al. ACC/AHA guidelines for coronary artery bypass graft surgery: executive summary and recommendations : A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1991 guidelines for coronary artery bypass graft surgery), Circulation, 1999. 100(13): p. 1464-1480., https://www.ncbi.nlm.nih.gov/pubmed/10500052
530. Lee, T. H., Marcantonio, E. R., Mangione, C. M., Thomas, E. J., Polanczyk, C. A., Cook, E. F., et.al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery, Circulation, 1999. 100(10): p. 1043-1049., https://www.ncbi.nlm.nih.gov/pubmed/10477528
531. Kelion, A. D., Banning, A. P., Is simple clinical assessment adequate for cardiac risk stratification before elective non-cardiac surgery?, Lancet, 1999. 354(9193): p. 1837-1838., https://www.ncbi.nlm.nih.gov/pubmed/10584716
532. North American Symptomatic Carotid Endarterectomy Trial, Collaborators, Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis, N.Engl.J.Med., 1991. 325(7): p. 445-453., https://www.ncbi.nlm.nih.gov/pubmed/1852179
533. Feld, R., Arriagada, R., Ball, D., Prognostic factors in non-small cell lung cancer: a consensus report, Lung Cancer, 1991. 7: p. 3-5., https://www.lungcancerjournal.info/article/0169-5002(94)91861-9/fulltext
534. Jagoe, R. T., Goodship, T. H., Gibson, G. J., The influence of nutritional status on complications after operations for lung cancer, Ann.Thorac.Surg., 2001. 71(3): p. 936-943., https://www.ncbi.nlm.nih.gov/pubmed/11269477
535. Reeves, B. C., Ascione, R., Chamberlain, M. H., Angelini, G. D., Effect of body mass index on early outcomes in patients undergoing coronary artery bypass surgery, J.Am.Coll.Cardiol., 2003. 42(4): p. 668-676., https://www.ncbi.nlm.nih.gov/pubmed/12932599
536. Kappauf, H., Kommunikation in der Onkologie, Onkologe, 2004. 10: p. 1251-1260., https://pubmed.ncbi.nlm.nih.gov/15241518/
537. Kuhlmann E., Spannungsfeld zwischen Informed Consent und konfliktvermeidender Fehlinformation: Patientenaufklärung unter ökonomischen Zwängen. Ergebnisse einer empirischen Studie., Ethik Med., 1999. 11: p. 146-161., https://link.springer.com/article/10.1007/s004810050070
538. Bundesministerium für Gesundheit, Patientenrechtegesetz, 2013.
539. Schroder C., Schmutzer G., Brahler E., Repräsentativbefragung der deutschen Bevölkerung zu Aufklärungswunsch und Patientenverfügung bei unheilbarer Krankheit, Psychother Psyhosom Med Psychol, 2002. 52: p. 236-243., https://pubmed.ncbi.nlm.nih.gov/12012266/
540. Baile, W. F., Kudelka, A. P., Beale, E. A., Glober, G. A., Myers, E. G., Greisinger, A. J., et.al. Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illness, Cancer, 1999. 86(5): p. 887-897., https://www.ncbi.nlm.nih.gov/pubmed/10463990
541. Keller M., Werner A., Aufklärung und Begleitung von Tumorpatienten -Trainingsprogramme für Ärzte, Onkologe, 2006. 12: p. 55-61., https://translate.google.com/website?sl=en&tl=de&hl=de&prev=search&u=https://doi.org/10.1007/s00761-005-0995-1
542. Beauchamp, T. L., Childress, J. F., Principles of Biomedical EthicsOxford University Press, 1994. 4th:
543. Informed Consent im klinischen Alltag - eine pragmatische Interpretation, Ethik Med, 2002. 14: p. 151-159., https://link.springer.com/article/10.1007/s00481-002-0165-6https://link.springer.com/article/10.1007/s00481-002-0165-6
544. Ernst, J., Krauá, O., Schwarz, R., Die Einbeziehung von Tumorpatienten in medizinische Entscheidungsprozesse, Onkologe, 2006. 12: p. 48-54., https://www.researchgate.net/publication/251309471_Die_Einbeziehung_von_Tumorpatienten_in_medizinische_Entscheidungsprozesse
545. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF):, Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung, Langversion 1.1, 2015, AWMF-Registernummer: 128/001OL, http://leitlinienprogrammonkologie.de/Palliativmedizin.80.0.html, (Zugriff am: 29.10.2015)., http://leitlinienprogrammonkologie.de/Palliativmedizin.80.0.html
546. Elkin, E. B., Kim, S. H., Casper, E. S., Kissane, D. W., Schrag, D., Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007. 25(33): p. 5275-5280., https://www.ncbi.nlm.nih.gov/pubmed/18024875
547. Ford, S., Schofield, T., Hope, T., Observing decision-making in the general practice consultation: who makes which decisions?, Health Expect, 2006. 9(2): p. 130-7., https://www.ncbi.nlm.nih.gov/pubmed/16677192
548. National Institute for Clinical, Excellence, The Diagnosis and Treatment of Lung Cancer. NICE guideline., URL: www.guidance.nice.org.uk/CG24, 2009.
549. Politi, M. C., Han, P. K., Col, N. F., Communicating the uncertainty of harms and benefits of medical interventions, Med Decis Making, 2007. 27(5): p. 681-95., https://www.ncbi.nlm.nih.gov/pubmed/17873256
550. Butow, P., Harrison, J. D., Choy, E. T., Young, J. M., Spillane, A., Evans, A., Health professional and consumer views on involving breast cancer patients in the multidisciplinary discussion of their disease and treatment plan, Cancer, 2007. 110(9): p. 1937-44., https://www.ncbi.nlm.nih.gov/pubmed/17823912
551. Bruera, E., Willey, J. S., Palmer, J. L., Rosales, M., Treatment decisions for breast carcinoma: patient preferences and physician perceptions, Cancer, 2002. 94(7): p. 2076-80., https://www.ncbi.nlm.nih.gov/pubmed/11932912
552. Rabben, J, Vivat, B, Fossum, M, Rohde, GE, Shared decision-making in palliative cancer care: A systematic review and metasynthesis., Palliat Med, 2024. 38 (4)(4): p. 406-422., https://pubmed.ncbi.nlm.nih.gov/38481012/
553. Borrell-Carrio, F., Suchman, A. L., Epstein, R. M., The biopsychosocial model 25 years later: principles, practice, and scientific inquiry, Ann Fam Med, 2004. 2(6): p. 576-82., https://www.ncbi.nlm.nih.gov/pubmed/15576544
554. Engel, G. L., The biopsychosocial model and the education of health professionals, Gen Hosp Psychiatry, 1979. 1(2): p. 156-65., https://pubmed.ncbi.nlm.nih.gov/499786/
555. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF):, Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung, Langversion 1.1, 2015, AWMF-Registernummer: 128/001OL, http://leitlinienprogrammonkologie.de/Palliativmedizin.80.0.html, (Zugriff am: 29.10.2015).
556. Dowsett, S. M., Saul, J. L., Butow, P. N., Dunn, S. M., Boyer, M. J., Findlow, R., et.al. Communication styles in the cancer consultation: preferences for a patient-centred approach, Psychooncology., 2000. 9(2): p. 147-156., https://www.ncbi.nlm.nih.gov/pubmed/10767752
557. Friedrichsen, M. J., Strang, P. M., Carlsson, M. E., Breaking bad news in the transition from curative to palliative cancer care--patient's view of the doctor giving the information, Support Care Cancer, 2000. 8(6): p. 472-8., https://www.ncbi.nlm.nih.gov/pubmed/11094992
558. Parker, P. A., Davison, B. J., Tishelman, C., Brundage, M. D., Team, Scrn Communication, What do we know about facilitating patient communication in the cancer care setting?, Psychooncology, 2005. 14(10): p. 848-58; discussion 859-60., https://www.ncbi.nlm.nih.gov/pubmed/16200511
559. Steinhauser, K. E., Christakis, N. A., Clipp, E. C., McNeilly, M., Grambow, S., Parker, J., et.al. Preparing for the end of life: preferences of patients, families, physicians, and other care providers, J Pain Symptom Manage, 2001. 22(3): p. 727-37., https://www.ncbi.nlm.nih.gov/pubmed/11532586
560. Thorne, S. E., Kuo, M., Armstrong, E. A., McPherson, G., Harris, S. R., Hislop, T. G., 'Being known': patients' perspectives of the dynamics of human connection in cancer care, Psychooncology, 2005. 14(10): p. 887-98; discussion 899-900., https://www.ncbi.nlm.nih.gov/pubmed/16200520
561. Zachariae, R., Pedersen, C. G., Jensen, A. B., Ehrnrooth, E., Rossen, P. B., von der Maase, H., Association of perceived physician communication style with patient satisfaction, distress, cancer-related self-efficacy, and perceived control over the disease, Br J Cancer, 2003. 88(5): p. 658-65., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376357/
562. Fogarty, LA, Curbow, BA, Wingard, JR, McDonnell, K, Somerfield, MR., Can 40 seconds of compassion reduce patient anxiety?, J Clin Oncol, 1999. 17 (1): p. 371-9., https://www.ncbi.nlm.nih.gov/pubmed/10458256
563. Tulsky, J. A., Arnold, R. M., Alexander, S. C., Olsen, M. K., Jeffreys, A. S., Rodriguez, K. L., et.al. Enhancing communication between oncologists and patients with a computer-based training program: a randomized trial, Ann Intern Med, 2011. 155(9): p. 593-601., https://www.ncbi.nlm.nih.gov/pubmed/22041948
564. Kahn, K. L., Schneider, E. C., Malin, J. L., Adams, J. L., Epstein, A. M., Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use, Med Care, 2007. 45(5): p. 431-9., https://www.ncbi.nlm.nih.gov/pubmed/17446829
565. Keller, MB., Y., Patientenzentrierte Kommunikation in der Onkologie - Erfahrungen mit dem KOMPASS Training., Psychoonkologie, 2013. p. 147-65., https://www.imabe.org/fileadmin/imago_hominis/pdf/IH020_267-276.pdf
566. Salmon, P., Young, B., Core assumptions and research opportunities in clinical communication., Patient education and counseling., 2005. 58(3): p. 225-34., https://www.ncbi.nlm.nih.gov/pubmed/16024210
567. Schmid Mast, M., Kindlimann, A., Langewitz, W., Recipients' perspective on breaking bad news: how you put it really makes a difference, Patient Educ Couns, 2005. 58(3): p. 244-51., https://www.ncbi.nlm.nih.gov/pubmed/16081235
568. Weeks, J.C., Catalano, P.J., Cronin, A., Finkelman, M.D., Mack, J.W., Keating, N.L., et.al. Patients' expectations about effects of chemotherapy for advanced cancer., N Engl J Med, 2012. 367(17): p. 1616-25., https://www.ncbi.nlm.nih.gov/pubmed/23094723
569. Gabrijel, S, Grize, L, Helfenstein, E, Brutsche, M, Grossman, P, Tamm, M, et.al. Receiving the Diagnosis of Lung Cancer: Patient Recall of Information and Satisfaction With Physician Communication., J Clin Oncol, 2008. 26 (2): p. 297-302., https://www.ncbi.nlm.nih.gov/pubmed/18182671
570. Nehls, W., Gabrijel, S., Kiss, A., Kollmeier, J., Schmalz, O., Albrecht, H., et.al. Physician Communication in a Lung Cancer Center – Does the Message Come Across ?, Journal of Respiratory Medicine, 2013. 67: p. 688-693., https://www.ncbi.nlm.nih.gov/pubmed/24323560
571. Quirt, CF, Mackillop, WJ, Ginsburg, AD, Sheldon, L, Brundage, M, Dixon, P, et.al. Do doctors know when their patients don't?: A survey of doctor–patient communication in lung cancer., Lung Cancer, 1997. 18(1): p. 1-20., https://www.ncbi.nlm.nih.gov/pubmed/9268944
572. Fallowfield, L., Jenkins, V., Farewell, V., Saul, J., Duffy, A., Eves, R., Efficacy of a Cancer Research UK communication skills training model for oncologists: a randomised controlled trial, Lancet, 2002. 359(9307): p. 650-656., https://www.ncbi.nlm.nih.gov/pubmed/11879860
573. Schofield, P. E., Butow, P. N., Thompson, J. F., Tattersall, M. H., Beeney, L. J., Dunn, S. M., Psychological responses of patients receiving a diagnosis of cancer, Ann Oncol, 2003. 14(1): p. 48-56., https://www.ncbi.nlm.nih.gov/pubmed/12488292
574. Fallowfield, L.J., Jenkins, V.A., Beveridge, H.A., Truth may hurt but deceit hurts more: communication in palliative care., Palliat Med, 2002. 16(4): p. 297-303., https://www.ncbi.nlm.nih.gov/pubmed/12132542
575. Baile, W. F., Beale, E. A., Giving bad news to cancer patients: matching process and content, J Clin Oncol, 2001. 19(9): p. 2575-7., https://www.ncbi.nlm.nih.gov/pubmed/11331340
576. Baile, W. F., De Panfilis, L., Tanzi, S., Moroni, M., Walters, R., Biasco, G., Using sociodrama and psychodrama to teach communication in end-of-life care, J Palliat Med, 2012. 15(9): p. 1006-10., https://www.ncbi.nlm.nih.gov/pubmed/22799884
577. Baile, W. F., Walters, R., Applying sociodramatic methods in teaching transition to palliative care, J Pain Symptom Manage, 2013. 45(3): p. 606-19., https://www.ncbi.nlm.nih.gov/pubmed/22889858
578. Evans, W. G., Tulsky, J. A., Back, A. L., Arnold, R. M., Communication at times of transitions: how to help patients cope with loss and re-define hope, Cancer J, 2006. 12(5): p. 417-24., https://www.ncbi.nlm.nih.gov/pubmed/17034677
579. Maguire, P., Pitceathly, C., Key communication skills and how to acquire them, BMJ, 2002. 325(7366): p. 697-700., https://pubmed.ncbi.nlm.nih.gov/12351365/
580. Stiefel, F., Barth, J., Bensing, J., Fallowfield, L., Jost, L., Razavi, D., et.al. Communication skills training in oncology: a position paper based on a consensus meeting among European experts in 2009, Ann Oncol, 2010. 21(2): p. 204-7., https://www.ncbi.nlm.nih.gov/pubmed/20026475
581. Vitinius, F., Sonntag, B., Barthel, Y., Brennfleck, B., Kuhnt, S., Werner, A., et.al. [KoMPASS--design, implementation and experiences concerning a structured communication skills training for physicians dealing with oncology], Psychother Psychosom Med Psychol, 2013. 63(12): p. 482-8., https://www.ncbi.nlm.nih.gov/pubmed/23677627
582. Schildmann, J., V., J., Die Ausbildung kommunikativer Fähigkeiten in der Medizin., Zeitschrift für Palliativmedizin, 2001. 2(4): p. 99-106.
583. Schildmann, J., S.C., Schildmann, E., Klambeck, A., Ortwein, H., Vollmann, J., „Wahrheit am Krankenbett“: Evaluation einer ärztlichen Fortbildung zur professionellen Aufklärung schwer kranker Patienten., Deutsche Medizinische Wochenschrift, 2011. 136(15): p. 757-761., https://pubmed.ncbi.nlm.nih.gov/21469043/
584. Gilligan, T, Coyle, N, Frankel, RM, Berry, DL, Bohlke, K, Epstein, RM, et.al. Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline., J Clin Oncol, 2017. 35 (31)(31): p. 3618-3632., https://pubmed.ncbi.nlm.nih.gov/28892432/
585. Baile, W. F., Aaron, J., Patient-physician communication in oncology: past, present, and future, Curr Opin Oncol, 2005. 17(4): p. 331-5., https://www.ncbi.nlm.nih.gov/pubmed/15933462
586. Baile, W. F., Lenzi, R., Kudelka, A. P., Maguire, P., Novack, D., Goldstein, M., et.al. Improving physician-patient communication in cancer care: outcome of a workshop for oncologists, J Cancer Educ, 1997. 12(3): p. 166-73., https://www.ncbi.nlm.nih.gov/pubmed/9376255
587. Campbell, E. M., Sanson-Fisher, R. W., Breaking bad news. 3: Encouraging the adoption of best practices, Behav Med, 1998. 24(2): p. 73-80., https://www.ncbi.nlm.nih.gov/pubmed/9695898
588. Davies, P, Delivering bad news. Communication skills must be part of medical education in all specialties., BMJ, 2001. 322(7290):, https://www.ncbi.nlm.nih.gov/pubmed/11321017
589. Improving communication skills--a randomized controlled behaviorally oriented intervention study for residents in internal medicine., Psychosom Med., 1998. 60(3): p. 268-76., https://www.ncbi.nlm.nih.gov/pubmed/9625213
590. Nehls, W., Gabrijel, S., Kiss, A., Delis, S., Black, N.B., al, et, Communication Skills Training Significantly Improves Lung Cancer Patient`s Understanding, J Palliat Care Med, 2014. 4(4): p. 182., https://www.ncbi.nlm.nih.gov/pubmed/15106217
591. Baile, W. F., Buckman, R., Lenzi, R., Glober, G., Beale, E. A., Kudelka, A. P., SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer, Oncologist., 2000. 5(4): p. 302-311., https://www.ncbi.nlm.nih.gov/pubmed/10964998
592. Back, A. L., Arnold, R. M., Baile, W. F., Tulsky, J. A., Fryer-Edwards, K., Approaching difficult communication tasks in oncology, CA Cancer J Clin, 2005. 55(3): p. 164-77., https://www.ncbi.nlm.nih.gov/pubmed/15890639
593. Turnbull, G., al, et, Psychosocial Health Care for Cancer Patients and Their Families., 2010.
594. Gasper, MW., Weber, M., Kommunikation in der Palliativmedizin, Z Palliativmed, 2010. 11: p. 167-179., http://dx.doi.org/10.1055/s-0030-1248494
595. Maguire, P., Improving communication with cancer patients, Eur J Cancer, 1999. 35(14): p. 2058-65., https://pubmed.ncbi.nlm.nih.gov/10711246/
596. Langewitz, W., Arzt-Patienten-Kommunikation. Mitteilen schlechter Nachrichten., Brähler ES, B., editor. Handlungsfelder in der psychosozialen Medizin. Göttingen: Hogrefe., 2002., https://www.researchgate.net/publication/292265952_Patientenzentrierte_Kommunikation
597. Epstein, RMS., Richard, L., Patient-Centered Communication in Cancer Care: Promoting Healing and Reducing Suffering., Institute USDDHAHS-NC, editor: National Cancer Institute, 2007., https://cancercontrol.cancer.gov/sites/default/files/2020-06/pcc_monograph.pdf
598. NationalInsituteOfClinicalExcellence, Guidance on Cancer Services: Improving Supportive and Palliative Care for Adults with Cancer - Face-to-face communication, 2004: London.
599. Smith, T. J., Temin, S., Alesi, E. R., Abernethy, A. P., Balboni, T. A., Basch, E. M., et.al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care, J Clin Oncol, 2012. 30(8): p. 880-7., https://www.ncbi.nlm.nih.gov/pubmed/22312101
600. Baile W, Parker P., Breaking Bad News. In: Kissane D, Bultz B, Butow P, Finlay I, editor, Handbook of Communication in Oncology and Palliative Care. Oxford: University Press, 2010. p. 101-12.
601. Arora, N. K., Interacting with cancer patients: the significance of physicians' communication behavior, Soc Sci Med, 2003. 57(5): p. 791-806., https://www.ncbi.nlm.nih.gov/pubmed/12850107
602. Thompson, DK., Pedersen, AF., Johansen, MB., Jensen, AB., Zachariae, R., Breast cancer patients`narratives about positive and negative communication experiences., Acta Oncol, 2007. 46(7): p. 900-8., https://www.ncbi.nlm.nih.gov/pubmed/17917822
603. Wright, E. B., Holcombe, C., Salmon, P., Doctors' communication of trust, care, and respect in breast cancer: qualitative study, BMJ, 2004. 328(7444): p. 864., https://www.ncbi.nlm.nih.gov/pubmed/15054034
604. Parker, S. M., Clayton, J. M., Hancock, K., Walder, S., Butow, P. N., Carrick, S., et.al. A systematic review of prognostic/end-of-life communication with adults in the advanced stages of a life-limiting illness: patient/caregiver preferences for the content, style, and timing of information, J Pain Symptom Manage, 2007. 34(1): p. 81-93., https://www.ncbi.nlm.nih.gov/pubmed/17531434
605. Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., et.al. Early palliative care for patients with metastatic non-small-cell lung cancer, N Engl J Med, 2010. 363(8): p. 733-42., https://www.ncbi.nlm.nih.gov/pubmed/20818875
606. Schapira, L, Butow, P, Brown, R, Boyle, F, Pessimism is no poison., J Clin Oncol, 2010. 28 (4): p. 705-7., https://www.ncbi.nlm.nih.gov/pubmed/19917853
607. Venetis, M. K., Robinson, J. D., Turkiewicz, K. L., Allen, M., An evidence base for patient-centered cancer care: a meta-analysis of studies of observed communication between cancer specialists and their patients, Patient Educ Couns, 2009. 77(3): p. 379-83., https://www.ncbi.nlm.nih.gov/pubmed/19836920
608. Zolnierek, K. B., Dimatteo, M. R., Physician communication and patient adherence to treatment: a meta-analysis, Med Care, 2009. 47(8): p. 826-34., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728700/
609. Levoy, K, Sullivan, SS, Chittams, J, Myers, RL, Hickman, SE, Meghani, SH, Don't Throw the Baby Out With the Bathwater: Meta-Analysis of Advance Care Planning and End-of-life Cancer Care., J Pain Symptom Manage, 2023. 65 (6)(6): p. e715-e743., https://pubmed.ncbi.nlm.nih.gov/36764411/
610. Malhotra, Chetna, Shafiq, Mahham, Batcagan-Abueg, Ada Portia Macarubbo, What is the evidence for efficacy of advance care planning in improving patient outcomes? A systematic review of randomised controlled trials 12(7): p. e060201., http://bmjopen.bmj.com/content/12/7/e060201.abstract
611. Bakitas, M., Lyons, K. D., Hegel, M. T., Balan, S., Brokaw, F. C., Seville, J., et.al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial, JAMA, 2009. 302(7): p. 741-9., https://www.ncbi.nlm.nih.gov/pubmed/19690306
612. Dyar, Stephen, Lesperance, Mary, Shannon, Robert, Sloan, Jeff, Colon-Otero, Gerardo, A nurse practitioner directed intervention Improves the quality of life of patients with metastatic cancer: Results of a randomized pilot study, Journal of Palliative Medicine, 2012. 15(8): p. 890-895., https://pubmed.ncbi.nlm.nih.gov/22559906/
613. Mack, J. W., Cronin, A., Keating, N. L., Taback, N., Huskamp, H. A., Malin, J. L., et.al. Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study, J Clin Oncol, 2012. 30(35): p. 4387-95., https://www.ncbi.nlm.nih.gov/pubmed/23150700
614. Wright, AA, Zhang, B, Ray, A, Mack, JW, Trice, E, Balboni, T, et.al. Association between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment., JAMA, 2008. 300 (14): p. 1665-73., https://www.ncbi.nlm.nih.gov/pubmed/18840840
615. Mack, J. W., Weeks, J. C., Wright, A. A., Block, S. D., Prigerson, H. G., End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences, J Clin Oncol, 2010. 28(7): p. 1203-8., https://www.ncbi.nlm.nih.gov/pubmed/20124172
616. Malhotra, Chetna, Shafiq, Mahham, Batcagan-Abueg, Ada Portia Macarubbo, What is the evidence for efficacy of advance care planning in improving patient outcomes? A systematic review of randomised controlled trials 12(7): p. e060201., http://bmjopen.bmj.com/content/12/7/e060201.abstract
617. Clayton, J. M., Butow, P. N., Tattersall, M. H., When and how to initiate discussion about prognosis and end-of-life issues with terminally ill patients, J Pain Symptom Manage, 2005. 30(2): p. 132-44., https://www.ncbi.nlm.nih.gov/pubmed/16125028
618. Huskamp, HA, Keating, NL, Malin, JL, Zaslavsky, AM, Weeks, JC, Earle, CC, et.al. Discussions with physicians about hospice among patients with metastatic lung cancer., Arch Intern Med, 2009. 169 (10): p. 954-62., https://www.ncbi.nlm.nih.gov/pubmed/19468089
619. Keating, NL, Landrum, MB, Rogers, SO, al, Jr et, Physician factors associated with discussions about end-of-life care., Cancer, 2010. 116 (4): p. 998-1006., https://www.ncbi.nlm.nih.gov/pubmed/20066693
620. Gysels, M., Richardson, A., Higginson, I. J., Communication training for health professionals who care for patients with cancer: a systematic review of training methods, Support Care Cancer, 2005. 13(6): p. 356-66., https://pubmed.ncbi.nlm.nih.gov/15586302/
621. Baile, W. F., Lenzi, R., Parker, P. A., Buckman, R., Cohen, L., Oncologists' attitudes toward and practices in giving bad news: an exploratory study, J Clin Oncol, 2002. 20(8): p. 2189-96., https://www.ncbi.nlm.nih.gov/pubmed/11956281
622. Christakis, N.A., Iwashyna, T.J., Attitude and self-reported practice regarding prognostication in a national sample of internists., Arch Intern Med, 1998. 158(21): p. 2389-95., https://www.ncbi.nlm.nih.gov/pubmed/9827791
623. Arnold, E. M., Artin, K. A., Person, J. L., Griffith, D. L., Consideration of hastening death among hospice patients and their families, J Pain Symptom Manage, 2004. 27(6): p. 523-32., https://www.ncbi.nlm.nih.gov/pubmed/15165650
624. Kohlwes, R. J., Koepsell, T. D., Rhodes, L. A., Pearlman, R. A., Physicians' responses to patients' requests for physician-assisted suicide, Arch Intern Med, 2001. 161(5): p. 657-63., https://www.ncbi.nlm.nih.gov/pubmed/11231697
625. Hagerty, R. G., Butow, P. N., Ellis, P. A., Lobb, E. A., Pendlebury, S., Leighl, N., et.al. Cancer patient preferences for communication of prognosis in the metastatic setting, J Clin Oncol, 2004. 22(9): p. 1721-30., https://www.ncbi.nlm.nih.gov/pubmed/15117995
626. Kirk, P., Kirk, I., Kristjanson, L.J., What do patients receiving palliative care for cancer and their families want to be told? A Canadian and Australian qualitative study., BMJ, 2004. 328(7452): p. 1343., https://www.ncbi.nlm.nih.gov/pubmed/15151964
627. Yun, Y. H., Lee, C. G., Kim, S. Y., Lee, S. W., Heo, D. S., Kim, J. S., et.al. The attitudes of cancer patients and their families toward the disclosure of terminal illness, J Clin Oncol, 2004. 22(2): p. 307-14., https://www.ncbi.nlm.nih.gov/pubmed/14722040
628. Hagerty, RG, Butow, PN, Ellis, PM, Dimitry, S, Tattersall, MH., Communicating prognosis in cancer care: a systematic review of the literature., Ann Oncol, 2005. 16 (7): p. 1005-53., https://www.ncbi.nlm.nih.gov/pubmed/15939716
629. Berry, S. R., Just say die, J Clin Oncol, 2008. 26(1): p. 157-9., https://www.ncbi.nlm.nih.gov/pubmed/18165651
630. Pardon, K, Deschepper, R, Vander Stichele, R, Bernheim, J, Mortier, F, Schallier, D, et.al. Are patients’ preferences for information and participation in medical decision-making being met? Interview study with lung cancer patients., Palliat Med, 2011. 25 (1): p. 62-70., https://pubmed.ncbi.nlm.nih.gov/20621948/
631. Clayton, J. M., Butow, P. N., Tattersall, M. H., Devine, R. J., Simpson, J. M., Aggarwal, G., et.al. Randomized controlled trial of a prompt list to help advanced cancer patients and their caregivers to ask questions about prognosis and end-of-life care, J Clin Oncol, 2007. 25(6): p. 715-23., https://www.ncbi.nlm.nih.gov/pubmed/17308275
632. Clayton, J. M., Hancock, K., Parker, S., Butow, P. N., Walder, S., Carrick, S., et.al. Sustaining hope when communicating with terminally ill patients and their families: a systematic review, Psychooncology, 2008. 17(7): p. 641-59., https://www.ncbi.nlm.nih.gov/pubmed/18022831
633. Birim, O., Maat, A. P., Kappetein, A. P., Van Meerbeeck, J. P., Damhuis, R. A., Bogers, A. J., Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer, Eur.J Cardiothorac.Surg, 2003. 23(1): p. 30-34., https://www.ncbi.nlm.nih.gov/pubmed/12493500
634. Sawada, S., Komori, E., Nogami, N., Bessho, A., Segawa, Y., Shinkai, T., et.al. Advanced age is not correlated with either short-term or long-term postoperative results in lung cancer patients in good clinical condition, Chest, 2005. 128(3): p. 1557-1563., https://www.ncbi.nlm.nih.gov/pubmed/16162758
635. Firat, S., Pleister, A., Byhardt, R. W., Gore, E., Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC), Am.J Clin Oncol, 2006. 29(3): p. 252-257., https://www.ncbi.nlm.nih.gov/pubmed/16755178
636. Detterbeck, F. C., General aspects of surgical treatment. In: Diagnosis and treatment of lung cancer : an evidence-based guide for the practicing clinician (Eds.Detterbeck FC, Rivera MP, Socinski MA, Roseman JG), ), 2001. p. 133-147.
637. Nagasaki, F., Flehinger, B. J., Martini, N., Complications of surgery in the treatment of carcinoma of the lung, Chest, 1982. 82(1): p. 25-29., https://www.ncbi.nlm.nih.gov/pubmed/7083931
638. Temel, JS, Jackson, VA, El-Jawahri, A, Rinaldi, SP, Petrillo, LA, Kumar, P, et.al. Stepped Palliative Care for Patients With Advanced Lung Cancer: A Randomized Clinical Trial., JAMA, 2024. 332 (6)(6): p. 471-481., https://pubmed.ncbi.nlm.nih.gov/38824442/
639. Pirl, W. F., Greer, J. A., Traeger, L., Jackson, V., Lennes, I. T., Gallagher, E. R., et.al. Depression and survival in metastatic non-small-cell lung cancer: effects of early palliative care, J Clin Oncol, 2012. 30(12): p. 1310-5., https://www.ncbi.nlm.nih.gov/pubmed/22430269
640. Kavalieratos, D, Corbelli, J, Zhang, D, Dionne-Odom, JN, Ernecoff, NC, Hanmer, J, et.al. Association Between Palliative Care and Patient and Caregiver Outcomes: A Systematic Review and Meta-analysis., JAMA, 2016. 316 (20)(20): p. 2104-2114., https://pubmed.ncbi.nlm.nih.gov/27893131/
641. Haun, MW, Estel, S, Rücker, G, Friederich, HC, Villalobos, M, Thomas, M, et.al. Early palliative care for adults with advanced cancer., Cochrane Database Syst Rev, 2017. 6 (): p. CD011129., https://pubmed.ncbi.nlm.nih.gov/28603881/
642. Greer, J. A., Pirl, W. F., Jackson, V. A., Muzikansky, A., Lennes, I. T., Heist, R. S., et.al. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer, J Clin Oncol, 2012. 30(4): p. 394-400., https://www.ncbi.nlm.nih.gov/pubmed/22203758
643. Temel, J. S., Greer, J. A., Admane, S., Gallagher, E. R., Jackson, V. A., Lynch, T. J., et.al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care, J Clin Oncol, 2011. 29(17): p. 2319-26., https://www.ncbi.nlm.nih.gov/pubmed/21555700
644. El-Jawahri, A., Greer, J. A., Temel, J. S., Does palliative care improve outcomes for patients with incurable illness? A review of the evidence, J Support Oncol, 2011. 9(3): p. 87-94., https://www.ncbi.nlm.nih.gov/pubmed/21702398
645. Jacobsen, J., Jackson, V., Dahlin, C., Greer, J., Perez-Cruz, P., Billings, J. A., et.al. Components of early outpatient palliative care consultation in patients with metastatic nonsmall cell lung cancer, J Palliat Med, 2011. 14(4): p. 459-64., https://www.ncbi.nlm.nih.gov/pubmed/21417739
646. Irwin, K. E., Greer, J. A., Khatib, J., Temel, J. S., Pirl, W. F., Early palliative care and metastatic non-small cell lung cancer: potential mechanisms of prolonged survival, Chron Respir Dis, 2013. 10(1): p. 35-47., https://www.ncbi.nlm.nih.gov/pubmed/23355404
647. Smith, M. E., Chiovaro, J. C., O'Neil, M., Kansagara, D., Quinones, A. R., Freeman, M., et.al. Early warning system scores for clinical deterioration in hospitalized patients: a systematic review, Ann Am Thorac Soc, 2014. 11(9): p. 1454-65., https://www.ncbi.nlm.nih.gov/pubmed/25296111
648. May, P, Normand, C, Cassel, JB, Del Fabbro, E, Fine, RL, Menz, R, et.al. Economics of Palliative Care for Hospitalized Adults With Serious Illness: A Meta-analysis., JAMA Intern Med, 2018. 178 (6)(6): p. 820-829., https://pubmed.ncbi.nlm.nih.gov/29710177/
649. Sanders, Justin J., Temin, Sarah, Ghoshal, Arun, Alesi, Erin R., Ali, Zipporah Vunoro, Chauhan, Cynthia, et.al. Palliative Care for Patients With Cancer: ASCO Guideline UpdateWolters Kluwer, Journal of Clinical Oncology, 2024. 42(19): p. 2336 - 2357., https://doi.org/10.1200/JCO.24.00542
650. Badr, H., Smith, C. B., Goldstein, N. E., Gomez, J. E., Redd, W. H., Dyadic psychosocial intervention for advanced lung cancer patients and their family caregivers: Results of a randomized pilot trial, Cancer, 2014., https://www.ncbi.nlm.nih.gov/pubmed/25209975
651. Bakitas, M. A., Tosteson, T. D., Li, Z., Lyons, K. D., Hull, J. G., Li, Z., et.al. Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial, J Clin Oncol, 2015. 33(13): p. 1438-45., https://www.ncbi.nlm.nih.gov/pubmed/25800768
652. Zimmermann, C., Swami, N., Krzyzanowska, M., Hannon, B., Leighl, N., Oza, A., et.al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial, Lancet, 2014. 383(9930): p. 1721-30., https://www.ncbi.nlm.nih.gov/pubmed/24559581
653. Hui, D., Kim, Y. J., Park, J. C., Zhang, Y., Strasser, F., Cherny, N., et.al. Integration of oncology and palliative care: a systematic review, Oncologist, 2015. 20(1): p. 77-83., https://www.ncbi.nlm.nih.gov/pubmed/25480826
654. Jackson, V. A., Jacobsen, J., Greer, J. A., Pirl, W. F., Temel, J. S., Back, A. L., The cultivation of prognostic awareness through the provision of early palliative care in the ambulatory setting: a communication guide, J Palliat Med, 2013. 16(8): p. 894-900., https://www.ncbi.nlm.nih.gov/pubmed/23786425
655. Lakhani, S, Scalzitti, DA, Padrone, L, Martins-Welch, D, From evidence to practice: early integration of palliative care in a comprehensive cancer center., Support Care Cancer, 2022. 31 (1)(1): p. 17., https://pubmed.ncbi.nlm.nih.gov/36513942/
656. Gärtner, J, Daun, M, Wolf, J, von Bergwelt-Baildon, M, Hallek, M, Early Palliative Care: Pro, but Please Be Precise!, Oncol Res Treat, 2019. 42 (1-2)(1-2): p. 11-18., https://pubmed.ncbi.nlm.nih.gov/30685764/
657. Lazenby, Mark, Dixon, Jane, Bai, Mei, McCorkle, Ruth, Comparing the distress thermometer (DT) with the patient health questionnaire (PHQ)-2 for screening for possible cases of depression among patients newly diagnosed with advanced cancer, Palliative & Supportive Care, 2014. 12(1): p. 63-68., https://www.ncbi.nlm.nih.gov/pubmed/24468423
658. Gaertner, J., Wolf, J., Voltz, R., Early palliative care for patients with metastatic cancer, Curr Opin Oncol, 2012. 24(4): p. 357-62., https://www.ncbi.nlm.nih.gov/pubmed/22476189
659. Gaertner, J., Wolf, J., Hallek, M., Glossmann, J. P., Voltz, R., Standardizing integration of palliative care into comprehensive cancer therapy--a disease specific approach, Support Care Cancer, 2011. 19(7): p. 1037-43., https://www.ncbi.nlm.nih.gov/pubmed/21432009
660. Ferrell, BR, Temel, JS, Temin, S, Alesi, ER, Balboni, TA, Basch, EM, et.al. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update., J Clin Oncol, 2017. 35 (1)(1): p. 96-112., https://pubmed.ncbi.nlm.nih.gov/28034065/
661. He, JC, Moffat, GT, Podolsky, S, Khan, F, Liu, N, Taback, N, et.al. Machine Learning to Allocate Palliative Care Consultations During Cancer Treatment., J Clin Oncol, 2024. 42 (14)(14): p. 1625-1634., https://pubmed.ncbi.nlm.nih.gov/38359380/
662. Hui, D, Bansal, S, Strasser, F, Morita, T, Caraceni, A, Davis, M, et.al. Indicators of integration of oncology and palliative care programs: an international consensus., Ann Oncol, 2015. 26 (9)(9): p. 1953-1959., https://pubmed.ncbi.nlm.nih.gov/26088196/
663. Kaasa, S, Loge, JH, Aapro, M, Albreht, T, Anderson, R, Bruera, E, et.al. Integration of oncology and palliative care: a Lancet Oncology Commission., Lancet Oncol, 2018. 19 (11)(11): p. e588-e653., https://pubmed.ncbi.nlm.nih.gov/30344075/
664. Basch, E, Dueck, AC, Rogak, LJ, Minasian, LM, Kelly, WK, O'Mara, AM, et.al. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials., JAMA Oncol, 2017. 3 (8)(8): p. 1043-1050., https://pubmed.ncbi.nlm.nih.gov/28208174/
665. Post, KE, Heuer, LB, Kamal, AH, Kumar, P, Elyze, M, Griffith, S, et.al. Study protocol for a randomised trial evaluating the non-inferiority of stepped palliative care versus early integrated palliative care for patients with advanced lung cancer., BMJ Open, 2022. 12 (2)(2): p. e057591., https://pubmed.ncbi.nlm.nih.gov/35144954/
666. Zimmermann, C, Pope, A, Hannon, B, Krzyzanowska, MK, Rodin, G, Li, M, et.al. Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer., J Natl Compr Canc Netw, 2021. 20 (4)(4): p. 361-370.e3., https://pubmed.ncbi.nlm.nih.gov/34492632/
667. Vanbutsele, G, Pardon, K, Van Belle, S, Surmont, V, De Laat, M, Colman, R, et.al. Effect of early and systematic integration of palliative care in patients with advanced cancer: a randomised controlled trial., Lancet Oncol, 2018. 19 (3)(3): p. 394-404., https://pubmed.ncbi.nlm.nih.gov/29402701/
668. Ginsberg, R. J., Rubinstein, L. V., Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group, Ann.Thorac Surg, 1995. 60(3): p. 615-622., https://www.ncbi.nlm.nih.gov/pubmed/7677489
669. Harada, H., Okada, M., Sakamoto, T., Matsuoka, H., Tsubota, N., Functional advantage after radical segmentectomy versus lobectomy for lung cancer, Ann.Thorac Surg, 2005. 80(6): p. 2041-2045., https://www.ncbi.nlm.nih.gov/pubmed/16305841
670. Keenan, R. J., Landreneau, R. J., Maley, R. H., Jr., Singh, D., Macherey, R., Bartley, S., et.al. Segmental resection spares pulmonary function in patients with stage I lung cancer, Ann.Thorac.Surg., 2004. 78(1): p. 228-233., https://www.ncbi.nlm.nih.gov/pubmed/15223434
671. Okada, M., Yoshikawa, K., Hatta, T., Tsubota, N., Is segmentectomy with lymph node assessment an alternative to lobectomy for non-small cell lung cancer of 2 cm or smaller?, Ann.Thorac.Surg., 2001. 71(3): p. 956-960., https://www.ncbi.nlm.nih.gov/pubmed/11269480
672. Date, H., Andou, A., Shimizu, N., The value of limited resection for "clinical" stage I peripheral non-small cell lung cancer in poor-risk patients: comparison of limited resection and lobectomy by a computer-assisted matched study, Tumori, 1994. 80(6): p. 422-426., https://www.ncbi.nlm.nih.gov/pubmed/7900230
673. Allen, M. S., Darling, G. E., Pechet, T. T., Mitchell, J. D., Herndon, J. E., Landreneau, R. J., et.al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial, Ann.Thorac.Surg., 2006. 81(3): p. 1013-1019., https://www.ncbi.nlm.nih.gov/pubmed/16488712
674. Harpole, D. H., Jr., DeCamp, M. M., Jr., Daley, J., Hur, K., Oprian, C. A., Henderson, W. G., et.al. Prognostic models of thirty-day mortality and morbidity after major pulmonary resection, J Thorac Cardiovasc Surg, 1999. 117(5): p. 969-979., https://www.ncbi.nlm.nih.gov/pubmed/10220692
675. Guckenberger, M, Andratschke, N, Alheit, H, Holy, R, Moustakis, C, Nestle, U, et.al. Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer., Strahlenther Onkol, 2014. 190 (1)(1): p. 26-33., https://pubmed.ncbi.nlm.nih.gov/24052011/
676. Ball, D, Mai, GT, Vinod, S, Babington, S, Ruben, J, Kron, T, et.al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial., Lancet Oncol, 2019. 20 (4)(4): p. 494-503., https://pubmed.ncbi.nlm.nih.gov/30770291/
677. De Ruysscher, D, Faivre-Finn, C, Nestle, U, Hurkmans, CW, Le Péchoux, C, Price, A, et.al. European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer., J Clin Oncol, 2010. 28 (36)(36): p. 5301-10., https://pubmed.ncbi.nlm.nih.gov/21079134/
678. Raz, DJ, Zell, JA, Ou, SH, Gandara, DR, Anton-Culver, H, Jablons, DM, Natural history of stage I non-small cell lung cancer: implications for early detection., Chest, 2007. 132 (1)(1): p. 193-9., https://pubmed.ncbi.nlm.nih.gov/17505036/
679. Benedict, SH, Yenice, KM, Followill, D, Galvin, JM, Hinson, W, Kavanagh, B, et.al. Stereotactic body radiation therapy: the report of AAPM Task Group 101., Med Phys, 2010. 37 (8)(8): p. 4078-101., https://pubmed.ncbi.nlm.nih.gov/20879569/
680. Stahl, JM, Ross, R, Harder, EM, Mancini, BR, Soulos, PR, Finkelstein, SE, et.al. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy., Int J Radiat Oncol Biol Phys, 2016. 96 (5)(5): p. 1011-1020., https://pubmed.ncbi.nlm.nih.gov/27869080/
681. Zhang, J, Yang, F, Li, B, Li, H, Liu, J, Huang, W, et.al. Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis., Int J Radiat Oncol Biol Phys, 2011. 81 (4)(4): p. e305-16., https://pubmed.ncbi.nlm.nih.gov/21658853/
682. Timmerman, R, McGarry, R, Yiannoutsos, C, Papiez, L, Tudor, K, DeLuca, J, et.al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer., J Clin Oncol, 2006. 24 (30)(30): p. 4833-9., https://pubmed.ncbi.nlm.nih.gov/17050868/
683. Haasbeek, CJ, Lagerwaard, FJ, Slotman, BJ, Senan, S, Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer., J Thorac Oncol, 2011. 6 (12)(12): p. 2036-43., https://pubmed.ncbi.nlm.nih.gov/21892102/
684. Bezjak, A, Paulus, R, Gaspar, LE, Timmerman, RD, Straube, WL, Ryan, WF, et.al. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial., J Clin Oncol, 2019. 37 (15)(15): p. 1316-1325., https://pubmed.ncbi.nlm.nih.gov/30943123/
685. Senthi, S, Haasbeek, CJ, Slotman, BJ, Senan, S, Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review., Radiother Oncol, 2013. 106 (3)(3): p. 276-82., https://pubmed.ncbi.nlm.nih.gov/23462705/
686. Grills, IS, Hope, AJ, Guckenberger, M, Kestin, LL, Werner-Wasik, M, Yan, D, et.al. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy., J Thorac Oncol, 2012. 7 (9)(9): p. 1382-93., https://pubmed.ncbi.nlm.nih.gov/22843086/
687. Creach, KM, El Naqa, I, Bradley, JD, Olsen, JR, Parikh, PJ, Drzymala, RE, et.al. Dosimetric predictors of chest wall pain after lung stereotactic body radiotherapy., Radiother Oncol, 2012. 104 (1)(1): p. 23-7., https://pubmed.ncbi.nlm.nih.gov/22385795/
688. Taremi, M, Hope, A, Dahele, M, Pearson, S, Fung, S, Purdie, T, et.al. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients., Int J Radiat Oncol Biol Phys, 2012. 82 (2)(2): p. 967-73., https://pubmed.ncbi.nlm.nih.gov/21377293/
689. Verstegen, NE, Lagerwaard, FJ, Haasbeek, CJ, Slotman, BJ, Senan, S, Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease., Radiother Oncol, 2011. 101 (2)(2): p. 250-4., https://pubmed.ncbi.nlm.nih.gov/22056535/
690. Powell, JW, Dexter, E, Scalzetti, EM, Bogart, JA, Treatment advances for medically inoperable non-small-cell lung cancer: emphasis on prospective trials., Lancet Oncol, 2009. 10 (9)(9): p. 885-94., https://pubmed.ncbi.nlm.nih.gov/19717090/
691. Onishi, H., Shirato, H., Nagata, Y., Hiraoka, M., Fujino, M., Gomi, K., et.al. Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional Study, J Thorac Oncol, 2007. 2(7 Suppl 3): p. S94-S100., https://www.ncbi.nlm.nih.gov/pubmed/17603311
692. Palma, D, Lagerwaard, F, Rodrigues, G, Haasbeek, C, Senan, S, Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review., Int J Radiat Oncol Biol Phys, 2012. 82 (3)(3): p. 1149-56., https://pubmed.ncbi.nlm.nih.gov/21640513/
693. Varlotto, J, Fakiris, A, Flickinger, J, Medford-Davis, L, Liss, A, Shelkey, J, et.al. Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery., Cancer, 2013. 119 (15)(15): p. 2683-91., https://pubmed.ncbi.nlm.nih.gov/23605504/
694. Yerokun, BA, Yang, CJ, Gulack, BC, Li, X, Mulvihill, MS, Gu, L, et.al. A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non-small cell lung cancer., J Thorac Cardiovasc Surg, 2017. 154 (2)(2): p. 675-686.e4., https://pubmed.ncbi.nlm.nih.gov/28461054/
695. Mokhles, S, Verstegen, N, Maat, AP, Birim, Ö, Bogers, AJ, Mokhles, MM, et.al. Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis., Lung Cancer, 2015. 87 (3)(3): p. 283-9., https://pubmed.ncbi.nlm.nih.gov/25622781/
696. Ezer, N, Veluswamy, RR, Mhango, G, Rosenzweig, KE, Powell, CA, Wisnivesky, JP, Outcomes after Stereotactic Body Radiotherapy versus Limited Resection in Older Patients with Early-Stage Lung Cancer., J Thorac Oncol, 2015. 10 (8)(8): p. 1201-6., https://pubmed.ncbi.nlm.nih.gov/26200275/
697. Fernandez, FG, Crabtree, TD, Liu, J, Meyers, BF, Sublobar resection versus definitive radiation in patients with stage IA non-small cell lung cancer., Ann Thorac Surg, 2012. 94 (2)(2): p. 354-60; discussion 360-1., https://pubmed.ncbi.nlm.nih.gov/22429673/
698. Fernando, HC, Landreneau, RJ, Mandrekar, SJ, Nichols, FC, Hillman, SL, Heron, DE, et.al. Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer., J Clin Oncol, 2014. 32 (23)(23): p. 2456-62., https://pubmed.ncbi.nlm.nih.gov/24982457/
699. Cao, C, Wang, D, Chung, C, Tian, D, Rimner, A, Huang, J, et.al. A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer., J Thorac Cardiovasc Surg, 2019. 157 (1)(1): p. 362-373.e8., https://pubmed.ncbi.nlm.nih.gov/30482524/
700. Altorki, N, Wang, X, Damman, B, Mentlick, J, Landreneau, R, Wigle, D, et.al. Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance)., J Thorac Cardiovasc Surg, 2024. 167 (1)(1): p. 338-347.e1., https://pubmed.ncbi.nlm.nih.gov/37473998/
701. Grills, IS, Mangona, VS, Welsh, R, Chmielewski, G, McInerney, E, Martin, S, et.al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer., J Clin Oncol, 2010. 28 (6)(6): p. 928-35., https://pubmed.ncbi.nlm.nih.gov/20065181/
702. Shirvani, SM, Jiang, J, Chang, JY, Welsh, JW, Gomez, DR, Swisher, S, et.al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly., Int J Radiat Oncol Biol Phys, 2012. 84 (5)(5): p. 1060-70., https://pubmed.ncbi.nlm.nih.gov/22975611/
703. Paul, S, Lee, PC, Mao, J, Isaacs, AJ, Sedrakyan, A, Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis., BMJ, 2016. 354 (): p. i3570., https://pubmed.ncbi.nlm.nih.gov/27400862/
704. De Ruysscher, D, Faivre-Finn, C, Moeller, D, Nestle, U, Hurkmans, CW, Le Péchoux, C, et.al. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer., Radiother Oncol, 2017. 124 (1)(1): p. 1-10., https://pubmed.ncbi.nlm.nih.gov/28666551/
705. Wu, J, Bai, HX, Chan, L, Su, C, Zhang, PJ, Yang, L, et.al. Sublobar resection compared with stereotactic body radiation therapy and ablation for early stage non-small cell lung cancer: A National Cancer Database study., J Thorac Cardiovasc Surg, 2020. 160 (5)(5): p. 1350-1357.e11., https://pubmed.ncbi.nlm.nih.gov/32033815/
706. Cao, C, Wang, D, Chung, C, Tian, D, Rimner, A, Huang, J, et.al. A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer., J Thorac Cardiovasc Surg, 2019. 157 (1)(1): p. 362-373.e8., https://pubmed.ncbi.nlm.nih.gov/30482524/
707. Matsuo, Y, Chen, F, Hamaji, M, Kawaguchi, A, Ueki, N, Nagata, Y, et.al. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis., Eur J Cancer, 2014. 50 (17)(17): p. 2932-8., https://pubmed.ncbi.nlm.nih.gov/25281527/
708. Mountain, C. F., Revisions in the International System for Staging Lung Cancer, Chest, 1997. 111(6): p. 1710-1717., https://www.ncbi.nlm.nih.gov/pubmed/9187198
709. Okada, M., Nishio, W., Sakamoto, T., Uchino, K., Yuki, T., Nakagawa, A., et.al. Evolution of surgical outcomes for nonsmall cell lung cancer: time trends in 1465 consecutive patients undergoing complete resection, Ann.Thorac Surg, 2004. 77(6): p. 1926-1930., https://www.ncbi.nlm.nih.gov/pubmed/15172237
710. Licker, M., Spiliopoulos, A., Frey, J. G., de, Perrot M., Chevalley, C., Tschopp, J. M., Management and outcome of patients undergoing thoracic surgery in a regional chest medical centre, Eur.J Anaesthesiol., 2001. 18(8): p. 540-547., https://www.ncbi.nlm.nih.gov/pubmed/11473561
711. Bernard, A., Ferrand, L., Hagry, O., Benoit, L., Cheynel, N., Favre, J. P., Identification of prognostic factors determining risk groups for lung resection, Ann.Thorac.Surg., 2000. 70(4): p. 1161-1167., https://www.ncbi.nlm.nih.gov/pubmed/11081862
712. Battafarano, R. J., Piccirillo, J. F., Meyers, B. F., et al., Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer, J Thorac Cardiovasc Surg, 2002. 123: p. 280-287., https://www.ncbi.nlm.nih.gov/pubmed/11828287
713. Van Meerbeeck, J. P., Damhuis, R. A., Vos de Wael, M. L., High postoperative risk after pneumonectomy in elderly patients with right-sided lung cancer, Eur.Respir.J., 2002. 19(1): p. 141-145., https://www.ncbi.nlm.nih.gov/pubmed/11852891
714. Sok, M., Dragas, A. Z., Erzen, J., Jerman, J., Sources of pathogens causing pleuropulmonary infections after lung cancer resection, Eur.J.Cardiothorac.Surg., 2002. 22(1): p. 23-27., https://www.ncbi.nlm.nih.gov/pubmed/12103368
715. Wahi, R., McMurtrey, M. J., DeCaro, L. F., Mountain, C. F., Ali, M. K., Smith, T. L., et.al. Determinants of perioperative morbidity and mortality after pneumonectomy, Ann.Thorac.Surg., 1989. 48(1): p. 33-37., https://www.ncbi.nlm.nih.gov/pubmed/2764597
716. Li, H, Shen, Y, Wu, Y, Cai, S, Zhu, Y, Chen, S, et.al. Stereotactic Body Radiotherapy Versus Surgery for Early-Stage Non-Small-Cell Lung Cancer., J Surg Res, 2019. 243 (): p. 346-353., https://pubmed.ncbi.nlm.nih.gov/31277011/
717. Wen, SW, Han, L, Lv, HL, Xu, YZ, Li, ZH, Wang, MB, et.al. A Propensity-Matched Analysis of Outcomes of Patients with Clinical Stage I Non-Small Cell Lung Cancer Treated surgically or with stereotactic radiotherapy: A Meta-Analysis., J Invest Surg, 2019. 32 (1)(1): p. 27-34., https://pubmed.ncbi.nlm.nih.gov/28985095/
718. Weinmann, M., Jeremic, B., Toomes, H., Friedel, G., Bamberg, M., Treatment of lung cancer in the elderly. Part I: non-small cell lung cancer, Lung Cancer, 2003. 39(3): p. 233-253., https://www.ncbi.nlm.nih.gov/pubmed/12609562
719. Bao, F, Ye, P, Yang, Y, Wang, L, Zhang, C, Lv, X, et.al. Segmentectomy or lobectomy for early stage lung cancer: a meta-analysis., Eur J Cardiothorac Surg, 2014. 46 (1)(1): p. 1-7., https://pubmed.ncbi.nlm.nih.gov/24321996/
720. Saji, H, Okada, M, Tsuboi, M, Nakajima, R, Suzuki, K, Aokage, K, et.al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial., Lancet, 2022. 399 (10335)(10335): p. 1607-1617., https://pubmed.ncbi.nlm.nih.gov/35461558/
721. Watanabe, Y, Hattori, A, Nojiri, S, Matsunaga, T, Takamochi, K, Oh, S, et.al. Clinical impact of a small component of ground-glass opacity in solid-dominant clinical stage IA non-small cell lung cancer., J Thorac Cardiovasc Surg, 2022. 163 (3)(3): p. 791-801.e4., https://pubmed.ncbi.nlm.nih.gov/33516459/
722. Jung, W, Chung, JH, Yum, S, Kim, K, Lee, CT, Jheon, S, et.al. The differential prognostic impact of spread through air spaces in early-stage lung adenocarcinoma after lobectomy according to the pT descriptor., J Thorac Cardiovasc Surg, 2022. 163 (1)(1): p. 277-284.e1., https://pubmed.ncbi.nlm.nih.gov/33158568/
723. Wang, Z, Pang, L, Tang, J, Cheng, J, Chen, N, Zhou, J, et.al. Video-assisted thoracoscopic surgery versus muscle-sparing thoracotomy for non-small cell lung cancer: a systematic review and meta-analysis., BMC Surg, 2019. 19 (1)(1): p. 144., https://pubmed.ncbi.nlm.nih.gov/31615490/
724. Bendixen, M, Jørgensen, OD, Kronborg, C, Andersen, C, Licht, PB, Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial., Lancet Oncol, 2016. 17 (6)(6): p. 836-844., https://pubmed.ncbi.nlm.nih.gov/27160473/
725. Long, H, Tan, Q, Luo, Q, Wang, Z, Jiang, G, Situ, D, et.al. Thoracoscopic Surgery Versus Thoracotomy for Lung Cancer: Short-Term Outcomes of a Randomized Trial., Ann Thorac Surg, 2018. 105 (2)(2): p. 386-392., https://pubmed.ncbi.nlm.nih.gov/29198623/
726. Palade, E, Passlick, B, Osei-Agyemang, T, Günter, J, Wiesemann, S, Video-assisted vs open mediastinal lymphadenectomy for Stage I non-small-cell lung cancer: results of a prospective randomized trial., Eur J Cardiothorac Surg, 2013. 44 (2)(2): p. 244-9; discussion 249., https://pubmed.ncbi.nlm.nih.gov/23295451/
727. Wang, Y, Video-assisted thoracoscopic surgery for non-small-cell lung cancer is beneficial to elderly patients., Int J Clin Exp Med, 2015. 8 (8)(8): p. 13604-9., https://pubmed.ncbi.nlm.nih.gov/26550301/
728. Yang H, , Liu X, , Meng X, , Feng W., Efficacy of video-assisted thoracoscopic surgery for radical resection of non-small cell lung cancer in elderly patients, 2019. 12(3): p. 2675 - 2682., http://www.ijcem.com/files/ijcem0087398.pdf
729. Ng, CSH, MacDonald, JK, Gilbert, S, Khan, AZ, Kim, YT, Louie, BE, et.al. Optimal Approach to Lobectomy for Non-Small Cell Lung Cancer: Systemic Review and Meta-Analysis., Innovations (Phila), 2019. 14 (2)(2): p. 90-116., https://pubmed.ncbi.nlm.nih.gov/31039680/
730. Wright, G., Manser, R. L., Jart, D., et.al, Surgery for early stage non-small cell lung cancer (Review), The Cochrane Library, 2006., https://www.ncbi.nlm.nih.gov/pubmed/15674959
731. Izbicki, J. R., Passlick, B., Karg, O., Bloechle, C., Pantel, K., Knoefel, W. T., et.al. Impact of radical systematic mediastinal lymphadenectomy on tumor staging in lung cancer, Ann.Thorac.Surg., 1995. 59(1): p. 209-214., https://pubmed.ncbi.nlm.nih.gov/7818326/
732. Keller, S. M., Adak, S., Wagner, H., Herskovic, A., Komaki, R., Brooks, B. J., et.al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group, N.Engl.J.Med., 2000. 343(17): p. 1217-1222., https://www.ncbi.nlm.nih.gov/pubmed/11071672
733. Izbicki, J. R., Thetter, O., Habekost, M., Karg, O., Passlick, B., Kubuschok, B., et.al. Radical systematic mediastinal lymphadenectomy in non-small cell lung cancer: a randomized controlled trial, Br.J.Surg., 1994. 81(2): p. 229-235., https://www.ncbi.nlm.nih.gov/pubmed/8156344
734. Sugi, K., Nawata, K., Fujita, N., Ueda, K., Tanaka, T., Matsuoka, T., et.al. Systematic lymph node dissection for clinically diagnosed peripheral non-small-cell lung cancer less than 2 cm in diameter, World J.Surg., 1998. 22(3): p. 290-294., https://www.ncbi.nlm.nih.gov/pubmed/9494422
735. Wu, Y., Huang, Z. F., Wang, S. Y., Yang, X. N., Ou, W., A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer, Lung Cancer, 2002. 36(1): p. 1-6., https://www.ncbi.nlm.nih.gov/pubmed/11891025
736. Perng, R. P., Wu, M. F., Lin, S. Y., Chen, Y. M., Lin, J. Y., Whang-Peng, J., A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions, Anticancer Drugs, 1997. 8(6): p. 565-573., https://www.ncbi.nlm.nih.gov/pubmed/9300570
737. Scott, W. J., Howington, J., Movsas, B., Treatment of stage II non-small cell lung cancer, Chest, 2003. 123(1 Suppl): p. 188S-201S., https://www.ncbi.nlm.nih.gov/pubmed/12527579
738. Magdeleinat, P., Alifano, M., Benbrahem, C., Spaggiari, L., Porrello, C., Puyo, P., et.al. Surgical treatment of lung cancer invading the chest wall: results and prognostic factors, Ann.Thorac Surg, 2001. 71(4): p. 1094-1099., https://www.ncbi.nlm.nih.gov/pubmed/11308142
739. McCaughan, B. C., Martini, N., Bains, M. S., McCormack, P. M., Chest wall invasion in carcinoma of the lung. Therapeutic and prognostic implications, J Thorac Cardiovasc Surg, 1985. 89(6): p. 836-841., https://www.ncbi.nlm.nih.gov/pubmed/2987619
740. Albertucci, M., DeMeester, T. R., Rothberg, M., Hagen, J. A., Santoscoy, R., Smyrk, T. C., Surgery and the management of peripheral lung tumors adherent to the parietal pleura, J Thorac.Cardiovasc.Surg., 1992. 103(1): p. 8-12., https://www.ncbi.nlm.nih.gov/pubmed/1309467
741. Trastek, V. F., Pairolero, P. C., Piehler, J. M., Weiland, L. H., O'Brien, P. C., Payne, W. S., et.al. En bloc (non-chest wall) resection for bronchogenic carcinoma with parietal fixation. Factors affecting survival, J.Thorac.Cardiovasc.Surg., 1984. 87(3): p. 352-358., https://www.ncbi.nlm.nih.gov/pubmed/6700242
742. Downey, R. J., Martini, N., Rusch, V. W., Bains, M. S., Korst, R. J., Ginsberg, R. J., Extent of chest wall invasion and survival in patients with lung cancer, Ann.Thorac Surg, 1999. 68(1): p. 188-193., https://www.ncbi.nlm.nih.gov/pubmed/10421139
743. Gould, P. M., Bonner, J. A., Sawyer, T. E., Deschamps, C., Lange, C. M., Li, H., Patterns of failure and overall survival in patients with completely resected T3 N0 M0 non-small cell lung cancer, Int J Radiat Oncol Biol Phys, 1999. 45(1): p. 91-95., https://www.ncbi.nlm.nih.gov/pubmed/10477011
744. Goldstraw, P., Chansky, K., Crowley, J., Rami-Porta, R., Asamura, H., Eberhardt, W. E., et.al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer, J Thorac Oncol, 2016. 11(1): p. 39-51., https://www.ncbi.nlm.nih.gov/pubmed/26762738
745. Ginsberg, R. J., Hill, L. D., Eagan, R. T., Thomas, P., Mountain, C. F., Deslauriers, J., et.al. Modern thirty-day operative mortality for surgical resections in lung cancer, J Thorac Cardiovasc Surg, 1983. 86(5): p. 654-658., https://www.ncbi.nlm.nih.gov/pubmed/6632940
746. Deslauriers, J., Ginsberg, R. J., Piantadosi, S., Fournier, B., Prospective assessment of 30-day operative morbidity for surgical resections in lung cancer, Chest, 1994. 106(6 Suppl): p. 329S-330S., https://www.ncbi.nlm.nih.gov/pubmed/7988256
747. Whittle, J., Steinberg, E. P., Anderson, G. F., Herbert, R., Use of Medicare claims data to evaluate outcomes in elderly patients undergoing lung resection for lung cancer, Chest, 1991. 100(3): p. 729-734., https://www.ncbi.nlm.nih.gov/pubmed/1889265
748. Thomas, P., Piraux, M., Jacques, L. F., Gregoire, J., Bedard, P., Deslauriers, J., Clinical patterns and trends of outcome of elderly patients with bronchogenic carcinoma, Eur J Cardiothorac.Surg., 1998. 13(3): p. 266-274., https://www.ncbi.nlm.nih.gov/pubmed/9628376
749. von Knorring, J., Lepantalo, M., Lindgren, L., Lindfors, O., Cardiac arrhythmias and myocardial ischemia after thoracotomy for lung cancer, Ann.Thorac.Surg., 1992. 53(4): p. 642-647., https://www.ncbi.nlm.nih.gov/pubmed/1554274
750. Romano, P. S., Mark, D. H., Patient and hospital characteristics related to in-hospital mortality after lung cancer resection, Chest, 1992. 101(5): p. 1332-1337., https://www.ncbi.nlm.nih.gov/pubmed/1582293
751. Martini, N., Bains, M. S., Burt, M. E., Zakowski, M. F., McCormack, P., Rusch, V. W., et.al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer, J Thorac.Cardiovasc.Surg., 1995. 109(1): p. 120-129., https://www.ncbi.nlm.nih.gov/pubmed/7815787
752. Deslauriers, J., Ginsberg, R. J., Dubois, P., Beaulieu, M., Goldberg, M., Piraux, M., Current operative morbidity associated with elective surgical resection for lung cancer, Can.J Surg, 1989. 32(5): p. 335-339., https://www.ncbi.nlm.nih.gov/pubmed/2766139
753. Damhuis, R. A., Schutte, P. R., Resection rates and postoperative mortality in 7,899 patients with lung cancer, Eur Respir.J, 1996. 9(1): p. 7-10., https://www.ncbi.nlm.nih.gov/pubmed/8834326
754. Duque, J. L., Ramos, G., Castrodeza, J., Cerezal, J., Castanedo, M., Yuste, M. G., et.al. Early complications in surgical treatment of lung cancer: a prospective, multicenter study. Grupo Cooperativo de Carcinoma Broncogenico de la Sociedad Espanola de Neumologia y Cirugia Toracica, Ann.Thorac.Surg., 1997. 63(4): p. 944-950., https://www.ncbi.nlm.nih.gov/pubmed/9124968
755. Silvestri, G. A., Handy, J., Lackland, D., Corley, E., Reed, C. E., Specialists achieve better outcomes than generalists for lung cancer surgery, Chest, 1998. 114(3): p. 675-680., https://www.ncbi.nlm.nih.gov/pubmed/9743149
756. Wada, H., Nakamura, T., Nakamoto, K., Maeda, M., Watanabe, Y., Thirty-day operative mortality for thoracotomy in lung cancer, J.Thorac.Cardiovasc.Surg., 1998. 115(1): p. 70-73., https://www.ncbi.nlm.nih.gov/pubmed/9451047
757. van Rens, M. T., de la Riviere, A. B., Elbers, H. R., van den Bosch, J. M., Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA, Chest, 2000. 117(2): p. 374-379., https://www.ncbi.nlm.nih.gov/pubmed/10669677
758. Onishi, H, Shirato, H, Nagata, Y, Hiraoka, M, Fujino, M, Gomi, K, et.al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?, Int J Radiat Oncol Biol Phys, 2011. 81 (5)(5): p. 1352-8., https://pubmed.ncbi.nlm.nih.gov/20638194/
759. Chang, Joe Y., Senan, Suresh, Paul, Marinus A., Mehran, Reza J., Louie, Alexander V., Balter, Peter, et.al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials, The Lancet Oncology, 2015. 16(6): p. 630-637., https://www.ncbi.nlm.nih.gov/pubmed/25981812
760. Chang, JY, Mehran, RJ, Feng, L, Verma, V, Liao, Z, Welsh, JW, et.al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery., Lancet Oncol, 2021. 22 (10)(10): p. 1448-1457., https://pubmed.ncbi.nlm.nih.gov/34529930/
761. Li, H, Shen, Y, Wu, Y, Cai, S, Zhu, Y, Chen, S, et.al. Stereotactic Body Radiotherapy Versus Surgery for Early-Stage Non-Small-Cell Lung Cancer., J Surg Res, 2019. 243 (): p. 346-353., https://pubmed.ncbi.nlm.nih.gov/31277011/
762. Izbicki, J. R., Passlick, B., Pantel, K., Pichlmeier, U., Hosch, S. B., Karg, O., et.al. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial, Ann.Surg., 1998. 227(1): p. 138-144., https://www.ncbi.nlm.nih.gov/pubmed/9445122
763. Wright, G., Manser, R. L., Byrnes, G., Hart, D., Campbell, D. A., Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials, Thorax, 2006. 61(7): p. 597-603., https://www.ncbi.nlm.nih.gov/pubmed/16449262
764. Depierre, A., Milleron, B., Moro-Sibilot, D., Chevret, S., Quoix, E., Lebeau, B., et.al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer (Comment see De-Pas, T. et al. and Mok, T. et al., J Clin Oncol Vol. 20, 2603-4 and 2604-5), J Clin Oncol, 2002. 20(1): p. 247-253., https://www.ncbi.nlm.nih.gov/pubmed/11773176
765. Nicolson, M., Gilligan, D., Smith, I., Groen, H., Manegold, C., van Meerbeeck, J., et.al. Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): First results of the MRC LU22/NVALT/EORTC 08012 multi-centre randomised trial, J Clin Oncol, 2007. 25(18S): p. 7518., https://www.ncbi.nlm.nih.gov/pubmed/17544497
766. Scagliotti, G. V., Pastorino, U., Vansteenkiste, J. F., Spaggiari, L., Facciolo, F., Orlowski, T. M., et.al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer, J Clin Oncol, 2012. 30(2): p. 172-8., https://www.ncbi.nlm.nih.gov/pubmed/22124104
767. Felip, E., Rosell, R., Maestre, J. A., Rodriguez-Paniagua, J. M., Moran, T., Astudillo, J., et.al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer, J Clin Oncol, 2010. 28(19): p. 3138-45., https://www.ncbi.nlm.nih.gov/pubmed/20516435
768. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data, Lancet, 2014. 383(9928): p. 1561-71., https://www.ncbi.nlm.nih.gov/pubmed/24576776
769. Pisters, K., Vallieres, E., Bunn, P. A., Crowley, J., Chansky, K., et.al. S9900: Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Follow-up on a phase III trial, J Clin Oncol, 2007. 25(No 18S (Suppl)): p. 7520.
770. Song, WA, Zhou, NK, Wang, W, Chu, XY, Liang, CY, Tian, XD, et.al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials., J Thorac Oncol, 2010. 5 (4)(4): p. 510-6., https://pubmed.ncbi.nlm.nih.gov/20107424/
771. Sedrakyan, A., Van Der, Meulen J., O'Byrne, K., Prendiville, J., Hill, J., Treasure, T., Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis, J.Thorac.Cardiovasc.Surg., 2004. 128(3): p. 414-419., https://www.ncbi.nlm.nih.gov/pubmed/15354101
772. Pignon, J. P., Stewart, L. A., Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis (Comment to Marino, P, Cancer, Vol. 76, p. 593 - 601), Cancer, 1996. 77(11): p. 2413-2414., https://www.ncbi.nlm.nih.gov/pubmed/8625152
773. West, H, McCleod, M, Hussein, M, Morabito, A, Rittmeyer, A, Conter, HJ, et.al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial., Lancet Oncol, 2019. 20 (7)(7): p. 924-937., https://pubmed.ncbi.nlm.nih.gov/31122901/
774. Burdett, S, Pignon, JP, Tierney, J, Tribodet, H, Stewart, L, Le Pechoux, C, et.al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer., Cochrane Database Syst Rev, 2015. (3)(3): p. CD011430., https://pubmed.ncbi.nlm.nih.gov/25730344/
775. Arriagada, R, Auperin, A, Burdett, S, Higgins, JP, Johnson, DH, Le Chevalier, T, et.al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data., Lancet, 2010. 375 (9722)(9722): p. 1267-77., https://pubmed.ncbi.nlm.nih.gov/20338627/
776. Wu, YL, Tsuboi, M, He, J, John, T, Grohe, C, Majem, M, et.al. Osimertinib in Resected , N Engl J Med, 2020. 383 (18)(18): p. 1711-1723., https://pubmed.ncbi.nlm.nih.gov/32955177/
777. Tsuboi, M, Herbst, RS, John, T, Kato, T, Majem, M, Grohé, C, et.al. Overall Survival with Osimertinib in Resected , N Engl J Med, 2023. 389 (2)(2): p. 137-147., https://pubmed.ncbi.nlm.nih.gov/37272535/
778. Lung Cancer Study, Group, The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. The Lung Cancer Study Group, J Clin Oncol, 1988. 6(1): p. 9-17., https://www.ncbi.nlm.nih.gov/pubmed/2891798
779. Niiranen, A., Niitamo-Korhonen, S., Kouri, M., Assendelft, A., Mattson, K., Pyrhonen, S., Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study, J.Clin.Oncol., 1992. 10(12): p. 1927-1932., https://www.ncbi.nlm.nih.gov/pubmed/1333518
780. Feld, R., Rubinstein, L., Thomas, P. A., Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer. An LCSG Trial, Chest, 1994. 106(6 Suppl): p. 307S-309S., https://www.ncbi.nlm.nih.gov/pubmed/7988250
781. Scagliotti, G. V., Fossati, R., Torri, V., Crino, L., Giaccone, G., Silvano, G., et.al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer, J.Natl.Cancer Inst., 2003. 95(19): p. 1453-1461., https://www.ncbi.nlm.nih.gov/pubmed/14519751
782. Postmus, P. E., Scagliotti, G., Groen, H. J., Gozzelino, F., Burghouts, J. T., Curran, D., et.al. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial, Eur J Cancer, 1996. 32A(9): p. 1498-1503., https://www.ncbi.nlm.nih.gov/pubmed/8911108
783. Roselli, M., Mariotti, S., Ferroni, P., Laudisi, A., Mineo, D., Pompeo, E., et.al. Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: Long-term survival in a randomized study, Int.J.Cancer, 2006. 119(4): p. 955-960., https://www.ncbi.nlm.nih.gov/pubmed/16550600
784. Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., et.al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer, N.Engl.J.Med., 2005. 352(25): p. 2589-2597., https://www.ncbi.nlm.nih.gov/pubmed/15972865
785. Douillard, J. Y., Rosell, R., De Lena, M., Carpagnano, F., Ramlau, R., Gonzales-Larriba, J. L., et.al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial, Lancet Oncol, 2006. 7(9): p. 719-27., https://www.ncbi.nlm.nih.gov/pubmed/16945766
786. Strauss, G. M., Herndon, J. E., Maddaus, M. A., et al., Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B protocol 9633, J.Clin.Oncol., 2006. 24(18S): p. 7007., https://ascopubs.org/doi/abs/10.1200/jco.2006.24.18_suppl.7007
787. Pignon, J. P., Tribodet, H., Scagliotti, G. V., Douillard, J. Y., Shepherd, F. A., Stephens, R. J., et.al. Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients (2006 ASCO Annual Meeting Proceedings Part I. ), J Clin Oncol, 2006. 24(No 18S): p. 7008., https://ascopubs.org/doi/abs/10.1200/jco.2006.24.18_suppl.7008
788. Mineo, T. C., Ambrogi, V., Corsaro, V., Roselli, M., Postoperative adjuvant therapy for stage IB non-small-cell lung cancer, Eur.J.Cardiothorac.Surg., 2001. 20(2): p. 378-384., https://www.ncbi.nlm.nih.gov/pubmed/11463561
789. Tsutani, Yasuhiro, Imai, Kentaro, Ito, Hiroyuki, Mimae, Takahiro, Miyata, Yoshihiro, Ikeda, Norihiko, et.al. Adjuvant chemotherapy for pathological stage I non-small cell lung cancer with high-risk factors for recurrence: A multicenter study.Wolters Kluwer, Journal of Clinical Oncology, 2019. 37(15_suppl): p. 8500 - 8500., https://doi.org/10.1200/JCO.2019.37.15_suppl.8500
790. Wu, YL, Tsuboi, M, He, J, John, T, Grohe, C, Majem, M, et.al. Osimertinib in Resected , N Engl J Med, 2020. 383 (18)(18): p. 1711-1723., https://pubmed.ncbi.nlm.nih.gov/32955177/
791. Sirzen, F., Kjellen, E., Sorenson, S., Cavallin-Stahl, E., A systematic overview of radiation therapy effects in non-small cell lung cancer, Acta Oncol., 2003. 42(5-6): p. 493-515., https://www.ncbi.nlm.nih.gov/pubmed/14596509
792. Bradley, J. D., Paulus, R., Graham, M. V., Ettinger, D. S., Johnstone, D. W., Pilepich, M. V., et.al. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705, J Clin Oncol, 2005. 23(15): p. 3480-3487., https://www.ncbi.nlm.nih.gov/pubmed/15908657
793. Dautzenberg, B., Chastang, C., Arriagada, R., Le Chevalier, T., Belpomme, D., Hurdebourcq, M., et.al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of 267 patients. GETCB (Groupe d'Etude et de Traitement des Cancers Bronchiques), Cancer, 1995. 76(5): p. 779-786., https://www.ncbi.nlm.nih.gov/pubmed/8625180
794. Wakelee, H. A., Stephenson, P., Keller, S. M., Wagner, H., Herskovic, A., Komaki, R., et.al. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590, Lung Cancer, 2005. 48(3): p. 389-397., https://www.ncbi.nlm.nih.gov/pubmed/15893008
795. Trodella, L., Granone, P., Valente, S., Valentini, V., Balducci, M., Mantini, G., et.al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial, Radiother.Oncol., 2002. 62(1): p. 11-19., https://www.ncbi.nlm.nih.gov/pubmed/11830308
796. Rusch, V. W., Giroux, D. J., Kraut, M. J., Crowley, J., Hazuka, M., Winton, T., et.al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160), J.Clin.Oncol., 2007. 25(3): p. 313-318., https://www.ncbi.nlm.nih.gov/pubmed/17235046
797. Buderi, SI, Shackcloth, M, Woolley, S, Does induction chemoradiotherapy increase survival in patients with Pancoast tumour?, Interact Cardiovasc Thorac Surg, 2016. 23 (5)(5): p. 821-825., https://pubmed.ncbi.nlm.nih.gov/27365009/
798. Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., et.al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC, N Engl J Med, 2018. 379(24): p. 2342-2350., https://pubmed.ncbi.nlm.nih.gov/30280658/
799. Setzer, M, Robinson, LA, Vrionis, FD, Management of locally advanced pancoast (superior sulcus) tumors with spine involvement., Cancer Control, 2014. 21 (2)(2): p. 158-67., https://pubmed.ncbi.nlm.nih.gov/24667403/
800. Blaauwgeers, JL, Kappers, I, Klomp, HM, Belderbos, JS, Dijksman, LM, Smit, EF, et.al. Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus., Virchows Arch, 2013. 462 (5)(5): p. 547-56., https://pubmed.ncbi.nlm.nih.gov/23549732/
801. Marra, A., Eberhardt, W., Pottgen, C., Theegarten, D., Korfee, S., Gauler, T., et.al. Induction chemotherapy, concurrent chemoradiation and surgery for Pancoast tumour, Eur Respir J, 2007. 29(1): p. 117-126., https://www.ncbi.nlm.nih.gov/pubmed/16971407
802. Eberhardt, WE, Pöttgen, C, Gauler, TC, Friedel, G, Veit, S, Heinrich, V, et.al. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)., J Clin Oncol, 2015. 33 (35)(35): p. 4194-201., https://pubmed.ncbi.nlm.nih.gov/26527789/
803. Martini, N., Kris, M. G., Flehinger, B. J., Gralla, R. J., Bains, M. S., Burt, M. E., et.al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients, Ann.Thorac Surg, 1993. 55(6): p. 1365-1373., https://www.ncbi.nlm.nih.gov/pubmed/8390230
804. Kernstine, Kemp H., Moon, James, Kraut, Michael J., Pisters, Katherine M. W., Sonett, Joshua R., Rusch, Valerie W., et.al. Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220, The Annals of thoracic surgery, 2014. 98(2): p. 402-410., https://pubmed.ncbi.nlm.nih.gov/24980603, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122593/
805. Aokage, K, Tsuboi, M, Zenke, Y, Horinouchi, H, Nakamura, N, Ishikura, S, et.al. Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancer., Jpn J Clin Oncol, 2022. 52 (4)(4): p. 383-387., https://pubmed.ncbi.nlm.nih.gov/34999817/
806. Wu, Y, Verma, V, Gay, CM, Chen, Y, Liang, F, Lin, Q, et.al. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis., Cancer, 2023. 129 (13)(13): p. 1969-1985., https://pubmed.ncbi.nlm.nih.gov/36994945/
807. Detterbeck, FC, Boffa, DJ, Kim, AW, Tanoue, LT, The Eighth Edition Lung Cancer Stage Classification., Chest, 2017. 151 (1)(1): p. 193-203., https://pubmed.ncbi.nlm.nih.gov/27780786/
808. Andre, F, Grunenwald, D, Pignon, JP, Dujon, A, Pujol, JL, Brichon, PY, et.al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications., J Clin Oncol, 2000. 18 (16)(16): p. 2981-9., https://pubmed.ncbi.nlm.nih.gov/10944131/
809. Asamura, H, Chansky, K, Crowley, J, Goldstraw, P, Rusch, VW, Vansteenkiste, JF, et.al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer., J Thorac Oncol, 2015. 10 (12)(12): p. 1675-84., https://pubmed.ncbi.nlm.nih.gov/26709477/
810. Pepe, C, Hasan, B, Winton, TL, Seymour, L, Graham, B, Livingston, RB, et.al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10., J Clin Oncol, 2007. 25 (12)(12): p. 1553-61., https://pubmed.ncbi.nlm.nih.gov/17442999/
811. Früh, M, Rolland, E, Pignon, JP, Seymour, L, Ding, K, Tribodet, H, et.al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer., J Clin Oncol, 2008. 26 (21)(21): p. 3573-81., https://pubmed.ncbi.nlm.nih.gov/18640938/
812. Cuffe, S, Booth, CM, Peng, Y, Darling, GE, Li, G, Kong, W, et.al. Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada., J Clin Oncol, 2012. 30 (15)(15): p. 1813-21., https://pubmed.ncbi.nlm.nih.gov/22529258/
813. Rocha Lima, CM, Herndon, JE, Kosty, M, Clamon, G, Green, MR, Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B., Cancer, 2002. 94 (1)(1): p. 181-7., https://pubmed.ncbi.nlm.nih.gov/11815975/
814. Schild, SE, Stella, PJ, Geyer, SM, Bonner, JA, McGinnis, WL, Mailliard, JA, et.al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly., J Clin Oncol, 2003. 21 (17)(17): p. 3201-6., https://pubmed.ncbi.nlm.nih.gov/12874270/
815. Jalal, SI, Riggs, HD, Melnyk, A, Richards, D, Agarwala, A, Neubauer, M, et.al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology., Ann Oncol, 2012. 23 (7)(7): p. 1730-8., https://pubmed.ncbi.nlm.nih.gov/22156624/
816. Takigawa, N, Kiura, K, Segawa, Y, Hotta, K, Tamaoki, A, Tokuda, Y, et.al. Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007., J Thorac Oncol, 2011. 6 (6)(6): p. 1087-91., https://pubmed.ncbi.nlm.nih.gov/21415777/
817. Stinchcombe, TE, Zhang, Y, Vokes, EE, Schiller, JH, Bradley, JD, Kelly, K, et.al. Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies., J Clin Oncol, 2017. 35 (25)(25): p. 2885-2892., https://pubmed.ncbi.nlm.nih.gov/28493811/
818. Atagi, S, Kawahara, M, Yokoyama, A, Okamoto, H, Yamamoto, N, Ohe, Y, et.al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)., Lancet Oncol, 2012. 13 (7)(7): p. 671-8., https://pubmed.ncbi.nlm.nih.gov/22622008/
819. Atagi, S, Mizusawa, J, Ishikura, S, Takahashi, T, Okamoto, H, Tanaka, H, et.al. Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301)., Clin Lung Cancer, 2018. 19 (5)(5): p. e619-e627., https://pubmed.ncbi.nlm.nih.gov/29887243/
820. Balducci, L, Beghe, C, The application of the principles of geriatrics to the management of the older person with cancer., Crit Rev Oncol Hematol, 2000. 35 (3)(3): p. 147-54., https://pubmed.ncbi.nlm.nih.gov/10960797/
821. Saliba, D, Elliott, M, Rubenstein, LZ, Solomon, DH, Young, RT, Kamberg, CJ, et.al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community., J Am Geriatr Soc, 2001. 49 (12)(12): p. 1691-9., https://pubmed.ncbi.nlm.nih.gov/11844005/
822. Antonio, M, Saldaña, J, Linares, J, Ruffinelli, JC, Palmero, R, Navarro, A, et.al. Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer., Br J Cancer, 2018. 118 (5)(5): p. 639-647., https://pubmed.ncbi.nlm.nih.gov/29381689/
823. Sher, A, Medavaram, S, Nemesure, B, Clouston, S, Keresztes, R, Risk Stratification of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Chemo-Radiotherapy: An Institutional Analysis., Cancer Manag Res, 2020. 12 (): p. 7165-7171., https://pubmed.ncbi.nlm.nih.gov/32848470/
824. Załeska, M, Szturmowicz, M, Zych, J, Roszkowska-Sliz, B, Demkow, U, Langfort, R, et.al. [Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival]., Pneumonol Alergol Pol, 2010. 78 (1)(1): p. 14-20., https://pubmed.ncbi.nlm.nih.gov/20162514/
825. Viñolas, N, Molina, R, Galán, MC, Casas, F, Callejas, MA, Filella, X, et.al. Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report., Anticancer Res 18 (1B)(1B): p. 631-4., https://pubmed.ncbi.nlm.nih.gov/9584045/
826. Merle, P, Janicot, H, Filaire, M, Roux, D, Bailly, C, Vincent, C, et.al. Early CYFRA 21-1 variation predicts tumor response to chemotherapy and survival in locally advanced non-small cell lung cancer patients., Int J Biol Markers 19 (4)(4): p. 310-5., https://pubmed.ncbi.nlm.nih.gov/15646838/
827. Pujol, JL, Molinier, O, Ebert, W, Daurès, JP, Barlesi, F, Buccheri, G, et.al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients., Br J Cancer, 2004. 90 (11)(11): p. 2097-105., https://pubmed.ncbi.nlm.nih.gov/15150567/
828. Berghmans, T, Lafitte, JJ, Thiriaux, J, VanHoutte, P, Lecomte, J, Efremidis, A, et.al. Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy., Lung Cancer, 2004. 45 (3)(3): p. 339-48., https://pubmed.ncbi.nlm.nih.gov/15301874/
829. Werner-Wasik, M, Scott, C, Cox, JD, Sause, WT, Byhardt, RW, Asbell, S, et.al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival., Int J Radiat Oncol Biol Phys, 2000. 48 (5)(5): p. 1475-82., https://pubmed.ncbi.nlm.nih.gov/11121651/
830. Hoffmann, M, Reitz, D, Taugner, J, Roengvoraphoj, O, Käsmann, L, Eze, C, et.al. Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy., Anticancer Res, 2020. 40 (4)(4): p. 2319-2322., https://pubmed.ncbi.nlm.nih.gov/32234932/
831. Paesmans, M, [Prognostic factors]., Rev Mal Respir, 1998. 15 (3 Pt 2)(3 Pt 2): p. 420-7., https://pubmed.ncbi.nlm.nih.gov/9690312/
832. van Laar, M, van Amsterdam, WAC, van Lindert, ASR, de Jong, PA, Verhoeff, JJC, Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: A systematic review and meta-analysis., Radiother Oncol, 2020. 151 (): p. 152-175., https://pubmed.ncbi.nlm.nih.gov/32710990/
833. Gerber, DE, Dahlberg, SE, Sandler, AB, Ahn, DH, Schiller, JH, Brahmer, JR, et.al. Baseline tumour measurements predict survival in advanced non-small cell lung cancer., Br J Cancer, 2013. 109 (6)(6): p. 1476-81., https://pubmed.ncbi.nlm.nih.gov/23942074/
834. Basaki, K, Abe, Y, Aoki, M, Kondo, H, Hatayama, Y, Nakaji, S, Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume., Int J Radiat Oncol Biol Phys, 2006. 64 (2)(2): p. 449-54., https://pubmed.ncbi.nlm.nih.gov/16226400./
835. Eberhardt, W., Wilke, H., Stamatis, G., Stuschke, M., Harstrick, A., Menker, H., et.al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial, J Clin Oncol, 1998. 16(2): p. 622-634., https://www.ncbi.nlm.nih.gov/pubmed/9469351
836. Kim, IH, Lee, GD, Choi, S, Kim, HR, Kim, YH, Kim, DK, et.al. Validation Study for the N Descriptor of the Newly Proposed Ninth Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer., J Thorac Oncol, 2024. 19 (8)(8): p. 1218-1227., https://pubmed.ncbi.nlm.nih.gov/38614456/
837. Houda, I, Bahce, I, Dickhoff, C, Kroese, TE, Kroeze, SGC, Mariolo, AV, et.al. An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer., Lung Cancer, 2025. 199 (): p. 108061., https://pubmed.ncbi.nlm.nih.gov/39705827/
838. Kim, SS, Cooke, DT, Kidane, B, Tapias, LF, Lazar, JF, Awori Hayanga, JW, et.al. The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-small Cell Lung Cancer., Ann Thorac Surg, 2025. 119 (1)(1): p. 16-33., https://pubmed.ncbi.nlm.nih.gov/39424119/
839. De Leyn, P, Dooms, C, Kuzdzal, J, Lardinois, D, Passlick, B, Rami-Porta, R, et.al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer., Eur J Cardiothorac Surg, 2014. 45 (5)(5): p. 787-98., https://pubmed.ncbi.nlm.nih.gov/24578407/
840. Riquet, M, Bagan, P, Le Pimpec Barthes, F, Banu, E, Scotte, F, Foucault, C, et.al. Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases., Ann Thorac Surg, 2007. 84 (6)(6): p. 1818-24., https://pubmed.ncbi.nlm.nih.gov/18036891/
841. Forde, PM, Spicer, JD, Provencio, M, Mitsudomi, T, Awad, MM, Wang, C, et.al. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer., N Engl J Med, 2025. 393 (8)(8): p. 741-752., https://pubmed.ncbi.nlm.nih.gov/40454642/
842. Forde, PM, Spicer, J, Lu, S, Provencio, M, Mitsudomi, T, Awad, MM, et.al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer., N Engl J Med, 2022. 386 (21)(21): p. 1973-1985., https://pubmed.ncbi.nlm.nih.gov/35403841/
843. Heymach, JV, Harpole, D, Mitsudomi, T, Taube, JM, Galffy, G, Hochmair, M, et.al. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer., N Engl J Med, 2023. 389 (18)(18): p. 1672-1684., https://pubmed.ncbi.nlm.nih.gov/37870974/
844. Spicer, JD, Garassino, MC, Wakelee, H, Liberman, M, Kato, T, Tsuboi, M, et.al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial., Lancet, 2024. 404 (10459)(10459): p. 1240-1252., https://pubmed.ncbi.nlm.nih.gov/39288781/
845. Cascone, T, Awad, MM, Spicer, JD, He, J, Lu, S, Sepesi, B, et.al. Perioperative Nivolumab in Resectable Lung Cancer., N Engl J Med, 2024. 390 (19)(19): p. 1756-1769., https://pubmed.ncbi.nlm.nih.gov/38749033/
846. Spigel, DR, Faivre-Finn, C, Gray, JE, Vicente, D, Planchard, D, Paz-Ares, L, et.al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer., J Clin Oncol, 2022. 40 (12)(12): p. 1301-1311., https://pubmed.ncbi.nlm.nih.gov/35108059/
847. Gray, JE, Villegas, A, Daniel, D, Vicente, D, Murakami, S, Hui, R, et.al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC., J Thorac Oncol, 2020. 15 (2)(2): p. 288-293., https://pubmed.ncbi.nlm.nih.gov/31622733/
848. Putora, PM, Leskow, P, McDonald, F, Batchelor, T, Evison, M, International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy?, ERJ Open Res, 2020. 6 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/32083114/
849. Glatzer, M, Leskow, P, Caparrotti, F, Elicin, O, Furrer, M, Gambazzi, F, et.al. Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists., Transl Lung Cancer Res, 2021. 10 (4)(4): p. 1960-1968., https://pubmed.ncbi.nlm.nih.gov/34012806/
850. Etienne, H, Battilana, B, Spicer, J, Werner, RS, Opitz, I, Defining resectability: When do you try to take it out?, JTCVS Open, 2024. 19 (): p. 338-346., https://pubmed.ncbi.nlm.nih.gov/39015436/
851. Eichhorn, F, Zaatar, M, Oggiano, M, Welter, S, Koryllos, A, Klotz, L, [Perioperative Therapy for Locally Advanced Non-small Cell Lung Cancer: Delphi Expert Consensus of the German Society for Thoracic Surgery]., Zentralbl Chir, 2025. ():, https://pubmed.ncbi.nlm.nih.gov/40774321/
852. Brunelli, A, Charloux, A, Bolliger, CT, Rocco, G, Sculier, JP, Varela, G, et.al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)., Eur Respir J, 2009. 34 (1)(1): p. 17-41., https://pubmed.ncbi.nlm.nih.gov/19567600/
853. Orlandi, R, Degiovanni, S, Uslenghi, C, Anghinelli, A, Besana, P, Palleschi, A, Pulmonary function prediction in lung cancer resection candidates: the latest insights., Breathe (Sheff), 2025. 21 (3)(3): p. 250041., https://pubmed.ncbi.nlm.nih.gov/40673067/
854. Brunelli, A, Kim, AW, Berger, KI, Addrizzo-Harris, DJ, Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines., Chest, 2013. 143 (5 Suppl)(5 Suppl): p. e166S-e190S., https://pubmed.ncbi.nlm.nih.gov/23649437/
855. Rami-Porta, R, Wittekind, C, Goldstraw, P, Complete resection in lung cancer surgery: proposed definition., Lung Cancer, 2005. 49 (1)(1): p. 25-33., https://pubmed.ncbi.nlm.nih.gov/15949587/
856. Kidane, B, Bott, M, Spicer, J, Backhus, L, Chaft, J, Chudgar, N, et.al. The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer., J Thorac Cardiovasc Surg, 2023. 166 (3)(3): p. 637-654., https://pubmed.ncbi.nlm.nih.gov/37306641/
857. Daly, ME, Singh, N, Ismaila, N, Management of Stage III Non-Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update., J Clin Oncol, 2024. 42 (25)(25): p. 3058-3060., https://pubmed.ncbi.nlm.nih.gov/39042842/
858. Aigner, C, Baldes, N, Begic, M, Doerr, F, Hoda, MA, Bölükbas, S, Current perspective on resectability in stage III locally advanced NSCLC - The thoracic surgeons' view., Eur J Cancer, 2025. 221 (): p. 115426., https://pubmed.ncbi.nlm.nih.gov/40239401/
859. Lorenzi, W, Mercier, O, The role of extracorporeal life support in extended lung resections for non-small cell lung cancer: a narrative review., J Thorac Dis, 2023. 15 (9)(9): p. 5232-5238., https://pubmed.ncbi.nlm.nih.gov/37868859/
860. D'Andrilli, A, Trabalza Marinucci, B, Ciccone, AM, Ibrahim, M, Andreetti, C, Messa, F, et.al. Carinal Reconstruction for Lung Cancer and Airway Tumors: Long-term Results., Ann Thorac Surg, 2025. 120 (2)(2): p. 271-281., https://pubmed.ncbi.nlm.nih.gov/39447856/
861. Provencio, M, Nadal, E, Insa, A, García-Campelo, MR, Casal-Rubio, J, Dómine, M, et.al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial., Lancet Oncol, 2020. 21 (11)(11): p. 1413-1422., https://pubmed.ncbi.nlm.nih.gov/32979984/
862. Provencio, Mariano, Awad, Mark M., Spicer, Jonathan, Janssens, Annelies, Moiseenko, Fedor Vladimirovich, Gao, Yang, et.al. Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.Wolters Kluwer, Journal of Clinical Oncology, 2024. 42(17_suppl): p. LBA8007 - LBA8007., https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA8007
863. Albain, K. S., Swann, R. S., Rusch, V. W., Turrisi, A. T., 3rd, Shepherd, F. A., Smith, C., et.al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial, Lancet, 2009. 374(9687): p. 379-86., https://www.ncbi.nlm.nih.gov/pubmed/19632716
864. Rusch, VW, Crowley, J, Giroux, DJ, Goldstraw, P, Im, JG, Tsuboi, M, et.al. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer., J Thorac Oncol, 2007. 2 (7)(7): p. 603-12., https://pubmed.ncbi.nlm.nih.gov/17607115/
865. Silvestri, G. A., Gonzalez, A. V., Jantz, M. A., Margolis, M. L., Gould, M. K., Tanoue, L. T., et.al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines, Chest, 2013. 143(5 Suppl): p. e211S-50S., https://www.ncbi.nlm.nih.gov/pubmed/23649440
866. Dehing-Oberije, C, De Ruysscher, D, van der Weide, H, Hochstenbag, M, Bootsma, G, Geraedts, W, et.al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy., Int J Radiat Oncol Biol Phys, 2008. 70 (4)(4): p. 1039-44., https://pubmed.ncbi.nlm.nih.gov/17889446/
867. Hishida, T, Yoshida, J, Nishimura, M, Nishiwaki, Y, Nagai, K, Problems in the current diagnostic standards of clinical N1 non-small cell lung cancer., Thorax, 2008. 63 (6)(6): p. 526-31., https://pubmed.ncbi.nlm.nih.gov/18024539/
868. Wang, J, Welch, K, Wang, L, Kong, FM, Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-small-cell lung cancer: a meta-analysis., Clin Lung Cancer, 2012. 13 (2)(2): p. 81-9., https://pubmed.ncbi.nlm.nih.gov/22056226/
869. Gómez-Caro, A, Boada, M, Cabañas, M, Sanchez, M, Arguis, P, Lomeña, F, et.al. False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancer., Eur J Cardiothorac Surg, 2012. 42 (1)(1): p. 93-100; discussion 100., https://pubmed.ncbi.nlm.nih.gov/22290911/
870. Pieterman, RM, van Putten, JW, Meuzelaar, JJ, Mooyaart, EL, Vaalburg, W, Koëter, GH, et.al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography., N Engl J Med, 2000. 343 (4)(4): p. 254-61., https://pubmed.ncbi.nlm.nih.gov/10911007/
871. De Leyn, P, Stroobants, S, De Wever, W, Lerut, T, Coosemans, W, Decker, G, et.al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study., J Clin Oncol, 2006. 24 (21)(21): p. 3333-9., https://pubmed.ncbi.nlm.nih.gov/16849747/
872. Fischer, B, Lassen, U, Mortensen, J, Larsen, S, Loft, A, Bertelsen, A, et.al. Preoperative staging of lung cancer with combined PET-CT., N Engl J Med, 2009. 361 (1)(1): p. 32-9., https://pubmed.ncbi.nlm.nih.gov/19571281/
873. Fischer, BM, Mortensen, J, Hansen, H, Vilmann, P, Larsen, SS, Loft, A, et.al. Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial., Thorax, 2011. 66 (4)(4): p. 294-300., https://pubmed.ncbi.nlm.nih.gov/21169287/
874. Annema, Jouke T., van Meerbeeck, Jan P., Rintoul, Robert C., Dooms, Christophe, Deschepper, Ellen, Dekkers, Olaf M., et.al. Mediastinoscopy vs Endosonography for Mediastinal Nodal Staging of Lung Cancer: A Randomized Trial, JAMA, 2010. 304(20): p. 2245 - 2252., https://doi.org/10.1001/jama.2010.1705
875. Yasufuku, K, Pierre, A, Darling, G, de Perrot, M, Waddell, T, Johnston, M, et.al. A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer., J Thorac Cardiovasc Surg, 2011. 142 (6)(6): p. 1393-400.e1., https://pubmed.ncbi.nlm.nih.gov/21963329/
876. Herth, FJ, Eberhardt, R, Krasnik, M, Ernst, A, Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer., Chest, 2008. 133 (4)(4): p. 887-91., https://pubmed.ncbi.nlm.nih.gov/18263680/
877. Bousema, JE, van Dorp, M, Noyez, VJJM, Dijkgraaf, MGW, Annema, JT, van den Broek, FJC, Unforeseen N2 Disease after Negative Endosonography Findings with or without Confirmatory Mediastinoscopy in Resectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis., J Thorac Oncol, 2019. 14 (6)(6): p. 979-992., https://pubmed.ncbi.nlm.nih.gov/30905829/
878. Tokito, T, Azuma, K, Kawahara, A, Ishii, H, Yamada, K, Matsuo, N, et.al. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy., Eur J Cancer, 2016. 55 (): p. 7-14., https://pubmed.ncbi.nlm.nih.gov/26771872/
879. Lin, Steven H., Lin, Yan, Price, Justina, Parker, Matthew, Gomez, Daniel Richard, Welsh, James William, et.al. DETERRED: PD-L1 blockade to evaluate the safety of lung cancer therapy using carboplatin, paclitaxel, and radiation combined with MPDL3280A (atezolizumab).Wolters Kluwer, Journal of Clinical Oncology, 2017. 35(15_suppl): p. 3064 - 3064., https://doi.org/10.1200/JCO.2017.35.15_suppl.3064
880. Durm, Greg Andrew, Althouse, Sandra K., Sadiq, Ahad Ali, Jalal, Shadia Ibrahim, Jabbour, Salma, Zon, Robin, et.al. Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.Wolters Kluwer, Journal of Clinical Oncology, 2018. 36(15_suppl): p. 8500 - 8500., https://doi.org/10.1200/JCO.2018.36.15_suppl.8500
881. Peters, S, Felip, E, Dafni, U, Belka, C, Guckenberger, M, Irigoyen, A, et.al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial., Lung Cancer, 2019. 133 (): p. 83-87., https://pubmed.ncbi.nlm.nih.gov/31200833/
882. Faivre-Finn, C, Vicente, D, Kurata, T, Planchard, D, Paz-Ares, L, Vansteenkiste, JF, et.al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial., J Thorac Oncol, 2021. 16 (5)(5): p. 860-867., https://pubmed.ncbi.nlm.nih.gov/33476803/
883. Antonia, SJ, Villegas, A, Daniel, D, Vicente, D, Murakami, S, Hui, R, et.al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC., N Engl J Med, 2018. 379 (24)(24): p. 2342-2350., https://pubmed.ncbi.nlm.nih.gov/30280658/
884. Hui, R, Özgüroğlu, M, Villegas, A, Daniel, D, Vicente, D, Murakami, S, et.al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study., Lancet Oncol, 2019. 20 (12)(12): p. 1670-1680., https://pubmed.ncbi.nlm.nih.gov/31601496/
885. Paz-Ares, L, Spira, A, Raben, D, Planchard, D, Cho, BC, Özgüroğlu, M, et.al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial., Ann Oncol, 2020. 31 (6)(6): p. 798-806., https://pubmed.ncbi.nlm.nih.gov/32209338/
886. Ghysen, K, Vansteenkiste, J, Immunotherapy in patients with early stage resectable nonsmall cell lung cancer., Curr Opin Oncol, 2019. 31 (1)(1): p. 13-17., https://pubmed.ncbi.nlm.nih.gov/30325753/
887. Vansteenkiste, J, Wauters, E, Reymen, B, Ackermann, CJ, Peters, S, De Ruysscher, D, Current status of immune checkpoint inhibition in early-stage NSCLC., Ann Oncol, 2019. 30 (8)(8): p. 1244-1253., https://pubmed.ncbi.nlm.nih.gov/31143921/
888. Forde, PM, Chaft, JE, Smith, KN, Anagnostou, V, Cottrell, TR, Hellmann, MD, et.al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer., N Engl J Med, 2018. 378 (21)(21): p. 1976-1986., https://pubmed.ncbi.nlm.nih.gov/29658848/
889. Hill, A, Gong, J, Wilczynski, S, Mirza, R, Erhunmwunsee, L, Salgia, R, Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer., J Oncol Pract, 2018. 14 (9)(9): p. 569-571., https://pubmed.ncbi.nlm.nih.gov/30044685/
890. Shu, CA, Gainor, JF, Awad, MM, Chiuzan, C, Grigg, CM, Pabani, A, et.al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial., Lancet Oncol, 2020. 21 (6)(6): p. 786-795., https://pubmed.ncbi.nlm.nih.gov/32386568/
891. Kwiatkowski, David J., Rusch, Valerie W., Chaft, Jamie E., Johnson, Bruce E., Nicholas, Alan, Wistuba, Ignacio Ivan, et.al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3), Journal of Clinical Oncology, 2019. 37(15_suppl): p. 8503-8503., https://doi.org/10.1200/JCO.2019.37.15_suppl.8503
892. Felip, E, Altorki, N, Zhou, C, Csőszi, T, Vynnychenko, I, Goloborodko, O, et.al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial., Lancet, 2021. 398 (10308)(10308): p. 1344-1357., https://pubmed.ncbi.nlm.nih.gov/34555333/
893. Goss, GD, O'Callaghan, C, Lorimer, I, Tsao, MS, Masters, GA, Jett, J, et.al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study., J Clin Oncol, 2013. 31 (27)(27): p. 3320-6., https://pubmed.ncbi.nlm.nih.gov/23980091/
894. Tsuboi, M, Kato, H, Nagai, K, Tsuchiya, R, Wada, H, Tada, H, et.al. Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer., Anticancer Drugs, 2005. 16 (10)(10): p. 1123-8., https://pubmed.ncbi.nlm.nih.gov/16222155/
895. Pennell, NA, Neal, JW, Chaft, JE, Azzoli, CG, Jänne, PA, Govindan, R, et.al. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer., J Clin Oncol, 2019. 37 (2)(2): p. 97-104., https://pubmed.ncbi.nlm.nih.gov/30444685/
896. D'Angelo, SP, Janjigian, YY, Ahye, N, Riely, GJ, Chaft, JE, Sima, CS, et.al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib., J Thorac Oncol, 2012. 7 (12)(12): p. 1815-1822., https://pubmed.ncbi.nlm.nih.gov/23154553/
897. Janjigian, YY, Park, BJ, Zakowski, MF, Ladanyi, M, Pao, W, D'Angelo, SP, et.al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations., J Thorac Oncol, 2011. 6 (3)(3): p. 569-75., https://pubmed.ncbi.nlm.nih.gov/21150674/
898. Kelly, K, Altorki, NK, Eberhardt, WE, O'Brien, ME, Spigel, DR, Crinò, L, et.al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial., J Clin Oncol, 2015. 33 (34)(34): p. 4007-14., https://pubmed.ncbi.nlm.nih.gov/26324372/
899. Zhong, WZ, Wang, Q, Mao, WM, Xu, ST, Wu, L, Shen, Y, et.al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study., Lancet Oncol, 2018. 19 (1)(1): p. 139-148., https://pubmed.ncbi.nlm.nih.gov/29174310/
900. Wu, Y. L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., et.al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer, N Engl J Med, 2020. 383(18): p. 1711-1723., https://www.nejm.org/doi/full/10.1056/NEJMoa2027071
901. Jelinek, MJ, Aggarwal, C, Adjuvant Osimertinib: A New Standard of Care., Oncologist, 2021. 26 (4)(4): p. 263-265., https://pubmed.ncbi.nlm.nih.gov/33301209/
902. Riquet, M, Mordant, P, Pricopi, C, Legras, A, Foucault, C, Dujon, A, et.al. A review of 250 ten-year survivors after pneumonectomy for non-small-cell lung cancer., Eur J Cardiothorac Surg, 2014. 45 (5)(5): p. 876-81., https://pubmed.ncbi.nlm.nih.gov/24132299/
903. Skrzypczak, P, Kasprzyk, M, Kamiński, M, Gabryel, P, Ochman, M, Chwalba, A, et.al. Key risk factors for mortality after pneumonectomy for lung cancer: insights from a large single-center cohort study., J Thorac Dis, 2025. 17 (7)(7): p. 4536-4549., https://pubmed.ncbi.nlm.nih.gov/40809274/
904. Deslauriers, J, Grégoire, J, Jacques, LF, Piraux, M, Guojin, L, Lacasse, Y, Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrences., Ann Thorac Surg, 2004. 77 (4)(4): p. 1152-6; discussion 1156., https://pubmed.ncbi.nlm.nih.gov/15063224/
905. Beauchamp, G, Fundamentals of Standard Sleeve Resection., Thorac Surg Clin, 2018. 28 (3)(3): p. 285-289., https://pubmed.ncbi.nlm.nih.gov/30054065/
906. Chen, J, Soultanis, KM, Sun, F, Gonzalez-Rivas, D, Duan, L, Wu, L, et.al. Outcomes of sleeve lobectomy versus pneumonectomy: A propensity score-matched study., J Thorac Cardiovasc Surg, 2021. 162 (6)(6): p. 1619-1628.e4., https://pubmed.ncbi.nlm.nih.gov/32919775/
907. Ma, Z, Dong, A, Fan, J, Cheng, H, Does sleeve lobectomy concomitant with or without pulmonary artery reconstruction (double sleeve) have favorable results for non-small cell lung cancer compared with pneumonectomy? A meta-analysis., Eur J Cardiothorac Surg, 2007. 32 (1)(1): p. 20-8., https://pubmed.ncbi.nlm.nih.gov/17442581/
908. Voltolini, L, Gonfiotti, A, Viggiano, D, Borgianni, S, Farronato, A, Bongiolatti, S, Extended sleeve-lobectomy for centrally located locally advanced non-small cell lung cancer is a feasible approach to avoid pneumonectomy., J Thorac Dis, 2020. 12 (8)(8): p. 4090-4098., https://pubmed.ncbi.nlm.nih.gov/32944320/
909. Shen, H, Wang, X, Nie, Y, Zhang, K, Wei, Z, Yang, F, et.al. Minimally invasive surgery versus thoracotomy for resectable stage II and III non-small-cell lung cancers: a systematic review and meta-analysis., Eur J Cardiothorac Surg, 2021. 59 (5)(5): p. 940-950., https://pubmed.ncbi.nlm.nih.gov/33370437/
910. Li, X, Huang, K, Deng, H, Zheng, Q, Xiao, T, Yu, J, et.al. Feasibility and oncological outcomes of video-assisted thoracic surgery versus thoracotomy for pathologic N2 disease in non-small cell lung cancer: A comprehensive systematic review and meta-analysis., Thorac Cancer, 2022. 13 (21)(21): p. 2917-2928., https://pubmed.ncbi.nlm.nih.gov/36102196/
911. Liu, S, Li, S, Tang, Y, Chen, R, Qiao, G, Minimally invasive surgery vs. open thoracotomy for non-small-cell lung cancer with N2 disease: a systematic review and meta-analysis., Front Med (Lausanne), 2023. 10 (): p. 1152421., https://pubmed.ncbi.nlm.nih.gov/37324136/
912. Li, Y, Mei, J, Yang, Z, Guo, C, Liu, C, Liao, H, et.al. Ten-year survival outcomes of video-assisted thoracic surgery , Transl Lung Cancer Res, 2024. 13 (9)(9): p. 2162-2174., https://pubmed.ncbi.nlm.nih.gov/39430323/
913. Chen, T, Chan, EG, Huang, B, Bertolaccini, L, Fernando, HC, Tasoudis, PT, et.al. Outcomes following minimally invasive approaches , Transl Lung Cancer Res, 2024. 13 (2)(2): p. 334-344., https://pubmed.ncbi.nlm.nih.gov/38496690/
914. Pan, H, Chen, H, Kong, W, Ning, J, Ge, Z, Tian, Y, et.al. Video-Assisted Thoracoscopic Surgery Versus Thoracotomy Following Neoadjuvant Immunochemotherapy in Resectable Stage III Non-Small Cell Lung Cancer Among Chinese Populations: A Multi-Center Retrospective Cohort Study., Clin Lung Cancer, 2024. 25 (5)(5): p. 395-406.e5., https://pubmed.ncbi.nlm.nih.gov/38705833/
915. Liu, S, Li, S, Tang, Y, Chen, R, Qiao, G, Minimally invasive surgery vs. open thoracotomy for non-small-cell lung cancer with N2 disease: a systematic review and meta-analysis., Front Med (Lausanne), 2023. 10 (): p. 1152421., https://pubmed.ncbi.nlm.nih.gov/37324136/
916. Tsubokawa, N, Tsutani, Y, Hishida, T, Saji, H, Wakabayashi, M, Endo, M, et.al. Quality comparison of mediastinal lymph node dissection between video-assisted thoracic surgery and open thoracotomy: a supplementary analysis of the phase 3 Japan Clinical Oncology Group 1413 trial†., Eur J Cardiothorac Surg, 2025. 67 (7)(7):, https://pubmed.ncbi.nlm.nih.gov/40578313/
917. Xu, Z, Li, C, Ni, Y, Gu, B, Zhou, H, Luo, Y, et.al. Retrospective comparative study of thoracoscopic lobectomy vs. segmentectomy: Enhancing recovery and lung function in early-stage non-small cell lung cancer., Medicine (Baltimore), 2025. 104 (47)(47): p. e45655., https://pubmed.ncbi.nlm.nih.gov/41305814/
918. Wang, C, Wu, S, Zhang, R, Jin, K, Qian, Y, Mao, N, et.al. Identifying Lung Cancer Patients Suitable for Segmentectomy: A Brief Review., Front Surg, 2021. 8 (): p. 637441., https://pubmed.ncbi.nlm.nih.gov/34307441/
919. Suzuki, S, Asakura, K, Masai, K, Kaseda, K, Hishida, T, Kazama, A, et.al. Real-World Outcomes of Limited Resection for Tumours Greater Than 20 mm in Non-Small Cell Lung Cancer., Eur J Cardiothorac Surg, 2025. 67 (10)(10):, https://pubmed.ncbi.nlm.nih.gov/41017644/
920. Kent, M, Landreneau, R, Mandrekar, S, Hillman, S, Nichols, F, Jones, D, et.al. Segmentectomy versus wedge resection for non-small cell lung cancer in high-risk operable patients., Ann Thorac Surg, 2013. 96 (5)(5): p. 1747-54; discussion 1754-5., https://pubmed.ncbi.nlm.nih.gov/23998400/
921. Lardinois, D, De Leyn, P, Van Schil, P, Porta, RR, Waller, D, Passlick, B, et.al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer., Eur J Cardiothorac Surg, 2006. 30 (5)(5): p. 787-92., https://pubmed.ncbi.nlm.nih.gov/16971134/
922. Mokhles, S, Macbeth, F, Treasure, T, Younes, RN, Rintoul, RC, Fiorentino, F, et.al. Systematic lymphadenectomy versus sampling of ipsilateral mediastinal lymph-nodes during lobectomy for non-small-cell lung cancer: a systematic review of randomized trials and a meta-analysis., Eur J Cardiothorac Surg, 2017. 51 (6)(6): p. 1149-1156., https://pubmed.ncbi.nlm.nih.gov/28158453/
923. Liu, Z, Liu, Y, Xie, C, Yang, J, Zeng, B, Yeung, SJ, et.al. Vagus nerve and phrenic nerve guided systematic nodal dissection for lung cancer., J Thorac Dis, 2019. 11 (9)(9): p. 4021-4027., https://pubmed.ncbi.nlm.nih.gov/31656677/
924. Liu, Y, Yang, W, Yang, J, Liao, S, Liu, Z, Zeng, B, et.al. Impact on quality of life after vagus nerve and phrenic nerve guided systematic nodal dissection for non-small cell lung cancer patients: a prospective, single-arm clinical trial., Ann Transl Med, 2021. 9 (24)(24): p. 1753., https://pubmed.ncbi.nlm.nih.gov/35071447/
925. Stoelben, E, Ludwig, C, Chest wall resection for lung cancer: indications and techniques., Eur J Cardiothorac Surg, 2009. 35 (3)(3): p. 450-6., https://pubmed.ncbi.nlm.nih.gov/19188079/
926. Elia, S, Griffo, S, Gentile, M, Costabile, R, Ferrante, G, Surgical treatment of lung cancer invading chest wall: a retrospective analysis of 110 patients., Eur J Cardiothorac Surg, 2001. 20 (2)(2): p. 356-60., https://pubmed.ncbi.nlm.nih.gov/11463557/
927. Santos, HT, Lopes, AJ, Higa, C, Nunes, RA, Saito, EH, Lung cancer with chest wall invasion: retrospective analysis comparing en-bloc resection and 'resection in bird cage'., J Cardiothorac Surg, 2014. 9 (): p. 57., https://pubmed.ncbi.nlm.nih.gov/24655354/
928. Yuan, M, Men, Y, Kang, J, Sun, X, Zhao, M, Bao, Y, et.al. Postoperative radiotherapy for pathological stage IIIA-N2 non-small cell lung cancer with positive surgical margins., Thorac Cancer, 2021. 12 (2)(2): p. 227-234., https://pubmed.ncbi.nlm.nih.gov/33247556/
929. Edwards, JG, Chansky, K, Van Schil, P, Nicholson, AG, Boubia, S, Brambilla, E, et.al. The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer., J Thorac Oncol, 2020. 15 (3)(3): p. 344-359., https://pubmed.ncbi.nlm.nih.gov/31731014/
930. Gu, C, Wang, R, Pan, X, Huang, Q, Luo, J, Zheng, J, et.al. Comprehensive study of prognostic risk factors of patients underwent pneumonectomy., J Cancer, 2017. 8 (11)(11): p. 2097-2103., https://pubmed.ncbi.nlm.nih.gov/28819411/
931. Petrella, F, Spaggiari, L, Therapeutic options following pneumonectomy in non-small cell lung cancer., Expert Rev Respir Med, 2016. 10 (8)(8): p. 919-25., https://pubmed.ncbi.nlm.nih.gov/27176616/
932. Brandt, WS, Yan, W, Leeman, JE, Tan, KS, Park, BJ, Adusumilli, PS, et.al. Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer., Ann Thorac Surg, 2018. 106 (3)(3): p. 848-855., https://pubmed.ncbi.nlm.nih.gov/29807005/
933. Francis, S, Orton, A, Stoddard, G, Tao, R, Hitchcock, YJ, Akerley, W, et.al. Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer., J Clin Oncol, 2018. 36 (4)(4): p. 333-341., https://pubmed.ncbi.nlm.nih.gov/29236592/
934. Weder, W, Collaud, S, Eberhardt, WE, Hillinger, S, Welter, S, Stahel, R, et.al. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer., J Thorac Cardiovasc Surg, 2010. 139 (6)(6): p. 1424-30., https://pubmed.ncbi.nlm.nih.gov/20416887/
935. Shepherd, AF, Iocolano, M, Leeman, J, Imber, BS, Wild, AT, Offin, M, et.al. Clinical and Dosimetric Predictors of Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation Therapy., Pract Radiat Oncol 11 (1)(1): p. e52-e62., https://pubmed.ncbi.nlm.nih.gov/33068790/
936. Paumier, A, Le Péchoux, C, Post-operative radiation therapy., Transl Lung Cancer Res, 2013. 2 (5)(5): p. 423-32., https://pubmed.ncbi.nlm.nih.gov/25806262/
937. Robert-Koch-Institut (RKI), Bericht zum Krebsgeschen in Deutschland 2016, 2916., https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebsgeschehen/Krebsgeschehen_download.pdf?__blob=publicationFile
938. Stamatis, G., Djuric, D., Eberhardt, W., Pottken, C., Zaboura, G., Fechner, S., et.al. Postoperative morbidity and mortality after induction chemoradiotherapy for locally advanced lung cancer: an analysis of 350 operated patients, Eur.J.Cardiothorac.Surg., 2002. 22(2): p. 292-297., https://www.ncbi.nlm.nih.gov/pubmed/12142202
939. Korevaar, DA, Crombag, LM, Cohen, JF, Spijker, R, Bossuyt, PM, Annema, JT, Added value of combined endobronchial and oesophageal endosonography for mediastinal nodal staging in lung cancer: a systematic review and meta-analysis., Lancet Respir Med, 2016. 4 (12)(12): p. 960-968., https://pubmed.ncbi.nlm.nih.gov/27773666/
940. Schmidt-Hansen, M, Baldwin, DR, Hasler, E, Zamora, J, Abraira, V, Roqué I Figuls, M, PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer., Cochrane Database Syst Rev, 2014. (11)(11): p. CD009519., https://pubmed.ncbi.nlm.nih.gov/25393718/
941. Eberhardt, WE, De Ruysscher, D, Weder, W, Le Péchoux, C, De Leyn, P, Hoffmann, H, et.al. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer., Ann Oncol, 2015. 26 (8)(8): p. 1573-88., https://pubmed.ncbi.nlm.nih.gov/25897013/
942. Waller, D, Peake, MD, Stephens, RJ, Gower, NH, Milroy, R, Parmar, MK, et.al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial., Eur J Cardiothorac Surg, 2004. 26 (1)(1): p. 173-82., https://pubmed.ncbi.nlm.nih.gov/15200998/
943. Strauss, GM, Herndon, JE, Maddaus, MA, Johnstone, DW, Johnson, EA, Harpole, DH, et.al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups., J Clin Oncol, 2008. 26 (31)(31): p. 5043-51., https://pubmed.ncbi.nlm.nih.gov/18809614/
944. Salazar, MC, Rosen, JE, Wang, Z, Arnold, BN, Thomas, DC, Herbst, RS, et.al. Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery., JAMA Oncol, 2017. 3 (5)(5): p. 610-619., https://pubmed.ncbi.nlm.nih.gov/28056112/
945. Sonobe, M, Yamada, T, Sato, M, Menju, T, Aoyama, A, Sato, T, et.al. Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer., Ann Surg Oncol, 2014. 21 (8)(8): p. 2546-54., https://pubmed.ncbi.nlm.nih.gov/24633668/
946. Arriagada, R., Bergman, B., Dunant, A., Le Chevalier, T., Pignon, J. P., Vansteenkiste, J., Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer, N Engl J Med, 2004. 350(4): p. 351-360., https://www.ncbi.nlm.nih.gov/pubmed/14736927
947. Pignon, J. P., Tribodet, H., Scagliotti, G. V., Douillard, J. Y., Shepherd, F. A., Stephens, R. J., et.al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group, J Clin Oncol, 2008. 26(21): p. 3552-9., https://www.ncbi.nlm.nih.gov/pubmed/18506026
948. Osieka, R, Bruntsch, U, Gallmeier, WM, Seeber, S, Schmidt, CG, [cis-Diamino-dichloro-platinum (II) in the treatment of otherwise treatment-resistant malignant testicular teratoma (author's transl)]., Dtsch Med Wochenschr, 1976. 101 (6)(6): p. 191-5, 199., https://pubmed.ncbi.nlm.nih.gov/1248396/
949. Einhorn, LH, Donohue, J, Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer., Ann Intern Med, 1977. 87 (3)(3): p. 293-8., https://pubmed.ncbi.nlm.nih.gov/71004/
950. Feldman, DR, Bosl, GJ, Sheinfeld, J, Motzer, RJ, Medical treatment of advanced testicular cancer., JAMA, 2008. 299 (6)(6): p. 672-84., https://pubmed.ncbi.nlm.nih.gov/18270356/
951. de Vries, G, Rosas-Plaza, X, van Vugt, MATM, Gietema, JA, de Jong, S, Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities., Cancer Treat Rev, 2020. 88 (): p. 102054., https://pubmed.ncbi.nlm.nih.gov/32593915/
952. Borner, MM, Joncourt, F, Hotz, MA, Similarity of apoptosis induction by 2-chlorodeoxyadenosine and cisplatin in human mononuclear blood cells., Br J Cancer, 1997. 76 (11)(11): p. 1448-54., https://pubmed.ncbi.nlm.nih.gov/9400941/
953. Einhorn, LH, Rapoport, B, Navari, RM, Herrstedt, J, Brames, MJ, 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting., Support Care Cancer, 2017. 25 (1)(1): p. 303-308., https://pubmed.ncbi.nlm.nih.gov/27815710/
954. Metzenmacher, M, Kopp, HG, Griesinger, F, Reinmuth, N, Sebastian, M, Serke, M, et.al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer., Ther Adv Med Oncol, 2021. 13 (): p. 1758835921996506., https://pubmed.ncbi.nlm.nih.gov/34104223/
955. Eberhardt, WE, Gauler, TC, Lepechoux, C, Stamatis, G, Bildat, S, Krbek, T, et.al. 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL)., Lung Cancer, 2013. 82 (1)(1): p. 83-9., https://pubmed.ncbi.nlm.nih.gov/23957964/
956. Stupp, R, Mayer, M, Kann, R, Weder, W, Zouhair, A, Betticher, DC, et.al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial., Lancet Oncol, 2009. 10 (8)(8): p. 785-93., https://pubmed.ncbi.nlm.nih.gov/19604722/
957. McHugh, DJ, Funt, SA, Silber, D, Knezevic, A, Patil, S, O'Donnell, D, et.al. Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors., J Clin Oncol, 2020. 38 (12)(12): p. 1332-1337., https://pubmed.ncbi.nlm.nih.gov/32109195/
958. Hainsworth, JD, Williams, SD, Einhorn, LH, Birch, R, Greco, FA, Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial., J Clin Oncol, 1985. 3 (5)(5): p. 666-71., https://pubmed.ncbi.nlm.nih.gov/2582097/
959. Kreuter, M, Vansteenkiste, J, Griesinger, F, Hoffmann, H, Dienemann, H, De Leyn, P, et.al. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol., BMC Cancer, 2007. 7 (): p. 77., https://pubmed.ncbi.nlm.nih.gov/17488518/
960. Tachihara, M, Dokuni, R, Okuno, K, Tokunaga, S, Nakata, K, Katsurada, N, et.al. Phase II study of adjuvant chemotherapy with pemetrexed and cisplatin with a short hydration method for completely resected nonsquamous non-small cell lung cancer., Thorac Cancer, 2020. 11 (9)(9): p. 2536-2541., https://pubmed.ncbi.nlm.nih.gov/32729237/
961. Turrisi, A. T., III, Kim, K., Blum, R., Sause, W. T., Livingston, R. B., Komaki, R., et.al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide, N.Engl.J.Med., 1999. 340(4): p. 265-271., https://www.ncbi.nlm.nih.gov/pubmed/9920950
962. Wakelee, H. A., Dahlberg, S. E., Keller, S. M., Tester, W. J., Gandara, D. R., Graziano, S. L., et.al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial, Lancet Oncol, 2017. 18(12): p. 1610-1623., https://www.ncbi.nlm.nih.gov/pubmed/29129443
963. Betticher, D. C., Hsu Schmitz, S. F., Totsch, M., Hansen, E., Joss, C., von, Briel C., et.al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial, J Clin Oncol, 2003. 21(9): p. 1752-1759., https://www.ncbi.nlm.nih.gov/pubmed/12721251
964. Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F. V., Schiller, J. H., Paesmans, M., et.al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis, J Natl Cancer Inst, 2007. 99(11): p. 847-57., https://www.ncbi.nlm.nih.gov/pubmed/17551145
965. Garon, EB, Hellmann, MD, Rizvi, NA, Carcereny, E, Leighl, NB, Ahn, MJ, et.al. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study., J Clin Oncol, 2019. 37 (28)(28): p. 2518-2527., https://pubmed.ncbi.nlm.nih.gov/31154919/
966. Borghaei, H, Gettinger, S, Vokes, EE, Chow, LQM, Burgio, MA, de Castro Carpeno, J, et.al. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer., J Clin Oncol, 2021. 39 (7)(7): p. 723-733., https://pubmed.ncbi.nlm.nih.gov/33449799/
967. Gandhi, L, Rodríguez-Abreu, D, Gadgeel, S, Esteban, E, Felip, E, De Angelis, F, et.al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer., N Engl J Med, 2018. 378 (22)(22): p. 2078-2092., https://pubmed.ncbi.nlm.nih.gov/29658856/
968. Peters, S, Camidge, DR, Shaw, AT, Gadgeel, S, Ahn, JS, Kim, DW, et.al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer., N Engl J Med, 2017. 377 (9)(9): p. 829-838., https://pubmed.ncbi.nlm.nih.gov/28586279/
969. Zhu, JF, Feng, XY, Zhang, XW, Wen, YS, Lin, P, Rong, TH, et.al. Time-varying pattern of postoperative recurrence risk of early-stage (T1a-T2bN0M0) non-small cell lung cancer (NSCLC): results of a single-center study of 994 Chinese patients., PLoS One, 2014. 9 (9)(9): p. e106668., https://pubmed.ncbi.nlm.nih.gov/25203402/
970. Boyd, JA, Hubbs, JL, Kim, DW, Hollis, D, Marks, LB, Kelsey, CR, Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure., J Thorac Oncol, 2010. 5 (2)(2): p. 211-4., https://pubmed.ncbi.nlm.nih.gov/19901853/
971. Kassam, F, Shepherd, FA, Johnston, M, Visbal, A, Feld, R, Darling, G, et.al. Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer., J Thorac Oncol, 2007. 2 (1)(1): p. 39-43., https://pubmed.ncbi.nlm.nih.gov/17410008/
972. Paz-Ares, L, Luft, A, Vicente, D, Tafreshi, A, Gümüş, M, Mazières, J, et.al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer., N Engl J Med, 2018. 379 (21)(21): p. 2040-2051., https://pubmed.ncbi.nlm.nih.gov/30280635/
973. Iyengar, P, Wardak, Z, Gerber, DE, Tumati, V, Ahn, C, Hughes, RS, et.al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial., JAMA Oncol, 2018. 4 (1)(1): p. e173501., https://pubmed.ncbi.nlm.nih.gov/28973074/
974. Brahmer, J., Reckamp, K. L., Baas, P., Crino, L., Eberhardt, W. E., Poddubskaya, E., et.al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med, 2015. 373(2): p. 123-35., https://www.ncbi.nlm.nih.gov/pubmed/26028407
975. Wu, YL, Tsuboi, M, He, J, John, T, Grohe, C, Majem, M, et.al. Osimertinib in Resected , N Engl J Med, 2020. 383 (18)(18): p. 1711-1723., https://pubmed.ncbi.nlm.nih.gov/32955177/
976. Wu, YL, Dziadziuszko, R, Ahn, JS, Barlesi, F, Nishio, M, Lee, DH, et.al. Alectinib in Resected , N Engl J Med, 2024. 390 (14)(14): p. 1265-1276., https://pubmed.ncbi.nlm.nih.gov/38598794/
977. Felip, E, Altorki, N, Zhou, C, Vallières, E, Martínez-Martí, A, Rittmeyer, A, et.al. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial., Ann Oncol, 2023. 34 (10)(10): p. 907-919., https://pubmed.ncbi.nlm.nih.gov/37467930/
978. O'Brien, M, Paz-Ares, L, Marreaud, S, Dafni, U, Oselin, K, Havel, L, et.al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial., Lancet Oncol, 2022. 23 (10)(10): p. 1274-1286., https://pubmed.ncbi.nlm.nih.gov/36108662/
979. Wu, SP, Shaikh, F, Cerfolio, R, Cooper, BT, PORT in Properly Selected Patients With Completely Resected Non-Small Cell Lung Cancer Should Not Be Quickly Dismissed., Ann Thorac Surg, 2019. 107 (5)(5): p. 1585-1586., https://pubmed.ncbi.nlm.nih.gov/30447194/
980. Douillard, JY, Rosell, R, De Lena, M, Riggi, M, Hurteloup, P, Mahe, MA, Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial., Int J Radiat Oncol Biol Phys, 2008. 72 (3)(3): p. 695-701., https://pubmed.ncbi.nlm.nih.gov/18439766/
981. Robinson, CG, Patel, AP, Bradley, JD, DeWees, T, Waqar, SN, Morgensztern, D, et.al. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base., J Clin Oncol, 2015. 33 (8)(8): p. 870-6., https://pubmed.ncbi.nlm.nih.gov/25667283/
982. Péchoux, CL, Mercier, O, Belemsagha, D, Bouaita, R, Besse, B, Fadel, E, Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer., EJC Suppl, 2013. 11 (2)(2): p. 123-30., https://pubmed.ncbi.nlm.nih.gov/26217121/
983. Le Pechoux, C., Pourel, N., Barlesi, F., Faivre-Finn, C., Lerouge, D., Zalcman, G., et.al. LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683Elsevier, Annals of Oncology, 2020. 31: p. S1178., https://doi.org/10.1016/j.annonc.2020.08.2280
984. Group, Port Meta-Analysis Trialists, Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group, Lancet, 1998. 352(9124): p. 257-263., https://www.ncbi.nlm.nih.gov/pubmed/27684386
985. Lally, B. E., Zelterman, D., Colasanto, J. M., Haffty, B. G., Detterbeck, F. C., Wilson, L. D., Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database, J Clin Oncol, 2006. 24(19): p. 2998-3006., https://www.ncbi.nlm.nih.gov/pubmed/16769986
986. Jahresbericht der zertifizierten Lungenkrebszentren - Auditjahr 2017 / Kennzahlenjahr 2016, 2018., https://onkozert.de/wordpress/wp-content/uploads/2018/07/lz_jahresbericht-2018-A1_180420.pdf?v=79579374
987. Jahresbericht der zertifizierten Lungenkrebszentren Kennzahlenauswertung 2019 - Auditjahr 2018 / Kennzahlenjahr 2017, 2019., https://www.onkozert.de/wordpress/wp-content/uploads/2019/07/lz_jahresbericht-2019-A1_190716.pdf?v=15864929
988. Jahresbericht der zertifizierten Lungenkrebszentren Kennzahlenauswertung 2020 Auditjahr 2019 / Kennzahlenjahr 2018, 2020., https://www.onkozert.de/wordpress/wp-content/uploads/2020/03/qualitaetsindikatoren_lungenkrebs_2020-A1_200320.pdf?v=14764787
989. Erhebungsbogen für Lungenkrebszentren der Deutschen Krebsgesellschaft, Inkraftsetzung am 18.07.2018, 2018., https://onkozert.de/wordpress/wp-content/uploads/2018/07/eb_lz-G1_180718.pdf
990. De Leyn, P, Lardinois, D, Van Schil, P, Rami-Porta, R, Passlick, B, Zielinski, M, et.al. European trends in preoperative and intraoperative nodal staging: ESTS guidelines., J Thorac Oncol, 2007. 2 (4)(4): p. 357-61., https://pubmed.ncbi.nlm.nih.gov/17409811/
991. Arriagada, R., Bergman, B., Dunant, A., Le Chevalier, T., Pignon, J. P., Vansteenkiste, J., Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer, N Engl J Med, 2004. 350(4): p. 351-360., https://pubmed.ncbi.nlm.nih.gov/14736927/
992. Pless, M, Stupp, R, Ris, HB, Stahel, RA, Weder, W, Thierstein, S, et.al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial., Lancet, 2015. 386 (9998)(9998): p. 1049-56., https://pubmed.ncbi.nlm.nih.gov/26275735/
993. Lungenkarzinom, nicht-kleinzellig (NSCLC) - Onkopedia DGHO Internetportal, 2021., https://www.onkopedia.com/de/onkopedia/guidelines/lungenkarzinom-nicht-kleinzellig-nsclc/@@guideline/html/index.htmlence=1&isAllowed=y
994. Zertifizierungssystem der DKG - Erhebungsbögen, Kennzahlen und Checklisten im Überblick, 2021., https://www.krebsgesellschaft.de/zertdokumente.html
995. Bericht zum Krebsgeschehen 2016, 2016., https://edoc.rki.de/bitstream/handle/176904/3264/28oaKVmif0wDk.pdf?sequence=1&isAllowed=y
996. Felip, E, Altorki, N, Zhou, C, Vallières, E, Csoszi, T, Vynnychenko, IO, et.al. Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial., J Clin Oncol, 2025. 43 (21)(21): p. 2343-2349., https://pubmed.ncbi.nlm.nih.gov/40446184/
997. Rosell, R., Maestre, J., Font, A., Moreno, I., Molina, F., Milla, A., et.al. A randomized trial of mitomycin/ifosfamide/cisplatin preoperative chemotherapy plus surgery versus surgery alone in stage IIIA non-small cell lung cancer, Semin.Oncol, 1994. 21(3 Suppl 4): p. 28-33., https://www.ncbi.nlm.nih.gov/pubmed/8209274
998. Girard, N, Mornex, F, Douillard, JY, Bossard, N, Quoix, E, Beckendorf, V, et.al. Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial., Lung Cancer, 2010. 69 (1)(1): p. 86-93., https://pubmed.ncbi.nlm.nih.gov/19879013/
999. Billiet, C, Decaluwé, H, Peeters, S, Vansteenkiste, J, Dooms, C, Haustermans, K, et.al. Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: a meta-analysis., Radiother Oncol, 2014. 110 (1)(1): p. 3-8., https://pubmed.ncbi.nlm.nih.gov/24100149/
1000. Shen, WY, Ji, J, Zuo, YS, Pu, J, Xu, YM, Zong, CD, et.al. Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial., Radiother Oncol, 2014. 110 (1)(1): p. 120-5., https://pubmed.ncbi.nlm.nih.gov/24183868/
1001. Sun, JM, Noh, JM, Oh, D, Kim, HK, Lee, SH, Choi, YS, et.al. Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer., J Thorac Oncol, 2017. 12 (12)(12): p. 1806-1813., https://pubmed.ncbi.nlm.nih.gov/28962948/
1002. Burdett, S, Rydzewska, L, Tierney, J, Fisher, D, Parmar, MK, Arriagada, R, et.al. Postoperative radiotherapy for non-small cell lung cancer., Cochrane Database Syst Rev, 2016. 10 (): p. CD002142., https://pubmed.ncbi.nlm.nih.gov/27727451/
1003. Le Pechoux, C, Pourel, N, Barlesi, F, Lerouge, D, Antoni, D, Lamezec, B, et.al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial., Lancet Oncol, 2022. 23 (1)(1): p. 104-114., https://pubmed.ncbi.nlm.nih.gov/34919827/
1004. Hui, Z, Men, Y, Hu, C, Kang, J, Sun, X, Bi, N, et.al. Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial., JAMA Oncol, 2021. 7 (8)(8): p. 1178-1185., https://pubmed.ncbi.nlm.nih.gov/34165501/
1005. Ogliari, FR, Huijs, JWJ, Jongbloed, M, Willmann, J, Hendriks, LEL, De Ruysscher, DKM, Adjuvant radiotherapy in the era of new peri-operative systemic treatments for surgically resected non-small-cell lung cancer: where do we stand?, Transl Lung Cancer Res, 2025. 14 (8)(8): p. 3142-3152., https://pubmed.ncbi.nlm.nih.gov/40948838/
1006. Süveg, K, Le Pechoux, C, Faivre-Finn, C, Putora, PM, De Ruysscher, D, Widder, J, et.al. Role of Postoperative Radiotherapy in the Management for Resected NSCLC - Decision Criteria in Clinical Routine Pre- and Post-LungART., Clin Lung Cancer, 2021. 22 (6)(6): p. 579-586., https://pubmed.ncbi.nlm.nih.gov/34538585/
1007. Osarogiagbon, RU, Faris, NR, Stevens, W, Fehnel, C, Houston-Harris, C, Ojeabulu, P, et.al. Beyond Margin Status: Population-Based Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification Recategorization., J Thorac Oncol, 2020. 15 (3)(3): p. 371-382., https://pubmed.ncbi.nlm.nih.gov/31783180/
1008. Shang, Xiaoling, Li, Zhenxiang, Lin, Jiamao, Yu, Haining, Zhao, Chenglong, Wang, Haiyong, et.al. Incorporating the Number of PLN into the AJCC Stage Could Better Predict the Survival for Patients with NSCLC: A Large Population-Based StudyHindawi, 2020. 2020: p. 1087237., https://doi.org/10.1155/2020/1087237
1009. Chiappetta, M, Leuzzi, G, Sperduti, I, Bria, E, Mucilli, F, Lococo, F, et.al. Mediastinal Up-Staging During Surgery in Non-Small-Cell Lung Cancer: Which Mediastinal Lymph Node Metastasis Patterns Better Predict The Outcome? A Multicenter Analysis., Clin Lung Cancer, 2020. 21 (5)(5): p. 464-471.e1., https://pubmed.ncbi.nlm.nih.gov/32389508/
1010. Billiet, C, De Ruysscher, D, Peeters, S, Decaluwé, H, Vansteenkiste, J, Dooms, C, et.al. Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes., J Thorac Oncol, 2016. 11 (9)(9): p. 1538-49., https://pubmed.ncbi.nlm.nih.gov/27374454/
1011. Chun, SG, Hu, C, Choy, H, Komaki, RU, Timmerman, RD, Schild, SE, et.al. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial., J Clin Oncol, 2017. 35 (1)(1): p. 56-62., https://pubmed.ncbi.nlm.nih.gov/28034064/
1012. Arriagada, R, Dunant, A, Pignon, JP, Bergman, B, Chabowski, M, Grunenwald, D, et.al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer., J Clin Oncol, 2010. 28 (1)(1): p. 35-42., https://pubmed.ncbi.nlm.nih.gov/19933916/
1013. Sun, X, Men, Y, Wang, J, Bao, Y, Yang, X, Zhao, M, et.al. Risk of cardiac-related mortality in stage IIIA-N2 non-small cell lung cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database., Thorac Cancer, 2021. 12 (9)(9): p. 1358-1365., https://pubmed.ncbi.nlm.nih.gov/33728811/
1014. Rieber, J, Deeg, A, Ullrich, E, Foerster, R, Bischof, M, Warth, A, et.al. Outcome and prognostic factors of postoperative radiation therapy (PORT) after incomplete resection of non-small cell lung cancer (NSCLC)., Lung Cancer, 2016. 91 (): p. 41-7., https://pubmed.ncbi.nlm.nih.gov/26711933/
1015. Dillman, R. O., Herndon, J., Seagren, S. L., Eaton, W. L., Jr., Green, M. R., Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial, J Natl Cancer Inst, 1996. 88(17): p. 1210-5., https://www.ncbi.nlm.nih.gov/pubmed/8780630
1016. Le, Chevalier T., Arriagada, R., Quoix, E., Ruffie, P., Martin, M., Douillard, J. Y., et.al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma, Lung Cancer, 1994. 10 Suppl 1: p. S239-S244., https://www.ncbi.nlm.nih.gov/pubmed/8087515
1017. Behera, M, Steuer, CE, Liu, Y, Fernandez, F, Fu, C, Higgins, KA, et.al. Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis., Oncologist, 2020. 25 (6)(6): p. e964-e975., https://pubmed.ncbi.nlm.nih.gov/31943520/
1018. Farray, D, Mirkovic, N, Albain, KS, Multimodality therapy for stage III non-small-cell lung cancer., J Clin Oncol, 2005. 23 (14)(14): p. 3257-69., https://pubmed.ncbi.nlm.nih.gov/15886313/
1019. Decaluwé, H, De Leyn, P, Vansteenkiste, J, Dooms, C, Van Raemdonck, D, Nafteux, P, et.al. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival., Eur J Cardiothorac Surg, 2009. 36 (3)(3): p. 433-9., https://pubmed.ncbi.nlm.nih.gov/19502079/
1020. Sause, W., Kolesar, P., Taylor, S. Iv, Johnson, D., Livingston, R., Komaki, R., et.al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group, Chest, 2000. 117(2): p. 358-364., https://www.ncbi.nlm.nih.gov/pubmed/10669675
1021. Senan, S, Brade, A, Wang, LH, Vansteenkiste, J, Dakhil, S, Biesma, B, et.al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer., J Clin Oncol, 2016. 34 (9)(9): p. 953-62., https://pubmed.ncbi.nlm.nih.gov/26811519/
1022. van Meerbeeck, J. P., Kramer, G. W., Van Schil, P. E., Legrand, C., Smit, E. F., Schramel, F., et.al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer, J Natl Cancer Inst, 2007. 99(6): p. 442-50., https://www.ncbi.nlm.nih.gov/pubmed/17374834
1023. Van Schil, P, Van Meerbeeck, J, Kramer, G, Splinter, T, Legrand, C, Giaccone, G, et.al. Morbidity and mortality in the surgery arm of EORTC 08941 trial., Eur Respir J, 2005. 26 (2)(2): p. 192-7., https://pubmed.ncbi.nlm.nih.gov/16055865/
1024. Junker, K, Langner, K, Klinke, F, Bosse, U, Thomas, M, Grading of tumor regression in non-small cell lung cancer : morphology and prognosis., Chest, 2001. 120 (5)(5): p. 1584-91., https://pubmed.ncbi.nlm.nih.gov/11713138/
1025. Eberhardt, WE, Stamatis, G, Stuschke, M, Surgery in stage III non-small-cell lung cancer., Lancet, 2009. 374 (9687)(9687): p. 359-60., https://pubmed.ncbi.nlm.nih.gov/19632715/
1026. Pöttgen, C, Eberhardt, W, Bildat, S, Stüben, G, Stamatis, G, Hillejan, L, et.al. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial., Ann Oncol, 2002. 13 (3)(3): p. 403-11., https://pubmed.ncbi.nlm.nih.gov/11996471/
1027. Vansteenkiste, J, De Ruysscher, D, Eberhardt, WE, Lim, E, Senan, S, Felip, E, et.al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol, 2013. 24 Suppl 6 (): p. vi89-98., https://pubmed.ncbi.nlm.nih.gov/23860613/
1028. Friedel, G, Budach, W, Dippon, J, Spengler, W, Eschmann, SM, Pfannenberg, C, et.al. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study., J Clin Oncol, 2010. 28 (6)(6): p. 942-8., https://pubmed.ncbi.nlm.nih.gov/20100967/
1029. Pezzetta, E, Stupp, R, Zouhair, A, Guillou, L, Taffé, P, von Briel, C, et.al. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC., Eur J Cardiothorac Surg, 2005. 27 (6)(6): p. 1092-8., https://pubmed.ncbi.nlm.nih.gov/15896624/
1030. Früh, M, Betticher, DC, Stupp, R, Xyrafas, A, Peters, S, Ris, HB, et.al. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)., J Thorac Oncol, 2019. 14 (1)(1): p. 115-123., https://pubmed.ncbi.nlm.nih.gov/30267838/
1031. Pöttgen, C, Gauler, T, Bellendorf, A, Guberina, M, Bockisch, A, Schwenzer, N, et.al. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer., J Clin Oncol, 2016. 34 (21)(21): p. 2526-33., https://pubmed.ncbi.nlm.nih.gov/27247220/
1032. Pöttgen, C, Eberhardt, W, Stamatis, G, Stuschke, M, Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence., Oncotarget, 2017. 8 (25)(25): p. 41670-41678., https://pubmed.ncbi.nlm.nih.gov/28415831/
1033. Friedel, G., Hruska, D., Budach, W., Wolf, M., Kyriss, T., Hurtgen, M., et.al. Neoadjuvant chemoradiotherapy of stage III non-small-cell lung cancer, Lung Cancer, 2000. 30(3): p. 175-185., https://www.ncbi.nlm.nih.gov/pubmed/11137202
1034. Pottgen, C., Eberhardt, W., Grannass, A., Korfee, S., Stuben, G., Teschler, H., et.al. Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial, J Clin Oncol, 2007. 25(31): p. 4987-92., https://pubmed.ncbi.nlm.nih.gov/17971598/
1035. Hainsworth, JD, Waterhouse, DM, Shih, KC, Boccia, RV, Priego, VM, McCleod, MJ, et.al. Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC)., Lung Cancer, 2018. 118 (): p. 6-12., https://pubmed.ncbi.nlm.nih.gov/29572004/
1036. Vokes, E. E., Herndon, J. E., Kelley, M. J., Cicchetti, M. G., Ramnath, N., Neill, H., et.al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B, J.Clin.Oncol, 2007. 25(13): p. 1698-1704., https://www.ncbi.nlm.nih.gov/pubmed/17404369
1037. De Candis, D, Stani, SC, Bidoli, P, Bedini, VA, Potepan, P, Navarria, P, et.al. Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC)., Am J Clin Oncol, 2003. 26 (3)(3): p. 265-9., https://pubmed.ncbi.nlm.nih.gov/12796598/
1038. Masters, GA, Wang, X, Hodgson, L, Shea, T, Vokes, E, Green, M, A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531., Lung Cancer, 2011. 74 (2)(2): p. 258-63., https://pubmed.ncbi.nlm.nih.gov/21529989/
1039. Chambers, A, Routledge, T, Billè, A, Scarci, M, Does surgery have a role in T4N0 and T4N1 lung cancer?, Interact Cardiovasc Thorac Surg, 2010. 11 (4)(4): p. 473-9., https://pubmed.ncbi.nlm.nih.gov/20621998/
1040. Ilonen, I, Jones, DR, Initial extended resection or neoadjuvant therapy for T4 non-small cell lung cancer-What is the evidence?, Shanghai Chest, 2018. 2 ():, https://pubmed.ncbi.nlm.nih.gov/30498811/
1041. Watanabe, S, Asamura, H, Miyaoka, E, Okumura, M, Yoshino, I, Fujii, Y, et.al. Results of T4 surgical cases in the Japanese Lung Cancer Registry Study: should mediastinal fat tissue invasion really be included in the T4 category?, J Thorac Oncol, 2013. 8 (6)(6): p. 759-65., https://pubmed.ncbi.nlm.nih.gov/23608818/
1042. Reardon, ES, Schrump, DS, Extended resections of non-small cell lung cancers invading the aorta, pulmonary artery, left atrium, or esophagus: can they be justified?, Thorac Surg Clin, 2014. 24 (4)(4): p. 457-64., https://pubmed.ncbi.nlm.nih.gov/25441139/
1043. Tsukioka, T, Takahama, M, Nakajima, R, Kimura, M, Inoue, H, Yamamoto, R, Surgical outcome of patients with lung cancer involving the left atrium., Int J Clin Oncol, 2016. 21 (6)(6): p. 1046-1050., https://pubmed.ncbi.nlm.nih.gov/27263106/
1044. Stella, F, Dell'Amore, A, Caroli, G, Dolci, G, Cassanelli, N, Luciano, G, et.al. Surgical results and long-term follow-up of T(4)-non-small cell lung cancer invading the left atrium or the intrapericardial base of the pulmonary veins., Interact Cardiovasc Thorac Surg, 2012. 14 (4)(4): p. 415-9., https://pubmed.ncbi.nlm.nih.gov/22269143/
1045. Kusumoto, H, Shintani, Y, Funaki, S, Inoue, M, Okumura, M, Kuratani, T, et.al. Combined resection of great vessels or the heart for non-small lung cancer., Ann Thorac Cardiovasc Surg, 2015. 21 (4)(4): p. 332-7., https://pubmed.ncbi.nlm.nih.gov/25740448/
1046. Langer, NB, Mercier, O, Fabre, D, Lawton, J, Mussot, S, Dartevelle, P, et.al. Outcomes After Resection of T4 Non-Small Cell Lung Cancer Using Cardiopulmonary Bypass., Ann Thorac Surg, 2016. 102 (3)(3): p. 902-910., https://pubmed.ncbi.nlm.nih.gov/27209605/
1047. Muralidaran, A, Detterbeck, FC, Boffa, DJ, Wang, Z, Kim, AW, Long-term survival after lung resection for non-small cell lung cancer with circulatory bypass: a systematic review., J Thorac Cardiovasc Surg, 2011. 142 (5)(5): p. 1137-42., https://pubmed.ncbi.nlm.nih.gov/21864854/
1048. Mody, GN, Janko, M, Vasudeva, V, Chi, JH, Davidson, MJ, Swanson, S, Thoracic Endovascular Aortic Stent Graft to Facilitate Aortic Resection During Pneumonectomy and Vertebrectomy for Locally Invasive Lung Cancer., Ann Thorac Surg, 2016. 101 (4)(4): p. 1587-9., https://pubmed.ncbi.nlm.nih.gov/27000584/
1049. Curioni-Fontecedro, A, Perentes, JY, Gelpke, H, Xyrafas, A, Bouchaab, H, Mach, N, et.al. Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)., Br J Cancer, 2019. 120 (10)(10): p. 968-974., https://pubmed.ncbi.nlm.nih.gov/30988393/
1050. Guberina, N, Pöttgen, C, Schuler, M, Guberina, M, Stamatis, G, Plönes, T, et.al. Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve., Eur J Cancer, 2020. 138 (): p. 156-168., https://pubmed.ncbi.nlm.nih.gov/32889370/
1051. De Leyn, P, Vansteenkiste, J, Lievens, Y, Van Raemdonck, D, Nafteux, P, Decker, G, et.al. Survival after trimodality treatment for superior sulcus and central T4 non-small cell lung cancer., J Thorac Oncol, 2009. 4 (1)(1): p. 62-8., https://pubmed.ncbi.nlm.nih.gov/19096308/
1052. Lococo, F, Cesario, A, Margaritora, S, Dall'Armi, V, Nachira, D, Cusumano, G, et.al. Induction therapy followed by surgery for T3-T4/N0 non-small cell lung cancer: long-term results., Ann Thorac Surg, 2012. 93 (5)(5): p. 1633-40., https://pubmed.ncbi.nlm.nih.gov/22480394/
1053. Perentes, J, Bopp, S, Krueger, T, Gonzalez, M, Jayet, PY, Lovis, A, et.al. Impact of lung function changes after induction radiochemotherapy on resected T4 non-small cell lung cancer outcome., Ann Thorac Surg, 2012. 94 (6)(6): p. 1815-22., https://pubmed.ncbi.nlm.nih.gov/23103000/
1054. Topkan, E, Selek, U, Ozdemir, Y, Besen, AA, Guler, OC, Yildirim, BA, et.al. Risk Factors for Fatal Pulmonary Hemorrhage following Concurrent Chemoradiotherapy in Stage 3B/C Squamous-Cell Lung Carcinoma Patients., J Oncol, 2018. 2018 (): p. 4518935., https://pubmed.ncbi.nlm.nih.gov/30515211/
1055. Phernambucq, EC, Hartemink, KJ, Smit, EF, Paul, MA, Postmus, PE, Comans, EF, et.al. Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes., J Thorac Oncol, 2012. 7 (8)(8): p. 1271-5., https://pubmed.ncbi.nlm.nih.gov/22659960/
1056. Ito, M, Niho, S, Nihei, K, Yoh, K, Ohmatsu, H, Ohe, Y, Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy., BMC Cancer, 2012. 12 (): p. 27., https://pubmed.ncbi.nlm.nih.gov/22260460/
1057. Bradley, JD, Hu, C, Komaki, RR, Masters, GA, Blumenschein, GR, Schild, SE, et.al. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer., J Clin Oncol, 2020. 38 (7)(7): p. 706-714., https://pubmed.ncbi.nlm.nih.gov/31841363/
1058. Bradley, JD, Paulus, R, Komaki, R, Masters, G, Blumenschein, G, Schild, S, et.al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study., Lancet Oncol, 2015. 16 (2)(2): p. 187-99., https://pubmed.ncbi.nlm.nih.gov/25601342/
1059. Pöttgen, C, Stuschke, M, Graupner, B, Theegarten, D, Gauler, T, Jendrossek, V, et.al. Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors., BMC Cancer, 2015. 15 (): p. 363., https://pubmed.ncbi.nlm.nih.gov/25943191/
1060. Chen, Y, Peng, X, Zhou, Y, Xia, K, Zhuang, W, Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small cell lung cancer: a meta-analysis., World J Surg Oncol, 2018. 16 (1)(1): p. 8., https://pubmed.ncbi.nlm.nih.gov/29338734/
1061. Cerfolio, RJ, Bryant, AS, Jones, VL, Cerfolio, RM, Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival., Eur J Cardiothorac Surg, 2009. 35 (4)(4): p. 718-23; discussion 723., https://pubmed.ncbi.nlm.nih.gov/19233668/
1062. Suntharalingam, M, Paulus, R, Edelman, MJ, Krasna, M, Burrows, W, Gore, E, et.al. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung., Int J Radiat Oncol Biol Phys, 2012. 84 (2)(2): p. 456-63., https://pubmed.ncbi.nlm.nih.gov/22543206/
1063. Wakelee, H, Liberman, M, Kato, T, Tsuboi, M, Lee, SH, Gao, S, et.al. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer., N Engl J Med, 2023. 389 (6)(6): p. 491-503., https://pubmed.ncbi.nlm.nih.gov/37272513/
1064. Mitsudomi, T, Heymach, JV, Reck, M, Taube, JM, Gao, S, Horio, Y, et.al. Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC., J Thorac Oncol, 2025. 20 (11)(11): p. 1639-1654., https://pubmed.ncbi.nlm.nih.gov/40545237/
1065. Liberman, M, Jones, DR, Wakelee, H, Gao, S, Halmos, B, Nadal, E, et.al. Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671., Ann Thorac Surg, 2026. 121 (2)(2): p. 281-289., https://pubmed.ncbi.nlm.nih.gov/41203001/
1066. Guberina, M, Metzenmacher, M, Pöttgen, C, Wiesweg, M, Guberina, N, Merkel-Jens, A, et.al. Pathologic Complete Response Predicts Long-Term Survival Following Neoadjuvant Induction Chemotherapy and Chemo-Radiotherapy in Stage-III Non-Small Cell Lung Cancer., Thorac Cancer, 2025. 16 (22)(22): p. e70183., https://pubmed.ncbi.nlm.nih.gov/41261778/
1067. Hamada, A, Soh, J, Hata, A, Nakamatsu, K, Shimokawa, M, Yatabe, Y, et.al. Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 NSCLC: Primary Results From the SQUAT Trial (WJOG 12119L)., J Thorac Oncol, 2025. 20 (8)(8): p. 1098-1107., https://pubmed.ncbi.nlm.nih.gov/40216327/
1068. Topkan, E, Selek, U, Ozdemir, Y, Yildirim, BA, Guler, OC, Ciner, F, et.al. Incidence and Impact of Pretreatment Tumor Cavitation on Survival Outcomes of Stage III Squamous Cell Lung Cancer Patients Treated With Radical Concurrent Chemoradiation Therapy., Int J Radiat Oncol Biol Phys, 2018. 101 (5)(5): p. 1123-1132., https://pubmed.ncbi.nlm.nih.gov/29887509/
1069. Hino, H, Utsumi, T, Maru, N, Matsui, H, Taniguchi, Y, Saito, T, et.al. Results of emergency salvage lung resection after chemo- and/or radiotherapy among patients with lung cancer., Interact Cardiovasc Thorac Surg, 2022. 35 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/35253874/
1070. Yamanashi, K, Okumura, N, Takahashi, A, Nakashima, T, Matsuoka, T, Surgical and survival outcomes of lung cancer patients with intratumoral lung abscesses., J Cardiothorac Surg, 2017. 12 (1)(1): p. 44., https://pubmed.ncbi.nlm.nih.gov/28549477/
1071. Li, Y, Tang, Y, Li, X, Li, J, Recovery of temperature to normal may indicate the best time for surgery in patients with lung cancer complicated by a lung abscess: A case report., Oncol Lett, 2024. 28 (6)(6): p. 608., https://pubmed.ncbi.nlm.nih.gov/39525608/
1072. Lobinger, D, Hiebinger, A, Eicher, F, Groß, G, Shalabi, I, Reiche, A, et.al. Rescue surgery in palliative indication as last therapeutic option for complicated advanced stage lung cancer., Eur J Surg Oncol, 2023. 49 (12)(12): p. 107253., https://pubmed.ncbi.nlm.nih.gov/37944369/
1073. Leonardi, B, Messina, G, Vicario, G, Pica, DG, Di Filippo, V, Vinciguerra, R, et.al. Rescue Surgery for Advanced Stage Lung Cancer: A Systematic Review., Thorac Cancer, 2025. 16 (16)(16): p. e70151., https://pubmed.ncbi.nlm.nih.gov/40836713/
1074. Auperin, A., Le Pechoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., et.al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer, J Clin Oncol, 2010. 28(13): p. 2181-90., https://www.ncbi.nlm.nih.gov/pubmed/20351327
1075. Xiao, W, Hong, M, Concurrent vs sequential chemoradiotherapy for patients with advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials., Medicine (Baltimore), 2021. 100 (11)(11): p. e21455., https://pubmed.ncbi.nlm.nih.gov/33725921/
1076. Flentje, M, Huber, RM, Engel-Riedel, W, Andreas, S, Kollmeier, J, Staar, S, et.al. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer., Strahlenther Onkol, 2016. 192 (4)(4): p. 216-22., https://pubmed.ncbi.nlm.nih.gov/26809652/
1077. Nestle, U, Schimek-Jasch, T, Kremp, S, Schaefer-Schuler, A, Mix, M, Küsters, A, et.al. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial., Lancet Oncol, 2020. 21 (4)(4): p. 581-592., https://pubmed.ncbi.nlm.nih.gov/32171429/
1078. Fournel, P., Robinet, G., Thomas, P., Souquet, P. J., Lena, H., Vergnenegre, A., et.al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study, J Clin Oncol, 2005. 23(25): p. 5910-5917., https://www.ncbi.nlm.nih.gov/pubmed/16087956
1079. Furuse, K., Fukuoka, M., Kawahara, M., Nishikawa, H., Takada, Y., Kudoh, S., et.al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer, J Clin Oncol, 1999. 17(9): p. 2692-2699., https://www.ncbi.nlm.nih.gov/pubmed/10561343
1080. Curran, WJ, Paulus, R, Langer, CJ, Komaki, R, Lee, JS, Hauser, S, et.al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410., J Natl Cancer Inst, 2011. 103 (19)(19): p. 1452-60., https://pubmed.ncbi.nlm.nih.gov/21903745/
1081. Bi, N, Liu, L, Liang, J, Wu, S, Chen, M, Lv, C, et.al. Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial., BMC Cancer, 2020. 20 (1)(1): p. 278., https://pubmed.ncbi.nlm.nih.gov/32252680/
1082. Liang, J, Bi, N, Wu, S, Chen, M, Lv, C, Zhao, L, et.al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial., Ann Oncol, 2017. 28 (4)(4): p. 777-783., https://pubmed.ncbi.nlm.nih.gov/28137739/
1083. Liu, T, He, Z, Dang, J, Li, G, Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis., Radiat Oncol, 2019. 14 (1)(1): p. 55., https://pubmed.ncbi.nlm.nih.gov/30925881/
1084. Palma, DA, Senan, S, Tsujino, K, Barriger, RB, Rengan, R, Moreno, M, et.al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis., Int J Radiat Oncol Biol Phys, 2013. 85 (2)(2): p. 444-50., https://pubmed.ncbi.nlm.nih.gov/22682812/
1085. Le Chevalier, T, Brisgand, D, Douillard, JY, Pujol, JL, Alberola, V, Monnier, A, et.al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients., J Clin Oncol, 1994. 12 (2)(2): p. 360-7., https://pubmed.ncbi.nlm.nih.gov/8113844/
1086. Gebbia, V, Galetta, D, Riccardi, F, Gridelli, C, Durini, E, Borsellino, N, et.al. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study., Lung Cancer, 2002. 37 (2)(2): p. 179-87., https://pubmed.ncbi.nlm.nih.gov/12140141/
1087. Faivre-Finn, C, Spigel, DR, Senan, S, Langer, C, Perez, BA, Özgüroğlu, M, et.al. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)., Lung Cancer, 2021. 151 (): p. 30-38., https://pubmed.ncbi.nlm.nih.gov/33285469/
1088. Ying, M, Liu, J, Zhou, W, Weng, K, Long, B, Wang, Y, The Role of Additional Chemotherapy in Combination with Concurrent Chemoradiotherapy for Locally Advanced Inoperable Non-Small Cell Lung Cancer, a Systematic Review and Meta-Analysis of 12 Randomized Trials., Cancer Invest, 2019. 37 (8)(8): p. 376-386., https://pubmed.ncbi.nlm.nih.gov/31474153/
1089. Schaake-Koning, C., van den, Bogaert W., Dalesio, O., Festen, J., Hoogenhout, J., van Houtte, P., et.al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer, N Engl J Med, 1992. 326(8): p. 524-530., https://www.ncbi.nlm.nih.gov/pubmed/1310160
1090. Guberina, M, Darwiche, K, Hautzel, H, Ploenes, T, Pöttgen, C, Guberina, N, et.al. Impact of EBUS-TBNA in addition to [, Eur J Nucl Med Mol Imaging, 2021. 48 (9)(9): p. 2894-2903., https://pubmed.ncbi.nlm.nih.gov/33547554/
1091. Gan, Q, Stewart, JM, Valik, E, Eapen, G, Caraway, NP, Cytologic Evaluation of Positron Emission Tomography-Computed Tomography-Positive Lymph Nodes Sampled by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: Experience at a Large Cancer Center., Arch Pathol Lab Med, 2019. 143 (10)(10): p. 1265-1270., https://pubmed.ncbi.nlm.nih.gov/31063012/
1092. Nestle, U, De Ruysscher, D, Ricardi, U, Geets, X, Belderbos, J, Pöttgen, C, et.al. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer., Radiother Oncol, 2018. 127 (1)(1): p. 1-5., https://pubmed.ncbi.nlm.nih.gov/29605476/
1093. Zhang, TW, Snir, J, Boldt, RG, Rodrigues, GB, Louie, AV, Gaede, S, et.al. Is the Importance of Heart Dose Overstated in the Treatment of Non-Small Cell Lung Cancer? A Systematic Review of the Literature., Int J Radiat Oncol Biol Phys, 2019. 104 (3)(3): p. 582-589., https://pubmed.ncbi.nlm.nih.gov/30630029/
1094. Banfill, K, Giuliani, M, Aznar, M, Franks, K, McWilliam, A, Schmitt, M, et.al. Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions., J Thorac Oncol, 2021. 16 (2)(2): p. 216-227., https://pubmed.ncbi.nlm.nih.gov/33278607/
1095. Totzeck, M, Schuler, M, Stuschke, M, Heusch, G, Rassaf, T, Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease., Int J Cardiol, 2019. 280 (): p. 163-175., https://pubmed.ncbi.nlm.nih.gov/30661849/
1096. Perez, C. A., Stanley, K., Rubin, P., Kramer, S., Brady, L., Perez-Tamayo, R., et.al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group, Cancer, 1980. 45(11): p. 2744-2753., https://www.ncbi.nlm.nih.gov/pubmed/6991092
1097. Perez, C. A., Pajak, T. F., Rubin, P., Simpson, J. R., Mohiuddin, M., Brady, L. W., et.al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group, Cancer, 1987. 59(11): p. 1874-1881., https://www.ncbi.nlm.nih.gov/pubmed/3032394
1098. Saunders, M., Dische, S., Barrett, A., Harvey, A., Griffiths, G., Palmar, M., Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee, Radiother.Oncol., 1999. 52(2): p. 137-148., https://www.ncbi.nlm.nih.gov/pubmed/10577699
1099. Fowler, JF, Chappell, R, Non-small cell lung tumors repopulate rapidly during radiation therapy., Int J Radiat Oncol Biol Phys, 2000. 46 (2)(2): p. 516-7., https://pubmed.ncbi.nlm.nih.gov/10661362/
1100. Feldmann, HJ, [Split-course radiotherapy or treatment interruption]., Strahlenther Onkol, 2000. 176 (10)(10): p. 458-61., https://pubmed.ncbi.nlm.nih.gov/11068590/
1101. Butts, C, Socinski, MA, Mitchell, PL, Thatcher, N, Havel, L, Krzakowski, M, et.al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial., Lancet Oncol, 2014. 15 (1)(1): p. 59-68., https://pubmed.ncbi.nlm.nih.gov/24331154/
1102. Huber, RM, Reck, M, Thomas, M, Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer., Eur Respir J, 2013. 42 (4)(4): p. 1119-33., https://pubmed.ncbi.nlm.nih.gov/23429914/
1103. Kelly, K, Chansky, K, Gaspar, LE, Albain, KS, Jett, J, Ung, YC, et.al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023., J Clin Oncol, 2008. 26 (15)(15): p. 2450-6., https://pubmed.ncbi.nlm.nih.gov/18378568/
1104. Antonia, SJ, Villegas, A, Daniel, D, Vicente, D, Murakami, S, Hui, R, et.al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer., N Engl J Med, 2017. 377 (20)(20): p. 1919-1929., https://pubmed.ncbi.nlm.nih.gov/28885881/
1105. Naidoo, J, Antonia, S, Wu, YL, Cho, BC, Thiyagarajah, P, Mann, H, et.al. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC., J Thorac Oncol, 2023. 18 (5)(5): p. 657-663., https://pubmed.ncbi.nlm.nih.gov/36841540/
1106. Lu, S, Kato, T, Dong, X, Ahn, MJ, Quang, LV, Soparattanapaisarn, N, et.al. Osimertinib after Chemoradiotherapy in Stage III , N Engl J Med, 2024. 391 (7)(7): p. 585-597., https://pubmed.ncbi.nlm.nih.gov/38828946/
1107. Gandara, D. R., Chansky, K., Albain, K. S., Leigh, B. R., Gaspar, L. E., Lara, P. N., Jr., et.al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504, J Clin Oncol, 2003. 21(10): p. 2004-2010., https://www.ncbi.nlm.nih.gov/pubmed/12743155
1108. Hanna, N. H., Neubauer, M., Ansari, R., et al., Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023, J Clin Oncol, 2007. 25: p. 7512., https://www.ncbi.nlm.nih.gov/pubmed/19001323
1109. Ahn, JS, Ahn, YC, Kim, JH, Lee, CG, Cho, EK, Lee, KC, et.al. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04., J Clin Oncol, 2015. 33 (24)(24): p. 2660-6., https://pubmed.ncbi.nlm.nih.gov/26150444/
1110. Hanna, N, Neubauer, M, Yiannoutsos, C, McGarry, R, Arseneau, J, Ansari, R, et.al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology., J Clin Oncol, 2008. 26 (35)(35): p. 5755-60., https://pubmed.ncbi.nlm.nih.gov/19001323/
1111. Nayak, L, Lee, EQ, Wen, PY, Epidemiology of brain metastases., Curr Oncol Rep, 2012. 14 (1)(1): p. 48-54., https://pubmed.ncbi.nlm.nih.gov/22012633/
1112. Zeng, H, Hendriks, LEL, van Geffen, WH, Witlox, WJA, Eekers, DBP, De Ruysscher, DKM, Risk factors for neurocognitive decline in lung cancer patients treated with prophylactic cranial irradiation: A systematic review., Cancer Treat Rev, 2020. 88 (): p. 102025., https://pubmed.ncbi.nlm.nih.gov/32512415/
1113. Liu, L, Zhao, T, Zhong, Q, Cui, J, Xiu, X, Li, G, The Role of Prophylactic Cranial Irradiation in Patients With Non-small Cell Lung Cancer: An Updated Systematic Review and Meta-Analysis., Front Oncol, 2020. 10 (): p. 11., https://pubmed.ncbi.nlm.nih.gov/32038987/
1114. Witlox, WJA, Ramaekers, BLT, Groen, HJM, Dingemans, AM, Praag, J, Belderbos, J, et.al. Factors determining the effect of prophylactic cranial irradiation (PCI) in patients with stage-III nonsmall cell lung cancer: exploratory subgroup analyses of the NVALT-11/DLCRG-02 phase-III study., Acta Oncol, 2019. 58 (10)(10): p. 1528-1531., https://pubmed.ncbi.nlm.nih.gov/31256737/
1115. Verma, V, Simone, CB, Approaches to stereotactic body radiation therapy for large (≥5 centimeter) non-small cell lung cancer., Transl Lung Cancer Res, 2019. 8 (1)(1): p. 70-77., https://pubmed.ncbi.nlm.nih.gov/30788236/
1116. Baker, S, Dahele, M, Lagerwaard, FJ, Senan, S, A critical review of recent developments in radiotherapy for non-small cell lung cancer., Radiat Oncol, 2016. 11 (1)(1): p. 115., https://pubmed.ncbi.nlm.nih.gov/27600665/
1117. Jumeau, R, Vilotte, F, Durham, AD, Ozsahin, EM, Current landscape of palliative radiotherapy for non-small-cell lung cancer., Transl Lung Cancer Res, 2019. 8 (Suppl 2)(Suppl 2): p. S192-S201., https://pubmed.ncbi.nlm.nih.gov/31673524/
1118. Stevens, R, Macbeth, F, Toy, E, Coles, B, Lester, JF, Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer., Cochrane Database Syst Rev, 2015. 1 (): p. CD002143., https://pubmed.ncbi.nlm.nih.gov/25586198/
1119. Fairchild, A, Harris, K, Barnes, E, Wong, R, Lutz, S, Bezjak, A, et.al. Palliative thoracic radiotherapy for lung cancer: a systematic review., J Clin Oncol, 2008. 26 (24)(24): p. 4001-11., https://pubmed.ncbi.nlm.nih.gov/18711191/
1120. Moeller, B, Balagamwala, EH, Chen, A, Creach, KM, Giaccone, G, Koshy, M, et.al. Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline., Pract Radiat Oncol 8 (4)(4): p. 245-250., https://pubmed.ncbi.nlm.nih.gov/29625898/
1121. Ball, D, Smith, J, Bishop, J, Olver, I, Davis, S, O'Brien, P, et.al. A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancer., Br J Cancer, 1997. 75 (5)(5): p. 690-7., https://pubmed.ncbi.nlm.nih.gov/9043026/
1122. Nawrocki, S, Krzakowski, M, Wasilewska-Tesluk, E, Kowalski, D, Rucinska, M, Dziadziuszko, R, et.al. Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment: results of a randomized phase II study., J Thorac Oncol, 2010. 5 (8)(8): p. 1255-62., https://pubmed.ncbi.nlm.nih.gov/20592630/
1123. Strøm, HH, Bremnes, RM, Sundstrøm, SH, Helbekkmo, N, Fløtten, O, Aasebø, U, Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group., Br J Cancer, 2013. 109 (6)(6): p. 1467-75., https://pubmed.ncbi.nlm.nih.gov/23963145/
1124. Reinfuss, M, Mucha-Małecka, A, Walasek, T, Blecharz, P, Jakubowicz, J, Skotnicki, P, et.al. Palliative thoracic radiotherapy in non-small cell lung cancer. An analysis of 1250 patients. Palliation of symptoms, tolerance and toxicity., Lung Cancer, 2011. 71 (3)(3): p. 344-9., https://pubmed.ncbi.nlm.nih.gov/20674068/
1125. Sezer, A, Kilickap, S, Gümüş, M, Bondarenko, I, Özgüroğlu, M, Gogishvili, M, et.al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial., Lancet, 2021. 397 (10274)(10274): p. 592-604., https://pubmed.ncbi.nlm.nih.gov/33581821/
1126. Makharadze, T, Gogishvili, M, Melkadze, T, Baramidze, A, Giorgadze, D, Penkov, K, et.al. Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial., J Thorac Oncol, 2023. 18 (6)(6): p. 755-768., https://pubmed.ncbi.nlm.nih.gov/37001859/
1127. Kalinka, E., Bondarenko, I., Gogishvili, M., Melkadze, T., Baramidze, A., Sezer, A., et.al. 114M0 First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3Elsevier, Journal of Thoracic Oncology, 2023. 18(4): p. S106., https://doi.org/10.1016/S1556-0864(23)00369-6
1128. Ross, HJ, Kozono, D, Wang, XF, Urbanic, JJ, Williams, TM, Nelson, GD, et.al. Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial., JAMA Oncol, 2024. 10 (9)(9): p. 1212-1219., https://pubmed.ncbi.nlm.nih.gov/39052256/
1129. Provencio, M, Campos, B, Guirado, M, Vila, L, García Campelo, R, Dorta, M, et.al. Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial., Nat Commun, 2025. 16 (1)(1): p. 10124., https://pubmed.ncbi.nlm.nih.gov/41436730/
1130. Filippi, AR, Agustoni, F, Arcangeli, S, Cortinovis, D, Ferrari, A, Cicognini, D, et.al. Rationale and Design of a Single-Arm, Phase 2, Multi-Center Study of Chemo-Immunotherapy Followed by Hypo-Fractionated RT and Maintenance Immunotherapy in Patients With Unresectable Stage III NSCLC: The DEDALUS Trial., Clin Lung Cancer, 2023. 24 (3)(3): p. e122-e125., https://pubmed.ncbi.nlm.nih.gov/36759266/
1131. Peters, S, Felip, E, Dafni, U, Tufman, A, Guckenberger, M, Álvarez, R, et.al. Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)., J Thorac Oncol, 2021. 16 (2)(2): p. 278-288., https://pubmed.ncbi.nlm.nih.gov/33188912/
1132. Bradley, JD, Sugawara, S, Lee, KH, Ostoros, G, Demirkazik, A, Zemanova, M, et.al. Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study., J Clin Oncol, 2025. 43 (33)(33): p. 3610-3621., https://pubmed.ncbi.nlm.nih.gov/41082707/
1133. Jabbour, SK, Lee, KH, Frost, N, Breder, V, Kowalski, DM, Pollock, T, et.al. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial., JAMA Oncol, 2021. 7 (9)(9): p. 1-9., https://pubmed.ncbi.nlm.nih.gov/34086039/
1134. Liu, Y, Yao, L, Kalhor, N, Carter, BW, Altan, M, Blumenschein, G, et.al. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial., Lung Cancer, 2022. 174 (): p. 112-117., https://pubmed.ncbi.nlm.nih.gov/36371941/
1135. Garassino, MC, Mazieres, J, Reck, M, Chouaid, C, Bischoff, H, Reinmuth, N, et.al. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial., J Thorac Oncol, 2022. 17 (12)(12): p. 1415-1427., https://pubmed.ncbi.nlm.nih.gov/35961520/
1136. Zhou, C, Wang, Z, Sun, M, Cao, L, Ma, Z, Wu, R, et.al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial., Lancet Oncol, 2025. 26 (7)(7): p. 887-897., https://pubmed.ncbi.nlm.nih.gov/40523368/
1137. Moore, S, Leung, B, Wu, J, Ho, C, Population-based analysis of curative therapies in stage II non-small cell lung cancer: the role of radiotherapy in medically inoperable patients., Radiat Oncol, 2020. 15 (1)(1): p. 23., https://pubmed.ncbi.nlm.nih.gov/32000829/
1138. Joo, JH, Song, SY, Kim, SS, Jeong, Y, Jeong, SY, Choi, W, et.al. Definitive radiotherapy alone over 60 Gy for patients unfit for combined treatment to stage II-III non-small cell lung cancer: retrospective analysis., Radiat Oncol, 2015. 10 (): p. 250., https://pubmed.ncbi.nlm.nih.gov/26635014/
1139. Kilickap, S, Baramidze, A, Sezer, A, Özgüroğlu, M, Gumus, M, Bondarenko, I, et.al. Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1., J Thorac Oncol, 2025. 20 (7)(7): p. 941-954., https://pubmed.ncbi.nlm.nih.gov/40118215/
1140. von Laffert, M., Schirmacher, P., Warth, A., Weichert, W., Büttner, R., Huber, R. M., et.al. Stellungnahme der DGP und der AG Thorakale Onkologie der AG Onkologie/Deutsche Krebsgesellschaft e. V. zur ALK-Testung beim NSCLC, Der Pathologe, 2016. 37(2): p. 187-192., https://doi.org/10.1007/s00292-016-0152-1
1141. Scagliotti, G. V., Parikh, P., von, Pawel J., Biesma, B., Vansteenkiste, J., Manegold, C., et.al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J.Clin.Oncol., 2008. 26(21): p. 3543-3551., https://www.ncbi.nlm.nih.gov/pubmed/18506025
1142. Crino, L., Dansin, E., Garrido, P., Griesinger, F., Laskin, J., Pavlakis, N., et.al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study, Lancet Oncol, 2010. 11(8): p. 733-40., https://www.ncbi.nlm.nih.gov/pubmed/20650686
1143. Fidias, P. M., Dakhil, S. R., Lyss, A. P., Loesch, D. M., Waterhouse, D. M., Bromund, J. L., et.al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer, J Clin Oncol, 2009. 27(4): p. 591-8., https://www.ncbi.nlm.nih.gov/pubmed/19075278
1144. Peppercorn, J. M., Smith, T. J., Helft, P. R., Debono, D. J., Berry, S. R., Wollins, D. S., et.al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer, J Clin Oncol, 2011. 29(6): p. 755-60., https://www.ncbi.nlm.nih.gov/pubmed/21263086
1145. Paz-Ares, L, Ciuleanu, TE, Cobo, M, Schenker, M, Zurawski, B, Menezes, J, et.al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial., Lancet Oncol, 2021. 22 (2)(2): p. 198-211., https://pubmed.ncbi.nlm.nih.gov/33476593/
1146. Wu, B, Lu, S, The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis., Transl Lung Cancer Res, 2020. 9 (5)(5): p. 1770-1784., https://pubmed.ncbi.nlm.nih.gov/33209600/
1147. Reck, M, Rodríguez-Abreu, D, Robinson, AG, Hui, R, Csőszi, T, Fülöp, A, et.al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater., J Clin Oncol, 2019. 37 (7)(7): p. 537-546., https://pubmed.ncbi.nlm.nih.gov/30620668/
1148. Herbst, RS, Giaccone, G, de Marinis, F, Reinmuth, N, Vergnenegre, A, Barrios, CH, et.al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC., N Engl J Med, 2020. 383 (14)(14): p. 1328-1339., https://pubmed.ncbi.nlm.nih.gov/32997907/
1149. Brahmer, J. R., Rodriguez-Abreu, D., Robinson, A. G., Hui, R., Csoszi, T., Fulop, A., et.al. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial, Lancet Oncol, 2017. 18(12): p. 1600-1609., https://www.ncbi.nlm.nih.gov/pubmed/29129441
1150. Gogishvili, M, Melkadze, T, Makharadze, T, Giorgadze, D, Dvorkin, M, Penkov, K, et.al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial., Nat Med, 2022. 28 (11)(11): p. 2374-2380., https://pubmed.ncbi.nlm.nih.gov/36008722/
1151. Johnson, ML, Cho, BC, Luft, A, Alatorre-Alexander, J, Geater, SL, Laktionov, K, et.al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study., J Clin Oncol, 2023. 41 (6)(6): p. 1213-1227., https://pubmed.ncbi.nlm.nih.gov/36327426/
1152. Wang, J, Lu, S, Yu, X, Hu, Y, Zhao, J, Sun, M, et.al. Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial., ESMO Open, 2024. 9 (10)(10): p. 103727., https://pubmed.ncbi.nlm.nih.gov/39461775/
1153. Hellmann, MD, Paz-Ares, L, Bernabe Caro, R, Zurawski, B, Kim, SW, Carcereny Costa, E, et.al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer., N Engl J Med, 2019. 381 (21)(21): p. 2020-2031., https://pubmed.ncbi.nlm.nih.gov/31562796/
1154. Mok, TSK, Wu, YL, Kudaba, I, Kowalski, DM, Cho, BC, Turna, HZ, et.al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial., Lancet, 2019. 393 (10183)(10183): p. 1819-1830., https://pubmed.ncbi.nlm.nih.gov/30955977/
1155. Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., et.al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer, J Clin Oncol, 2020. 38(14): p. 1505-1517., https://pubmed.ncbi.nlm.nih.gov/32150489/
1156. Nishio, M., Barlesi, F., West, H., Ball, S., Bordoni, R., Cobo, M., et.al. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial, J Thorac Oncol, 2021. 16(4): p. 653-664., https://pubmed.ncbi.nlm.nih.gov/33333328/
1157. Reck, Martin, Mok, Tony S. K., Nishio, Makoto, Jotte, Robert M., Cappuzzo, Federico, Orlandi, Francisco, et.al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial, The Lancet Respiratory Medicine, 2019. 7(5): p. 387-401., https://doi.org/10.1016/S2213-2600(19)30084-0
1158. Reck, M., Schenker, M., Lee, K. H., Provencio, M., Nishio, M., Lesniewski-Kmak, K., et.al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial, Eur J Cancer, 2019. 116: p. 137-147., https://pubmed.ncbi.nlm.nih.gov/31195357/
1159. de Castria, T. B., da Silva, E. M., Gois, A. F., Riera, R., Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer, Cochrane Database Syst Rev, 2013. 8: p. CD009256., https://www.ncbi.nlm.nih.gov/pubmed/23949842
1160. Rajeswaran, A., Trojan, A., Burnand, B., Giannelli, M., Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials, Lung Cancer, 2008. 59(1): p. 1-11., https://www.ncbi.nlm.nih.gov/pubmed/17720276
1161. Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., Tanimoto, M., Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer, J Clin Oncol, 2004. 22(19): p. 3852-3859., https://www.ncbi.nlm.nih.gov/pubmed/15326195
1162. Cartei, G., Cartei, F., Cantone, A., Causarano, D., Genco, G., Tobaldin, A., et.al. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer, J Natl.Cancer Inst., 1993. 85(10): p. 794-800., https://www.ncbi.nlm.nih.gov/pubmed/8387607
1163. Ranson, M., Davidson, N., Nicolson, M., Falk, S., Carmichael, J., Lopez, P., et.al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer, J Natl Cancer Inst, 2000. 92(13): p. 1074-80., https://www.ncbi.nlm.nih.gov/pubmed/10880550
1164. D'Addario, G., Pintilie, M., Leighl, N. B., Feld, R., Cerny, T., Shepherd, F. A., Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature, J Clin Oncol, 2005. 23(13): p. 2926-36., https://www.ncbi.nlm.nih.gov/pubmed/15728229
1165. Thongprasert, S., Sanguanmitra, P., Juthapan, W., Clinch, J., Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy, Lung Cancer, 1999. 24(1): p. 17-24., https://www.ncbi.nlm.nih.gov/pubmed/10403690
1166. Group, Nsclc Meta-Analyses Collaborative, Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials, J Clin Oncol, 2008. 26(28): p. 4617-25., https://www.ncbi.nlm.nih.gov/pubmed/18678835
1167. Spiro, S. G., Rudd, R. M., Souhami, R. L., Brown, J., Fairlamb, D. J., Gower, N. H., et.al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life, Thorax, 2004. 59(10): p. 828-836., https://www.ncbi.nlm.nih.gov/pubmed/15454647
1168. Kilickap, S., Sezer, A., Özgüroğlu, M., Gumus, M., Bondarenko, I., Gogishvili, M., et.al. OA11.06 Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung 1Elsevier, Journal of Thoracic Oncology, 2024. 19(10): p. S35., https://doi.org/10.1016/j.jtho.2024.09.064
1169. Makharadze, T., Gogishvili, M., Melkadze, T., Baramidze, A., Sezer, A., Kilickap, S., et.al. 144P First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1Elsevier, Immuno-Oncology and Technology, 2024. 24:, https://doi.org/10.1016/j.iotech.2024.100773
1170. Carbone, DP, Reck, M, Paz-Ares, L, Creelan, B, Horn, L, Steins, M, et.al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer., N Engl J Med, 2017. 376 (25)(25): p. 2415-2426., https://pubmed.ncbi.nlm.nih.gov/28636851/
1171. Nosaki, K, Saka, H, Hosomi, Y, Baas, P, de Castro, G, Reck, M, et.al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies., Lung Cancer, 2019. 135 (): p. 188-195., https://pubmed.ncbi.nlm.nih.gov/31446994/
1172. Paz-Ares, L, Vicente, D, Tafreshi, A, Robinson, A, Soto Parra, H, Mazières, J, et.al. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407., J Thorac Oncol, 2020. 15 (10)(10): p. 1657-1669., https://pubmed.ncbi.nlm.nih.gov/32599071/
1173. Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., et.al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial, J Clin Oncol, 2012. 30(17): p. 2055-62., https://www.ncbi.nlm.nih.gov/pubmed/22547591
1174. Socinski, M. A., Okamoto, I., Hon, J. K., Hirsh, V., Dakhil, S. R., Page, R. D., et.al. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer, Ann Oncol, 2013. 24(9): p. 2390-6., https://www.ncbi.nlm.nih.gov/pubmed/23842283
1175. Sugi, K., Kaneda, Y., Esato, K., Video-assisted thoracoscopic lobectomy achieves a satisfactory long-term prognosis in patients with clinical stage IA lung cancer, World J.Surg., 2000. 24(1): p. 27-30., https://www.ncbi.nlm.nih.gov/pubmed/10594199
1176. Kong, F. M., Ten, Haken R., Eisbruch, A., Lawrence, T. S., Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis, Semin.Oncol., 2005. 32(2 Suppl 3): p. S42-S54., https://www.ncbi.nlm.nih.gov/pubmed/16015535
1177. Belani, C. P., Barstis, J., Perry, M. C., La Rocca, R. V., Nattam, S. R., Rinaldi, D., et.al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation, J Clin Oncol, 2003. 21(15): p. 2933-9., https://www.ncbi.nlm.nih.gov/pubmed/12885812
1178. Westeel, V., Quoix, E., Moro-Sibilot, D., Mercier, M., Breton, J. L., Debieuvre, D., et.al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer, J Natl Cancer Inst, 2005. 97(7): p. 499-506., https://www.ncbi.nlm.nih.gov/pubmed/15812075
1179. Brodowicz, T., Krzakowski, M., Zwitter, M., Tzekova, V., Ramlau, R., Ghilezan, N., et.al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial, Lung Cancer, 2006. 52(2): p. 155-63., https://www.ncbi.nlm.nih.gov/pubmed/16569462
1180. Socinski, M. A., Schell, M. J., Peterman, A., Bakri, K., Yates, S., Gitten, R., et.al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer, J Clin Oncol, 2002. 20(5): p. 1335-1343., https://www.ncbi.nlm.nih.gov/pubmed/11870177
1181. Smith, I. E., O'Brien, M. E., Talbot, D. C., Nicolson, M. C., Mansi, J. L., Hickish, T. F., et.al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin, J.Clin.Oncol., 2001. 19(5): p. 1336-1343., https://www.ncbi.nlm.nih.gov/pubmed/11230476
1182. Borget, I., Perol, M., Perol, D., Lavole, A., Greillier, L., Do, P., et.al. Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study, BMC Cancer, 2014. 14: p. 953., https://www.ncbi.nlm.nih.gov/pubmed/25511923
1183. Bylicki, O., Ferlay, C., Chouaid, C., Lavole, A., Barlesi, F., Dubos, C., et.al. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study, J Thorac Oncol, 2013. 8(7): p. 906-14., https://www.ncbi.nlm.nih.gov/pubmed/23591160
1184. Toy, E., Macbeth, F., Coles, B., Melville, A., Eastwood, A., Palliative thoracic radiotherapy for non-small-cell lung cancer: a systematic review, Am J Clin Oncol, 2003. 26(2): p. 112-20., https://www.ncbi.nlm.nih.gov/pubmed/12714878
1185. Teo, P., Tai, T. H., Choy, D., Tsui, K. H., A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung, Int J Radiat Oncol Biol Phys, 1988. 14(5): p. 867-71., https://www.ncbi.nlm.nih.gov/pubmed/2452146
1186. Bezjak, A., Dixon, P., Brundage, M., Tu, D., Palmer, M. J., Blood, P., et.al. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15), Int J Radiat Oncol Biol Phys, 2002. 54(3): p. 719-728., https://www.ncbi.nlm.nih.gov/pubmed/12377323
1187. Falk, S. J., Girling, D. J., White, R. J., Hopwood, P., Harvey, A., Qian, W., et.al. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial, BMJ, 2002. 325(7362): p. 465-471., https://www.ncbi.nlm.nih.gov/pubmed/12202326
1188. Senan, S., De, Ruysscher D., Giraud, P., Mirimanoff, R., Budach, V., Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer, Radiother.Oncol., 2004. 71(2): p. 139-146., https://www.ncbi.nlm.nih.gov/pubmed/15110446
1189. Chang, D. T., Zlotecki, R. A., Olivier, K. R., Re-examining the role of elective nodal irradiation: finding ways to maximize the therapeutic ratio, Am.J Clin Oncol, 2005. 28(6): p. 597-602., https://www.ncbi.nlm.nih.gov/pubmed/16317271
1190. Mehta, V., Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention, Int.J.Radiat.Oncol.Biol.Phys., 2005. 63(1): p. 5-24., https://www.ncbi.nlm.nih.gov/pubmed/15963660
1191. Tsao, M. S., Sakurada, A., Cutz, J. C., Zhu, C. Q., Kamel-Reid, S., Squire, J., et.al. Erlotinib in lung cancer - molecular and clinical predictors of outcome, N Engl J Med, 2005. 353(2): p. 133-44., https://www.ncbi.nlm.nih.gov/pubmed/16014883
1192. Shepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O'Rourke, M., et.al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, J Clin Oncol, 2000. 18(10): p. 2095-103., https://www.ncbi.nlm.nih.gov/pubmed/10811675
1193. Fossella, F. V., DeVore, R., Kerr, R. N., Crawford, J., Natale, R. R., Dunphy, F., et.al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group, J Clin Oncol, 2000. 18(12): p. 2354-2362., https://www.ncbi.nlm.nih.gov/pubmed/10856094
1194. Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., de, Marinis F., von, Pawel J., et.al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, J Clin Oncol, 2004. 22(9): p. 1589-1597., https://www.ncbi.nlm.nih.gov/pubmed/15117980
1195. Soria, J. C., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K. H., et.al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial, Lancet Oncol, 2015. 16(8): p. 897-907., https://www.ncbi.nlm.nih.gov/pubmed/26156651
1196. Garon, E. B., Ciuleanu, T. E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., et.al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial, Lancet, 2014., https://www.ncbi.nlm.nih.gov/pubmed/24933332
1197. Zhou, C, Huang, D, Fan, Y, Yu, X, Liu, Y, Shu, Y, et.al. Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial., J Thorac Oncol, 2023. 18 (1)(1): p. 93-105., https://pubmed.ncbi.nlm.nih.gov/36184068/
1198. Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., et.al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, 2017. 389(10066): p. 255-265., https://pubmed.ncbi.nlm.nih.gov/27979383/
1199. Herbst, R. S., Baas, P., Kim, D. W., Felip, E., Perez-Gracia, J. L., Han, J. Y., et.al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 2016. 387(10027): p. 1540-50., https://www.ncbi.nlm.nih.gov/pubmed/26712084
1200. Fehrenbacher, L, Spira, A, Ballinger, M, Kowanetz, M, Vansteenkiste, J, Mazieres, J, et.al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial., Lancet, 2016. 387 (10030)(10030): p. 1837-46., https://pubmed.ncbi.nlm.nih.gov/26970723/
1201. Leal, T, Kotecha, R, Ramlau, R, Zhang, L, Milanowski, J, Cobo, M, et.al. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study., Lancet Oncol, 2023. 24 (9)(9): p. 1002-1017., https://pubmed.ncbi.nlm.nih.gov/37657460/
1202. Frost, N, Kollmeier, J, Misch, D, Vollbrecht, C, Grah, C, Matthes, B, et.al. Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids., Clin Lung Cancer, 2021. 22 (5)(5): p. 411-422., https://pubmed.ncbi.nlm.nih.gov/33648877/
1203. Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., et.al. Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 1982. 5(6): p. 649-55., https://www.ncbi.nlm.nih.gov/pubmed/7165009
1204. Lilenbaum, R., Axelrod, R., Thomas, S., Dowlati, A., Seigel, L., Albert, D., et.al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2, J Clin Oncol, 2008. 26(6): p. 863-9., https://www.ncbi.nlm.nih.gov/pubmed/18281658
1205. Saunders, M., Dische, S., Barrett, A., Harvey, A., Gibson, D., Parmar, M., Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee, Lancet, 1997. 350(9072): p. 161-165., https://www.ncbi.nlm.nih.gov/pubmed/9250182
1206. Syn, N. L., Teng, M. W. L., Mok, T. S. K., Soo, R. A., De-novo and acquired resistance to immune checkpoint targeting, Lancet Oncol, 2017. 18(12): p. e731-e741., https://pubmed.ncbi.nlm.nih.gov/29208439/
1207. Lim, S. W., Ahn, M. J., Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer, Korean J Intern Med, 2019. 34(1): p. 50-59., https://pubmed.ncbi.nlm.nih.gov/30612418/
1208. Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., et.al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N Engl J Med, 2018. 378(22): p. 2078-2092., https://pubmed.ncbi.nlm.nih.gov/29658856/
1209. Reck, Martin, Mok, Tony S. K., Nishio, Makoto, Jotte, Robert M., Cappuzzo, Federico, Orlandi, Francisco, et.al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial, The Lancet Respiratory Medicine, 2019. 7(5): p. 387-401., https://doi.org/10.1016/S2213-2600(19)30084-0
1210. Lu, S, Wang, J, Yu, Y, Yu, X, Hu, Y, Ma, Z, et.al. Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial)., ESMO Open, 2024. 9 (10)(10): p. 103728., https://pubmed.ncbi.nlm.nih.gov/39461773/
1211. Zhou, C, Wang, Z, Sun, Y, Cao, L, Ma, Z, Wu, R, et.al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial., Lancet Oncol, 2022. 23 (2)(2): p. 220-233., https://pubmed.ncbi.nlm.nih.gov/35038432/
1212. Park, J. H., Lee, C. T., Lee, H. W., Baek, H. J., Zo, J. I., Shim, Y. M., Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer, Eur.J.Cardiothorac.Surg., 2005. 27(6): p. 1086-1091., https://www.ncbi.nlm.nih.gov/pubmed/15896623
1213. Alam, N., Shepherd, F. A., Winton, T., Graham, B., Johnson, D., Livingston, R., et.al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature, Lung Cancer, 2005. 47(3): p. 385-394., https://www.ncbi.nlm.nih.gov/pubmed/15713522
1214. Endo, C., Saito, Y., Iwanami, H., Tsushima, T., Imai, T., Kawamura, M., et.al. A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery, Lung Cancer, 2003. 40(2): p. 181-186., https://www.ncbi.nlm.nih.gov/pubmed/12711119
1215. Kato, H., Ichinose, Y., Ohta, M., Hata, E., Tsubota, N., Tada, H., et.al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung, N.Engl.J.Med., 2004. 350(17): p. 1713-1721., https://www.ncbi.nlm.nih.gov/pubmed/15102997
1216. Nakagawa, M., Tanaka, F., Tsubota, N., Ohta, M., Takao, M., Wada, H., A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)--the 4th study, Ann.Oncol., 2005. 16(1): p. 75-80., https://www.ncbi.nlm.nih.gov/pubmed/15598942
1217. Hamada, C., Tanaka, F., Ohta, M., Fujimura, S., Kodama, K., Imaizumi, M., et.al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer, J Clin Oncol, 2005. 23(22): p. 4999-5006., https://www.ncbi.nlm.nih.gov/pubmed/16051951
1218. Wada, H., Miyahara, R., Tanaka, F., Hitomi, S., Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG), Eur.J.Cardiothorac.Surg., 1999. 15(4): p. 438-443., https://www.ncbi.nlm.nih.gov/pubmed/10371118
1219. Sawyer, T. E., Bonner, J. A., Gould, P. M., Foote, R. L., Deschamps, C., Trastek, V. F., et.al. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks, Ann.Thorac.Surg., 1997. 64(5): p. 1402-1407., https://www.ncbi.nlm.nih.gov/pubmed/9386711
1220. Rowell, N. P., Williams, C. J., Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable), Cochrane Database Syst Rev, 2001. p. CD002935., https://www.ncbi.nlm.nih.gov/pubmed/11406051
1221. Jeremic, B., Shibamoto, Y., Acimovic, L., Milicic, B., Milisavljevic, S., Nikolic, N., et.al. A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain, Int J Radiat Oncol Biol Phys, 1998. 42(1): p. 161-167., https://www.ncbi.nlm.nih.gov/pubmed/9747834
1222. Gridelli, C., Ardizzoni, A., Le Chevalier, T., Manegold, C., Perrone, F., Thatcher, N., et.al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel, Ann Oncol, 2004. 15(3): p. 419-26., https://www.ncbi.nlm.nih.gov/pubmed/14998843
1223. Pujol, J. L., Paz-Ares, L., de Marinis, F., Dediu, M., Thomas, M., Bidoli, P., et.al. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer, Clin Lung Cancer, 2014. 15(6): p. 418-25., https://www.ncbi.nlm.nih.gov/pubmed/25104617
1224. Reck, M., Paz-Ares, L. G., de Marinis, F., Molinier, O., Sahoo, T. P., Laack, E., et.al. PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer, J Thorac Oncol, 2014. 9(2): p. 205-13., https://www.ncbi.nlm.nih.gov/pubmed/24419418
1225. Paz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Pujol, J. L., Bidoli, P., et.al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer, J Clin Oncol, 2013. 31(23): p. 2895-902., https://www.ncbi.nlm.nih.gov/pubmed/23835707
1226. Garon, E. B., Aerts, J., Kim, J. S., Muehlenbein, C. E., Peterson, P., Rizzo, M. T., et.al. Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189, Lung Cancer, 2021. 155: p. 53-60., https://pubmed.ncbi.nlm.nih.gov/33730652/
1227. Reck, M, Wehler, T, Orlandi, F, Nogami, N, Barone, C, Moro-Sibilot, D, et.al. Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer., J Clin Oncol, 2020. 38 (22)(22): p. 2530-2542., https://pubmed.ncbi.nlm.nih.gov/32459597/
1228. Socinski, Mark A., Jotte, Robert M., Cappuzzo, Federico, Orlandi, Francisco, Stroyakovskiy, Daniil, Nogami, Naoyuki, et.al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, New England Journal of Medicine, 2018. 378(24): p. 2288-2301., https://doi.org/10.1056/NEJMoa1716948
1229. Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., et.al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial, Lancet Respir Med, 2019. 7(5): p. 387-401., https://pubmed.ncbi.nlm.nih.gov/30922878/
1230. Reck, M, Ciuleanu, TE, Lee, JS, Schenker, M, Audigier-Valette, C, Zurawski, B, et.al. First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1., J Thorac Oncol, 2021. 16 (4): p. 665-676., https://pubmed.ncbi.nlm.nih.gov/33485960/
1231. Reck, M, Ciuleanu, TE, Schenker, M, Bordenave, S, Cobo, M, Juan-Vidal, O, et.al. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial., Eur J Cancer, 2024. 211 (): p. 114296., https://pubmed.ncbi.nlm.nih.gov/39270380/
1232. Reck, M, Rodríguez-Abreu, D, Robinson, AG, Hui, R, Csőszi, T, Fülöp, A, et.al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50., J Clin Oncol, 2021. (): p. JCO2100174., https://pubmed.ncbi.nlm.nih.gov/33872070/
1233. Chen, Li, Walker, Mark S., Zhi, Jizu, Komatsoulis, George Anthony, Jun, Monika, Stepanski, Edward, et.al. Real-world prevalence of autoimmune disease (AD) among patients (pts) receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ database, Journal of Clinical Oncology, 2019. 37(15_suppl): p. 6583-6583., https://doi.org/10.1200/JCO.2019.37.15_suppl.6583
1234. Remon, J, Hendriks, L, Aspeslagh, S, Besse, B, Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?, J Thorac Oncol, 2019. 14 (10)(10): p. 1701-1703., https://pubmed.ncbi.nlm.nih.gov/31420287/
1235. Cortellini, A, Buti, S, Santini, D, Perrone, F, Giusti, R, Tiseo, M, et.al. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study., Oncologist, 2019. 24 (6)(6): p. e327-e337., https://pubmed.ncbi.nlm.nih.gov/30796151/
1236. Danlos, F. X., Voisin, A. L., Dyevre, V., Michot, J. M., Routier, E., Taillade, L., et.al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease, Eur J Cancer, 2018. 91: p. 21-29., https://pubmed.ncbi.nlm.nih.gov/29331748/
1237. Petruzziello, A, Marigliano, S, Loquercio, G, Cozzolino, A, Cacciapuoti, C, Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes., World J Gastroenterol, 2016. 22 (34)(34): p. 7824-40., https://pubmed.ncbi.nlm.nih.gov/27678366/
1238. El-Khoueiry, AB, Sangro, B, Yau, T, Crocenzi, TS, Kudo, M, Hsu, C, et.al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial., Lancet, 2017. 389 (10088)(10088): p. 2492-2502., https://pubmed.ncbi.nlm.nih.gov/28434648/
1239. Ott, JJ, Stevens, GA, Groeger, J, Wiersma, ST, Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity., Vaccine, 2012. 30 (12)(12): p. 2212-9., https://pubmed.ncbi.nlm.nih.gov/22273662/
1240. Byeon, S, Cho, JH, Jung, HA, Sun, JM, Lee, SH, Ahn, JS, et.al. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence., Cancer Med, 2020. 9 (7)(7): p. 2352-2362., https://pubmed.ncbi.nlm.nih.gov/32027780/
1241. Yarchoan, R, Uldrick, TS, HIV-Associated Cancers and Related Diseases., N Engl J Med, 2018. 378 (11)(11): p. 1029-1041., https://pubmed.ncbi.nlm.nih.gov/29539283/
1242. Sigel, K, Makinson, A, Thaler, J, Lung cancer in persons with HIV., Curr Opin HIV AIDS, 2017. 12 (1)(1): p. 31-38., https://pubmed.ncbi.nlm.nih.gov/27607596/
1243. Engsig, FN, Kronborg, G, Larsen, CS, Pedersen, G, Pedersen, C, Gerstoft, J, et.al. Lung cancer in HIV patients and their parents: a Danish cohort study., BMC Cancer, 2011. 11 (): p. 272., https://pubmed.ncbi.nlm.nih.gov/21702995/
1244. Reddy, KP, Kong, CY, Hyle, EP, Baggett, TP, Huang, M, Parker, RA, et.al. Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States., JAMA Intern Med, 2017. 177 (11)(11): p. 1613-1621., https://pubmed.ncbi.nlm.nih.gov/28975270/
1245. Gonzalez-Cao, M, Morán, T, Dalmau, J, Garcia-Corbacho, J, Bracht, JWP, Bernabe, R, et.al. Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study., JAMA Oncol, 2020. 6 (7)(7): p. 1063-1067., https://pubmed.ncbi.nlm.nih.gov/32271353/
1246. Barlesi, F., Audigier-Valette, C., Felip, E., Ciuleanu, T., Jao, K., Rijavec, E., et.al. OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC, Journal of Thoracic Oncology, 2019. 14(10): p. S214-S215., https://doi.org/10.1016/j.jtho.2019.08.424
1247. Uldrick, TS, Gonçalves, PH, Abdul-Hay, M, Claeys, AJ, Emu, B, Ernstoff, MS, et.al. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study., JAMA Oncol, 2019. 5 (9)(9): p. 1332-1339., https://pubmed.ncbi.nlm.nih.gov/31154457/
1248. Guihot, A, Marcelin, AG, Massiani, MA, Samri, A, Soulié, C, Autran, B, et.al. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer., Ann Oncol, 2018. 29 (2)(2): p. 517-518., https://pubmed.ncbi.nlm.nih.gov/29206889/
1249. Owonikoko, TK, Ragin, CC, Belani, CP, Oton, AB, Gooding, WE, Taioli, E, et.al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database., J Clin Oncol, 2007. 25 (35)(35): p. 5570-7., https://pubmed.ncbi.nlm.nih.gov/18065729/
1250. Lee, CK, Man, J, Lord, S, Cooper, W, Links, M, Gebski, V, et.al. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis., JAMA Oncol, 2018. 4 (2)(2): p. 210-216., https://pubmed.ncbi.nlm.nih.gov/29270615/
1251. Onishi, H., Kuriyama, K., Komiyama, T., Tanaka, S., Sano, N., Marino, K., et.al. Clinical outcomes of stereotactic radiotherapy for stage I non-small cell lung cancer using a novel irradiation technique: patient self-controlled breath-hold and beam switching using a combination of linear accelerator and CT scanner, Lung Cancer, 2004. 45(1): p. 45-55., https://www.ncbi.nlm.nih.gov/pubmed/15196734
1252. Uematsu, M., Shioda, A., Suda, A., Fukui, T., Ozeki, Y., Hama, Y., et.al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience, Int.J.Radiat.Oncol Biol.Phys., 2001. 51(3): p. 666-670., https://www.ncbi.nlm.nih.gov/pubmed/15196734
1253. Rossi, A., Chiodini, P., Sun, J. M., O'Brien, M. E., von Plessen, C., Barata, F., et.al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data, Lancet Oncol, 2014. 15(11): p. 1254-62., https://www.ncbi.nlm.nih.gov/pubmed/25232001
1254. Perol, M., Chouaid, C., Perol, D., Barlesi, F., Gervais, R., Westeel, V., et.al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer, J Clin Oncol, 2012. 30(28): p. 3516-24., https://pubmed.ncbi.nlm.nih.gov/22949150/
1255. Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczesna, A., Juhasz, E., et.al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study, Lancet Oncol, 2010. 11(6): p. 521-9., https://pubmed.ncbi.nlm.nih.gov/20493771/
1256. Brugger, W., Triller, N., Blasinska-Morawiec, M., Curescu, S., Sakalauskas, R., Manikhas, G. M., et.al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer, J Clin Oncol, 2011. 29(31): p. 4113-20., https://www.ncbi.nlm.nih.gov/pubmed/21969500
1257. Wada, H., Hitomi, S., Teramatsu, T., Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery, J.Clin.Oncol., 1996. 14(4): p. 1048-1054., https://www.ncbi.nlm.nih.gov/pubmed/8648356
1258. Imaizumi, M., Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer, Lung Cancer, 2005. 49(1): p. 85-94., https://www.ncbi.nlm.nih.gov/pubmed/15949594
1259. Vasconcellos, VF, Marta, GN, da Silva, EM, Gois, AF, de Castria, TB, Riera, R, Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer., Cochrane Database Syst Rev, 2020. 1 (): p. CD009256., https://pubmed.ncbi.nlm.nih.gov/31930743/
1260. Cui, J., Cai, X., Zhu, M., Liu, T., Zhao, N., The efficacy of bevacizumab compared with other targeted drugs for patients with advanced NSCLC: a meta-analysis from 30 randomized controlled clinical trials, PLoS One, 2013. 8(4): p. e62038., https://www.ncbi.nlm.nih.gov/pubmed/23614008
1261. Thatcher, N., Hirsch, F. R., Luft, A. V., Szczesna, A., Ciuleanu, T. E., Dediu, M., et.al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial, Lancet Oncol, 2015. 16(7): p. 763-74., https://www.ncbi.nlm.nih.gov/pubmed/26045340
1262. Reck, M., Socinski, M. A., Luft, A., Szczesna, A., Dediu, M., Ramlau, R., et.al. The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial, J Thorac Oncol, 2016. 11(6): p. 808-18., https://www.ncbi.nlm.nih.gov/pubmed/26980471
1263. Bordoni, R, Ciardiello, F, von Pawel, J, Cortinovis, D, Karagiannis, T, Ballinger, M, et.al. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer., Clin Lung Cancer, 2018. 19 (5)(5): p. 441-449.e4., https://pubmed.ncbi.nlm.nih.gov/30017645/
1264. Reck, M, Brahmer, J, Bennett, B, Taylor, F, Penrod, JR, DeRosa, M, et.al. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057., Eur J Cancer, 2018. 102 (): p. 23-30., https://pubmed.ncbi.nlm.nih.gov/30103096/
1265. Barlesi, F, Garon, EB, Kim, DW, Felip, E, Han, JY, Kim, JH, et.al. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC., J Thorac Oncol, 2019. 14 (5)(5): p. 793-801., https://pubmed.ncbi.nlm.nih.gov/30711649/
1266. Zinner, R. G., Obasaju, C. K., Spigel, D. R., Weaver, R. W., Beck, J. T., Waterhouse, D. M., et.al. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer, J Thorac Oncol, 2015. 10(1): p. 134-42., https://www.ncbi.nlm.nih.gov/pubmed/25371077
1267. Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J. Y., Orlov, S., Krzakowski, M., et.al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial, Lancet Oncol, 2014. 15(2): p. 143-55., https://www.ncbi.nlm.nih.gov/pubmed/24411639
1268. Pirker, R., Pereira, J. R., Szczesna, A., et al., Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (FLEX): an open-label randomised phase III trial, Lancet, 2009. 373: p. 1525-1531., https://www.ncbi.nlm.nih.gov/pubmed/19410716
1269. Lee, CK, Man, J, Lord, S, Cooper, W, Links, M, Gebski, V, et.al. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis., JAMA Oncol, 2018. 4 (2)(2): p. 210-216., https://pubmed.ncbi.nlm.nih.gov/29270615/
1270. Spigel, DR, McCleod, M, Jotte, RM, Einhorn, L, Horn, L, Waterhouse, DM, et.al. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)., J Thorac Oncol, 2019. 14 (9)(9): p. 1628-1639., https://pubmed.ncbi.nlm.nih.gov/31121324/
1271. Lee, SM, Schulz, C, Prabhash, K, Kowalski, D, Szczesna, A, Han, B, et.al. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study., Lancet, 2023. 402 (10400)(10400): p. 451-463., https://pubmed.ncbi.nlm.nih.gov/37423228/
1272. Alessi, JV, Ricciuti, B, Jiménez-Aguilar, E, Hong, F, Wei, Z, Nishino, M, et.al. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status., J Immunother Cancer, 2020. 8 (2)(2):, https://pubmed.ncbi.nlm.nih.gov/32753547/
1273. Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Jr., Brahmer, J. R., et.al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, 2015. 33(30): p. 3488-515., https://www.ncbi.nlm.nih.gov/pubmed/26324367
1274. Quoix, E., Zalcman, G., Oster, J. P., Westeel, V., Pichon, E., Lavole, A., et.al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial, Lancet, 2011. 378(9796): p. 1079-88., https://www.ncbi.nlm.nih.gov/pubmed/21831418
1275. Le Chevalier, T., Brisgand, D., Soria, J. C., Douillard, J. Y., Pujol, J. L., Ruffie, P., et.al. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer, Oncologist, 2001. 6 Suppl 1: p. 8-11., https://www.ncbi.nlm.nih.gov/pubmed/11181998
1276. Billingham, L. J., Cullen, M. H., The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer, Ann Oncol, 2001. 12(12): p. 1671-5., https://www.ncbi.nlm.nih.gov/pubmed/11843243
1277. Sweeney, C. J., Zhu, J., Sandler, A. B., Schiller, J., Belani, C. P., Langer, C., et.al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma, Cancer, 2001. 92(10): p. 2639-47., https://www.ncbi.nlm.nih.gov/pubmed/11745199
1278. Lilenbaum, R. C., Herndon, J. E., 2nd, List, M. A., Desch, C., Watson, D. M., Miller, A. A., et.al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730), J Clin Oncol, 2005. 23(1): p. 190-6., https://www.ncbi.nlm.nih.gov/pubmed/15625373
1279. Langer, C., Li, S., Schiller, J., Tester, W., Rapoport, B. L., Johnson, D. H., et.al. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599, J Clin Oncol, 2007. 25(4): p. 418-23., https://www.ncbi.nlm.nih.gov/pubmed/17264337
1280. Kosmidis, P. A., Dimopoulos, M. A., Syrigos, K., Nicolaides, C., Aravantinos, G., Boukovinas, I., et.al. Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group, J Thorac Oncol, 2007. 2(2): p. 135-40., https://www.ncbi.nlm.nih.gov/pubmed/17410029
1281. Goss, G., Ferry, D., Wierzbicki, R., Laurie, S. A., Thompson, J., Biesma, B., et.al. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status, J Clin Oncol, 2009. 27(13): p. 2253-60., https://www.ncbi.nlm.nih.gov/pubmed/19289623
1282. Reynolds, C., Obasaju, C., Schell, M. J., Li, X., Zheng, Z., Boulware, D., et.al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer, J Clin Oncol, 2009. 27(34): p. 5808-15., https://www.ncbi.nlm.nih.gov/pubmed/19884554
1283. Langer, C. J., O'Byrne, K. J., Socinski, M. A., Mikhailov, S. M., Lesniewski-Kmak, K., Smakal, M., et.al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer, J Thorac Oncol, 2008. 3(6): p. 623-30., https://www.ncbi.nlm.nih.gov/pubmed/18520802
1284. Zukin, M., Barrios, C. H., Pereira, J. R., Ribeiro Rde, A., Beato, C. A., do Nascimento, Y. N., et.al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2, J Clin Oncol, 2013. 31(23): p. 2849-53., https://www.ncbi.nlm.nih.gov/pubmed/23775961
1285. Lee, S. M., Khan, I., Upadhyay, S., Lewanski, C., Falk, S., Skailes, G., et.al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 2012. 13(11): p. 1161-70., https://www.ncbi.nlm.nih.gov/pubmed/23078958
1286. Morabito, A., Gebbia, V., Di Maio, M., Cinieri, S., Vigano, M. G., Bianco, R., et.al. Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study, Lung Cancer, 2013. 81(1): p. 77-83., https://www.ncbi.nlm.nih.gov/pubmed/23643177
1287. Morth, C., Valachis, A., Single-agent versus combination chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer and performance status 2: a literature-based meta-analysis of randomized studies, Lung Cancer, 2014. 84(3): p. 209-14., https://www.ncbi.nlm.nih.gov/pubmed/24702946
1288. Charlson, M. E., Pompei, P., Ales, K. L., MacKenzie, C. R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic.Dis., 1987. 40(5): p. 373-383., https://www.ncbi.nlm.nih.gov/pubmed/3558716
1289. Barlesi, F., Scherpereel, A., Rittmeyer, A., Pazzola, A., Ferrer Tur, N., Kim, J. H., et.al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089), J Clin Oncol, 2013. 31(24): p. 3004-11., https://pubmed.ncbi.nlm.nih.gov/23835708/
1290. Schuette, W., Schirmacher, P., Eberhardt, W. E., Fischer, J. R., von der Schulenburg, J. M., Mezger, J., et.al. EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study, Cancer Epidemiol Biomarkers Prev, 2015. 24(8): p. 1254-61., https://www.ncbi.nlm.nih.gov/pubmed/26070531
1291. A genomics-based classification of human lung tumors, Sci Transl Med, 2013. 5(209): p. 209ra153., https://www.ncbi.nlm.nih.gov/pubmed/24174329
1292. Fukuoka, M., Wu, Y. L., Thongprasert, S., Sunpaweravong, P., Leong, S. S., Sriuranpong, V., et.al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS), J Clin Oncol, 2011. 29(21): p. 2866-74., https://www.ncbi.nlm.nih.gov/pubmed/21670455
1293. Han, J. Y., Park, K., Kim, S. W., Lee, D. H., Kim, H. Y., Kim, H. T., et.al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung, J Clin Oncol, 2012. 30(10): p. 1122-8., https://www.ncbi.nlm.nih.gov/pubmed/22370314
1294. Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., et.al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 2010. 362(25): p. 2380-8., https://www.ncbi.nlm.nih.gov/pubmed/20573926
1295. Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., et.al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol, 2010. 11(2): p. 121-8., https://pubmed.ncbi.nlm.nih.gov/20022809/
1296. Mok, T., Wu, Y. L., Thongprasert, S., et al., Gefitinib or Carboplatin-Paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 2009. 361: p. 947-957., https://www.ncbi.nlm.nih.gov/pubmed/19692680
1297. Park, K., Tan, E. H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., et.al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial, Lancet Oncol, 2016. 17(5): p. 577-89., https://www.ncbi.nlm.nih.gov/pubmed/27083334
1298. Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., et.al. Screening for epidermal growth factor receptor mutations in lung cancer, N Engl J Med, 2009. 361(10): p. 958-67., https://www.ncbi.nlm.nih.gov/pubmed/19692684
1299. Sequist, L. V., Yang, J. C., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., et.al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, J Clin Oncol, 2013. 31(27): p. 3327-34., https://www.ncbi.nlm.nih.gov/pubmed/23816960
1300. Yang, J. C., Hirsh, V., Schuler, M., Yamamoto, N., O'Byrne, K. J., Mok, T. S., et.al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations, J Clin Oncol, 2013. 31(27): p. 3342-50., https://www.ncbi.nlm.nih.gov/pubmed/23816967
1301. Yang, J. C., Wu, Y. L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., et.al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials, Lancet Oncol, 2015. 16(2): p. 141-51., https://www.ncbi.nlm.nih.gov/pubmed/25589191
1302. Zhou, C., Wu, Y. L., Chen, G., Feng, J., Liu, X. Q., Wang, C., et.al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 2011. 12(8): p. 735-42., https://www.ncbi.nlm.nih.gov/pubmed/21783417
1303. Yang, J. C., Sequist, L. V., Geater, S. L., Tsai, C. M., Mok, T. S., Schuler, M., et.al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6, Lancet Oncol, 2015. 16(7): p. 830-8., https://www.ncbi.nlm.nih.gov/pubmed/26051236
1304. Greenhalgh, J., Boland, A., Bates, V., Vecchio, F., Dundar, Y., Chaplin, M., et.al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer, Cochrane Database Syst Rev, 2021. 3(3): p. Cd010383., https://pubmed.ncbi.nlm.nih.gov/33734432/
1305. Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., et.al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC, N Engl J Med, 2020. 382(1): p. 41-50., https://pubmed.ncbi.nlm.nih.gov/31751012/
1306. Planchard, D, Jänne, PA, Cheng, Y, Yang, JC, Yanagitani, N, Kim, SW, et.al. Osimertinib with or without Chemotherapy in , N Engl J Med, 2023. 389 (21)(21): p. 1935-1948., https://pubmed.ncbi.nlm.nih.gov/37937763/
1307. Jänne, PA, Planchard, D, Kobayashi, K, Cheng, Y, Lee, CK, Valdiviezo, N, et.al. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer., J Clin Oncol, 2024. 42 (7)(7): p. 808-820., https://pubmed.ncbi.nlm.nih.gov/38042525/
1308. Cho, BC, Felip, E, Hayashi, H, Thomas, M, Lu, S, Besse, B, et.al. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer., Future Oncol, 2022. 18 (6)(6): p. 639-647., https://pubmed.ncbi.nlm.nih.gov/34911336/
1309. Jänne Pasi A., Planchard David, Kobayashi Kunihiko, Yang James Chih-Hsin, Liu Ying, Valdiviezo Natalia, et.al. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLCMassachusetts Medical Society, New England Journal of Medicine, 2025. 394(1): p. 27 - 38., https://doi.org/10.1056/NEJMoa2510308
1310. Cho, JH, Lim, SH, An, HJ, Kim, KH, Park, KU, Kang, EJ, et.al. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)., J Clin Oncol, 2020. 38 (5)(5): p. 488-495., https://pubmed.ncbi.nlm.nih.gov/31825714/
1311. Kobayashi, Y, Mitsudomi, T, Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy., Cancer Sci, 2016. 107 (9)(9): p. 1179-86., https://pubmed.ncbi.nlm.nih.gov/27323238/
1312. Mok, Tony S., Wu, Yi-Long, Ahn, Myung-Ju, Garassino, Marina C., Kim, Hye R., Ramalingam, Suresh S., et.al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer, New England Journal of Medicine, 2017. 376(7): p. 629-640., https://pubmed.ncbi.nlm.nih.gov/27959700/
1313. Park, K, Haura, EB, Leighl, NB, Mitchell, P, Shu, CA, Girard, N, et.al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study., J Clin Oncol, 2021. 39 (30)(30): p. 3391-3402., https://pubmed.ncbi.nlm.nih.gov/34339292/
1314. Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., et.al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 2009. 361(10): p. 947-57., https://www.ncbi.nlm.nih.gov/pubmed/19692680
1315. Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., et.al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol, 2010. 11(2): p. 121-8., https://pubmed.ncbi.nlm.nih.gov/20022809/
1316. Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., et.al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 2012. 13(3): p. 239-46., https://www.ncbi.nlm.nih.gov/pubmed/22285168
1317. Wu, Y. L., Zhou, C., Hu, C. P., Feng, J., Lu, S., Huang, Y., et.al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial, Lancet Oncol, 2014. 15(2): p. 213-22., https://www.ncbi.nlm.nih.gov/pubmed/24439929
1318. Janne, P. A., Yang, J. C., Kim, D. W., Planchard, D., Ohe, Y., Ramalingam, S. S., et.al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer, N Engl J Med, 2015. 372(18): p. 1689-99., https://www.ncbi.nlm.nih.gov/pubmed/25923549
1319. Paz-Ares, L., Tan, E. H., O'Byrne, K., Zhang, L., Hirsh, V., Boyer, M., et.al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial, Ann Oncol, 2017. 28(2): p. 270-277., https://www.ncbi.nlm.nih.gov/pubmed/28426106
1320. Mok, TS, Cheng, Y, Zhou, X, Lee, KH, Nakagawa, K, Niho, S, et.al. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations., Drugs, 2021. 81 (2)(2): p. 257-266., https://pubmed.ncbi.nlm.nih.gov/33331989/
1321. Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., et.al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer, N Engl J Med, 2018. 378(2): p. 113-125., https://pubmed.ncbi.nlm.nih.gov/29151359/
1322. Gadgeel, S., Cho, B.C., Lu, S., Felip, E., Hayashi, H., Spira, A.I., et.al. OA02.03 Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA StudyElsevier, Journal of Thoracic Oncology, 2024. 19(10): p. S10 - S11., https://doi.org/10.1016/j.jtho.2024.09.026
1323. Nguyen, D., Besse, B., Cho, B.C., Lee, S.-H., Lee, K.H., Lu, S., et.al. MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSAElsevier, Journal of Thoracic Oncology, 2024. 19(10): p. S103 - S104., https://doi.org/10.1016/j.jtho.2024.09.187
1324. Passaro, A, Wang, J, Wang, Y, Lee, SH, Melosky, B, Shih, JY, et.al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study., Ann Oncol, 2024. 35 (1)(1): p. 77-90., https://pubmed.ncbi.nlm.nih.gov/37879444/
1325. Hosomi, Yukio, Morita, Satoshi, Sugawara, Shunichi, Kato, Terufumi, Fukuhara, Tatsuro, Gemma, Akihiko, et.al. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study, Journal of Clinical Oncology, 2020. 38(2): p. 115-123., https://ascopubs.org/doi/abs/10.1200/JCO.19.01488
1326. Noronha, V, Patil, VM, Joshi, A, Menon, N, Chougule, A, Mahajan, A, et.al. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in , J Clin Oncol, 2020. 38 (2)(2): p. 124-136., https://pubmed.ncbi.nlm.nih.gov/31411950/
1327. Rosell, Rafael, Moran, Teresa, Queralt, Cristina, Porta, Rut, Cardenal, Felipe, Camps, Carlos, et.al. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer, New England Journal of Medicine, 2009. 361(10): p. 958-967., https://doi.org/10.1056/NEJMoa0904554
1328. Yang, JC, Schuler, M, Popat, S, Miura, S, Heeke, S, Park, K, et.al. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases., J Thorac Oncol, 2020. 15 (5)(5): p. 803-815., https://pubmed.ncbi.nlm.nih.gov/31931137/
1329. Cho, JH, Lim, SH, An, HJ, Kim, KH, Park, KU, Kang, EJ, et.al. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)., J Clin Oncol, 2020. 38 (5)(5): p. 488-495., https://pubmed.ncbi.nlm.nih.gov/31825714/
1330. Vyse, Simon, Huang, Paul H., Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer, Signal Transduction and Targeted Therapy, 2019. 4(1): p. 5., https://doi.org/10.1038/s41392-019-0038-9
1331. Piotrowska, Zofia, Wang, Yating, Sequist, Lecia V., Ramalingam, Suresh S., ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions, Journal of Clinical Oncology, 2020. 38(15_suppl): p. 9513-9513., https://doi.org/10.1200/JCO.2020.38.15_suppl.9513
1332. Zhou, C, Tang, KJ, Cho, BC, Liu, B, Paz-Ares, L, Cheng, S, et.al. Amivantamab plus Chemotherapy in NSCLC with , N Engl J Med, 2023. 389 (22)(22): p. 2039-2051., https://pubmed.ncbi.nlm.nih.gov/37870976/
1333. Paz-Ares, L., Veillon, R., Majem, M., Zhou, C., Tang, K-J., Kim, S-W., et.al. 7P Patient-relevant endpoints from PAPILLON: Amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated (Ex20ins) advanced NSCLCElsevier, ESMO Open, 2024. 9:, https://doi.org/10.1016/j.esmoop.2024.102586
1334. Seto, T., Kato, T., Nishio, M., Goto, K., Atagi, S., Hosomi, Y., et.al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study, Lancet Oncol, 2014. 15(11): p. 1236-44., https://www.ncbi.nlm.nih.gov/pubmed/25175099
1335. Zhang, Z., Luo, F., Zhang, Y., Ma, Y., Hong, S., Yang, Y., et.al. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706), Cancer Commun (Lond), 2019. 39(1): p. 69., https://pubmed.ncbi.nlm.nih.gov/31699150/
1336. Akamatsu, H, Toi, Y, Hayashi, H, Fujimoto, D, Tachihara, M, Furuya, N, et.al. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial., JAMA Oncol, 2021. 7 (3)(3): p. 386-394., https://pubmed.ncbi.nlm.nih.gov/33410885/
1337. Mok, Tony S., Wu, Yi-Long, Ahn, Myung-Ju, Garassino, Marina C., Kim, Hye R., Ramalingam, Suresh S., et.al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer, New England Journal of Medicine, 2017. 376(7): p. 629-640., https://pubmed.ncbi.nlm.nih.gov/27959700/
1338. Popat, S., Reckamp, K.L., Califano, R., Lee, S-H., Melosky, B., Wang, J., et.al. LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2Elsevier, Annals of Oncology, 2024. 35: p. S1244 - S1245., https://doi.org/10.1016/j.annonc.2024.08.2296
1339. Papadimitrakopoulou, V., Wu, Y-L., Han, J-Y., Ahn, M., Ramalingam, S., John, T., et.al. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study, Annals of oncology : official journal of the European Society for Medical Oncology, 2018. 29 Suppl 8: p. viii741.
1340. Ramalingam, S., Cheng, Y., Zhou, C., Ohe, Y., Imamura, F., Cho, B., et.al. Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study, Annals of oncology : official journal of the European Society for Medical Oncology, 2018. 29 Suppl 8: p. viii740., https://www.researchgate.net/publication/328503661_LBA50Mechanisms_of_acquired_resistance_to_first-line_osimertinib_Preliminary_data_from_the_phase_III_FLAURA_study
1341. Oxnard, GR, Thress, KS, Alden, RS, Lawrance, R, Paweletz, CP, Cantarini, M, et.al. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer., J Clin Oncol, 2016. 34 (28)(28): p. 3375-82., https://pubmed.ncbi.nlm.nih.gov/27354477/
1342. Passiglia, F, Rizzo, S, Di Maio, M, Galvano, A, Badalamenti, G, Listì, A, et.al. Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis., Sci Rep, 2018. 8 (1)(1): p. 17270., https://pubmed.ncbi.nlm.nih.gov/30451938/
1343. Mok, Tony S., Wu, Yi-Long, Ahn, Myung-Ju, Garassino, Marina C., Kim, Hye R., Ramalingam, Suresh S., et.al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer, New England Journal of Medicine, 2017. 376(7): p. 629-640., https://pubmed.ncbi.nlm.nih.gov/27959700/
1344. Schmid, S., Klingbiel, D., Aeppli, S., Britschgi, C., Gautschi, O., Pless, M., et.al. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study, Lung Cancer, 2019. 130: p. 149-155., https://pubmed.ncbi.nlm.nih.gov/30885336/
1345. Weickhardt, A. J., Scheier, B., Burke, J. M., Gan, G., Lu, X., Bunn, P. A., Jr., et.al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer, J Thorac Oncol, 2012. 7(12): p. 1807-14., https://www.ncbi.nlm.nih.gov/pubmed/23154552
1346. Xu, Q, Liu, H, Meng, S, Jiang, T, Li, X, Liang, S, et.al. First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease., J Cancer, 2019. 10 (2)(2): p. 522-529., https://pubmed.ncbi.nlm.nih.gov/30719148/
1347. Yu, HA, Sima, CS, Huang, J, Solomon, SB, Rimner, A, Paik, P, et.al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors., J Thorac Oncol, 2013. 8 (3)(3): p. 346-51., https://pubmed.ncbi.nlm.nih.gov/23407558/
1348. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., et.al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, 2015. 373(17): p. 1627-39., https://www.ncbi.nlm.nih.gov/pubmed/26412456
1349. Lee, CK, Man, J, Lord, S, Links, M, Gebski, V, Mok, T, et.al. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis., J Thorac Oncol, 2017. 12 (2)(2): p. 403-407., https://pubmed.ncbi.nlm.nih.gov/27765535/
1350. Socinski, Mark A., Jotte, Robert M., Cappuzzo, Federico, Orlandi, Francisco, Stroyakovskiy, Daniil, Nogami, Naoyuki, et.al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, New England Journal of Medicine, 2018. 378(24): p. 2288-2301., https://doi.org/10.1056/NEJMoa1716948
1351. Marcoux, N, Gettinger, SN, O'Kane, G, Arbour, KC, Neal, JW, Husain, H, et.al. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes., J Clin Oncol, 2019. 37 (4)(4): p. 278-285., https://pubmed.ncbi.nlm.nih.gov/30550363/
1352. Solomon, B. J., Mok, T., Kim, D. W., Wu, Y. L., Nakagawa, K., Mekhail, T., et.al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, 2014. 371(23): p. 2167-77., https://www.ncbi.nlm.nih.gov/pubmed/25470694
1353. Soria, Jean-Charles, Tan, Daniel S. W., Chiari, Rita, Wu, Yi-Long, Paz-Ares, Luis, Wolf, Juergen, et.al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, The Lancet, 2017. 389(10072): p. 917-929., https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(17)30123-X.pdf
1354. Kron, A, Alidousty, C, Scheffler, M, Merkelbach-Bruse, S, Seidel, D, Riedel, R, et.al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer., Ann Oncol, 2018. 29 (10)(10): p. 2068-2075., https://pubmed.ncbi.nlm.nih.gov/30165392/
1355. Mok, T, Camidge, DR, Gadgeel, SM, Rosell, R, Dziadziuszko, R, Kim, DW, et.al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study., Ann Oncol, 2020. 31 (8)(8): p. 1056-1064., https://pubmed.ncbi.nlm.nih.gov/32418886/
1356. Cho, B. C., Kim, D. W., Bearz, A., Laurie, S. A., McKeage, M., Borra, G., et.al. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC), J Thorac Oncol, 2017. 12(9): p. 1357-1367., https://www.ncbi.nlm.nih.gov/pubmed/28729021
1357. Peters, Solange, Camidge, D. Ross, Shaw, Alice T., Gadgeel, Shirish, Ahn, Jin S., Kim, Dong-Wan, et.al. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer, New England Journal of Medicine, 2017. 377(9): p. 829-838., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296421/
1358. Camidge, DR, Kim, HR, Ahn, MJ, Yang, JCH, Han, JY, Hochmair, MJ, et.al. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial., J Thorac Oncol, 2021. 16 (12)(12): p. 2091-2108., https://pubmed.ncbi.nlm.nih.gov/34537440/
1359. Camidge, DR, Kim, HR, Ahn, MJ, Yang, JCH, Han, JY, Hochmair, MJ, et.al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial., J Clin Oncol, 2020. 38 (31)(31): p. 3592-3603., https://pubmed.ncbi.nlm.nih.gov/32780660/
1360. Camidge, DR, Kim, HR, Ahn, MJ, Yang, JC, Han, JY, Lee, JS, et.al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer., N Engl J Med, 2018. 379 (21)(21): p. 2027-2039., https://pubmed.ncbi.nlm.nih.gov/30280657/
1361. Gettinger, SN, Huber, RM, Kim, DW, Bazhenova, L, Hansen, KH, Tiseo, M, et.al. Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory , JTO Clin Res Rep, 2022. 3 (9)(9): p. 100385., https://pubmed.ncbi.nlm.nih.gov/36065449/
1362. Ignatius Ou, SH, Nishio, M, Ahn, MJ, Mok, T, Barlesi, F, Zhou, C, et.al. Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study., J Thorac Oncol, 2022. ():, https://pubmed.ncbi.nlm.nih.gov/36096442/
1363. Shaw, AT, Bauer, TM, de Marinis, F, Felip, E, Goto, Y, Liu, G, et.al. First-Line Lorlatinib or Crizotinib in Advanced , N Engl J Med, 2020. 383 (21)(21): p. 2018-2029., https://pubmed.ncbi.nlm.nih.gov/33207094/
1364. Solomon, BJ, Bauer, TM, Mok, TSK, Liu, G, Mazieres, J, de Marinis, F, et.al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study., Lancet Respir Med, 2023. 11 (4)(4): p. 354-366., https://pubmed.ncbi.nlm.nih.gov/36535300/
1365. Solomon, BJ, Liu, G, Felip, E, Mok, TSK, Soo, RA, Mazieres, J, et.al. Lorlatinib Versus Crizotinib in Patients With Advanced , J Clin Oncol, 2024. 42 (29)(29): p. 3400-3409., https://pubmed.ncbi.nlm.nih.gov/38819031/
1366. Mok, T, Camidge, DR, Gadgeel, SM, Rosell, R, Dziadziuszko, R, Kim, DW, et.al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study., Ann Oncol, 2020. 31 (8)(8): p. 1056-1064., https://pubmed.ncbi.nlm.nih.gov/32418886/
1367. Shaw, A. T., Kim, D. W., Nakagawa, K., Seto, T., Crino, L., Ahn, M. J., et.al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, 2013. 368(25): p. 2385-94., https://www.ncbi.nlm.nih.gov/pubmed/23724913
1368. Camidge, DR, Kim, HR, Ahn, MJ, Yang, JCH, Han, JY, Hochmair, MJ, et.al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial., J Clin Oncol, 2020. 38 (31)(31): p. 3592-3603., https://pubmed.ncbi.nlm.nih.gov/32780660/
1369. Shaw, A. T., Kim, D. W., Mehra, R., Tan, D. S., Felip, E., Chow, L. Q., et.al. Ceritinib in ALK-rearranged non-small-cell lung cancer, N Engl J Med, 2014. 370(13): p. 1189-97., https://www.ncbi.nlm.nih.gov/pubmed/24670165
1370. Gainor, JF, Dardaei, L, Yoda, S, Friboulet, L, Leshchiner, I, Katayama, R, et.al. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer., Cancer Discov, 2016. 6 (10)(10): p. 1118-1133., https://pubmed.ncbi.nlm.nih.gov/27432227/
1371. Ou, SH, Ahn, JS, De Petris, L, Govindan, R, Yang, JC, Hughes, B, et.al. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study., J Clin Oncol, 2016. 34 (7)(7): p. 661-8., https://pubmed.ncbi.nlm.nih.gov/26598747/
1372. Shaw, Alice T., Gandhi, Leena, Gadgeel, Shirish, Riely, Gregory J., Cetnar, Jeremy, West, Howard, et.al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial, The Lancet. Oncology, 2016. 17(2): p. 234-242., https://pubmed.ncbi.nlm.nih.gov/26708155, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752892/
1373. Gadgeel, Shirish M., Shaw, Alice T., Govindan, Ramaswamy, Gandhi, Leena, Socinski, Mark A., Camidge, D. Ross, et.al. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer, Journal of Clinical Oncology, 2016. 34(34): p. 4079-4085., https://doi.org/10.1200/JCO.2016.68.4639
1374. Kim, Dong-Wan, Tiseo, Marcello, Ahn, Myung-Ju, Reckamp, Karen L., Hansen, Karin Holmskov, Kim, Sang-We, et.al. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial, Journal of Clinical Oncology, 2017. 35(22): p. 2490-2498., https://doi.org/10.1200/JCO.2016.71.5904
1375. Gettinger, S. N., Bazhenova, L. A., Langer, C. J., Salgia, R., Gold, K. A., Rosell, R., et.al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial, Lancet Oncol, 2016. 17(12): p. 1683-1696., https://www.ncbi.nlm.nih.gov/pubmed/27836716
1376. Shaw, A. T., Kim, T. M., Crino, L., Gridelli, C., Kiura, K., Liu, G., et.al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, 2017. 18(7): p. 874-886., https://www.ncbi.nlm.nih.gov/pubmed/28602779
1377. Kim, D. W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., et.al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial, Lancet Oncol, 2016. 17(4): p. 452-463., https://pubmed.ncbi.nlm.nih.gov/26973324/
1378. Shaw, A. T., Solomon, B. J., Besse, B., Bauer, T. M., Lin, C. C., Soo, R. A., et.al. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer, J Clin Oncol, 2019. 37(16): p. 1370-1379., https://pubmed.ncbi.nlm.nih.gov/30892989/
1379. Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., et.al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study, Lancet Oncol, 2018. 19(12): p. 1654-1667., https://pubmed.ncbi.nlm.nih.gov/30413378/
1380. Kim, ES, Barlesi, F, Mok, T, Ahn, MJ, Shen, J, Zhang, P, et.al. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib., Future Oncol, 2021. 17 (14)(14): p. 1709-1719., https://pubmed.ncbi.nlm.nih.gov/33569983/
1381. Lin, M. M., Pan, X., Hou, P., Allen, S., Baumann, P., Hochmair, M. J., Treatment duration of brigatinib in patients enrolled in the international expanded access program (EAP), Annals of Oncology, 2019. 30: p. ii48., https://doi.org/10.1093/annonc/mdz063.006
1382. Gan, G. N., Weickhardt, A. J., Scheier, B., Doebele, R. C., Gaspar, L. E., Kavanagh, B. D., et.al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib, Int J Radiat Oncol Biol Phys, 2014. 88(4): p. 892-8., https://pubmed.ncbi.nlm.nih.gov/24462383/
1383. Shaw, A. T., Ou, S. H., Bang, Y. J., Camidge, D. R., Solomon, B. J., Salgia, R., et.al. Crizotinib in ROS1-rearranged non-small-cell lung cancer, N Engl J Med, 2014. 371(21): p. 1963-71., https://www.ncbi.nlm.nih.gov/pubmed/25264305
1384. Drilon, A., Siena, S., Dziadziuszko, R., Barlesi, F., Krebs, M. G., Shaw, A. T., et.al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials, 2020., https://pubmed.ncbi.nlm.nih.gov/31838015/
1385. Wu, YL, Yang, JC, Kim, DW, Lu, S, Zhou, J, Seto, T, et.al. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer., J Clin Oncol, 2018. 36 (14)(14): p. 1405-1411., https://pubmed.ncbi.nlm.nih.gov/29596029/
1386. Mazieres, J., Zalcman, G., Crino, L., Biondani, P., Barlesi, F., Filleron, T., et.al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort, J Clin Oncol, 2015. 33(9): p. 992-9., https://www.ncbi.nlm.nih.gov/pubmed/25667280
1387. Michels, S, Massutí, B, Schildhaus, HU, Franklin, J, Sebastian, M, Felip, E, et.al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial., J Thorac Oncol, 2019. 14 (7)(7): p. 1266-1276., https://pubmed.ncbi.nlm.nih.gov/30978502/
1388. Landi, L, Chiari, R, Tiseo, M, D'Incà, F, Dazzi, C, Chella, A, et.al. Crizotinib in , Clin Cancer Res, 2019. 25 (24)(24): p. 7312-7319., https://pubmed.ncbi.nlm.nih.gov/31416808/
1389. Drilon, A, Camidge, DR, Lin, JJ, Kim, SW, Solomon, BJ, Dziadziuszko, R, et.al. Repotrectinib in , N Engl J Med, 2024. 390 (2)(2): p. 118-131., https://pubmed.ncbi.nlm.nih.gov/38197815/
1390. Shaw, AT, Riely, GJ, Bang, YJ, Kim, DW, Camidge, DR, Solomon, BJ, et.al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001., Ann Oncol, 2019. 30 (7)(7): p. 1121-1126., https://pubmed.ncbi.nlm.nih.gov/30980071/
1391. Michels, S, Massutí, B, Vasyliv, I, Stratmann, J, Frank, J, Adams, A, et.al. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial., ESMO Open, 2024. 9 (2)(2): p. 102237., https://pubmed.ncbi.nlm.nih.gov/38350336/
1392. Drilon, A, Camidge, DR, Lin, JJ, Kim, SW, Solomon, BJ, Dziadziuszko, R, et.al. Repotrectinib in , N Engl J Med, 2024. 390 (2)(2): p. 118-131., https://pubmed.ncbi.nlm.nih.gov/38197815/
1393. Gainor, J. F., Tseng, D., Yoda, S., Dagogo-Jack, I., Friboulet, L., Lin, J. J., et.al. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer, JCO Precis Oncol, 2017. 2017:, https://pubmed.ncbi.nlm.nih.gov/29333528/
1394. Cho, Byoung Chul, Drilon, Alexander E., Doebele, Robert Charles, Kim, Dong-Wan, Lin, Jessica Jiyeong, Lee, Jeeyun, et.al. Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study), Journal of Clinical Oncology, 2019. 37(15_suppl): p. 9011-9011., https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9011
1395. Solomon, B. J., Martini, J. F., Ou, S. H. I., Chiari, R., Soo, R. A., Bearz, A., et.al. Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations, Annals of Oncology, 2018. 29: p. viii495., https://doi.org/10.1093/annonc/mdy292.003
1396. Shaw, AT, Solomon, BJ, Chiari, R, Riely, GJ, Besse, B, Soo, RA, et.al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial., Lancet Oncol, 2019. 20 (12)(12): p. 1691-1701., https://pubmed.ncbi.nlm.nih.gov/31669155/
1397. Sun, TY, Niu, X, Chakraborty, A, Neal, JW, Wakelee, HA, Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer., J Thorac Oncol, 2019. 14 (2)(2): p. e21-e24., https://pubmed.ncbi.nlm.nih.gov/30217491/
1398. Katayama, R, Kobayashi, Y, Friboulet, L, Lockerman, EL, Koike, S, Shaw, AT, et.al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer., Clin Cancer Res, 2015. 21 (1)(1): p. 166-74., https://pubmed.ncbi.nlm.nih.gov/25351743/
1399. Scheffler, M, Bos, M, Gardizi, M, König, K, Michels, S, Fassunke, J, et.al. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies., Oncotarget, 2015. 6 (2)(2): p. 1315-26., https://pubmed.ncbi.nlm.nih.gov/25473901/
1400. Wiesweg, M, Eberhardt, WEE, Reis, H, Ting, S, Savvidou, N, Skiba, C, et.al. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer., J Thorac Oncol, 2017. 12 (1)(1): p. 54-64., https://pubmed.ncbi.nlm.nih.gov/27575422/
1401. Drilon, A, Rekhtman, N, Arcila, M, Wang, L, Ni, A, Albano, M, et.al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial., Lancet Oncol, 2016. 17 (12)(12): p. 1653-1660., https://pubmed.ncbi.nlm.nih.gov/27825636/
1402. Occhipinti, M, Falcone, R, Onesti, CE, Botticelli, A, Mazzuca, F, Marchetti, P, et.al. Crizotinib plus radiotherapy in brain oligoprogressive NSCLC , J Thorac Dis, 2017. 9 (11)(11): p. E985-E989., https://pubmed.ncbi.nlm.nih.gov/29268554/
1403. McCoach, CE, Le, AT, Gowan, K, Jones, K, Schubert, L, Doak, A, et.al. Resistance Mechanisms to Targeted Therapies in , Clin Cancer Res, 2018. 24 (14)(14): p. 3334-3347., https://pubmed.ncbi.nlm.nih.gov/29636358/
1404. Ng, TL, Smith, DE, Mushtaq, R, Patil, T, Dimou, A, Yang, S, et.al. ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events., J Thorac Oncol, 2019. 14 (4)(4): p. 596-605., https://pubmed.ncbi.nlm.nih.gov/30543838/
1405. Planchard, D, Smit, EF, Groen, HJM, Mazieres, J, Besse, B, Helland, Å, et.al. Dabrafenib plus trametinib in patients with previously untreated BRAF, Lancet Oncol, 2017. 18 (10)(10): p. 1307-1316., https://pubmed.ncbi.nlm.nih.gov/28919011/
1406. Gautschi, O, Milia, J, Cabarrou, B, Bluthgen, MV, Besse, B, Smit, EF, et.al. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort., J Thorac Oncol, 2015. 10 (10)(10): p. 1451-7., https://pubmed.ncbi.nlm.nih.gov/26200454/
1407. Hyman, DM, Puzanov, I, Subbiah, V, Faris, JE, Chau, I, Blay, JY, et.al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations., N Engl J Med, 2015. 373 (8)(8): p. 726-36., https://pubmed.ncbi.nlm.nih.gov/26287849/
1408. Planchard, D, Kim, TM, Mazieres, J, Quoix, E, Riely, G, Barlesi, F, et.al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial., Lancet Oncol, 2016. 17 (5)(5): p. 642-50., https://pubmed.ncbi.nlm.nih.gov/27080216/
1409. Barlesi, F., Mazieres, J., Merlio, J. P., Debieuvre, D., Mosser, J., Lena, H., et.al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet, 2016. 387(10026): p. 1415-1426., https://pubmed.ncbi.nlm.nih.gov/26777916/
1410. Planchard, D, Besse, B, Groen, HJM, Souquet, PJ, Quoix, E, Baik, CS, et.al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial., Lancet Oncol, 2016. 17 (7)(7): p. 984-993., https://pubmed.ncbi.nlm.nih.gov/27283860/
1411. Drilon, A, Laetsch, TW, Kummar, S, DuBois, SG, Lassen, UN, Demetri, GD, et.al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children., N Engl J Med, 2018. 378 (8)(8): p. 731-739., https://pubmed.ncbi.nlm.nih.gov/29466156/
1412. Drilon, A, Oxnard, GR, Tan, DSW, Loong, HHF, Johnson, M, Gainor, J, et.al. Efficacy of Selpercatinib in , N Engl J Med, 2020. 383 (9)(9): p. 813-824., https://pubmed.ncbi.nlm.nih.gov/32846060/
1413. Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., et.al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials, Lancet Oncol, 2020. 21(2): p. 271-282., https://pubmed.ncbi.nlm.nih.gov/31838007/
1414. Paz-Ares, L., Doebele, R. C., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., et.al. Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001, Annals of Oncology, 2019. 30: p. ii48-ii49., https://doi.org/10.1093/annonc/mdz063.011
1415. Besse, Benjamin, Lin, Jessica J., Bazhenova, Lyudmila, Goto, Koichi, de Langen, Adrianus Johannes, Kim, Dong-Wan, et.al. Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial, 2026. 32(2): p. 682 - 689., https://doi.org/10.1038/s41591-025-04079-7
1416. Griesinger, F, Curigliano, G, Thomas, M, Subbiah, V, Baik, CS, Tan, DSW, et.al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial., Ann Oncol, 2022. ():, https://pubmed.ncbi.nlm.nih.gov/35973665/
1417. Gainor, JF, Curigliano, G, Kim, DW, Lee, DH, Besse, B, Baik, CS, et.al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study., Lancet Oncol, 2021. 22 (7)(7): p. 959-969., https://pubmed.ncbi.nlm.nih.gov/34118197/
1418. Zhou, C, Solomon, B, Loong, HH, Park, K, Pérol, M, Arriola, E, et.al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in , N Engl J Med, 2023. 389 (20)(20): p. 1839-1850., https://pubmed.ncbi.nlm.nih.gov/37870973/
1419. Gainor, Justin F., Lee, Dae Ho, Curigliano, Giuseppe, Doebele, Robert Charles, Kim, Dong-Wan, Baik, Christina S, et.al. Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC), Journal of Clinical Oncology, 2019. 37(15_suppl): p. 9008-9008., https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9008
1420. European Medicines Agency, Fachinformation Gavreto, Anhang I: ZUSAMMENFASSUNG DER MERKMALE DES ARZNEIMITTELS, 2021., https://www.ema.europa.eu/en/documents/product-information/gavreto-epar-product-information_de.pdf
1421. Gemeinsamer Bundesausschuss (G-BA), Nutzenbewertungsverfahren zum Wirkstoff Pralsetinib (Lungenkarzinom, nicht-kleinzelliges, RET-Fusion+), 2022., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/770/
1422. Paik, PK, Felip, E, Veillon, R, Sakai, H, Cortot, AB, Garassino, MC, et.al. Tepotinib in Non-Small-Cell Lung Cancer with , N Engl J Med, 2020. 383 (10)(10): p. 931-943., https://pubmed.ncbi.nlm.nih.gov/32469185/
1423. Wolf, J., Seto, T., Han, J. Y., Reguart, N., Garon, E. B., Groen, H. J. M., et.al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer, N Engl J Med, 2020. 383(10): p. 944-957., https://www.nejm.org/doi/full/10.1056/NEJMoa2002787
1424. Wolf, J., Seto, T., Han, J. Y., Reguart, N., Garon, E. B., Groen, H. J. M., et.al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer, N Engl J Med, 2020. 383(10): p. 944-957., https://pubmed.ncbi.nlm.nih.gov/32877583/
1425. Le, X, Sakai, H, Felip, E, Veillon, R, Garassino, MC, Raskin, J, et.al. Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice., Clin Cancer Res, 2022. 28 (6)(6): p. 1117-1126., https://pubmed.ncbi.nlm.nih.gov/34789481/
1426. Skoulidis, F, Li, BT, Dy, GK, Price, TJ, Falchook, GS, Wolf, J, et.al. Sotorasib for Lung Cancers with , N Engl J Med, 2021. 384 (25)(25): p. 2371-2381., https://pubmed.ncbi.nlm.nih.gov/34096690/
1427. de Langen, AJ, Johnson, ML, Mazieres, J, Dingemans, AC, Mountzios, G, Pless, M, et.al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS, Lancet, 2023. 401 (10378)(10378): p. 733-746., https://pubmed.ncbi.nlm.nih.gov/36764316/
1428. Barlesi, Fabrice, Yao, Wenxiu, Duruisseaux, Michaël, Doucet, Ludovic, Martínez, Aitor Azkárate, Gregorc, Vanesa, et.al. Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trialElsevier, The Lancet, 2025. 406(10503): p. 615 - 626., https://doi.org/10.1016/S0140-6736(25)00866-9
1429. Li, BT, Smit, EF, Goto, Y, Nakagawa, K, Udagawa, H, Mazières, J, et.al. Trastuzumab Deruxtecan in , N Engl J Med, 2022. 386 (3)(3): p. 241-251., https://pubmed.ncbi.nlm.nih.gov/34534430/
1430. Goto, K, Goto, Y, Kubo, T, Ninomiya, K, Kim, SW, Planchard, D, et.al. Trastuzumab Deruxtecan in Patients With , J Clin Oncol, 2023. 41 (31)(31): p. 4852-4863., https://pubmed.ncbi.nlm.nih.gov/37694347/
1431. Tarantino, P, Tolaney, SM, Detecting and Managing T-DXd-Related Interstitial Lung Disease: The Five "S" Rules., JCO Oncol Pract, 2023. 19 (8)(8): p. 526-527., https://pubmed.ncbi.nlm.nih.gov/37207309/
1432. Janne, Pasi A., Goto, Yasushi, Kubo, Toshio, Ninomiya, Kiichiro, Kim, Sang-We, Planchard, David, et.al. Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.Wolters Kluwer, Journal of Clinical Oncology, 2024. 42(16_suppl): p. 8543 - 8543., https://doi.org/10.1200/JCO.2024.42.16_suppl.8543
1433. Gomez, DR, Blumenschein, GR, Lee, JJ, Hernandez, M, Ye, R, Camidge, DR, et.al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study., Lancet Oncol, 2016. 17 (12)(12): p. 1672-1682., https://pubmed.ncbi.nlm.nih.gov/27789196/
1434. De Ruysscher, D, Wanders, R, Hendriks, LE, van Baardwijk, A, Reymen, B, Houben, R, et.al. Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450)., J Thorac Oncol, 2018. 13 (12)(12): p. 1958-1961., https://pubmed.ncbi.nlm.nih.gov/30253974/
1435. Giaj-Levra, N, Giaj-Levra, M, Durieux, V, Novello, S, Besse, B, Hasan, B, et.al. Defining Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Systematic Review., J Thorac Oncol, 2019. 14 (12)(12): p. 2053-2061., https://pubmed.ncbi.nlm.nih.gov/31195177/
1436. Schanne, DH, Heitmann, J, Guckenberger, M, Andratschke, NHJ, Evolution of treatment strategies for oligometastatic NSCLC patients - A systematic review of the literature., Cancer Treat Rev, 2019. 80 (): p. 101892., https://pubmed.ncbi.nlm.nih.gov/31522079/
1437. Dingemans, AC, Hendriks, LEL, Berghmans, T, Levy, A, Hasan, B, Faivre-Finn, C, et.al. Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report., J Thorac Oncol, 2019. 14 (12)(12): p. 2109-2119., https://pubmed.ncbi.nlm.nih.gov/31398540/
1438. Collen, C., Christian, N., Schallier, D., Meysman, M., Duchateau, M., Storme, G., et.al. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients, Ann Oncol, 2014. 25(10): p. 1954-9., https://www.ncbi.nlm.nih.gov/pubmed/25114022
1439. Petty, WJ, Urbanic, JJ, Ahmed, T, Hughes, R, Levine, B, Rusthoven, K, et.al. Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer., Int J Radiat Oncol Biol Phys, 2018. 102 (3)(3): p. 527-535., https://pubmed.ncbi.nlm.nih.gov/30003996/
1440. Arrieta, O, Barrón, F, Maldonado, F, Cabrera, L, Corona-Cruz, JF, Blake, M, et.al. Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study., Lung Cancer, 2019. 130 (): p. 67-75., https://pubmed.ncbi.nlm.nih.gov/30885354/
1441. Bauml, JM, Mick, R, Ciunci, C, Aggarwal, C, Davis, C, Evans, T, et.al. Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial., JAMA Oncol, 2019. 5 (9)(9): p. 1283-1290., https://pubmed.ncbi.nlm.nih.gov/31294762/
1442. Gomez, DR, Tang, C, Zhang, J, Blumenschein, GR, Hernandez, M, Lee, JJ, et.al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study., J Clin Oncol, 2019. 37 (18)(18): p. 1558-1565., https://pubmed.ncbi.nlm.nih.gov/31067138/
1443. Palma, DA, Olson, R, Harrow, S, Gaede, S, Louie, AV, Haasbeek, C, et.al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial., Lancet, 2019. 393 (10185)(10185): p. 2051-2058., https://pubmed.ncbi.nlm.nih.gov/30982687/
1444. Wang, XS, Bai, YF, Verma, V, Yu, RL, Tian, W, Ao, R, et.al. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC., J Natl Cancer Inst, 2022. ():, https://pubmed.ncbi.nlm.nih.gov/35094066/
1445. Niibe, Y, Hayakawa, K, Oligometastases and oligo-recurrence: the new era of cancer therapy., Jpn J Clin Oncol, 2010. 40 (2)(2): p. 107-11., https://pubmed.ncbi.nlm.nih.gov/20047860/
1446. Ashworth, A. B., Senan, S., Palma, D. A., Riquet, M., Ahn, Y. C., Ricardi, U., et.al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer, Clin Lung Cancer, 2014. 15(5): p. 346-55., https://www.ncbi.nlm.nih.gov/pubmed/24894943
1447. Andrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., et.al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial, Lancet, 2004. 363(9422): p. 1665-1672., https://www.ncbi.nlm.nih.gov/pubmed/15158627
1448. Kocher, M., Soffietti, R., Abacioglu, U., Villa, S., Fauchon, F., Baumert, B. G., et.al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study, J Clin Oncol, 2011. 29(2): p. 134-41., https://www.ncbi.nlm.nih.gov/pubmed/21041710
1449. Brown, P. D., Jaeckle, K., Ballman, K. V., Farace, E., Cerhan, J. H., Anderson, S. K., et.al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial, Jama, 2016. 316(4): p. 401-9., https://www.ncbi.nlm.nih.gov/pubmed/27458945
1450. Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., et.al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial, Jama, 2006. 295(21): p. 2483-91., https://www.ncbi.nlm.nih.gov/pubmed/16757720
1451. Hörner-Rieber, J, Bernhardt, D, Blanck, O, Duma, M, Eich, HT, Gerum, S, et.al. Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT., Clin Lung Cancer, 2019. 20 (6)(6): p. e667-e677., https://pubmed.ncbi.nlm.nih.gov/31327644/
1452. Lodeweges, JE, Klinkenberg, TJ, Ubbels, JF, Groen, HJM, Langendijk, JA, Widder, J, Long-term Outcome of Surgery or Stereotactic Radiotherapy for Lung Oligometastases., J Thorac Oncol, 2017. 12 (9)(9): p. 1442-1445., https://pubmed.ncbi.nlm.nih.gov/28576747/
1453. Klement, RJ, Hoerner-Rieber, J, Adebahr, S, Andratschke, N, Blanck, O, Boda-Heggemann, J, et.al. Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy., Radiother Oncol, 2018. 127 (2)(2): p. 246-252., https://pubmed.ncbi.nlm.nih.gov/29510865/
1454. Gunjur, A, Duong, C, Ball, D, Siva, S, Surgical and ablative therapies for the management of adrenal 'oligometastases' - A systematic review., Cancer Treat Rev, 2014. 40 (7)(7): p. 838-46., https://pubmed.ncbi.nlm.nih.gov/24791623/
1455. Chance, WW, Nguyen, QN, Mehran, R, Welsh, JW, Gomez, DR, Balter, P, et.al. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity., Pract Radiat Oncol 7 (3)(3): p. e195-e203., https://pubmed.ncbi.nlm.nih.gov/27743801/
1456. Andratschke, N, Alheid, H, Allgäuer, M, Becker, G, Blanck, O, Boda-Heggemann, J, et.al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases., BMC Cancer, 2018. 18 (1)(1): p. 283., https://pubmed.ncbi.nlm.nih.gov/29534687/
1457. Klein, J, Dawson, LA, Jiang, H, Kim, J, Dinniwell, R, Brierley, J, et.al. Prospective Longitudinal Assessment of Quality of Life for Liver Cancer Patients Treated With Stereotactic Body Radiation Therapy., Int J Radiat Oncol Biol Phys, 2015. 93 (1)(1): p. 16-25., https://pubmed.ncbi.nlm.nih.gov/26279020/
1458. Bates, JE, Milano, MT, Prognostic significance of sites of extrathoracic metastasis in patients with non-small cell lung cancer., J Thorac Dis, 2017. 9 (7)(7): p. 1903-1910., https://pubmed.ncbi.nlm.nih.gov/28839988/
1459. Guckenberger, M., Mantel, F., Gerszten, P. C., Flickinger, J. C., Sahgal, A., Letourneau, D., et.al. Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis, Radiat Oncol, 2014. 9: p. 226., https://www.ncbi.nlm.nih.gov/pubmed/25319530
1460. Shang, S, Su, Y, Zhu, Z, Li, B, Guo, M, Xu, Y, et.al. Local ablative therapy with or without chemotherapy for non-small-cell lung cancer patients with postoperative oligometastases., Cancer Manag Res, 2018. 10 (): p. 6421-6429., https://pubmed.ncbi.nlm.nih.gov/30568503/
1461. Mordant, P, Arame, A, De Dominicis, F, Pricopi, C, Foucault, C, Dujon, A, et.al. Which metastasis management allows long-term survival of synchronous solitary M1b non-small cell lung cancer?, Eur J Cardiothorac Surg, 2012. 41 (3)(3): p. 617-22., https://pubmed.ncbi.nlm.nih.gov/22223700/
1462. Ettinghausen, SE, Burt, ME, Prospective evaluation of unilateral adrenal masses in patients with operable non-small-cell lung cancer., J Clin Oncol, 1991. 9 (8)(8): p. 1462-6., https://pubmed.ncbi.nlm.nih.gov/1649268/
1463. Kuruba, R, Gallagher, SF, Current management of adrenal tumors., Curr Opin Oncol, 2008. 20 (1)(1): p. 34-46., https://pubmed.ncbi.nlm.nih.gov/18043254/
1464. Tanvetyanon, T., Robinson, L. A., Schell, M. J., Strong, V. E., Kapoor, R., Coit, D. G., et.al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis, J Clin Oncol, 2008. 26(7): p. 1142-7., https://www.ncbi.nlm.nih.gov/pubmed/18309950
1465. De Wolf, J, Bellier, J, Lepimpec-Barthes, F, Tronc, F, Peillon, C, Bernard, A, et.al. Exhaustive preoperative staging increases survival in resected adrenal oligometastatic non-small-cell lung cancer: a multicentre study., Eur J Cardiothorac Surg, 2017. 52 (4)(4): p. 698-703., https://pubmed.ncbi.nlm.nih.gov/29156014/
1466. Alemanno, G, Bergamini, C, Prosperi, P, Valeri, A, Adrenalectomy: indications and options for treatment., Updates Surg, 2017. 69 (2)(2): p. 119-125., https://pubmed.ncbi.nlm.nih.gov/28421470/
1467. Salah, S., Tanvetyanon, T., Abbasi, S., Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases: systematic review and analysis of reported cases, Lung Cancer, 2012. 75(1): p. 9-14., https://www.ncbi.nlm.nih.gov/pubmed/21864934
1468. DeLuzio, MR, Moores, C, Dhamija, A, Wang, Z, Cha, C, Boffa, DJ, et.al. Resection of oligometastatic lung cancer to the pancreas may yield a survival benefit in select patients--a systematic review., Pancreatology 15 (5)(5): p. 456-462., https://pubmed.ncbi.nlm.nih.gov/25900320/
1469. Tonnies, S., Tonnies, M., Kollmeier, J., Bauer, T. T., Forster, G. J., Kaiser, D., et.al. Impact of preoperative 18F-FDG PET/CT on survival of resected mono-metastatic non-small cell lung cancer, Lung Cancer, 2016. 93: p. 28-34., https://www.ncbi.nlm.nih.gov/pubmed/26898611
1470. Okubo, K, Bando, T, Miyahara, R, Sakai, H, Shoji, T, Sonobe, M, et.al. Resection of pulmonary metastasis of non-small cell lung cancer., J Thorac Oncol, 2009. 4 (2)(2): p. 203-7., https://pubmed.ncbi.nlm.nih.gov/19179897/
1471. Tonnies, M., Pfannschmidt, J., Bauer, T. T., Kollmeier, J., Tonnies, S., Kaiser, D., Metastasectomy for synchronous solitary non-small cell lung cancer metastases, Ann Thorac Surg, 2014. 98(1): p. 249-56., https://www.ncbi.nlm.nih.gov/pubmed/24820385
1472. Xu, Q, Wang, Y, Liu, H, Meng, S, Zhou, S, Xu, J, et.al. Treatment outcome for patients with primary NSCLC and synchronous solitary metastasis., Clin Transl Oncol, 2013. 15 (10)(10): p. 802-9., https://pubmed.ncbi.nlm.nih.gov/23430537/
1473. Govindan, R., Page, N., Morgensztern, D., Read, W., Tierney, R., Vlahiotis, A., et.al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database, J.Clin.Oncol., 2006. 24(28): p. 4539-4544., https://www.ncbi.nlm.nih.gov/pubmed/17008692
1474. Lüchtenborg, M, Riaz, SP, Lim, E, Page, R, Baldwin, DR, Jakobsen, E, et.al. Survival of patients with small cell lung cancer undergoing lung resection in England, 1998-2009., Thorax, 2014. 69 (3)(3): p. 269-73., https://pubmed.ncbi.nlm.nih.gov/24172710/
1475. Liu, T, Chen, Z, Dang, J, Li, G, The role of surgery in stage I to III small cell lung cancer: A systematic review and meta-analysis., PLoS One, 2018. 13 (12)(12): p. e0210001., https://pubmed.ncbi.nlm.nih.gov/30596754/
1476. Albain, K. S., Crowley, J. J., LeBlanc, M., Livingston, R. B., Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base, J Clin Oncol, 1990. 8(9): p. 1563-74., https://www.ncbi.nlm.nih.gov/pubmed/2167954
1477. Rawson, N. S., Peto, J., An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research, Br.J.Cancer, 1990. 61(4): p. 597-604., https://www.ncbi.nlm.nih.gov/pubmed/2158808
1478. Bremnes, R. M., Sundstrom, S., Aasebo, U., Kaasa, S., Hatlevoll, R., Aamdal, S., The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up, Lung Cancer, 2003. 39(3): p. 303-313., https://www.ncbi.nlm.nih.gov/pubmed/12609569
1479. Cerny, T., Blair, V., Anderson, H., Bramwell, V., Thatcher, N., Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients, Int.J.Cancer, 1987. 39(2): p. 146-149., https://www.ncbi.nlm.nih.gov/pubmed/3026969
1480. Spiegelman, D., Maurer, L. H., Ware, J. H., Perry, M. C., Chahinian, A. P., Comis, R., et.al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients, J.Clin.Oncol., 1989. 7(3): p. 344-354., https://www.ncbi.nlm.nih.gov/pubmed/2537384
1481. Sagman, U., Maki, E., Evans, W. K., Warr, D., Shepherd, F. A., Sculier, J. P., et.al. Small-cell carcinoma of the lung: derivation of a prognostic staging system, J.Clin.Oncol., 1991. 9(9): p. 1639-1649., https://www.ncbi.nlm.nih.gov/pubmed/1651996
1482. Wolf, M., Holle, R., Hans, K., Drings, P., Havemann, K., Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival, Br.J.Cancer, 1991. 63(6): p. 986-992., https://www.ncbi.nlm.nih.gov/pubmed/1648949
1483. Singh, S., Parulekar, W., Murray, N., Feld, R., Evans, W. K., Tu, D., et.al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer, J.Clin.Oncol., 2005. 23(4): p. 850-856., https://www.ncbi.nlm.nih.gov/pubmed/15681530
1484. Ludbrook, J. J., Truong, P. T., MacNeil, M. V., Lesperance, M., Webber, A., Joe, H., et.al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis, Int J Radiat Oncol Biol Phys, 2003. 55(5): p. 1321-1330., https://www.ncbi.nlm.nih.gov/pubmed/12654444
1485. Johnson, P. W., Joel, S. P., Love, S., Butcher, M., Pandian, M. R., Squires, L., et.al. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer, Br J Cancer, 1993. 67(4): p. 760-766., https://pubmed.ncbi.nlm.nih.gov/8385978/
1486. Johnson, P. W., Joel, S. P., Love, S., Butcher, M., Pandian, M. R., Squires, L., et.al. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer, Br J Cancer, 1993. 67(4): p. 760-766., https://pubmed.ncbi.nlm.nih.gov/8385978/
1487. Earl, H. M., Rudd, R. M., Spiro, S. G., Ash, C. M., James, L. E., Law, C. S., et.al. A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial, Br.J.Cancer, 1991. 64(3): p. 566-572., https://www.ncbi.nlm.nih.gov/pubmed/1654983
1488. Lowenbraun, S., Bartolucci, A., Smalley, R. V., Lynn, M., Krauss, S., Durant, J. R., The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma, Cancer, 1979. 44(2): p. 406-413., https://www.ncbi.nlm.nih.gov/pubmed/224997
1489. Wolf, M., Havemann, K., Holle, R., Harms, V., Drings, P., Hans, K., et.al. The prognostic value of response to the first cycle of chemotherapy in small cell lung cancer. Results of a multicenter German trial, Eur J Cancer Clin Oncol, 1987. 23(8): p. 1197-1205., https://www.ncbi.nlm.nih.gov/pubmed/2443363
1490. Osterlind, K., Sorenson, S., Hansen, H. H., Dombernowsky, P., Hirsch, F. R., Hansen, M., et.al. Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung, Cancer Res., 1983. 43(12 Pt 1): p. 6085-6089., https://www.ncbi.nlm.nih.gov/pubmed/6315227
1491. Daniels, J. R., Chak, L. Y., Sikic, B. I., Lockbaum, P., Kohler, M., Carter, S. K., et.al. Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs, J Clin Oncol, 1984. 2(11): p. 1192-1199., https://www.ncbi.nlm.nih.gov/pubmed/6092554
1492. Evans, W. K., Feld, R., Murray, N., Willan, A., Coy, P., Osoba, D., et.al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada, Ann.Intern.Med., 1987. 107(4): p. 451-458., https://www.ncbi.nlm.nih.gov/pubmed/2820289
1493. Feld, R., Evans, W. K., Coy, P., Hodson, I., MacDonald, A. S., Osoba, D., et.al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung, J Clin Oncol, 1987. 5(9): p. 1401-1409., https://www.ncbi.nlm.nih.gov/pubmed/3040923
1494. Havemann, K., Wolf, M., Holle, R., Gropp, C., Drings, P., Manke, H. G., et.al. Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial, Cancer, 1987. 59(6): p. 1072-1082., https://www.ncbi.nlm.nih.gov/pubmed/3028596
1495. Ettinger, D. S., Finkelstein, D. M., Abeloff, M. D., A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group, J Clin Oncol, 1990. 8: p. 230-240., https://www.ncbi.nlm.nih.gov/pubmed/2153765
1496. Wolf, M., Pritsch, M., Drings, P., et al., Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients, J Clin Oncol, 1991. 9: p. 614-624., https://www.ncbi.nlm.nih.gov/pubmed/1648598
1497. Urban, T., Baleyte, T., Chastang, C. L., Jeannin, L., Delaval, P., Zaegel, M., et.al. Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. 'Petites Cellules' Group, Lung Cancer, 1999. 25(2): p. 105-113., https://www.ncbi.nlm.nih.gov/pubmed/10470844
1498. Spiro, S. G., Souhami, R. L., Geddes, D. M., et al., Duration of chemotherapy in small cell lung cancer. Research Campaign trial, Br J Cancer, 1989. 59: p. 578-583., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247136/
1499. Sculier, J. P., Berghmans, T., Castaigne, C., Luce, S., Sotiriou, C., Vermylen, P., et.al. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature (Comment see Osterlind, K., Lung Cancer Vol. 19, p. 99-100), Lung Cancer, 1998. 19(2): p. 141-151., https://pubmed.ncbi.nlm.nih.gov/9567251/
1500. Wakeam, E, Acuna, SA, Leighl, NB, Giuliani, ME, Finlayson, SRG, Varghese, TK, et.al. Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival., Lung Cancer, 2017. 109 (): p. 78-88., https://pubmed.ncbi.nlm.nih.gov/28577955/
1501. Combs, SE, Hancock, JG, Boffa, DJ, Decker, RH, Detterbeck, FC, Kim, AW, Bolstering the case for lobectomy in stages I, II, and IIIA small-cell lung cancer using the National Cancer Data Base., J Thorac Oncol, 2015. 10 (2)(2): p. 316-23., https://pubmed.ncbi.nlm.nih.gov/25319182/
1502. Schreiber, D, Rineer, J, Weedon, J, Vongtama, D, Wortham, A, Kim, A, et.al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated?, Cancer, 2010. 116 (5)(5): p. 1350-7., https://pubmed.ncbi.nlm.nih.gov/20082453/
1503. Liu, Y, Shan, L, Shen, J, Liu, L, Wang, J, He, J, et.al. Choice of surgical procedure - lobectomy, segmentectomy, or wedge resection - for patients with stage T1-2N0M0 small cell lung cancer: A population-based study., Thorac Cancer, 2019. 10 (4)(4): p. 593-600., https://pubmed.ncbi.nlm.nih.gov/30854808/
1504. Li, Y, Hu, S, Xie, J, Zhang, X, Zong, Y, Xu, B, et.al. Effects of surgery on survival of elderly patients with stage I small-cell lung cancer: analysis of the SEER database., J Cancer Res Clin Oncol, 2019. 145 (9)(9): p. 2397-2404., https://pubmed.ncbi.nlm.nih.gov/31302755/
1505. Xu, J, Yang, H, Fu, X, Jin, B, Lou, Y, Zhang, Y, et.al. Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer., J Thorac Oncol, 2017. 12 (2)(2): p. 347-353., https://pubmed.ncbi.nlm.nih.gov/27725211/
1506. Yang, CJ, Chan, DY, Shah, SA, Yerokun, BA, Wang, XF, D'Amico, TA, et.al. Long-term Survival After Surgery Compared With Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer., Ann Surg, 2018. 268 (6)(6): p. 1105-1112., https://pubmed.ncbi.nlm.nih.gov/28475559/
1507. Babakoohi, S, Fu, P, Yang, M, Linden, PA, Dowlati, A, Combined SCLC clinical and pathologic characteristics., Clin Lung Cancer, 2013. 14 (2)(2): p. 113-9., https://pubmed.ncbi.nlm.nih.gov/23010092/
1508. Ulsperger, E., Karrer, K., Denck, H., Multimodality treatment for small cell bronchial carcinoma. Preliminary results of a prospective, multicenter trial. The ISC-Lung Cancer Study Group, Eur J Cardiothorac Surg, 1991. 5: p. 306-309., https://www.ncbi.nlm.nih.gov/pubmed/1651741
1509. Shepherd, F. A., Ginsberg, R. J., Feld, R., et al., Surgical treatment for limited small-cell lung cancer, J Thorac Cardiovasc Surg, 1991. 101: p. 385-393., https://www.ncbi.nlm.nih.gov/pubmed/1847981
1510. Tsuchiya, R., Suzuki, K., Ichinose, Y., Watanabe, Y., Yasumitsu, T., Ishizuka, N., et.al. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101), J.Thorac.Cardiovasc.Surg., 2005. 129(5): p. 977-983., https://www.ncbi.nlm.nih.gov/pubmed/15867769
1511. Fox, W., Scadding, J. G., Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up, Lancet, 1973. 2(7820): p. 63-5., https://www.ncbi.nlm.nih.gov/pubmed/4123619
1512. Maassen, W., Greschuchna, D., Martinez, I., The role of surgery in the treatment of small cell carcinoma of the lung, Recent Results Cancer Res., 1985. 97: p. 107-115., https://www.ncbi.nlm.nih.gov/pubmed/2986238
1513. Osterlind, K., Hansen, M., Hansen, H. H., Dombernowsky, P., Rorth, M., Treatment policy of surgery in small cell carcinoma of the lung: retrospective analysis of a series of 874 consecutive patients, Thorax, 1985. 40(4): p. 272-277., https://www.ncbi.nlm.nih.gov/pubmed/2992111
1514. Waddell, T. K., Shepherd, F. A., Should aggressive surgery ever be part of the management of small cell lung cancer?, Thorac.Surg.Clin., 2004. 14(2): p. 271-281., https://www.ncbi.nlm.nih.gov/pubmed/15382303
1515. Wakeam, E, Giuliani, M, Leighl, NB, Finlayson, SRG, Varghese, TK, Darling, GE, Indications for Adjuvant Mediastinal Radiotherapy in Surgically Resected Small Cell Lung Cancer., Ann Thorac Surg, 2017. 103 (5)(5): p. 1647-1653., https://pubmed.ncbi.nlm.nih.gov/28267977/
1516. Brock, MV, Hooker, CM, Syphard, JE, Westra, W, Xu, L, Alberg, AJ, et.al. Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come., J Thorac Cardiovasc Surg, 2005. 129 (1)(1): p. 64-72., https://pubmed.ncbi.nlm.nih.gov/15632826/
1517. Salem, A, Mistry, H, Hatton, M, Locke, I, Monnet, I, Blackhall, F, et.al. Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial., JAMA Oncol, 2019. 5 (3)(3): p. e185335., https://pubmed.ncbi.nlm.nih.gov/30520977/
1518. Cheng, Y, Spigel, DR, Cho, BC, Laktionov, KK, Fang, J, Chen, Y, et.al. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer., N Engl J Med, 2024. 391 (14)(14): p. 1313-1327., https://pubmed.ncbi.nlm.nih.gov/39268857/
1519. Mascaux, C., Paesmans, M., Berghmans, T., Branle, F., Lafitte, J. J., Lemaitre, F., et.al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis, Lung Cancer, 2000. 30(1): p. 23-36., https://www.ncbi.nlm.nih.gov/pubmed/11008007
1520. Pujol, J. L., Carestia, L., Daures, J. P., Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent, Br.J.Cancer, 2000. 83(1): p. 8-15., https://www.ncbi.nlm.nih.gov/pubmed/10883661
1521. Maksymiuk, A. W., Jett, J. R., Earle, J. D., Su, J. Q., Diegert, F. A., Mailliard, J. A., et.al. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial, J Clin Oncol, 1994. 12(1): p. 70-76., https://www.ncbi.nlm.nih.gov/pubmed/8270988
1522. Sundstrom, S., Bremnes, R. M., Kaasa, S., et al., Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small cell lung cancer: results from a randomized phase III trial with 5 years' follow-up, J Clin Oncol, 2002. 20: p. 4665-4672., https://www.ncbi.nlm.nih.gov/pubmed/12488411
1523. Thatcher, N., Qian, W., Clark, P. I., Hopwood, P., Sambrook, R. J., Owens, R., et.al. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial, J.Clin.Oncol., 2005. 23(33): p. 8371-8379., https://www.ncbi.nlm.nih.gov/pubmed/16293867
1524. Einhorn, L. H., Crawford, J., Birch, R., Omura, G., Johnson, D. H., Greco, F. A., Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer, J Clin Oncol, 1988. 6(3): p. 451-456., https://www.ncbi.nlm.nih.gov/pubmed/2832549
1525. Wolf, M., Havemann, K., Holle, R., Gropp, C., Drings, P., Hans, K., et.al. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial, J Clin Oncol, 1987. 5(12): p. 1880-1889., https://www.ncbi.nlm.nih.gov/pubmed/2824710
1526. Jackson, D. V., Jr., Zekan, P. J., Caldwell, R. D., Slatkoff, M. L., Harding, R. W., Case, L. D., et.al. VP-16-213 in combination chemotherapy with chest irradiation for small-cell lung cancer: a randomized trial of the Piedmont Oncology Association, J Clin Oncol, 1984. 2(12): p. 1343-1351., https://www.ncbi.nlm.nih.gov/pubmed/6096517
1527. Jett, J. R., Everson, L., Therneau, T. M., et.al, Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxurubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group, J Clin Oncol, 1990. 8: p. 33-38., https://www.ncbi.nlm.nih.gov/pubmed/2153193
1528. Goodman, G. E., Crowley, J. J., Blasko, J. C., Livingston, R. B., Beck, T. M., Demattia, M. D., et.al. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study, J Clin Oncol, 1990. 8(1): p. 39-47., https://www.ncbi.nlm.nih.gov/pubmed/2153194
1529. Fukuoka, M., Furuse, K., Saijo, N., Nishiwaki, Y., Ikegami, H., Tamura, T., et.al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer, J Natl.Cancer Inst., 1991. 83(12): p. 855-861., https://www.ncbi.nlm.nih.gov/pubmed/1648142
1530. Skarlos, D. V., Samantas, E., Kosmidis, P., Fountzilas, G., Angelidou, M., Palamidas, P., et.al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study, Ann Oncol, 1994. 5(7): p. 601-607., https://www.ncbi.nlm.nih.gov/pubmed/7993835
1531. Lassen, U., Kristjansen, P. E., Osterlind, K., Bergman, B., Sigsgaard, T. C., Hirsch, F. R., et.al. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up, Ann Oncol, 1996. 7(4): p. 365-371., https://www.ncbi.nlm.nih.gov/pubmed/8805928
1532. Hirsch, F. R., Osterlind, K., Jeppesen, N., Dombernowsky, P., Ingeberg, S., Sorensen, P. G., et.al. Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients, Ann.Oncol., 2001. 12(5): p. 647-653., https://www.ncbi.nlm.nih.gov/pubmed/11432623
1533. Kim, E, Biswas, T, Bakaki, P, Dowlati, A, Sharma, N, Machtay, M, Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age >65 years) using national SEER-Medicare data., Pract Radiat Oncol 6 (5)(5): p. e163-e169., https://pubmed.ncbi.nlm.nih.gov/27142494/
1534. Gregor, A., Drings, P., Burghouts, J., Postmus, P. E., Morgan, D., Sahmoud, T., et.al. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study, J Clin Oncol, 1997. 15(8): p. 2840-2849., https://www.ncbi.nlm.nih.gov/pubmed/9256127
1535. Perry, M. C., Eaton, W. L., Propert, K. J., Ware, J. H., Zimmer, B., Chahinian, A. P., et.al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung, N.Engl.J Med., 1987. 316(15): p. 912-918., https://www.ncbi.nlm.nih.gov/pubmed/3029592
1536. Perry, M. C., Herndon, J. E., III, Eaton, W. L., Green, M. R., Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083, J.Clin.Oncol., 1998. 16(7): p. 2466-2467., https://www.ncbi.nlm.nih.gov/pubmed/9667265
1537. Lebeau, B., Urban, T., Brechot, J. M., Paillotin, D., Vincent, J., Leclerc, P., et.al. A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small cell lung carcinoma. "Petites Cellules" Group, Cancer, 1999. 86(8): p. 1480-1487., https://www.ncbi.nlm.nih.gov/pubmed/10526276
1538. Ettinger, D. S., Berkey, B. A., Abrams, R. A., Fontanesi, J., Machtay, M., Duncan, P. J., et.al. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study, J.Clin.Oncol., 2005. 23(22): p. 4991-4998., https://www.ncbi.nlm.nih.gov/pubmed/15939930
1539. Bremnes, R. M., Sundstrom, S., Vilsvik, J., Aasebo, U., Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer, J.Clin.Oncol., 2001. 19(15): p. 3532-3538., https://www.ncbi.nlm.nih.gov/pubmed/11481360
1540. Glisson, B., Scott, C., Komaki, R., Movsas, B., Wagner, H., Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12, J.Clin.Oncol., 2000. 18(16): p. 2990-2995., https://www.ncbi.nlm.nih.gov/pubmed/10944132
1541. Hanna, N., Ansari, R., Fisher, W., Shen, J., Jung, S. H., Sandler, A., Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study, Lung Cancer, 2002. 35(3): p. 293-297., https://www.ncbi.nlm.nih.gov/pubmed/11844604
1542. Kubota, K, Hida, T, Ishikura, S, Mizusawa, J, Nishio, M, Kawahara, M, et.al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study., Lancet Oncol, 2014. 15 (1)(1): p. 106-13., https://pubmed.ncbi.nlm.nih.gov/24309370/
1543. Bunn, P. A., Jr., Lichter, A. S., Makuch, R. W., Cohen, M. H., Veach, S. R., Matthews, M. J., et.al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial, Ann.Intern.Med., 1987. 106(5): p. 655-662., https://www.ncbi.nlm.nih.gov/pubmed/3032033
1544. Kies, M. S., Mira, J. G., Crowley, J. J., Chen, T. T., Pazdur, R., Grozea, P. N., et.al. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study, J Clin Oncol, 1987. 5(4): p. 592-600., https://www.ncbi.nlm.nih.gov/pubmed/3031226
1545. Lung Cancer Working, Party, Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung.Medical Research Council Lung Cancer Working Party, Br.J Cancer, 1979. 40(1): p. 1-10., https://www.ncbi.nlm.nih.gov/pubmed/222312
1546. Osterlind, K., Hansen, H. H., Hansen, H. S., Dombernowsky, P., Hansen, M., Rorth, M., Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up, Br J Cancer, 1986. 54(1): p. 7-17., https://www.ncbi.nlm.nih.gov/pubmed/3015184
1547. Perez, C. A., Einhorn, L., Oldham, R. K., Greco, F. A., Cohen, H. J., Silberman, H., et.al. Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report, J Clin Oncol, 1984. 2(11): p. 1200-1208., https://www.ncbi.nlm.nih.gov/pubmed/6092555
1548. Souhami, R. L., Geddes, D. M., Spiro, S. G., Harper, P. G., Tobias, J. S., Mantell, B. S., et.al. Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial, Br.Med.J (Clin Res.Ed), 1984. 288(6431): p. 1643-1646., https://www.ncbi.nlm.nih.gov/pubmed/6326932
1549. Pignon, J. P., Arriagada, R., Ihde, D. C., Johnson, D. H., Perry, M. C., Souhami, R. L., et.al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer, N.Engl.J Med., 1992. 327(23): p. 1618-1624., https://www.ncbi.nlm.nih.gov/pubmed/1331787
1550. Warde, P., Payne, D., Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis, J Clin Oncol, 1992. 10(6): p. 890-895., https://www.ncbi.nlm.nih.gov/pubmed/1316951
1551. McCracken, J. D., Janaki, L. M., Crowley, J. J., Taylor, S. A., Giri, P. G., Weiss, G. B., et.al. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study, J Clin Oncol, 1990. 8(5): p. 892-898., https://www.ncbi.nlm.nih.gov/pubmed/2159055
1552. Thomas, C. R., Jr., Giroux, D. J., Janaki, L. M., Turrisi, A. T., III, Crowley, J. J., Taylor, S. A., et.al. Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancer, Lung Cancer, 2001. 33(2-3): p. 213-219., https://www.ncbi.nlm.nih.gov/pubmed/11551416
1553. Takada, M., Fukuoka, M., Kawahara, M., Sugiura, T., Yokoyama, A., Yokota, S., et.al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104, J.Clin.Oncol., 2002. 20(14): p. 3054-3060., https://www.ncbi.nlm.nih.gov/pubmed/12118018
1554. Murray, N., Coy, P., Pater, J. L., Hodson, I., Arnold, A., Zee, B. C., et.al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 1993. 11(2): p. 336-344., https://www.ncbi.nlm.nih.gov/pubmed/8381164
1555. Spiro, S. G., James, L. E., Rudd, R. M., Trask, C. W., Tobias, J. S., Snee, M., et.al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis, J Clin Oncol, 2006. 24(24): p. 3823-3830., https://www.ncbi.nlm.nih.gov/pubmed/16921033
1556. Jeremic, B., Shibamoto, Y., Acimovic, L., Milisavljevic, S., Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study, J Clin Oncol, 1997. 15(3): p. 893-900., https://www.ncbi.nlm.nih.gov/pubmed/9060525
1557. Skarlos, D. V., Samantas, E., Briassoulis, E., Panoussaki, E., Pavlidis, N., Kalofonos, H. P., et.al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG), Ann.Oncol., 2001. 12(9): p. 1231-1238., https://www.ncbi.nlm.nih.gov/pubmed/11697833
1558. Work, E., Nielsen, O. S., Bentzen, S. M., Fode, K., Palshof, T., Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group, J Clin Oncol, 1997. 15(9): p. 3030-3037., https://www.ncbi.nlm.nih.gov/pubmed/9294465
1559. Fried, D. B., Morris, D. E., Poole, C., Rosenman, J. G., Halle, J. S., Detterbeck, F. C., et.al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer, J.Clin.Oncol., 2004. 22(23): p. 4837-4845., https://www.ncbi.nlm.nih.gov/pubmed/15570087
1560. Huncharek, M., McGarry, R., A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer, Oncologist., 2004. 9(6): p. 665-672., https://www.ncbi.nlm.nih.gov/pubmed/15561810
1561. Pijls-Johannesma, M. C., De, Ruysscher D., Lambin, P., Rutten, I., Vansteenkiste, J. F., Early versus late chest radiotherapy for limited stage small cell lung cancer, Cochrane.Database.Syst.Rev., 2005. p. CD004700., https://www.ncbi.nlm.nih.gov/pubmed/15674960
1562. De Ruysscher, D., Pijls-Johannesma, M., Bentzen, S. M., Minken, A., Wanders, R., Lutgens, L., et.al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer, J.Clin.Oncol., 2006. 24(7): p. 1057-1063., https://www.ncbi.nlm.nih.gov/pubmed/16505424
1563. Coy, P., Hodson, I., Payne, D. G., Evans, W. K., Feld, R., MacDonald, A. S., et.al. The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian Multicenter Randomized Trial, Int J Radiat Oncol Biol Phys, 1988. 14(2): p. 219-226., https://www.ncbi.nlm.nih.gov/pubmed/2828289
1564. Choi, N. C., Herndon, J. E., Rosenman, J., Carey, R. W., Chung, C. T., Bernard, S., et.al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer, J.Clin.Oncol., 1998. 16(11): p. 3528-3536., https://www.ncbi.nlm.nih.gov/pubmed/9817271
1565. Bogart, J. A., Herndon, J. E., Lyss, A. P., Watson, D., Miller, A. A., Lee, M. E., et.al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808, Int.J.Radiat.Oncol.Biol.Phys., 2004. 59(2): p. 460-468., https://www.ncbi.nlm.nih.gov/pubmed/15145163
1566. Komaki, R., Swann, R. S., Ettinger, D. S., Glisson, B. S., Sandler, A. B., Movsas, B., et.al. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12, Int.J.Radiat.Oncol.Biol.Phys., 2005. 62(2): p. 342-350., https://www.ncbi.nlm.nih.gov/pubmed/15890573
1567. Bonner, J. A., Sloan, J. A., Shanahan, T. G., Brooks, B. J., Marks, R. S., Krook, J. E., et.al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma, J.Clin.Oncol., 1999. 17(9): p. 2681-2691., https://www.ncbi.nlm.nih.gov/pubmed/10561342
1568. Schild, S. E., Bonner, J. A., Shanahan, T. G., Brooks, B. J., Marks, R. S., Geyer, S. M., et.al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer, Int.J.Radiat.Oncol.Biol.Phys., 2004. 59(4): p. 943-951., https://www.ncbi.nlm.nih.gov/pubmed/15234027
1569. Shaw, Alice T., Kim, Tae Min, Crinò, Lucio, Gridelli, Cesare, Kiura, Katsuyuki, Liu, Geoffrey, et.al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial, The Lancet Oncology, 2017. 18(7): p. 874-886., https://doi.org/10.1016/S1470-2045(17)30339-X
1570. Faivre-Finn, C., Snee, M., Ashcroft, L., Appel, W., Barlesi, F., Bhatnagar, A., et.al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial, Lancet Oncol, 2017. 18(8): p. 1116-1125., https://pubmed.ncbi.nlm.nih.gov/28642008/
1571. Grønberg, B. H., Halvorsen, T. O., Fløtten, Ø, Brustugun, O. T., Brunsvig, P. F., Aasebø, U., et.al. Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer, Acta Oncol, 2016. 55(5): p. 591-7., https://pubmed.ncbi.nlm.nih.gov/26494411/
1572. Arriagada, R., Le, Chevalier T., Riviere, A., Chomy, P., Monnet, I., Bardet, E., et.al. Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients, Ann.Oncol., 2002. 13(5): p. 748-754., https://www.ncbi.nlm.nih.gov/pubmed/12075744
1573. Auperin, A., Arriagada, R., Pignon, J. P., Le, Pechoux C., Gregor, A., Stephens, R. J., et.al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group, N.Engl.J.Med., 1999. 341(7): p. 476-484., https://www.ncbi.nlm.nih.gov/pubmed/10441603
1574. Meert, A. P., Paesmans, M., Berghmans, T., Martin, B., Mascaux, C., Vallot, F., et.al. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis, BMC.Cancer, 2001. 1: p. 5., https://www.ncbi.nlm.nih.gov/pubmed/11432756
1575. Le Pechoux, C., Dunant, A., Senan, S., Wolfson, A., Quoix, E., Faivre-Finn, C., et.al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial, Lancet Oncol, 2009. 10(5): p. 467-474., https://www.ncbi.nlm.nih.gov/pubmed/19386548
1576. Yin, X, Yan, D, Qiu, M, Huang, L, Yan, SX, Prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis., BMC Cancer, 2019. 19 (1)(1): p. 95., https://pubmed.ncbi.nlm.nih.gov/30665432/
1577. Arriagada, R., Le, Chevalier T., Riviere, A., Chomy, P., Monnet, I., Bardet, E., et.al. Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients, Ann.Oncol., 2002. 13(5): p. 748-754., https://pubmed.ncbi.nlm.nih.gov/12075744/
1578. Rodríguez de Dios, N, Couñago, F, Murcia-Mejía, M, Rico-Oses, M, Calvo-Crespo, P, Samper, P, et.al. Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study., J Clin Oncol, 2021. 39 (28)(28): p. 3118-3127., https://pubmed.ncbi.nlm.nih.gov/34379442/
1579. Siegel, RL, Miller, KD, Jemal, A, Cancer Statistics, 2017., CA Cancer J Clin, 2017. 67 (1)(1): p. 7-30., https://pubmed.ncbi.nlm.nih.gov/28055103/
1580. Paz-Ares, L, Chen, Y, Reinmuth, N, Hotta, K, Trukhin, D, Statsenko, G, et.al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN., ESMO Open, 2022. 7 (2)(2): p. 100408., https://pubmed.ncbi.nlm.nih.gov/35279527/
1581. Reck, Martin, Dziadziuszko, Rafal, Sugawara, Shunichi, Kao, Steven, Hochmair, Maximilian, Huemer, Florian, et.al. Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study, 2024. 196: p. 107924., https://www.sciencedirect.com/science/article/pii/S0169500224004586
1582. Sun, Y, Zhai, C, Chen, X, Dong, Z, Hou, L, Zhou, C, et.al. Characterization of PD-L1 protein expression and CD8, Transl Lung Cancer Res, 2019. 8 (6)(6): p. 748-759., https://pubmed.ncbi.nlm.nih.gov/32010554/
1583. Cai, H, Zhang, H, Jiang, Y, Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis., Front Oncol, 2020. 10 (): p. 1079., https://pubmed.ncbi.nlm.nih.gov/32670887/
1584. Cheng, Ying, Han, Liang, Wu, Lin, Chen, Jun, Sun, Hongmei, Wen, Guilan, et.al. Serplulimab versus placebo plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Efficacy and safety from the end-of-study analysis of the international phase 3 ASTRUM-005 study.Wolters Kluwer, Journal of Clinical Oncology, 2025. 43(16_suppl): p. 8093 - 8093., https://doi.org/10.1200/JCO.2025.43.16_suppl.8093
1585. Cheng, Y, Han, L, Wu, L, Chen, J, Sun, H, Wen, G, et.al. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial., JAMA, 2022. 328 (12)(12): p. 1223-1232., https://pubmed.ncbi.nlm.nih.gov/36166026/
1586. Cheng, Y, Fan, Y, Zhao, Y, Huang, D, Li, X, Zhang, P, et.al. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial., J Thorac Oncol, 2024. 19 (7)(7): p. 1073-1085., https://pubmed.ncbi.nlm.nih.gov/38460751/
1587. Horn, L, Mansfield, AS, Szczęsna, A, Havel, L, Krzakowski, M, Hochmair, MJ, et.al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer., N Engl J Med, 2018. 379 (23)(23): p. 2220-2229., https://pubmed.ncbi.nlm.nih.gov/30280641/
1588. Liu, SV, Reck, M, Mansfield, AS, Mok, T, Scherpereel, A, Reinmuth, N, et.al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)., J Clin Oncol, 2021. 39 (6)(6): p. 619-630., https://pubmed.ncbi.nlm.nih.gov/33439693/
1589. Paz-Ares, Luis G., Dvorkin, Mikhail, Chen, Yuanbin, Reinmuth, Niels, Hotta, Katsuyuki, Trukhin, Dmytro, et.al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.Wolters Kluwer, Journal of Clinical Oncology, 2020. 38(15_suppl): p. 9002 - 9002., https://doi.org/10.1200/JCO.2020.38.15_suppl.9002
1590. Paz-Ares, L, Dvorkin, M, Chen, Y, Reinmuth, N, Hotta, K, Trukhin, D, et.al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial., Lancet, 2019. 394 (10212)(10212): p. 1929-1939., https://pubmed.ncbi.nlm.nih.gov/31590988/
1591. Rudin, Charles M., Awad, Mark M., Navarro, Alejandro, Gottfried, Maya, Peters, Solange, Csőszi, Tibor, et.al. KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).Wolters Kluwer, Journal of Clinical Oncology, 2020. 38(15_suppl): p. 9001 - 9001., https://doi.org/10.1200/JCO.2020.38.15_suppl.9001
1592. Leal, Ticiana, Wang, Yating, Dowlati, Afshin, Lewis, DeQuincy Andrew, Chen, Yuanbin, Mohindra, Amit Ramesh, et.al. Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.Wolters Kluwer, Journal of Clinical Oncology, 2020. 38(15_suppl): p. 9000 - 9000., https://doi.org/10.1200/JCO.2020.38.15_suppl.9000
1593. Paz-Ares, L, Borghaei, H, Liu, SV, Peters, S, Herbst, RS, Stencel, K, et.al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial., Lancet, 2025. 405 (10495)(10495): p. 2129-2143., https://pubmed.ncbi.nlm.nih.gov/40473449/
1594. Huo, Z, Duan, Y, Zhan, D, Xu, X, Zheng, N, Cai, J, et.al. Proteomic Stratification of Prognosis and Treatment Options for Small Cell Lung Cancer., Genomics Proteomics Bioinformatics, 2024. 22 (2)(2):, https://pubmed.ncbi.nlm.nih.gov/38961535/
1595. Lorenzi, M, Resi, MV, Bonanno, L, Frega, S, Dal Maso, A, Ferro, A, et.al. Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients., Front Immunol, 2024. 15 (): p. 1308109., https://pubmed.ncbi.nlm.nih.gov/38348046/
1596. Chan, JM, Quintanal-Villalonga, Á, Gao, VR, Xie, Y, Allaj, V, Chaudhary, O, et.al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer., Cancer Cell, 2021. 39 (11)(11): p. 1479-1496.e18., https://pubmed.ncbi.nlm.nih.gov/34653364/
1597. Gay, CM, Stewart, CA, Park, EM, Diao, L, Groves, SM, Heeke, S, et.al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities., Cancer Cell, 2021. 39 (3)(3): p. 346-360.e7., https://pubmed.ncbi.nlm.nih.gov/33482121/
1598. Horita, N, Yamamoto, M, Sato, T, Tsukahara, T, Nagakura, H, Tashiro, K, et.al. Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients., Sci Rep, 2015. 5 (): p. 15437., https://pubmed.ncbi.nlm.nih.gov/26486755/
1599. Kakolyris, S., Mavroudis, D., Tsavaris, N., Souglakos, J., Tsiafaki, P., Kalbakis, K., et.al. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study, Ann.Oncol., 2001. 12(2): p. 193-197., https://www.ncbi.nlm.nih.gov/pubmed/11300323
1600. Masuda, N., Matsui, K., Negoro, S., Takifuji, N., Takeda, K., Yana, T., et.al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer, J Clin.Oncol, 1998. 16(10): p. 3329-3334., https://www.ncbi.nlm.nih.gov/pubmed/9779709
1601. O'Brien, M. E., Ciuleanu, T. E., Tsekov, H., Shparyk, Y., Cucevia, B., Juhasz, G., et.al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer, J Clin Oncol, 2006. 24(34): p. 5441-7., https://www.ncbi.nlm.nih.gov/pubmed/17135646
1602. Kosmas, C., Tsavaris, N. B., Malamos, N. A., Vadiaka, M., Koufos, C., Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer, J.Clin.Oncol., 2001. 19(1): p. 119-126., https://www.ncbi.nlm.nih.gov/pubmed/11134204
1603. Naka, N., Kawahara, M., Okishio, K., Hosoe, S., Ogawara, M., Atagi, S., et.al. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer, Lung Cancer, 2002. 37(3): p. 319-323., https://www.ncbi.nlm.nih.gov/pubmed/12234702
1604. von Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., et.al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer, J.Clin.Oncol., 1999. 17(2): p. 658-667., https://www.ncbi.nlm.nih.gov/pubmed/10080612
1605. von Pawel, J., Gatzemeier, U., Pujol, J. L., Moreau, L., Bildat, S., Ranson, M., et.al. Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer, J.Clin.Oncol., 2001. 19(6): p. 1743-1749., https://www.ncbi.nlm.nih.gov/pubmed/11251005
1606. Eckardt, J. R., von, Pawel J., Pujol, J. L., Papai, Z., Quoix, E., Ardizzoni, A., et.al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer, J.Clin.Oncol., 2007. 25(15): p. 2086-2092., https://www.ncbi.nlm.nih.gov/pubmed/17513814
1607. Groen, H. J., Fokkema, E., Biesma, B., Kwa, B., van Putten, J. W., Postmus, P. E., et.al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule, J.Clin.Oncol., 1999. 17(3): p. 927-932., https://www.ncbi.nlm.nih.gov/pubmed/10071286
1608. Mountzios, G, Sun, L, Cho, BC, Demirci, U, Baka, S, Gümüş, M, et.al. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy., N Engl J Med, 2025. 393 (4)(4): p. 349-361., https://pubmed.ncbi.nlm.nih.gov/40454646/
1609. Rudin, Charles M., Mountzios, Giannis Socrates, Sun, Longhua, Cho, Byoung Chul, Demirci, Umut, Baka, Sofia, et.al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304.Wolters Kluwer, Journal of Clinical Oncology, 2025. 43(17_suppl): p. LBA8008 - LBA8008., https://doi.org/10.1200/JCO.2025.43.17_suppl.LBA8008
1610. Goto, K, Ohe, Y, Shibata, T, Seto, T, Takahashi, T, Nakagawa, K, et.al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol, 2016. 17 (8)(8): p. 1147-1157., https://pubmed.ncbi.nlm.nih.gov/27312053/
1611. Ott, PA, Elez, E, Hiret, S, Kim, DW, Morosky, A, Saraf, S, et.al. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study., J Clin Oncol, 2017. 35 (34)(34): p. 3823-3829., https://pubmed.ncbi.nlm.nih.gov/28813164/
1612. Marabelle, A, Le, DT, Ascierto, PA, Di Giacomo, AM, De Jesus-Acosta, A, Delord, JP, et.al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study., J Clin Oncol, 2020. 38 (1)(1): p. 1-10., https://pubmed.ncbi.nlm.nih.gov/31682550/
1613. Antonia, SJ, López-Martin, JA, Bendell, J, Ott, PA, Taylor, M, Eder, JP, et.al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial., Lancet Oncol, 2016. 17 (7)(7): p. 883-895., https://pubmed.ncbi.nlm.nih.gov/27269741/
1614. Trigo, J, Subbiah, V, Besse, B, Moreno, V, López, R, Sala, MA, et.al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial., Lancet Oncol, 2020. 21 (5)(5): p. 645-654., https://pubmed.ncbi.nlm.nih.gov/32224306/
1615. Aix, SP, Ciuleanu, TE, Navarro, A, Cousin, S, Bonanno, L, Smit, EF, et.al. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial., Lancet Respir Med, 2023. 11 (1)(1): p. 74-86., https://pubmed.ncbi.nlm.nih.gov/36252599/
1616. Ahn, MJ, Cho, BC, Felip, E, Korantzis, I, Ohashi, K, Majem, M, et.al. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer., N Engl J Med, 2023. 389 (22)(22): p. 2063-2075., https://pubmed.ncbi.nlm.nih.gov/37861218/
1617. Wermke, Martin, Felip, Enriqueta, Kuboki, Yasutoshi, Morgensztern, Daniel, Sayehli, Cyrus, Sanmamed, Miguel F., et.al. First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).Wolters Kluwer, Journal of Clinical Oncology, 2023. 41(16_suppl): p. 8502 - 8502., https://doi.org/10.1200/JCO.2023.41.16_suppl.8502
1618. Johnson, M., Awad, M., Koyama, T., Gutierrez, M., Falchook, G.S., Piha-Paul, S.A., et.al. OA05.05 Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 StudyElsevier, Journal of Thoracic Oncology, 2023. 18(11): p. S54 - S55., https://doi.org/10.1016/j.jtho.2023.09.042
1619. Takahashi, T, Yamanaka, T, Seto, T, Harada, H, Nokihara, H, Saka, H, et.al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial., Lancet Oncol, 2017. 18 (5)(5): p. 663-671., https://pubmed.ncbi.nlm.nih.gov/28343976/
1620. Kristensen, C. A., Kristjansen, P. E., Hansen, H. H., Systemic chemotherapy of brain metastases from small-cell lung cancer: a review, J.Clin.Oncol., 1992. 10(9): p. 1498-1502., https://www.ncbi.nlm.nih.gov/pubmed/1325541
1621. Seute, T., Leffers, P., Wilmink, J. T., ten Velde, G. P., Twijnstra, A., Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy, J.Clin.Oncol., 2006. 24(13): p. 2079-2083., https://www.ncbi.nlm.nih.gov/pubmed/16648509
1622. Postmus, P. E., Haaxma-Reiche, H., Smit, E. F., Groen, H. J., Karnicka, H., Lewinski, T., et.al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group, J.Clin.Oncol., 2000. 18(19): p. 3400-3408., https://www.ncbi.nlm.nih.gov/pubmed/11013281
1623. Gondi, V, Pugh, SL, Tome, WA, Caine, C, Corn, B, Kanner, A, et.al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial., J Clin Oncol, 2014. 32 (34)(34): p. 3810-6., https://pubmed.ncbi.nlm.nih.gov/25349290/
1624. De Dios, N. Rodriguez, Murcia, M., Counago, F., Lopez, J., Oses, M. Rico, Ots, P. M. Samper, et.al. Phase III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for SMALL-CELL LUNG CancerElsevier, International Journal of Radiation Oncology, Biology, Physics, 2019. 105(1): p. S35 - S36., https://doi.org/10.1016/j.ijrobp.2019.06.451
1625. Slotman, BJ, van Tinteren, H, Praag, JO, Knegjens, JL, El Sharouni, SY, Hatton, M, et.al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial., Lancet, 2015. 385 (9962)(9962): p. 36-42., https://pubmed.ncbi.nlm.nih.gov/25230595/
1626. Palma, DA, Warner, A, Louie, AV, Senan, S, Slotman, B, Rodrigues, GB, Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis., Clin Lung Cancer, 2016. 17 (4)(4): p. 239-44., https://pubmed.ncbi.nlm.nih.gov/26498503/
1627. Jeremic, B., Shibamoto, Y., Nikolic, N., Milicic, B., Milisavljevic, S., Dagovic, A., et.al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study, J.Clin.Oncol., 1999. 17(7): p. 2092-2099., https://www.ncbi.nlm.nih.gov/pubmed/10561263
1628. Neubauer, M., Schwartz, J., Caracandas, J., Conkling, P., Ilegbodu, D., Tuttle, T., et.al. Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group Performance Status of 2, or age > or = 70 years, J.Clin.Oncol., 2004. 22(10): p. 1872-1877., https://www.ncbi.nlm.nih.gov/pubmed/15143079
1629. Ardizzoni, A., Favaretto, A., Boni, L., Baldini, E., Castiglioni, F., Antonelli, P., et.al. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study (Comment to Ardizzoni A, J Clin Oncol 20 (19): 3947-3955), J.Clin.Oncol., 2005. 23(3): p. 569-575., https://www.ncbi.nlm.nih.gov/pubmed/15659503
1630. Okamoto, H., Watanabe, K., Kunikane, H., et al., Randomized phase III trial of carboplatin(C) plus etoposide (E) vs. split doses of cisplatin (P) plus etoposide (E) in elderly or poor-risk patients with extensive disease small cell lung cancer (ED-SCLC): JCOG9702, Proc.ASCO, 2005. p. abs. 7003., https://www.ncbi.nlm.nih.gov/pubmed/17579629
1631. Killingberg, KT, Grønberg, BH, Slaaen, M, Kirkevold, Ø, Halvorsen, TO, Treatment Outcomes of Older Participants in a Randomized Trial Comparing Two Schedules of Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC., J Thorac Oncol, 2023. 18 (6)(6): p. 803-812., https://pubmed.ncbi.nlm.nih.gov/36716960/
1632. Stinchcombe, TE, Fan, W, Schild, SE, Vokes, EE, Bogart, J, Le, QT, et.al. A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients., Cancer, 2019. 125 (3)(3): p. 382-390., https://pubmed.ncbi.nlm.nih.gov/30343497/
1633. Yuen, AR, Zou, G, Turrisi, AT, Sause, W, Komaki, R, Wagner, H, et.al. Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma., Cancer, 2000. 89 (9)(9): p. 1953-60., https://pubmed.ncbi.nlm.nih.gov/11064352/
1634. Christodoulou, M, Blackhall, F, Mistry, H, Leylek, A, Knegjens, J, Remouchamps, V, et.al. Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial., J Thorac Oncol, 2019. 14 (1)(1): p. 63-71., https://pubmed.ncbi.nlm.nih.gov/30391573/
1635. Schild, S. E., Stella, P. J., Brooks, B. J., Mandrekar, S., Bonner, J. A., McGinnis, W. L., et.al. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly, Cancer, 2005. 103(11): p. 2349-2354., https://www.ncbi.nlm.nih.gov/pubmed/15852407
1636. Le Péchoux, C, Laplanche, A, Faivre-Finn, C, Ciuleanu, T, Wanders, R, Lerouge, D, et.al. Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)., Ann Oncol, 2011. 22 (5)(5): p. 1154-1163., https://pubmed.ncbi.nlm.nih.gov/21139020/
1637. Dipper, A, Jones, HE, Bhatnagar, R, Preston, NJ, Maskell, N, Clive, A, Interventions for the management of malignant pleural effusions: an updated network meta-analysis., Eur Respir Rev, 2021. 30 (160)(160):, https://pubmed.ncbi.nlm.nih.gov/33952602/
1638. Diacon, A. H., Wyser, C., Bolliger, C. T., Tamm, M., Pless, M., Perruchoud, A. P., et.al. Prospective randomized comparison of thoracoscopic talc poudrage under local anesthesia versus bleomycin instillation for pleurodesis in malignant pleural effusions, Am.J.Respir.Crit Care Med., 2000. 162(4 Pt 1): p. 1445-1449., https://www.ncbi.nlm.nih.gov/pubmed/11029359
1639. Dresler, C. M., Olak, J., Herndon, J. E., Richards, W. G., Scalzetti, E., Fleishman, S. B., et.al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion, Chest, 2005. 127(3): p. 909-915., https://www.ncbi.nlm.nih.gov/pubmed/15764775
1640. Shaw, P., Agarwal, R., Pleurodesis for malignant pleural effusion, Cochrane-database-of-systematic-reviews, 2004. (1)(CD002916):, https://www.ncbi.nlm.nih.gov/pubmed/14973997
1641. Shaw, P., Agarwal, R., Pleurodesis for malignant pleural effusion, Cochrane-database-of-systematic-reviews, 2009. (1)(CD002916):, https://pubmed.ncbi.nlm.nih.gov/14973997/
1642. Yim, A. P., Chan, A. T., Lee, T. W., Wan, I. Y., Ho, J. K., Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion, Ann.Thorac.Surg., 1996. 62(6): p. 1655-1658., https://www.ncbi.nlm.nih.gov/pubmed/8957368
1643. Ukale, V., Agrenius, V., Hillerdal, G., Mohlkert, D., Widstrom, O., Pleurodesis in recurrent pleural effusions: a randomized comparison of a classical and a currently popular drug, Lung Cancer, 2004. 43(3): p. 323-328., https://www.ncbi.nlm.nih.gov/pubmed/15165091
1644. Walker-Renard, P. B., Vaughan, L. M., Sahn, S. A., Chemical pleurodesis for malignant pleural effusions, Ann.Intern.Med., 1994. 120(1): p. 56-64., https://www.ncbi.nlm.nih.gov/pubmed/8250457
1645. Maskel, N. A., Lee, Y. C. G., Gleeson, F. V., et al., Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size, Am J Respir Crit Care Med, 2004. 170: p. 377-382., https://www.ncbi.nlm.nih.gov/pubmed/15142871
1646. Janssen, J. P., Collier, G., Astoul, P., et al., Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study, Lancet, 2007. 369: p. 1535-1539., https://www.ncbi.nlm.nih.gov/pubmed/17482984
1647. Cardillo, G., Facciolo, F., Carbone, L., Regal, M., Corzani, F., Ricci, A., et.al. Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions, Eur.J.Cardiothorac.Surg., 2002. 21(2): p. 302-305., https://www.ncbi.nlm.nih.gov/pubmed/11825740
1648. de, Campos, Jr., Vargas, F. S., de Campos, Werebe E., Cardoso, P., Teixeira, L. R., Jatene, F. B., et.al. Thoracoscopy talc poudrage : a 15-year experience, Chest, 2001. 119(3): p. 801-806., https://www.ncbi.nlm.nih.gov/pubmed/11243960
1649. Kolschmann, S., Ballin, A., Gillissen, A., Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions, Chest, 2005. 128(3): p. 1431-1435., https://www.ncbi.nlm.nih.gov/pubmed/16162739
1650. Tan, C., Sedrakyan, A., Browne, J., Swift, S., Treasure, T., The evidence on the effectiveness of management for malignant pleural effusion: a systematic review, Eur.J.Cardiothorac.Surg., 2006. 29(5): p. 829-838., https://www.ncbi.nlm.nih.gov/pubmed/16626967
1651. Viallat, J. R., Rey, F., Astoul, P., Boutin, C., Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases, Chest, 1996. 110(6): p. 1387-1393., https://www.ncbi.nlm.nih.gov/pubmed/8989050
1652. Genc, O., Petrou, M., Ladas, G., Goldstraw, P., The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions, Eur.J.Cardiothorac.Surg., 2000. 18(2): p. 143-146., https://www.ncbi.nlm.nih.gov/pubmed/10925221
1653. Musani, A. I., Haas, A. R., Seijo, L., Wilby, M., Sterman, D. H., Outpatient management of malignant pleural effusions with small-bore, tunneled pleural catheters, Respiration, 2004. 71(6): p. 559-566., https://www.ncbi.nlm.nih.gov/pubmed/15627865
1654. Ohm, C., Park, D., Vogen, M., Bendick, P., Welsh, R., Pursel, S., et.al. Use of an indwelling pleural catheter compared with thorascopic talc pleurodesis in the management of malignant pleural effusions, Am.Surg., 2003. 69(3): p. 198-202., https://www.ncbi.nlm.nih.gov/pubmed/12678474
1655. Wahidi, MM, Reddy, C, Yarmus, L, Feller-Kopman, D, Musani, A, Shepherd, RW, et.al. Randomized Trial of Pleural Fluid Drainage Frequency in Patients with Malignant Pleural Effusions. The ASAP Trial., Am J Respir Crit Care Med, 2017. 195 (8)(8): p. 1050-1057., https://pubmed.ncbi.nlm.nih.gov/27898215/
1656. Muruganandan, S, Azzopardi, M, Fitzgerald, DB, Shrestha, R, Kwan, BCH, Lam, DCL, et.al. Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial., Lancet Respir Med, 2018. 6 (9)(9): p. 671-680., https://pubmed.ncbi.nlm.nih.gov/30037711/
1657. Davies, HE, Mishra, EK, Kahan, BC, Wrightson, JM, Stanton, AE, Guhan, A, et.al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial., JAMA, 2012. 307 (22)(22): p. 2383-9., https://pubmed.ncbi.nlm.nih.gov/22610520/
1658. Thomas, R, Fysh, ETH, Smith, NA, Lee, P, Kwan, BCH, Yap, E, et.al. Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial., JAMA, 2017. 318 (19)(19): p. 1903-1912., https://pubmed.ncbi.nlm.nih.gov/29164255/
1659. Iyer, NP, Reddy, CB, Wahidi, MM, Lewis, SZ, Diekemper, RL, Feller-Kopman, D, et.al. Indwelling Pleural Catheter versus Pleurodesis for Malignant Pleural Effusions. A Systematic Review and Meta-Analysis., Ann Am Thorac Soc, 2019. 16 (1)(1): p. 124-131., https://pubmed.ncbi.nlm.nih.gov/30272486/
1660. Herth, F., Ernst, A., Becker, H. D., Long-term outcome and lung cancer incidence in patients with hemoptysis of unknown origin, Chest, 2001. 120: p. 1592-1594., https://www.ncbi.nlm.nih.gov/pubmed/11713139
1661. Fidan, A., Ozdogan, S., Oruc, O., et al., Hemoptysis: a retrospective analysis of 108 cases, Respir Med, 2002. 96: p. 677-680., https://www.ncbi.nlm.nih.gov/pubmed/12243312
1662. Hirshberg, B., Biran, I., Glazer, M., et al., Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital, Chest, 1997. 112: p. 440-444., https://www.ncbi.nlm.nih.gov/pubmed/9266882
1663. O'Mahony, AC, Kennedy, MP, Meta-Analysis on Utility of Bronchoscopy in Addition to Computed Tomography Thorax in the Investigation of Lung Cancer in Patients with Haemoptysis., Respiration, 2022. 101 (12)(12): p. 1139-1147., https://pubmed.ncbi.nlm.nih.gov/36353770/
1664. Tsoumakidou, M., Chrysofakis, G., Tsiligianni, I., et al., A prospective analysis of 184 hemoptysis cases - diagnostic impact of chest x-ray, computed tomography, bronchoscopy, Respiration, 2006. 73: p. 808-814., https://www.ncbi.nlm.nih.gov/pubmed/16446530
1665. Freitag, L., Tekolf, E., Stamatis, G., et al., Three years experience with a new balloon catheter for the management of haemoptysis, Eur Respir J, 1994. 7: p. 2033-2037., https://pubmed.ncbi.nlm.nih.gov/7875278/
1666. Kato, A., Kudo, S., Matsumoto, K., et al., Bronchial artery embolization for hemoptysis due to benign diseases: immediate and long-term reusults, Cardiovasc.Intervent.Radiol., 2000. 23: p. 351-357., https://www.ncbi.nlm.nih.gov/pubmed/11060364
1667. Schmidt, B., Liebers, U., Kroncke, T., John, M., Witt, C., [Bronchial artery embolisation using platinum coils in 52 patients with severe pulmonary hemorrhage], Dtsch Med Wochenschr, 2005. 130(9): p. 440-3., https://www.ncbi.nlm.nih.gov/pubmed/15731954
1668. Witt, Ch, Schmidt, B., Geisler, A., et al., Value of bronchial artery embolisation with platinum coils in tumorous pulmonary bleeding, Eur J Cancer, 2000. 36: p. 1949-1954., https://pubmed.ncbi.nlm.nih.gov/11000576/
1669. Mal, H., Rullom, I., Mellot, F., et al., Immediate and long-term results of bronchial artery embolization for life-threatening hemoptysis, Chest, 1999. 115: p. 996-1001., https://www.ncbi.nlm.nih.gov/pubmed/10208199
1670. Swanson, K. L., Johnson, C. M., Prakas, U. B., et al., Bronchial artery embolization: experience with 54 patients, Chest, 2002. 121: p. 789-795., https://www.ncbi.nlm.nih.gov/pubmed/11888961
1671. Yoon, W., Kim, J. K., Kim, Y. H., et al., Bronchial and nonbronchial systemic artery embolization for life-threatening hemoptysis: a comprehensive review, Radiographics, 2002. 22: p. 1395-1409., https://www.ncbi.nlm.nih.gov/pubmed/12432111
1672. Hetzel.M.R, Nixon, C., Edmondstone, W. M., et al., Laser therapy in 100 tracheobronchial tumours, Thorax, 1985. 40: p. 341-345., https://pubmed.ncbi.nlm.nih.gov/4023988/
1673. Morice, R. C., Ece, T., Ece, F., et al., Endobronchial argon plasma coagulation for treatment of hemoptysis and neoplastic airway obstruction, Chest, 2001. 119: p. 781-787., https://www.ncbi.nlm.nih.gov/pubmed/11243957
1674. Rowell, N. P., Gleeson, F. V., Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus, Cochrane.Database.Syst.Rev., 2001. p. CD001316., https://pubmed.ncbi.nlm.nih.gov/11687105/
1675. Garcia, Monaco R., Bertoni, H., Pallota, G., Lastiri, R., Varela, M., Beveraggi, E. M., et.al. Use of self-expanding vascular endoprostheses in superior vena cava syndrome, Eur J Cardiothorac.Surg, 2003. 24(2): p. 208-211., https://www.ncbi.nlm.nih.gov/pubmed/12895609
1676. Ahmann, F. R., A reassessment of the clinical implications of the superior vena caval syndrome, J Clin.Oncol., 1984. 2(8): p. 961-969., https://www.ncbi.nlm.nih.gov/pubmed/6205125
1677. Varricchio, C., Clinical management of superior vena cava syndrome, Heart Lung, 1985. 14(4): p. 411-416., https://www.ncbi.nlm.nih.gov/pubmed/3891692
1678. Hennequin, L. M., Fade, O., Fays, J. G., Bic, J. F., Jaafar, S., Bertal, A., et.al. Superior vena cava stent placement: results with the Wallstent endoprosthesis, Radiology, 1995. 196(2): p. 353-361., https://www.ncbi.nlm.nih.gov/pubmed/7617844
1679. Stock, K. W., Jacob, A. L., Proske, M., Bolliger, C. T., Rochlitz, C., Steinbrich, W., Treatment of malignant obstruction of the superior vena cava with the self-expanding Wallstent, Thorax, 1995. 50(11): p. 1151-1156., https://www.ncbi.nlm.nih.gov/pubmed/8553270
1680. Wilhelm, K., Schild, H., Textor, J., Mildenberger, P., Strunk, H., Terjung, B., et.al. Stentimplantation zur palliativen Therapie der oberen Einfluástauung bei Bronchialkarzinomen, Dtsch.Med Wochenschr., 1995. 120(42): p. 1419-1425., https://pubmed.ncbi.nlm.nih.gov/7555670/
1681. Ostler, P. J., Clarke, D. P., Watkinson, A. F., Gaze, M. N., Superior vena cava obstruction: a modern management strategy, Clin.Oncol.(R.Coll.Radiol.), 1997. 9(2): p. 83-89., https://www.ncbi.nlm.nih.gov/pubmed/9135892
1682. Mason, B. A., Axillary-subclavian vein occlusion in patients with lung neoplasms, Cancer, 1981. 48(8): p. 1886-1889., https://www.ncbi.nlm.nih.gov/pubmed/6269730
1683. Hosna, A, Haseeb Ul Rasool, M, Noff, NC, Makhoul, K, Miller, D, Umar, Z, et.al. Cryotherapy for the Treatment of Tracheal Stenosis: A Systematic Review., Cureus, 2023. 15 (6)(6): p. e41012., https://pubmed.ncbi.nlm.nih.gov/37519508/
1684. Umar, Z, Haseeb Ul Rasool, M, Ashfaq, S, Parikh, A, Maqsood, HA, Hosna, AU, et.al. Malignant Airway Obstruction and the Use of Nd:YAG Laser: A Systematic Review on Its Efficacy and Safety., Cureus, 2023. 15 (1)(1): p. e34434., https://pubmed.ncbi.nlm.nih.gov/36874755/
1685. Bolliger, C. T., Sutedja, T. G., Strausz, J., Freitag, L., Therapeutic bronchoscopy with immediate effect: laser, electrocautery, argon plasma coagulation and stents, Eur Respir J, 2006. 27(6): p. 1258-1271., https://www.ncbi.nlm.nih.gov/pubmed/16772389
1686. Amjadi, K., Voduc, N., Cruysberghs, Y., Lemmens, R., Fergusson, D. A., Doucette, S., et.al. Impact of interventional bronchoscopy on quality of life in malignant airway obstruction, Respiration, 2008. 76(4): p. 421-8., https://www.ncbi.nlm.nih.gov/pubmed/18758153
1687. Ong, P, Grosu, HB, Debiane, L, Casal, RF, Eapen, GA, Jimenez, CA, et.al. Long-term quality-adjusted survival following therapeutic bronchoscopy for malignant central airway obstruction., Thorax, 2019. 74 (2)(2): p. 141-156., https://pubmed.ncbi.nlm.nih.gov/30254139/
1688. Ost, D. E., Ernst, A., Grosu, H. B., Lei, X., Diaz-Mendoza, J., Slade, M., et.al. Therapeutic bronchoscopy for malignant central airway obstruction: success rates and impact on dyspnea and quality of life, Chest, 2015. 147(5): p. 1282-98., https://www.ncbi.nlm.nih.gov/pubmed/25358019
1689. Hautmann, H., Gamarra, F., Pfeifer, K. J., Huber, R. M., Fiberoptic bronchoscopic balloon dilatation in malignant tracheobronchial disease: indications and results, Chest, 2001. 120(1): p. 43-49., https://www.ncbi.nlm.nih.gov/pubmed/11451814
1690. Dumon, J. F., Shapshay, S., Bourcereau, J., Cavaliere, S., Meric, B., Garbi, N., et.al. Principles for safety in application of neodymium-YAG laser in bronchology, Chest, 1984. 86(2): p. 163-168., https://www.ncbi.nlm.nih.gov/pubmed/6547662
1691. Cavaliere, S., Venuta, F., Foccoli, P., Toninelli, C., La, Face B., Endoscopic treatment of malignant airway obstructions in 2,008 patients, Chest, 1996. 110(6): p. 1536-1542., https://www.ncbi.nlm.nih.gov/pubmed/8989073
1692. Macha, H. N., Becker, K. O., Kemmer, H. P., Pattern of failure and survival in endobronchial laser resection. A matched pair study, Chest, 1994. 105(6): p. 1668-1672., https://www.ncbi.nlm.nih.gov/pubmed/7515777
1693. Fujisawa, T., Yamaguchi, Y., Baba, M., Shiba, M., Kadoyama, C., Yusa, T., et.al. Endoscopic Nd:YAG laser surgery on malignant and benign lesions of the trachea and carina, Jpn.J.Surg., 1990. 20(6): p. 650-659., https://www.ncbi.nlm.nih.gov/pubmed/2084289
1694. George, P. J., Clarke, G., Tolfree, S., Garrett, C. P., Hetzel, M. R., Changes in regional ventilation and perfusion of the lung after endoscopic laser treatment, Thorax, 1990. 45(4): p. 248-253., https://www.ncbi.nlm.nih.gov/pubmed/1694049
1695. Casey, K. R., Fairfax, W. R., Smith, S. J., Dixon, J. A., Intratracheal fire ignited by the Nd-YAG laser during treatment of tracheal stenosis, Chest, 1983. 84(3): p. 295-296., https://www.ncbi.nlm.nih.gov/pubmed/6688392
1696. Vanderschueren, R. G., Westermann, C. J., Complications of endobronchial neodymium-Yag (Nd:Yag) laser application, Lung, 1990. 168 Suppl: p. 1089-1094., https://www.ncbi.nlm.nih.gov/pubmed/2117110
1697. Freitag, L., Chapman, G. A., Sielczak, M., Ahmed, A., Russin, D., Laser smoke effect on the bronchial system, Lasers Surg Med, 1987. 7(3): p. 283-288., https://www.ncbi.nlm.nih.gov/pubmed/3626753
1698. Chan, A. L., Tharratt, R. S., Siefkin, A. D., Albertson, T. E., Volz, W. G., Allen, R. P., Nd:YAG laser bronchoscopy. Rigid or fiberoptic mode?, Chest, 1990. 98(2): p. 271-275., https://www.ncbi.nlm.nih.gov/pubmed/2376156
1699. Desai, S. J., Mehta, A. C., VanderBrug, Medendorp S., Golish, J. A., Ahmad, M., Survival experience following Nd:YAG laser photoresection for primary bronchogenic carcinoma, Chest, 1988. 94(5): p. 939-944., https://www.ncbi.nlm.nih.gov/pubmed/2460297
1700. Hetzel, M. R., Smith, S. G., Endoscopic palliation of tracheobronchial malignancies, Thorax, 1991. 46(5): p. 325-333., https://pubmed.ncbi.nlm.nih.gov/1712516/
1701. Personne, C., Colchen, A., Leroy, M., Vourc'h, G., Toty, L., Indications and technique for endoscopic laser resections in bronchology. A critical analysis based upon 2,284 resections, J Thorac Cardiovasc Surg, 1986. 91(5): p. 710-715., https://www.ncbi.nlm.nih.gov/pubmed/3009998
1702. Ross, D. J., Mohsenifar, Z., Koerner, S. K., Survival characteristics after neodymium: YAG laser photoresection in advanced stage lung cancer, Chest, 1990. 98(3): p. 581-585., https://www.ncbi.nlm.nih.gov/pubmed/1697520
1703. Gerasin, V. A., Shafirovsky, B. B., Endobronchial electrosurgery, Chest, 1988. 93(2): p. 270-274., https://www.ncbi.nlm.nih.gov/pubmed/3338293
1704. Sutedja, T. G., van Boxem, T., Schramel, F. M., et al., Endobronchial electrocautery is an excellent alternative for Nd: YAG laser to to treat airway tumors, J Bronchol, 1997. 4: p. 101-105.
1705. Reichle, G., Freitag, L., Kullmann, H. J., Prenzel, R., Macha, H. N., Farin, G., [Argon plasma coagulation in bronchology: a new method--alternative or complementary?], Pneumologie, 2000. 54(11): p. 508-516., https://www.ncbi.nlm.nih.gov/pubmed/11132548
1706. Mahmood, K., Wahidi, M. M., Thomas, S., Argento, A. C., Ninan, N. A., Smathers, E. C., et.al. Therapeutic bronchoscopy improves spirometry, quality of life, and survival in central airway obstruction, Respiration, 2015. 89(5): p. 404-13., https://www.ncbi.nlm.nih.gov/pubmed/25925488
1707. Oviatt, P. L., Stather, D. R., Michaud, G., Maceachern, P., Tremblay, A., Exercise capacity, lung function, and quality of life after interventional bronchoscopy, J Thorac Oncol, 2011. 6(1): p. 38-42., https://www.ncbi.nlm.nih.gov/pubmed/21150471
1708. Neumann, K., Sundset, A., Espinoza, A., Kongerud, J., Fosse, E., Changes in quality of life, dyspnea scores, and lung function in lung cancer patients with airway obstruction after a therapeutic bronchoscopy, J Bronchology Interv Pulmonol, 2013. 20(2): p. 134-9., https://www.ncbi.nlm.nih.gov/pubmed/23609247
1709. Amjadi, K., Voduc, N., Cruysberghs, Y., Lemmens, R., Fergusson, D. A., Doucette, S., et.al. Impact of interventional bronchoscopy on quality of life in malignant airway obstruction, Respiration, 2008. 76(4): p. 421-8., https://pubmed.ncbi.nlm.nih.gov/18758153/
1710. Boxem, T., Muller, M., Venmans, B., Postmus, P., Sutedja, T., Nd-YAG laser vs bronchoscopic electrocautery for palliation of symptomatic airway obstruction: a cost-effectiveness study, Chest, 1999. 116(4): p. 1108-1112., https://www.ncbi.nlm.nih.gov/pubmed/10531180
1711. Vonk-Noordegraaf, A., Postmus, P. E., Sutedja, T. G., Bronchoscopic treatment of patients with intraluminal microinvasive radiographically occult lung cancer not eligible for surgical resection: a follow-up study, Lung Cancer, 2003. 39(1): p. 49-53., https://www.ncbi.nlm.nih.gov/pubmed/12499094
1712. Reddy, C., Majid, A., Michaud, G., Feller-Kopman, D., Eberhardt, R., Herth, F., et.al. Gas embolism following bronchoscopic argon plasma coagulation: a case series, Chest, 2008. 134(5): p. 1066-1069., https://www.ncbi.nlm.nih.gov/pubmed/18988782
1713. Mathur, P. N., Wolf, K. M., Busk, M. F., Briete, W. M., Datzman, M., Fiberoptic bronchoscopic cryotherapy in the management of tracheobronchial obstruction, Chest, 1996. 110(3): p. 718-723., https://www.ncbi.nlm.nih.gov/pubmed/8797417
1714. Vergnon, J. M., Huber, R. M., Moghissi, K., Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers, Eur Respir J, 2006. 28(1): p. 200-218., https://www.ncbi.nlm.nih.gov/pubmed/16816349
1715. Marasso, A., Gallo, E., Massaglia, G. M., Onoscuri, M., Bernardi, V., Cryosurgery in bronchoscopic treatment of tracheobronchial stenosis. Indications, limits, personal experience, Chest, 1993. 103(2): p. 472-474., https://www.ncbi.nlm.nih.gov/pubmed/8432138
1716. Maiwand, M. O., The role of cryosurgery in palliation of tracheo-bronchial carcinoma, Eur J Cardiothorac.Surg, 1999. 15(6): p. 764-768., https://www.ncbi.nlm.nih.gov/pubmed/10431856
1717. Marasso, A., Bernardi, V., Gai, R., Gallo, E., Massaglia, G. M., Onoscuri, M., et.al. Radiofrequency resection of bronchial tumours in combination with cryotherapy: evaluation of a new technique, Thorax, 1998. 53(2): p. 106-109., https://www.ncbi.nlm.nih.gov/pubmed/9624294
1718. Vergnon, J. M., Schmitt, T., Alamartine, E., Barthelemy, J. C., Fournel, P., Emonot, A., Initial combined cryotherapy and irradiation for unresectable non-small cell lung cancer. Preliminary results, Chest, 1992. 102(5): p. 1436-1440., https://www.ncbi.nlm.nih.gov/pubmed/1330447
1719. Homasson, J. P., Pecking, A., Roden, S., Angebault, M., Bonniot, J. P., Tumor fixation of bleomycin labeled with 57 cobalt before and after cryotherapy of bronchial carcinoma, Cryobiology, 1992. 29(5): p. 543-548., https://www.ncbi.nlm.nih.gov/pubmed/1385037
1720. Deygas, N., Froudarakis, M., Ozenne, G., Vergnon, J. M., Cryotherapy in early superficial bronchogenic carcinoma, Chest, 2001. 120(1): p. 26-31., https://www.ncbi.nlm.nih.gov/pubmed/11451811
1721. Furukawa, K., Kato, H., Konaka, C., Okunaka, T., Usuda, J., Ebihara, Y., Locally recurrent central-type early stage lung cancer < 1.0 cm in diameter after complete remission by photodynamic therapy, Chest, 2005. 128(5): p. 3269-3275., https://www.ncbi.nlm.nih.gov/pubmed/16306036
1722. Maziak, D. E., Markman, B. R., Mackay, J. A., Evans, W. K., Photodynamic therapy in nonsmall cell lung cancer: a systematic review, Ann.Thorac.Surg., 2004. 77(4): p. 1484-1491., https://www.ncbi.nlm.nih.gov/pubmed/15063303
1723. Miyazu, Y., Miyazawa, T., Kurimoto, N., Iwamoto, Y., Kanoh, K., Kohno, N., Endobronchial ultrasonography in the assessment of centrally located early-stage lung cancer before photodynamic therapy, Am.J Respir Crit Care Med, 2002. 165(6): p. 832-837., https://www.ncbi.nlm.nih.gov/pubmed/11897652
1724. Moghissi, K., Dixon, K., Is bronchoscopic photodynamic therapy a therapeutic option in lung cancer?, Eur Respir J, 2003. 22(3): p. 535-541., https://www.ncbi.nlm.nih.gov/pubmed/14516148
1725. az-Jimenez, J. P., Martinez-Ballarin, J. E., Llunell, A., Farrero, E., Rodriguez, A., Castro, M. J., Efficacy and safety of photodynamic therapy versus Nd-YAG laser resection in NSCLC with airway obstruction, Eur.Respir.J., 1999. 14(4): p. 800-805., https://www.ncbi.nlm.nih.gov/pubmed/10573224
1726. Furuse, K., Fukuoka, M., Kato, H., Horai, T., Kubota, K., Kodama, N., et.al. A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group, J Clin.Oncol., 1993. 11(10): p. 1852-1857., https://www.ncbi.nlm.nih.gov/pubmed/8410109
1727. Freitag, L., Ernst, A., Thomas, M., Prenzel, R., Wahlers, B., Macha, H. N., Sequential photodynamic therapy (PDT) and high dose brachytherapy for endobronchial tumour control in patients with limited bronchogenic carcinoma, Thorax, 2004. 59(9): p. 790-793., https://www.ncbi.nlm.nih.gov/pubmed/15333857
1728. Wayne, MT, Ali, MS, Wakeam, E, Maldonado, F, Yarmus, LB, Prescott, HC, et.al. Current Practices in Airway Stent Management: A National Survey of US Practitioners., Respiration, 2023. 102 (8)(8): p. 608-612., https://pubmed.ncbi.nlm.nih.gov/37429267/
1729. Sabath, BF, Casal, RF, Airway stenting for central airway obstruction: a review., Mediastinum, 2023. 7 (): p. 18., https://pubmed.ncbi.nlm.nih.gov/37261090/
1730. Allison, R., Sibata, C., Sarma, K., Childs, C. J., Downie, G. H., High-dose-rate brachytherapy in combination with stenting offers a rapid and statistically significant improvement in quality of life for patients with endobronchial recurrence, Cancer J., 2004. 10(6): p. 368-373., https://pubmed.ncbi.nlm.nih.gov/15701268/
1731. Bolliger, C. T., Probst, R., Tschopp, K., Soler, M., Perruchoud, A. P., Silicone stents in the management of inoperable tracheobronchial stenoses. Indications and limitations, Chest, 1993. 104(6): p. 1653-1659., https://www.ncbi.nlm.nih.gov/pubmed/7504608
1732. Bolliger, C. T., Breitenbuecher, A., Brutsche, M., Heitz, M., Stanzel, F., Use of studded Polyflex stents in patients with neoplastic obstructions of the central airways, Respiration, 2004. 71(1): p. 83-87., https://www.ncbi.nlm.nih.gov/pubmed/14872116
1733. Davis, N., Madden, B. P., Sheth, A., Crerar-Gilbert, A. J., Airway management of patients with tracheobronchial stents, Br.J.Anaesth., 2006. 96(1): p. 132-135., https://www.ncbi.nlm.nih.gov/pubmed/16257995
1734. Dumon, J. F., A dedicated tracheobronchial stent, Chest, 1990. 97(2): p. 328-332., https://www.ncbi.nlm.nih.gov/pubmed/1688757
1735. Hauck, R. W., Lembeck, R. M., Emslander, H. P., Schomig, A., Implantation of Accuflex and Strecker stents in malignant bronchial stenoses by flexible bronchoscopy, Chest, 1997. 112(1): p. 134-144., https://www.ncbi.nlm.nih.gov/pubmed/9228369
1736. Miyazawa, T., Yamakido, M., Ikeda, S., Furukawa, K., Takiguchi, Y., Tada, H., et.al. Implantation of ultraflex nitinol stents in malignant tracheobronchial stenoses, Chest, 2000. 118(4): p. 959-965., https://www.ncbi.nlm.nih.gov/pubmed/11035663
1737. Miyazawa, T., Miyazu, Y., Iwamoto, Y., Ishida, A., Kanoh, K., Sumiyoshi, H., et.al. Stenting at the flow-limiting segment in tracheobronchial stenosis due to lung cancer, Am.J.Respir.Crit Care Med., 2004. 169(10): p. 1096-1102., https://www.ncbi.nlm.nih.gov/pubmed/15132959
1738. Mohnke, M., Freitag, L., Greschuchna, D., Endobronchiale Prosthesen; ein Erfahrungsbericht, Pneumologie, 1992. 46(4): p. 148-152., https://pubmed.ncbi.nlm.nih.gov/1579563/
1739. Nakajima, Y., Kurihara, Y., Niimi, H., Konno, S., Ishikawa, T., Osada, H., et.al. Efficacy and complications of the Gianturco-Z tracheobronchial stent for malignant airway stenosis, Cardiovasc.Intervent.Radiol., 1999. 22(4): p. 287-292., https://www.ncbi.nlm.nih.gov/pubmed/10415217
1740. Nam, D. H., Shin, J. H., Song, H. Y., Jung, G. S., Han, Y. M., Malignant esophageal-tracheobronchial strictures: parallel placement of covered retrievable expandable nitinol stents, Acta Radiol., 2006. 47(1): p. 3-9., https://www.ncbi.nlm.nih.gov/pubmed/16498926
1741. Nomori, H., Horio, H., Suemasu, K., Bougienage and balloon dilation using a conventional tracheal tube for tracheobronchial stenosis before stent placement, Surg.Endosc., 2000. 14(6): p. 587-591., https://www.ncbi.nlm.nih.gov/pubmed/10890972
1742. Nomori, H., Horio, H., Imazu, Y., Suemasu, K., Double stenting for esophageal and tracheobronchial stenoses, Ann.Thorac.Surg., 2000. 70(6): p. 1803-1807., https://www.ncbi.nlm.nih.gov/pubmed/11156075
1743. Rieger, J., Linsenmaier, U., Hautmann, H., Fedorowski, A., Huber, R. M., Pfeifer, K. J., [Interdisciplinary interventional therapy for tracheobronchial stenosis with modern metal net stents], Rofo, 2002. 174(8): p. 1009-1014., https://www.ncbi.nlm.nih.gov/pubmed/12142979
1744. Sawada, S., Tanigawa, N., Kobayashi, M., Furui, S., Ohta, Y., Malignant tracheobronchial obstructive lesions: treatment with Gianturco expandable metallic stents, Radiology, 1993. 188(1): p. 205-208., https://www.ncbi.nlm.nih.gov/pubmed/8511298
1745. Schmitz, E., Hurter, T., Bohndorf, K., Gunther, R. W., Hanrath, P., [Metal endoprostheses for endoscopic therapy in malignant bronchial tumors], Dtsch.Med.Wochenschr., 1992. 117(44): p. 1663-1668., https://www.ncbi.nlm.nih.gov/pubmed/1385060
1746. Shin, J. H., Kim, S. W., Shim, T. S., Jung, G. S., Kim, T. H., Ko, G. Y., et.al. Malignant tracheobronchial strictures: palliation with covered retrievable expandable nitinol stent, J.Vasc.Interv.Radiol., 2003. 14(12): p. 1525-1534., https://www.ncbi.nlm.nih.gov/pubmed/14654487
1747. Shin, J. H., Song, H. Y., Ko, G. Y., Lim, J. O., Yoon, H. K., Sung, K. B., Esophagorespiratory fistula: long-term results of palliative treatment with covered expandable metallic stents in 61 patients, Radiology, 2004. 232(1): p. 252-259., https://www.ncbi.nlm.nih.gov/pubmed/15166325
1748. Shiraishi, T., Kawahara, K., Shirakusa, T., Inada, K., Okabayashi, K., Iwasaki, A., Stenting for airway obstruction in the carinal region, Ann.Thorac.Surg., 1998. 66(6): p. 1925-1929., https://www.ncbi.nlm.nih.gov/pubmed/9930470
1749. Stockton, P. A., Ledson, M. J., Hind, C. R., Walshaw, M. J., Bronchoscopic insertion of Gianturco stents for the palliation of malignant lung disease: 10 year experience, Lung Cancer, 2003. 42(1): p. 113-117., https://www.ncbi.nlm.nih.gov/pubmed/14512195
1750. Urschel, J. D., Delayed massive hemoptysis after expandable bronchial stent placement, J.Laparoendosc.Adv.Surg.Tech.A, 1999. 9(2): p. 155-158., https://www.ncbi.nlm.nih.gov/pubmed/10235353
1751. Vonk-Noordegraaf, A., Postmus, P. E., Sutedja, T. G., Tracheobronchial stenting in the terminal care of cancer patients with central airways obstruction, Chest, 2001. 120(6): p. 1811-1814., https://www.ncbi.nlm.nih.gov/pubmed/11742906
1752. Wassermann, K., Eckel, H. E., Michel, O., Muller, R. P., Emergency stenting of malignant obstruction of the upper airways: long-term follow-up with two types of silicone prostheses, J.Thorac.Cardiovasc.Surg., 1996. 112(4): p. 859-866., https://www.ncbi.nlm.nih.gov/pubmed/8873710
1753. Wassermann, K., Koch, A., Muller-Ehmsen, J., Reuter, M., Michel, O., Eckel, H. E., Clinical and laboratory evaluation of a new thin-walled self-expanding tracheobronchial silicone stent: progress and pitfalls, J.Thorac.Cardiovasc.Surg., 1997. 114(4): p. 527-534., https://www.ncbi.nlm.nih.gov/pubmed/9338637
1754. Wassermann, K., Eckel, H. E., Michel, O., Muller, R. P., Emergency stenting of malignant obstruction of the upper airways: long-term follow-up with two types of silicone prostheses, Ann.Otol.Rhinol.Laryngol., 1998. 107(2): p. 149-154., https://pubmed.ncbi.nlm.nih.gov/9486910/
1755. Wilhelm, K., Schild, H., Duber, C., Mitze, M., Schlegel, J., Lorenz, J., [Stent implantation as a palliative therapeutic measure in stenosing tumors of central airways], Rofo, 1996. 164(6): p. 496-501., https://www.ncbi.nlm.nih.gov/pubmed/8688507
1756. Wilson, G. E., Walshaw, M. J., Hind, C. R., Treatment of large airway obstruction in lung cancer using expandable metal stents inserted under direct vision via the fibreoptic bronchoscope, Thorax, 1996. 51(3): p. 248-252., https://www.ncbi.nlm.nih.gov/pubmed/8779125
1757. Witt, C., Dinges, S., Schmidt, B., Ewert, R., Budach, V., Baumann, G., Temporary tracheobronchial stenting in malignant stenoses, Eur.J.Cancer, 1997. 33(2): p. 204-208., https://www.ncbi.nlm.nih.gov/pubmed/9135489
1758. Xu, X., Tajima, H., Ishioh, M., Watari, J., Miyashita, T., Kumazaki, T., et.al. Study on the treatment of tracheobronchial stenosis using expandable metallic stents, J.Nippon Med.Sch, 2001. 68(4): p. 318-327., https://www.ncbi.nlm.nih.gov/pubmed/11505279
1759. Yamamoto, R., Tada, H., Kishi, A., Tojo, T., Asada, H., Double stent for malignant combined esophago-airway lesions, Jpn.J.Thorac.Cardiovasc.Surg., 2002. 50(1): p. 1-5., https://www.ncbi.nlm.nih.gov/pubmed/11855093
1760. Sabath, BF, Casal, RF, Airway stenting for central airway obstruction: a review., Mediastinum, 2023. 7 (): p. 18., https://pubmed.ncbi.nlm.nih.gov/37261090/
1761. Chella, A., Ambrogi, M. C., Ribechini, A., Mussi, A., Fabrini, M. G., Silvano, G., et.al. Combined Nd-YAG laser/HDR brachytherapy versus Nd-YAG laser only in malignant central airway involvement: a prospective randomized study, Lung Cancer, 2000. 27(3): p. 169-75., https://www.ncbi.nlm.nih.gov/pubmed/10699690
1762. Stout, R., Barber, P., Burt, P., Hopwood, P., Swindell, R., Hodgetts, J., et.al. Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs. external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer, Radiother Oncol, 2000. 56(3): p. 323-7., https://www.ncbi.nlm.nih.gov/pubmed/10974381
1763. Langendijk, H., de, Jong J., Tjwa, M., Muller, M., ten, Velde G., Aaronson, N., et.al. External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study, Radiother.Oncol., 2001. 58(3): p. 257-268., https://www.ncbi.nlm.nih.gov/pubmed/11230886
1764. Huber, R. M., Fischer, R., Hautmann, H., Pollinger, B., Haussinger, K., Wendt, T., Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central lung tumors, Int.J.Radiat.Oncol.Biol.Phys., 1997. 38(3): p. 533-540., https://www.ncbi.nlm.nih.gov/pubmed/9231677
1765. Ung.Yc, Yu, E., Falkson, C., et al., The role of high-dose-rate brachytherapy in the palliation of symptoms in patients with non-small cell lung cancer. A systematic review, Brachytherapy, 2006. 5: p. 189-202., https://www.ncbi.nlm.nih.gov/pubmed/16864071
1766. Macha, H. N., Bach.P, Wahlers, B., et al., šberleben und Todesursachen nach palliativer endobronchialer Brachytherapie mit Iridium 192-High-dose bei rezidivierendem Bronchialkarzinom, Pneumologie, 2005. 59: p. 12-17., https://pubmed.ncbi.nlm.nih.gov/15685483/
1767. Nag, S., Abitbol, A. A., Anderson, L. L., Blasko, J. C., Flores, A., Harrison, L. B., et.al. Consensus guidelines for high dose rate remote brachytherapy in cervical, endometrial, and endobronchial tumors.Clinical Research Committee, American Endocurietherapy Society, Int.J.Radiat.Oncol.Biol.Phys., 1993. 27(5): p. 1241-1244., https://www.ncbi.nlm.nih.gov/pubmed/8262853
1768. Reveiz, L, Rueda, JR, Cardona, AF, Palliative endobronchial brachytherapy for non-small cell lung cancer., Cochrane Database Syst Rev, 2012. 12 (12)(12): p. CD004284., https://pubmed.ncbi.nlm.nih.gov/23235606/
1769. Dudgeon, D. J., Lertzman, M., Dyspnea in the advanced cancer patient, J Pain Symptom Manage, 1998. 16(4): p. 212-219., https://www.ncbi.nlm.nih.gov/pubmed/9803048
1770. Jennings, A. L., Davies, A. N., Higgins, J. P., Gibbs, J. S., Broadley, K. E., A systematic review of the use of opioids in the management of dyspnoea, Thorax, 2002. 57(11): p. 939-944., https://www.ncbi.nlm.nih.gov/pubmed/12403875
1771. Bredin, M., Corner, J., Krishnasamy, M., Plant, H., Bailey, C., A'Hern, R., Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer, BMJ, 1999. 318(7188): p. 901-904., https://www.ncbi.nlm.nih.gov/pubmed/10102851
1772. Altfelder, N., al, et, Characteristics of patients with breathlessness - a German national survey, Palliative Med, 2010. 24: p. 37.
1773. Reuben, D. B., Mor, V., Dyspnea in terminally ill cancer patients, Chest, 1986. 89(2): p. 234-6., https://www.ncbi.nlm.nih.gov/pubmed/3943383
1774. Walsh, D., Donnelly, S., Rybicki, L., The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients, Support Care Cancer, 2000. 8(3): p. 175-9., https://www.ncbi.nlm.nih.gov/pubmed/10789956
1775. Currow, D.C., al., et, Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study., J Pain Symptom Manage, 2010. 39(4): p. 680-90., https://www.ncbi.nlm.nih.gov/pubmed/20413056
1776. Alt-Epping, B., al., et, What is special about patients with lung cancer and pulmonary metastases in palliative care? Results from a nationwide survey., J Palliat Med, 2012. 19(9): p. 971-7., https://www.ncbi.nlm.nih.gov/pubmed/22731513
1777. Conill, C., Verger, E., Henriquez, I., Saiz, N., Espier, M., Lugo, F., et.al. Symptom prevalence in the last week of life, J Pain Symptom Manage, 1997. 14(6): p. 328-31., https://www.ncbi.nlm.nih.gov/pubmed/9409097
1778. Bausewein, C., Booth, S., Gysels, M., Kuhnbach, R., Haberland, B., Higginson, I. J., Individual breathlessness trajectories do not match summary trajectories in advanced cancer and chronic obstructive pulmonary disease: results from a longitudinal study, Palliat Med, 2010. 24(8): p. 777-86., https://www.ncbi.nlm.nih.gov/pubmed/20847087
1779. Eakin, E. G., Kaplan, R. M., Ries, A. L., Measurement of dyspnoea in chronic obstructive pulmonary disease, Qual Life Res, 1993. 2(3): p. 181-91., https://www.ncbi.nlm.nih.gov/pubmed/8401454
1780. Abernethy, A. P., Wheeler, J. L., Total dyspnoea, Curr Opin Support Palliat Care, 2008. 2(2): p. 110-3., https://www.ncbi.nlm.nih.gov/pubmed/18685406
1781. Parshall, M. B., Schwartzstein, R. M., Adams, L., Banzett, R. B., Manning, H. L., Bourbeau, J., et.al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea, Am J Respir Crit Care Med, 2012. 185(4): p. 435-52., https://www.ncbi.nlm.nih.gov/pubmed/22336677
1782. Allard, P., Lamontagne, C., Bernard, P., Tremblay, C., How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial, J Pain Symptom Manage, 1999. 17(4): p. 256-65., https://pubmed.ncbi.nlm.nih.gov/10203878/
1783. Bruera, Eduardo, Sala, Raul, Spruyt, Odette, Palmer, J. Lynn, Zhang, Tao, Willey, Jie, Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study, Journal of Pain & Symptom Management, 2005. 29(6): p. 613-8., https://pubmed.ncbi.nlm.nih.gov/15963870/
1784. Charles, Margaret A., Reymond, Liz, Israel, Fiona, Relief of incident dyspnea in palliative cancer patients: A pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline, Journal of Pain and Symptom Management, 2008. 36(1): p. 29-38., https://pubmed.ncbi.nlm.nih.gov/18358689/
1785. Grimbert, D., Lubin, O., de Monte, M., Vecellio None, L., Perrier, M., Carre, P., et.al. [Dyspnea and morphine aerosols in the palliative care of lung cancer], Rev Mal Respir, 2004. 21(6 Pt 1): p. 1091-7., https://www.ncbi.nlm.nih.gov/pubmed/15767953
1786. Jennings, A. L., Davies, A. N., Higgins, J. P., Broadley, K., Opioids for the palliation of breathlessness in terminal illness, Cochrane Database Syst Rev, 2001. p. CD002066., https://www.ncbi.nlm.nih.gov/pubmed/11687137
1787. Jensen, D., Alsuhail, A., Viola, R., Dudgeon, D. J., O'Donnell, D. E., Inhaled Fentanyl Citrate Improves Dynamic Airway Function, Exertional Dyspnea And Exercise Endurance In COPD [Abstract], American Journal of Respiratory and Critical Care Medicine, 2011. p. A5627.
1788. Johnson, M. J., McDonagh, T. A., Harkness, A., McKay, S. E., Dargie, H. J., Morphine for the relief of breathlessness in patients with chronic heart failure - A pilot study, European journal of heart failure, 2002. 4(6): p. 753-756., https://www.ncbi.nlm.nih.gov/pubmed/12453546
1789. Mazzocato, C., Buclin, T., Rapin, C. H., The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double-blind controlled trial, Annals of Oncology, 1999. 10(12): p. 1511-1514., https://www.ncbi.nlm.nih.gov/pubmed/10643545
1790. Navigante, A. H., Cerchietti, L. C., Castro, M. A., Lutteral, M. A., Cabalar, M. E., Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer, J Pain Symptom Manage, 2006. 31(1): p. 38-47., https://www.ncbi.nlm.nih.gov/pubmed/16442481
1791. Navigante, A. H., Castro, M. A., Cerchietti Leandro, C., Morphine Versus Midazolam as Upfront Therapy to Control Dyspnea Perception in Cancer Patients While Its Underlying Cause Is Sought or Treated, Journal of pain and symptom management, 2010. 39(5): p. 820-830., https://www.ncbi.nlm.nih.gov/pubmed/20471543
1792. Oxberry, S. G., Torgerson, D. J., Bland, J. M., Clark, A. L., Cleland, J. G., Johnson, M. J., Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial, Eur J Heart Fail, 2011. 13(9): p. 1006-12., https://www.ncbi.nlm.nih.gov/pubmed/21712288
1793. Ekström, M, Bajwah, S, Bland, JM, Currow, DC, Hussain, J, Johnson, MJ, One evidence base; three stories: do opioids relieve chronic breathlessness?, Thorax, 2018. 73 (1)(1): p. 88-90., https://pubmed.ncbi.nlm.nih.gov/28377491/
1794. Hui, D, Bruera, E, Integrating palliative care into the trajectory of cancer care., Nat Rev Clin Oncol, 2016. 13 (3)(3): p. 159-71., https://pubmed.ncbi.nlm.nih.gov/26598947/
1795. Pinna, R, Campus, G, Cumbo, E, Mura, I, Milia, E, Xerostomia induced by radiotherapy: an overview of the physiopathology, clinical evidence, and management of the oral damage., Ther Clin Risk Manag, 2015. 11 (): p. 171-88., https://pubmed.ncbi.nlm.nih.gov/25691810/
1796. Simon, K, Colorectal cancer development and advances in screening., Clin Interv Aging, 2016. 11 (): p. 967-76., https://pubmed.ncbi.nlm.nih.gov/27486317/
1797. Barnes, H, McDonald, J, Smallwood, N, Manser, R, Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness., Cochrane Database Syst Rev, 2016. 3 (): p. CD011008., https://pubmed.ncbi.nlm.nih.gov/27030166/
1798. Verberkt, CA, van den Beuken-van Everdingen, MHJ, Schols, JMGA, Datla, S, Dirksen, CD, Johnson, MJ, et.al. Respiratory adverse effects of opioids for breathlessness: a systematic review and meta-analysis., Eur Respir J, 2017. 50 (5)(5):, https://pubmed.ncbi.nlm.nih.gov/29167300/
1799. Abernethy, A. P., Currow, D. C., Frith, P., Fazekas, B. S., McHugh, A., Bui, C., Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea, BMJ, 2003. 327(7414): p. 523-528., https://www.ncbi.nlm.nih.gov/pubmed/12958109
1800. Allard, P., Lamontagne, C., Bernard, P., Tremblay, C., How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial, J Pain Symptom Manage, 1999. 17(4): p. 256-65., https://www.ncbi.nlm.nih.gov/pubmed/10203878
1801. Bruera, Eduardo, Sala, Raul, Spruyt, Odette, Palmer, J. Lynn, Zhang, Tao, Willey, Jie, Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study, Journal of Pain & Symptom Management, 2005. 29(6): p. 613-8., https://pubmed.ncbi.nlm.nih.gov/15963870/
1802. Johnson, M. J., Abernethy, A. P., Currow, D. C., Gaps in the evidence base of opioids for refractory breathlessness. A future work plan?, J Pain Symptom Manage, 2012. 43(3): p. 614-24., https://www.ncbi.nlm.nih.gov/pubmed/22285285
1803. Perna, G. P., Modoni, S., Valle, G., Stanislao, M., Loperfido, F., Plasma beta-endorphin response to exercise in patients with congestive heart failure, Chest, 1997. 111(1): p. 19-22., https://www.ncbi.nlm.nih.gov/pubmed/8995987
1804. von Leupoldt, A., Sommer, T., Kegat, S., Baumann, H. J., Klose, H., Dahme, B., et.al. Dyspnea and pain share emotion-related brain network, Neuroimage, 2009. 48(1): p. 200-6., https://www.ncbi.nlm.nih.gov/pubmed/19527787
1805. von Leupoldt, A., Sommer, T., Kegat, S., Eippert, F., Baumann, H. J., Klose, H., et.al. Down-regulation of insular cortex responses to dyspnea and pain in asthma, Am J Respir Crit Care Med, 2009. 180(3): p. 232-8., https://www.ncbi.nlm.nih.gov/pubmed/19483110
1806. von Leupoldt, A., Sommer, T., Kegat, S., Baumann, H. J., Klose, H., Dahme, B., et.al. The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala, Am J Respir Crit Care Med, 2008. 177(9): p. 1026-32., https://www.ncbi.nlm.nih.gov/pubmed/18263796
1807. Pattinson, K. T., Governo, R. J., MacIntosh, B. J., Russell, E. C., Corfield, D. R., Tracey, I., et.al. Opioids depress cortical centers responsible for the volitional control of respiration, J Neurosci, 2009. 29(25): p. 8177-86., https://www.ncbi.nlm.nih.gov/pubmed/19553457
1808. Currow, D. C., McDonald, C., Oaten, S., Kenny, B., Allcroft, P., Frith, P., et.al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study, J Pain Symptom Manage, 2011. 42(3): p. 388-99., https://www.ncbi.nlm.nih.gov/pubmed/21458217
1809. Ekström, M, Nilsson, F, Abernethy, AA, Currow, DC, Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review., Ann Am Thorac Soc, 2015. 12 (7)(7): p. 1079-92., https://pubmed.ncbi.nlm.nih.gov/25803110/
1810. Clemens, K. E., Klaschik, E., Effect of hydromorphone on ventilation in palliative care patients with dyspnea, Support Care Cancer, 2008. 16(1): p. 93-9., https://www.ncbi.nlm.nih.gov/pubmed/17929063
1811. Clemens, K. E., Klaschik, E., Symptomatic therapy of dyspnea with strong opioids and its effect on ventilation in palliative care patients, J Pain Symptom Manage, 2007. 33(4): p. 473-81., https://www.ncbi.nlm.nih.gov/pubmed/17397708
1812. Hardy, A, Emsley, R, Freeman, D, Bebbington, P, Garety, PA, Kuipers, EE, et.al. Psychological Mechanisms Mediating Effects Between Trauma and Psychotic Symptoms: The Role of Affect Regulation, Intrusive Trauma Memory, Beliefs, and Depression., Schizophr Bull, 2016. 42 Suppl 1 (): p. S34-43., https://pubmed.ncbi.nlm.nih.gov/27460616/
1813. Simon, ST, Higginson, IJ, Booth, S, Harding, R, Weingärtner, V, Bausewein, C, Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults., Cochrane Database Syst Rev, 2016. 10 (10)(10): p. CD007354., https://pubmed.ncbi.nlm.nih.gov/27764523/
1814. Simon, S. T., Higginson, I. J., Booth, S., Harding, R., Bausewein, C., Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults, Cochrane Database Syst Rev, 2010. p. CD007354., https://pubmed.ncbi.nlm.nih.gov/20091630/
1815. Allcroft, P., Margitanovic, V., Greene, A., Agar, M. R., Clark, K., Abernethy, A. P., et.al. The role of benzodiazepines in breathlessness: a single site, open label pilot of sustained release morphine together with clonazepam, J Palliat Med, 2013. 16(7): p. 741-4., https://pubmed.ncbi.nlm.nih.gov/23597092/
1816. Albert, RK, Au, DH, Blackford, AL, Casaburi, R, Cooper, JA, Criner, GJ, et.al. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation., N Engl J Med, 2016. 375 (17)(17): p. 1617-1627., https://pubmed.ncbi.nlm.nih.gov/27783918/
1817. Abernethy, A. P., McDonald, C. F., Frith, P. A., Clark, K., Herndon, J. E., 2nd, Marcello, J., et.al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial, Lancet, 2010. 376(9743): p. 784-93., https://www.ncbi.nlm.nih.gov/pubmed/20816546
1818. Cranston, J. M., Crockett, A., Currow, D., Oxygen therapy for dyspnoea in adults, Cochrane Database Syst Rev, 2008. p. CD004769., https://www.ncbi.nlm.nih.gov/pubmed/18646110
1819. Uronis, H. E., Currow, D. C., McCrory, D. C., Samsa, G. P., Abernethy, A. P., Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis, Br J Cancer, 2008. 98(2): p. 294-9., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361446/
1820. von Leupoldt, A., Balewski, S., Petersen, S., Taube, K., Schubert-Heukeshoven, S., Magnussen, H., et.al. Verbal descriptors of dyspnea in patients with COPD at different intensity levels of dyspnea, Chest, 2007. 132(1): p. 141-7., https://www.ncbi.nlm.nih.gov/pubmed/17475633
1821. Simon, ST, Weingärtner, V, Higginson, IJ, Benalia, H, Gysels, M, Murtagh, FE, et.al. "I Can Breathe Again!" Patients' Self-Management Strategies for Episodic Breathlessness in Advanced Disease, Derived From Qualitative Interviews., J Pain Symptom Manage, 2016. 52 (2)(2): p. 228-34., https://pubmed.ncbi.nlm.nih.gov/27220949/
1822. Booth, S., Moosavi, S. H., Higginson, I. J., The etiology and management of intractable breathlessness in patients with advanced cancer: a systematic review of pharmacological therapy, Nat Clin Pract Oncol, 2008. 5(2): p. 90-100., https://www.ncbi.nlm.nih.gov/pubmed/18235441
1823. Booth, S., Moffat, C., Farquhar, M., Higginson, I. J., Burkin, J., Developing a breathlessness intervention service for patients with palliative and supportive care needs, irrespective of diagnosis, J Palliat Care, 2011. 27(1): p. 28-36., https://www.ncbi.nlm.nih.gov/pubmed/21510129
1824. Probst, V. S., Troosters, T., Coosemans, I., Spruit, M. A., Pitta Fde, O., Decramer, M., et.al. Mechanisms of improvement in exercise capacity using a rollator in patients with COPD, Chest, 2004. 126(4): p. 1102-7., https://www.ncbi.nlm.nih.gov/pubmed/15486370
1825. Bausewein, C., Booth, S., Gysels, M., Higginson, I., Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases, Cochrane Database Syst Rev, 2008. p. CD005623., https://www.ncbi.nlm.nih.gov/pubmed/18425927
1826. Bausewein, C., Booth, S., Gysels, M., Kuhnbach, R., Higginson, I. J., Effectiveness of a hand-held fan for breathlessness: a randomised phase II trial, BMC Palliat Care, 2010. 9: p. 22., https://www.ncbi.nlm.nih.gov/pubmed/20958972
1827. Galbraith, S., Fagan, P., Perkins, P., Lynch, A., Booth, S., Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial, J Pain Symptom Manage, 2010. 39(5): p. 831-8., https://www.ncbi.nlm.nih.gov/pubmed/20471544
1828. Saunders, C., The evolution of palliative care, J R Soc Med, 2001. 94(9): p. 430-2., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1282179/
1829. Merskey, H., Classification of chronic pain: description of chronic pain syndromes and definition of pain terms., Pain, 1986. Suppl. (3): p. 1., https://pubmed.ncbi.nlm.nih.gov/3461421/
1830. Saunders, C, The evolution of palliative care., J R Soc Med, 2001. 94 (9)(9): p. 430-2., https://pubmed.ncbi.nlm.nih.gov/11535742/
1831. Price, D. D., Psychological and neural mechanisms of the affective dimension of pain, Science, 2000. 288(5472): p. 1769-72., https://www.ncbi.nlm.nih.gov/pubmed/10846154
1832. Caraceni, A., Cherny, N., Fainsinger, R., Kaasa, S., Poulain, P., Radbruch, L., et.al. Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care, J Pain Symptom Manage, 2002. 23(3): p. 239-55., https://www.ncbi.nlm.nih.gov/pubmed/11888722
1833. Caraceni, A., Hanks, G., Kaasa, S., Bennett, M. I., Brunelli, C., Cherny, N., et.al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC, Lancet Oncol, 2012. 13(2): p. e58-68., https://www.ncbi.nlm.nih.gov/pubmed/22300860
1834. Tassinari, D., Drudi, F., Rosati, M., Maltoni, M., Transdermal opioids as front line treatment of moderate to severe cancer pain: a systemic review, Palliat Med, 2011. 25(5): p. 478-87., https://pubmed.ncbi.nlm.nih.gov/21708854/
1835. Leppert, W., Majkowicz, M., The impact of tramadol and dihydrocodeine treatment on quality of life of patients with cancer pain, Int J Clin Pract, 2010. 64(12): p. 1681-7., https://www.ncbi.nlm.nih.gov/pubmed/20946274
1836. Caraceni, Augusto, Pigni, Alessandra, Brunelli, Cinzia, Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project, Palliative Medicine, 2011. 25(5): p. 402-409., https://pubmed.ncbi.nlm.nih.gov/21708848/
1837. King, S., Forbes, K., Hanks, G. W., Ferro, C. J., Chambers, E. J., A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: A European Palliative Care Research Collaborative opioid guidelines project, Palliative Medicine, 2011. 25(5): p. 525-552., https://pubmed.ncbi.nlm.nih.gov/21708859/
1838. King, Samuel James, Reid, Colette, Forbes, Karen, Hanks, Geoffrey, A systematic review of oxycodone in the management of cancer pain, Palliative Medicine, 2011. 25(5): p. 454-470., https://pubmed.ncbi.nlm.nih.gov/21708852/
1839. Pigni, A., Brunelli, C., Caraceni, A., The role of hydromorphone in cancer pain treatment: a systematic review, Palliat Med, 2011. 25(5): p. 471-7., https://www.ncbi.nlm.nih.gov/pubmed/21708853
1840. Mercadante, S., Tirelli, W., David, F., Arcara, C., Fulfaro, F., Casuccio, A., et.al. Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study, Clin J Pain, 2010. 26(9): p. 794-7., https://www.ncbi.nlm.nih.gov/pubmed/20973155
1841. Gourlay, G. K., Cherry, D. A., Cousins, M. J., A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer, Pain, 1986. 25(3): p. 297-312., https://www.ncbi.nlm.nih.gov/pubmed/3528988
1842. Gourlay, G. K., Treatment of cancer pain with transdermal fentanyl, Lancet Oncol, 2001. 2(3): p. 165-72., https://www.ncbi.nlm.nih.gov/pubmed/11902567
1843. Bruera, E., Brenneis, C., Michaud, M., Bacovsky, R., Chadwick, S., Emeno, A., et.al. Use of the subcutaneous route for the administration of narcotics in patients with cancer pain, Cancer, 1988. 62(2): p. 407-11., https://pubmed.ncbi.nlm.nih.gov/2454724/
1844. Ventafridda, V., Ripamonti, C., Bianchi, M., Sbanotto, A., De Conno, F., A randomized study on oral administration of morphine and methadone in the treatment of cancer pain, J Pain Symptom Manage, 1986. 1(4): p. 203-7., https://www.ncbi.nlm.nih.gov/pubmed/3537160
1845. Candy, B., Jones, L., Goodman, M. L., Drake, R., Tookman, A., Laxatives or methylnaltrexone for the management of constipation in palliative care patients, Cochrane Database Syst Rev, 2011. p. CD003448., https://www.ncbi.nlm.nih.gov/pubmed/21249653
1846. Zeppetella, Giovambattista, Opioids for the management of breakthrough cancer pain in adults: A systematic review undertaken as part of an EPCRC opioid guidelines project, Palliative Medicine, 2011. 25(5): p. 516-524., https://pubmed.ncbi.nlm.nih.gov/21708858/
1847. Zeppetella, G., Davies, A. N., Opioids for the management of breakthrough pain in cancer patients, Cochrane Database Syst Rev, 2013. 10: p. CD004311., https://www.ncbi.nlm.nih.gov/pubmed/24142465
1848. Siegel, R., Ma, J., Zou, Z., Jemal, A., Cancer statistics, 2014, CA Cancer J Clin, 2014. 64(1): p. 9-29., https://www.ncbi.nlm.nih.gov/pubmed/24399786
1849. Hopwood, P., Stephens, R. J., Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data, J Clin Oncol, 2000. 18(4): p. 893-903., https://www.ncbi.nlm.nih.gov/pubmed/10673533
1850. Hopwood, P., Stephens, R. J., Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party, Br J Cancer, 1995. 71(3): p. 633-6., https://pubmed.ncbi.nlm.nih.gov/7533520/
1851. Lutz, S., Norrell, R., Bertucio, C., Kachnic, L., Johnson, C., Arthur, D., et.al. Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the Lung Cancer Symptom Scale in a community hospital, J Palliat Med, 2001. 4(2): p. 157-65., https://www.ncbi.nlm.nih.gov/pubmed/11441624
1852. Raijmakers, N. J. H., van Zuylen, L., Costantini, M., Caraceni, A., Clark, J., Lundquist, G., et.al. Artificial nutrition and hydration in the last week of life in cancer patients. A systematic literature review of practices and effects, Annals of Oncology, 2011. 22(7): p. 1478-86., https://www.ncbi.nlm.nih.gov/pubmed/21199887
1853. Bruera, E., Hui, D., Dalal, S., Torres-Vigil, I., Trumble, J., Roosth, J., et.al. Parenteral hydration in patients with advanced cancer: a multicenter, double-blind, placebo-controlled randomized trial, J Clin Oncol, 2013. 31(1): p. 111-8., https://www.ncbi.nlm.nih.gov/pubmed/23169523
1854. Nakajima, N., Hata, Y., Kusumuto, K., A clinical study on the influence of hydration volume on the signs of terminally ill cancer patients with abdominal malignancies, J Palliat Med, 2013. 16(2): p. 185-9., https://www.ncbi.nlm.nih.gov/pubmed/23327196
1855. Steinhauser, K. E., Christakis, N. A., Clipp, E. C., McNeilly, M., McIntyre, L., Tulsky, J. A., Factors considered important at the end of life by patients, family, physicians, and other care providers, JAMA, 2000. 284(19): p. 2476-82., https://www.ncbi.nlm.nih.gov/pubmed/11074777
1856. Moneymaker, K., Comfort measures only, J Palliat Med, 2005. 8(3): p. 688., https://www.ncbi.nlm.nih.gov/pubmed/15992217
1857. Bundesarztekammer, Grundsätze der Bundesärztekammer zur ärztlichen Sterbebegleitung., Deutsches Ärzteblatt, 2011. 108(7): p. A346-A348.
1858. Dodson, J. A., Fried, T. R., Van Ness, P. H., Goldstein, N. E., Lampert, R., Patient preferences for deactivation of implantable cardioverter-defibrillators, JAMA Intern Med, 2013. 173(5): p. 377-9., https://pubmed.ncbi.nlm.nih.gov/23358714/
1859. Lindqvist, O., Lundquist, G., Dickman, A., Bukki, J., Lunder, U., Hagelin, C. L., et.al. Four essential drugs needed for quality care of the dying: a Delphi-study based international expert consensus opinion, J Palliat Med, 2013. 16(1): p. 38-43., https://www.ncbi.nlm.nih.gov/pubmed/23234300
1860. Carlsson, J., Paul, N. W., Dann, M., Neuzner, J., Pfeiffer, D., The deactivation of implantable cardioverter-defibrillators: medical, ethical, practical, and legal considerations, Dtsch Arztebl Int, 2012. 109(33-34): p. 535-41., https://pubmed.ncbi.nlm.nih.gov/23152737/
1861. Wee, B., Hillier, R., Interventions for noisy breathing in patients near to death, Cochrane Database Syst Rev, 2008. p. CD005177., https://www.ncbi.nlm.nih.gov/pubmed/18254072
1862. Fainsinger, R. L., Bruera, E., When to treat dehydration in a terminally ill patient?, Support Care Cancer, 1997. 5(3): p. 205-11., https://www.ncbi.nlm.nih.gov/pubmed/9176966
1863. Noble, H., Meyer, P. J., Bridge, D. J., Johnson, D. B., Kelly, D. D., Exploring symptoms in patients managed without dialysis: a qualitative research study, J Ren Care, 2010. 36(1): p. 9-15., https://pubmed.ncbi.nlm.nih.gov/20214703/
1864. Mercadante, S., Ferrera, P., Girelli, D., Casuccio, A., Patients' and relatives' perceptions about intravenous and subcutaneous hydration, J Pain Symptom Manage, 2005. 30(4): p. 354-8., https://www.ncbi.nlm.nih.gov/pubmed/16256899
1865. Wee, B. L., Coleman, P. G., Hillier, R., Holgate, S. H., The sound of death rattle I: are relatives distressed by hearing this sound?, Palliat Med, 2006. 20(3): p. 171-5., https://www.ncbi.nlm.nih.gov/pubmed/16764221
1866. Lübbe A. S., Prinzipien und Standards der onkologischen Rehabilitation, TumorDiagn u Ther, 2004. 25: p. 65-71.
1867. Lübbe A. S., König V., Konzepte onkologischer Rehabilitation, in Therapiekonzepte Onkologie, Seeber S., Schütte J. , Editor. 2003, Springer Verlag.
1868. Fialka-Moser, V., Crevenna, R., Korpan, M., Quittan, M., Cancer rehabilitation: particularly with aspects on physical impairments, J.Rehabil.Med., 2003. 35(4): p. 153-162., https://www.ncbi.nlm.nih.gov/pubmed/12892240
1869. Nazarian, J., Cardiopulmonary rehabilitation after treatment for lung cancer, Curr.Treat Options.Oncol, 2004. 5(1): p. 75-82., https://www.ncbi.nlm.nih.gov/pubmed/14697159
1870. Spruit, M. A., Janssen, P. P., Willemsen, S. C., Hochstenbag, M. M., Wouters, E. F., Exercise capacity before and after an 8-week multidisciplinary inpatient rehabilitation program in lung cancer patients: a pilot study, Lung Cancer, 2006. 52(2): p. 257-260., https://www.ncbi.nlm.nih.gov/pubmed/16529844
1871. Thompson, E., Sola, I., Subirana, M., Non-invasive interventions for improving well-being and quality of life in patients with lung cancer--a systematic review of the evidence, Lung Cancer, 2005. 50(2): p. 163-176., https://www.ncbi.nlm.nih.gov/pubmed/16137786
1872. Sola, I., Thompson, E., Subirana, M., et al., Non-invasive interventions for improving well-being and quality of life in patients with lung cancer (Review), The Cochrane Library, Issue 1, 2007., https://www.ncbi.nlm.nih.gov/pubmed/16137786
1873. Christman, N. J., Cain, L. B., The effects of concrete objective information and relaxation on maintaining usual activity during radiation therapy, Oncol.Nurs.Forum, 2004. 31(2): p. E39-E45., https://www.ncbi.nlm.nih.gov/pubmed/15017453
1874. Doorenbos, A., Given, B., Given, C., Verbitsky, N., Physical functioning: effect of behavioral intervention for symptoms among individuals with cancer, Nurs.Res., 2006. 55(3): p. 161-171., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2012950/
1875. Dimeo, F. C., Tilmann, M. H., Bertz, H., Kanz, L., Mertelsmann, R., Keul, J., Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation, Cancer, 1997. 79(9): p. 1717-1722., https://www.ncbi.nlm.nih.gov/pubmed/9128987
1876. Dimeo, F. C., Stieglitz, R. D., Novelli-Fischer, U., Fetscher, S., Keul, J., Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy, Cancer, 1999. 85(10): p. 2273-2277., https://www.ncbi.nlm.nih.gov/pubmed/10326708
1877. Dimeo, F. C., Thomas, F., Raabe-Menssen, C., Propper, F., Mathias, M., Effect of aerobic exercise and relaxation training on fatigue and physical performance of cancer patients after surgery. A randomised controlled trial, Support.Care Cancer, 2004. 12(11): p. 774-779., https://www.ncbi.nlm.nih.gov/pubmed/15338385
1878. Schultz, K., Bergmann, K. C., Kenn, K., Petro, W., Heitmann, R. H., Fischer, R., et.al. Effektivit„t der pneumologischen Anschluss-Rehabilitation (AHB), Dtsch Med Wochenschr., 2006. 131(33): p. 1793-1798., https://pubmed.ncbi.nlm.nih.gov/16902901/
1879. Riesenberg H., Lübbe A. S., Prädiktoren und Outcome stationärer Rehabilitation bei Patienten mit Bronchialkarzinom, TumorDiagnostik und Therapie, 2007. 28: p. 1-6., https://www.researchgate.net/publication/245811674_Pradiktoren_und_Outcome_stationarer_Rehabilitation_bei_Patienten_mit_Bronchialkarzinom
1880. Egermann, U., Jaeggi, K., Habicht, J. M., Perruchoud, A. P., Dalquen, P., Soler, M., Regular follow-up after curative resection of nonsmall cell lung cancer: a real benefit for patients?, Eur Respir J, 2002. 19(3): p. 464-468., https://www.ncbi.nlm.nih.gov/pubmed/11936523
1881. Pisters, K. M., Le, Chevalier T., Adjuvant chemotherapy in completely resected non-small-cell lung cancer, J Clin Oncol, 2005. 23(14): p. 3270-3278., https://www.ncbi.nlm.nih.gov/pubmed/15886314
1882. Westeel, V., Choma, D., Clement, F., Woronoff-Lemsi, M. C., Pugin, J. F., Dubiez, A., et.al. Relevance of an intensive postoperative follow-up after surgery for non-small cell lung cancer, Ann Thorac.Surg., 2000. 70(4): p. 1185-1190., https://www.ncbi.nlm.nih.gov/pubmed/11081867
1883. Cramer-van der Welle, CM, Verschueren, MV, Tonn, M, Peters, BJM, Schramel, FMNH, Klungel, OH, et.al. Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands., Sci Rep, 2021. 11 (1)(1): p. 6306., https://pubmed.ncbi.nlm.nih.gov/33737641/
1884. Waterhouse, D, Lam, J, Betts, KA, Yin, L, Gao, S, Yuan, Y, et.al. Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer., Lung Cancer, 2021. 156 (): p. 41-49., https://pubmed.ncbi.nlm.nih.gov/33894493/
1885. Vaporciyan, A. A., Merriman, K. W., Ece, F., Roth, J. A., Smythe, W. R., Swisher, S. G., et.al. Incidence of major pulmonary morbidity after pneumonectomy: association with timing of smoking cessation, Ann.Thorac.Surg., 2002. 73(2): p. 420-425., https://www.ncbi.nlm.nih.gov/pubmed/11845853
1886. Tsao, A. S., Liu, D., Lee, J. J., Spitz, M., Hong, W. K., Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer, Cancer, 2006. 106(11): p. 2428-2436., https://www.ncbi.nlm.nih.gov/pubmed/16634096
1887. Richardson, G. E., Tucker, M. A., Venzon, D. J., Linnoila, R. I., Phelps, R., Phares, J. C., et.al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers, Ann.Intern.Med, 1993. 119(5): p. 383-390., https://www.ncbi.nlm.nih.gov/pubmed/8393311
1888. Tucker, M. A., Murray, N., Shaw, E. G., Ettinger, D. S., Mabry, M., Huber, M. H., et.al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre, J Natl.Cancer Inst., 1997. 89(23): p. 1782-1788., https://www.ncbi.nlm.nih.gov/pubmed/9392619
1889. Abratt, R. P., Morgan, G. W., Lung toxicity following chest irradiation in patients with lung cancer, Lung Cancer, 2002. 35(2): p. 103-109., https://www.ncbi.nlm.nih.gov/pubmed/11804681
1890. Cox, J. D., Azarnia, N., Byhardt, R. W., Shin, K. H., Emami, B., Pajak, T. F., A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11, J Clin Oncol, 1990. 8(9): p. 1543-1555., https://www.ncbi.nlm.nih.gov/pubmed/2167952
1891. Handy, J. R., Jr., Child, A. I., Grunkemeier, G. L., Fowler, P., Asaph, J. W., Douville, E. C., et.al. Hospital readmission after pulmonary resection: prevalence, patterns, and predisposing characteristics, Ann Thorac.Surg., 2001. 72(6): p. 1855-1859., https://www.ncbi.nlm.nih.gov/pubmed/11789760
1892. Colice, G. L., Rubins, J., Unger, M., Follow-up and surveillance of the lung cancer patient following curative-intent therapy 1, Chest, 2003. 123(1 Suppl): p. 272S-283S., https://www.ncbi.nlm.nih.gov/pubmed/12527585
1893. Pairolero, P. C., Williams, D. E., Bergstralh, E. J., Piehler, J. M., Bernatz, P. E., Payne, W. S., Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease, Ann Thorac.Surg., 1984. 38(4): p. 331-338., https://www.ncbi.nlm.nih.gov/pubmed/6091575
1894. Chiu, C. H., Chern, M. S., Wu, M. H., Hsu, W. H., Wu, Y. C., Huang, M. H., et.al. Usefulness of low-dose spiral CT of the chest in regular follow-up of postoperative non-small cell lung cancer patients: Preliminary report, J Thorac.Cardiovasc.Surg., 2003. 125(6): p. 1300-1305., https://www.ncbi.nlm.nih.gov/pubmed/12830048
1895. Lamont, J. P., Kakuda, J. T., Smith, D., Wagman, L. D., Grannis, F. W., Jr., Systematic postoperative radiologic follow-up in patients with non-small cell lung cancer for detecting second primary lung cancer in stage IA, Arch Surg, 2002. 137(8): p. 935-8; discussion 938-40., https://www.ncbi.nlm.nih.gov/pubmed/12146993
1896. Walsh, G. L., O'Connor, M., Willis, K. M., Milas, M., Wong, R. S., Nesbitt, J. C., et.al. Is follow-up of lung cancer patients after resection medically indicated and cost-effective?, Ann Thorac.Surg., 1995. 60(6): p. 1563-1570., https://www.ncbi.nlm.nih.gov/pubmed/8787445
1897. Virgo, K. S., Naunheim, K. S., McKirgan, L. W., Kissling, M. E., Lin, J. C., Johnson, F. E., Cost of patient follow-up after potentially curative lung cancer treatment, J Thorac.Cardiovasc.Surg., 1996. 112(2): p. 356-363., https://pubmed.ncbi.nlm.nih.gov/8751503/
1898. Younes, R. N., Gross, J. L., Deheinzelin, D., Follow-up in lung cancer: how often and for what purpose?, Chest, 1999. 115(6): p. 1494-1499., https://www.ncbi.nlm.nih.gov/pubmed/10378539
1899. Westeel, V, Foucher, P, Scherpereel, A, Domas, J, Girard, P, Trédaniel, J, et.al. Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial., Lancet Oncol, 2022. 23 (9)(9): p. 1180-1188., https://pubmed.ncbi.nlm.nih.gov/35964621/
1900. Brundage, M. D., Davies, D., Mackillop, W. J., Prognostic factors in non-small cell lung cancer: a decade of progress, Chest, 2002. 122(3): p. 1037-1057., https://www.ncbi.nlm.nih.gov/pubmed/12226051
1901. Faivre-Finn, C, Vicente, D, Kurata, T, Planchard, D, Paz-Ares, L, Vansteenkiste, JF, et.al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial., J Thorac Oncol, 2021. 16 (5)(5): p. 860-867., https://pubmed.ncbi.nlm.nih.gov/33476803/
1902. Moore, S., Corner, J., Haviland, J., Wells, M., Salmon, E., Normand, C., et.al. Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial, BMJ, 2002. 325(7373): p. 1145., https://www.ncbi.nlm.nih.gov/pubmed/12433764
1903. Wolf, U, Barnes, B, Bertz, J, Haberland, J, Laudi, A, Stöcker, M, et.al. [The (German) Center for Cancer Registry Data (ZfKD) at the Robert Koch Institute (RKI) in Berlin]., Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2011. 54 (11)(11): p. 1229-34., https://pubmed.ncbi.nlm.nih.gov/22015795/
1904. Fuchs, J, Busch, M, Lange, C, Scheidt-Nave, C, Prevalence and patterns of morbidity among adults in Germany. Results of the German telephone health interview survey German Health Update (GEDA) 2009., Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2012. 55 (4)(4): p. 576-86., https://pubmed.ncbi.nlm.nih.gov/22441528/
1905. Wildiers, H, Tryfonidis, K, Dal Lago, L, Vuylsteke, P, Curigliano, G, Waters, S, et.al. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group., Lancet Oncol, 2018. 19 (3)(3): p. 323-336., https://pubmed.ncbi.nlm.nih.gov/29433963/
1906. Wildiers, H, Mauer, M, Pallis, A, Hurria, A, Mohile, SG, Luciani, A, et.al. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article., J Clin Oncol, 2013. 31 (29)(29): p. 3711-8., https://pubmed.ncbi.nlm.nih.gov/24019549/
1907. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie, Version 3.0Leitlinienprogramm Onkologie, 2021. 2021:, https://www.leitlinienprogramm-onkologie.de/methodik/grundlegende-informationen-zur-methodik/